{ "disease": "lung-cancer", "label": "Lung cancer", "url": "https://usebiotransfer.org/disease/lung-cancer/", "built": "2026-09-12", "facts_hash": { "answers": "352bad12aba4", "targets": "1d8cbc6acaaf" }, "sources": { "targets": "Open Targets Platform GraphQL API v4", "trials": "ClinicalTrials.gov API v2" }, "retrieved": { "targets": "2026-09-11", "trials": "2026-09-11" }, "query": { "endpoint": "https://clinicaltrials.gov/api/v2/studies", "shape": "query.cond=&query.intr=&pageSize=200", "active_statuses": [ "ACTIVE_NOT_RECRUITING", "ENROLLING_BY_INVITATION", "NOT_YET_RECRUITING", "RECRUITING" ], "dedup": "by NCT id across synonyms", "study_types": "interventional counted in headline; observational reported separately", "known_floor": "trials naming an antigen only by product code are not retrieved by an intervention-name search" }, "targets": [ { "symbol": "EGFR", "ensembl": "ENSG00000146648", "n_drug_entries": 82, "n_distinct_drugs": 74, "drugs": { "ABIVERTINIB": "PHASE_3", "AC-480": "PHASE_2", "AEE-788": "PHASE_1_2", "AFATINIB": "APPROVAL", "AFATINIB DIMALEATE": "APPROVAL", "ALLITINIB": "PHASE_1", "AMIVANTAMAB": "APPROVAL", "AUMOLERTINIB": "APPROVAL", "AV-412": "PHASE_1", "AZD-3759": "PHASE_2_3", "AZD-4769": "PHASE_1", "BAFISONTAMAB": "PHASE_2", "BMS-690514": "PHASE_2", "BRIGATINIB": "APPROVAL", "CANERTINIB": "PHASE_2", "CEP-32496": "PHASE_1_2", "CETUXIMAB": "APPROVAL", "CETUXIMAB SAROTALOCAN": "APPROVAL", "CLN-081": "PHASE_3", "CUDC-101": "PHASE_1", "DACOMITINIB": "APPROVAL", "DEPATUXIZUMAB": "PHASE_2", "DEPATUXIZUMAB MAFODOTIN": "PHASE_3", "DULIGOTUZUMAB": "PHASE_2", "EPITINIB": "PHASE_1", "ERLOTINIB": "APPROVAL", "FALNIDAMOL": "PHASE_1", "FIRMONERTINIB": "PHASE_3", "FUTUXIMAB": "PHASE_3", "GC1118": "PHASE_2", "GEFITINIB": "APPROVAL", "ICOTINIB": "APPROVAL", "IMGATUZUMAB": "PHASE_2", "JNJ-26483327": "PHASE_1", "KBP5209": "PHASE_1", "LAPATINIB": "APPROVAL", "LAPATINIB DITOSYLATE": "APPROVAL", "LAZERTINIB": "APPROVAL", "LOSATUXIZUMAB VEDOTIN": "PHASE_1", "MAB-425": "UNKNOWN", "MATUZUMAB": "PHASE_2", "MAVELERTINIB": "PHASE_1_2", "MDX-447": "PHASE_1", "MOBOCERTINIB": "APPROVAL", "MODOTUXIMAB": "PHASE_2", "NAQUOTINIB": "PHASE_3", "NAZARTINIB": "PHASE_3", "NECITUMUMAB": "APPROVAL", "NERATINIB": "APPROVAL", "NIMOTUZUMAB": "APPROVAL", "OLMUTINIB": "APPROVAL", "OSIMERTINIB": "APPROVAL", "PANITUMUMAB": "APPROVAL", "PELITINIB": "PHASE_2", "PF-06459988": "PHASE_2", "PIMURUTAMAB": "PHASE_2_3", "PKI-166": "PHASE_2", "POZIOTINIB": "PHASE_3", "PYROTINIB": "PHASE_3", "RINDOPEPIMUT": "PHASE_3", "ROCILETINIB": "APPROVAL", "RUSERONTINIB": "PHASE_3", "S-222611": "PHASE_1", "SAPITINIB": "PHASE_2", "SIMOTINIB": "PHASE_1", "TAK-285": "PHASE_1", "TARLOXOTINIB": "PHASE_2", "TESEVATINIB": "PHASE_3", "THELIATINIB": "PHASE_1", "TOMUZOTUXIMAB": "PHASE_2", "TUXOBERTINIB": "PHASE_1_2", "VANDETANIB": "APPROVAL", "VARLITINIB": "PHASE_2_3", "ZALUTUMUMAB": "PHASE_3" }, "approved": [ "AFATINIB", "AFATINIB DIMALEATE", "AMIVANTAMAB", "AUMOLERTINIB", "BRIGATINIB", "CETUXIMAB", "CETUXIMAB SAROTALOCAN", "DACOMITINIB", "ERLOTINIB", "GEFITINIB", "ICOTINIB", "LAPATINIB", "LAPATINIB DITOSYLATE", "LAZERTINIB", "MOBOCERTINIB", "NECITUMUMAB", "NERATINIB", "NIMOTUZUMAB", "OLMUTINIB", "OSIMERTINIB", "PANITUMUMAB", "ROCILETINIB", "VANDETANIB" ], "n_approved": 23, "approved_for": { "AFATINIB": [ "non-small cell lung carcinoma" ], "AFATINIB DIMALEATE": [ "non-small cell lung carcinoma" ], "AMIVANTAMAB": [ "non-small cell lung carcinoma" ], "AUMOLERTINIB": [ "non-small cell lung carcinoma" ], "BRIGATINIB": [ "non-small cell lung carcinoma", "anaplastic large cell lymphoma" ], "CETUXIMAB": [ "malignant tumor of neck", "squamous cell carcinoma", "colorectal adenocarcinoma", "colorectal carcinoma", "colorectal cancer", "head and neck neoplasm", "colorectal neoplasm" ], "CETUXIMAB SAROTALOCAN": [ "head and neck cancer" ], "DACOMITINIB": [ "non-small cell lung carcinoma" ], "ERLOTINIB": [ "non-small cell lung carcinoma", "pancreatic neoplasm" ], "GEFITINIB": [ "non-small cell lung carcinoma", "head and neck squamous cell carcinoma" ], "ICOTINIB": [], "LAPATINIB": [ "breast cancer" ], "LAPATINIB DITOSYLATE": [ "breast cancer", "breast neoplasm", "breast carcinoma" ], "LAZERTINIB": [ "non-small cell lung carcinoma" ], "MOBOCERTINIB": [ "non-small cell lung carcinoma" ], "NECITUMUMAB": [ "non-small cell lung carcinoma", "colorectal cancer", "non-small cell squamous lung carcinoma" ], "NERATINIB": [ "breast cancer", "breast neoplasm", "breast carcinoma" ], "NIMOTUZUMAB": [ "head and neck cancer" ], "OLMUTINIB": [], "OSIMERTINIB": [ "non-small cell lung carcinoma" ], "PANITUMUMAB": [ "colorectal cancer", "colorectal adenocarcinoma", "colorectal neoplasm" ], "ROCILETINIB": [], "VANDETANIB": [ "thyroid gland carcinoma", "medullary thyroid gland carcinoma", "thyroid tumor" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "High-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "Approved Drug" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt loc med conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "AB", "bucket": "Human Protein Atlas loc" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Advanced Clinical" } ] }, { "symbol": "ALK", "ensembl": "ENSG00000171094", "n_drug_entries": 12, "n_distinct_drugs": 11, "drugs": { "ALECTINIB": "APPROVAL", "ASP-3026": "PHASE_1", "BRIGATINIB": "APPROVAL", "CEP-37440": "PHASE_1", "CERITINIB": "APPROVAL", "CONTELTINIB": "PHASE_1_2", "CRIZOTINIB": "APPROVAL", "ENSARTINIB": "PHASE_3", "ENTRECTINIB": "APPROVAL", "LORLATINIB": "APPROVAL", "PLB1003": "PHASE_1" }, "approved": [ "ALECTINIB", "BRIGATINIB", "CERITINIB", "CRIZOTINIB", "ENTRECTINIB", "LORLATINIB" ], "n_approved": 6, "approved_for": { "ALECTINIB": [ "non-small cell lung carcinoma" ], "BRIGATINIB": [ "non-small cell lung carcinoma", "anaplastic large cell lymphoma" ], "CERITINIB": [ "non-small cell lung carcinoma" ], "CRIZOTINIB": [ "non-small cell lung carcinoma" ], "ENTRECTINIB": [ "non-small cell lung carcinoma" ], "LORLATINIB": [ "lymphoma", "non-small cell lung carcinoma" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "High-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "AB", "bucket": "Human Protein Atlas loc" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Phase 1 Clinical" } ] }, { "symbol": "KRAS", "ensembl": "ENSG00000133703", "n_drug_entries": 3, "n_distinct_drugs": 3, "drugs": { "ADAGRASIB": "APPROVAL", "SALIRASIB": "PHASE_2", "SOTORASIB": "APPROVAL" }, "approved": [ "ADAGRASIB", "SOTORASIB" ], "n_approved": 2, "approved_for": { "ADAGRASIB": [ "non-small cell lung carcinoma" ], "SOTORASIB": [ "non-small cell lung carcinoma" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "ROS1", "ensembl": "ENSG00000047936", "n_drug_entries": 4, "n_distinct_drugs": 4, "drugs": { "CRIZOTINIB": "APPROVAL", "ENTRECTINIB": "APPROVAL", "REPOTRECTINIB": "APPROVAL", "TALETRECTINIB": "PHASE_3" }, "approved": [ "CRIZOTINIB", "ENTRECTINIB", "REPOTRECTINIB" ], "n_approved": 3, "approved_for": { "CRIZOTINIB": [ "non-small cell lung carcinoma" ], "ENTRECTINIB": [ "non-small cell lung carcinoma" ], "REPOTRECTINIB": [ "non-small cell lung carcinoma" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "AB", "bucket": "GO CC med conf" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "BRAF", "ensembl": "ENSG00000157764", "n_drug_entries": 18, "n_distinct_drugs": 16, "drugs": { "ARQ-736": "PHASE_1", "BELVARAFENIB": "PHASE_2", "CEP-32496": "PHASE_1_2", "DABRAFENIB": "APPROVAL", "ENCORAFENIB": "APPROVAL", "LIFIRAFENIB": "PHASE_1_2", "LY-3009120": "PHASE_1", "NAPORAFENIB": "PHASE_3", "PLIXORAFENIB": "PHASE_2", "RAF-265": "PHASE_2", "REGORAFENIB": "APPROVAL", "RG-7256": "PHASE_1", "SORAFENIB": "APPROVAL", "TOVORAFENIB": "APPROVAL", "VEMURAFENIB": "APPROVAL", "XL-281": "PHASE_1_2" }, "approved": [ "DABRAFENIB", "ENCORAFENIB", "REGORAFENIB", "SORAFENIB", "TOVORAFENIB", "VEMURAFENIB" ], "n_approved": 6, "approved_for": { "DABRAFENIB": [ "metastatic melanoma", "melanoma", "low grade glioma", "glioma" ], "ENCORAFENIB": [ "melanoma", "colorectal neoplasm", "metastatic melanoma" ], "REGORAFENIB": [ "colorectal cancer", "metastatic colorectal cancer", "colorectal neoplasm" ], "SORAFENIB": [ "renal cell carcinoma", "hepatocellular carcinoma", "thyroid gland carcinoma" ], "TOVORAFENIB": [ "glioma", "low grade glioma" ], "VEMURAFENIB": [ "melanoma", "metastatic melanoma" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "High-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "Human Protein Atlas loc" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "MET", "ensembl": "ENSG00000105976", "n_drug_entries": 38, "n_distinct_drugs": 36, "drugs": { "ALTIRATINIB": "PHASE_1", "AMG-208": "PHASE_2", "AMG-337": "PHASE_2", "AMIVANTAMAB": "APPROVAL", "AMUVATINIB": "PHASE_2", "ARRY-300": "PHASE_1", "BAFISONTAMAB": "PHASE_2", "BEPERMINOGENE PERPLASMID": "PHASE_3", "BMS-777607": "PHASE_1_2", "BMS-817378": "PHASE_1", "BPI-9016": "PHASE_1", "CABOZANTINIB": "APPROVAL", "CABOZANTINIB S-MALATE": "APPROVAL", "CAPMATINIB": "APPROVAL", "CRIZOTINIB": "APPROVAL", "EMD-1204831": "PHASE_1", "EMIBETUZUMAB": "PHASE_2", "FORETINIB": "PHASE_2", "GLESATINIB": "PHASE_2", "GOLVATINIB": "PHASE_1_2", "JNJ-38877605": "PHASE_1", "MERESTINIB": "PHASE_2", "MK-2461": "PHASE_1_2", "MK-8033": "PHASE_1", "NINGETINIB": "PHASE_2", "ONARTUZUMAB": "PHASE_3", "PF-04217903": "PHASE_1", "SAR-125844": "PHASE_2", "SAVOLITINIB": "PHASE_3", "SGX-523": "PHASE_1", "TAS-115": "PHASE_1", "TELISOTUZUMAB": "PHASE_1", "TELISOTUZUMAB VEDOTIN": "PHASE_3", "TEPOTINIB": "APPROVAL", "TEREVALEFIM": "PHASE_3", "TIVANTINIB": "PHASE_3" }, "approved": [ "AMIVANTAMAB", "CABOZANTINIB", "CABOZANTINIB S-MALATE", "CAPMATINIB", "CRIZOTINIB", "TEPOTINIB" ], "n_approved": 6, "approved_for": { "AMIVANTAMAB": [ "non-small cell lung carcinoma" ], "CABOZANTINIB": [ "thyroid cancer", "thyroid tumor", "hepatocellular carcinoma", "renal cell carcinoma", "medullary thyroid gland carcinoma" ], "CABOZANTINIB S-MALATE": [ "thyroid gland carcinoma", "renal cell carcinoma" ], "CAPMATINIB": [ "non-small cell lung carcinoma" ], "CRIZOTINIB": [ "non-small cell lung carcinoma" ], "TEPOTINIB": [ "non-small cell lung carcinoma" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "High-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "Approved Drug" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt loc med conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "AB", "bucket": "Human Protein Atlas loc" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Advanced Clinical" } ] }, { "symbol": "RET", "ensembl": "ENSG00000165731", "n_drug_entries": 16, "n_distinct_drugs": 14, "drugs": { "ALECTINIB": "APPROVAL", "BOS-589": "PHASE_2", "CEP-2563": "PHASE_1", "CEP-32496": "PHASE_1_2", "LESTAURTINIB": "APPROVAL", "MOTESANIB": "PHASE_3", "PRALSETINIB": "APPROVAL", "QUIZARTINIB": "APPROVAL", "REGORAFENIB": "APPROVAL", "SELPERCATINIB": "APPROVAL", "SORAFENIB": "APPROVAL", "SUNITINIB": "APPROVAL", "SUNITINIB MALATE": "APPROVAL", "VANDETANIB": "APPROVAL" }, "approved": [ "ALECTINIB", "LESTAURTINIB", "PRALSETINIB", "QUIZARTINIB", "REGORAFENIB", "SELPERCATINIB", "SORAFENIB", "SUNITINIB", "SUNITINIB MALATE", "VANDETANIB" ], "n_approved": 10, "approved_for": { "ALECTINIB": [ "non-small cell lung carcinoma" ], "LESTAURTINIB": [ "acute myeloid leukemia by FAB classification" ], "PRALSETINIB": [ "medullary thyroid gland carcinoma", "non-small cell lung carcinoma" ], "QUIZARTINIB": [ "acute myeloid leukemia by FAB classification" ], "REGORAFENIB": [ "colorectal cancer", "metastatic colorectal cancer", "colorectal neoplasm" ], "SELPERCATINIB": [ "medullary thyroid gland carcinoma", "non-small cell lung carcinoma", "thyroid cancer", "thyroid tumor" ], "SORAFENIB": [ "renal cell carcinoma", "thyroid gland carcinoma", "hepatocellular carcinoma" ], "SUNITINIB": [ "gastrointestinal stromal tumor", "renal cell carcinoma", "neuroendocrine neoplasm" ], "SUNITINIB MALATE": [ "renal cell carcinoma", "gastrointestinal stromal tumor", "neuroendocrine neoplasm" ], "VANDETANIB": [ "thyroid gland carcinoma", "medullary thyroid gland carcinoma", "thyroid tumor" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "High-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Advanced Clinical" } ] }, { "symbol": "ERBB2", "ensembl": "ENSG00000141736", "n_drug_entries": 48, "n_distinct_drugs": 45, "drugs": { "AC-480": "PHASE_2", "AEE-788": "PHASE_1_2", "AFATINIB": "APPROVAL", "AFATINIB DIMALEATE": "APPROVAL", "ALLITINIB": "PHASE_1", "ANVATABART OPADOTIN": "PHASE_2_3", "AV-412": "PHASE_1", "BMS-690514": "PHASE_2", "CANERTINIB": "PHASE_2", "CP-724714": "PHASE_2", "CUDC-101": "PHASE_1", "DACOMITINIB": "APPROVAL", "DISITAMAB VEDOTIN": "PHASE_3", "ERTUMAXOMAB": "PHASE_2", "GANCOTAMAB": "PHASE_2_3", "HEMAY-022": "PHASE_3", "JNJ-26483327": "PHASE_1", "KBP5209": "PHASE_1", "KN-026": "PHASE_3", "LAPATINIB": "APPROVAL", "LAPATINIB DITOSYLATE": "APPROVAL", "MARGETUXIMAB": "APPROVAL", "MASOPROCOL": "APPROVAL", "MM-111": "PHASE_2", "MUBRITINIB": "PHASE_1", "NERATINIB": "APPROVAL", "PERTUZUMAB": "APPROVAL", "POZIOTINIB": "PHASE_3", "PYROTINIB": "PHASE_3", "S-222611": "PHASE_1", "SAPITINIB": "PHASE_2", "TAK-285": "PHASE_1", "TARLOXOTINIB": "PHASE_2", "TESEVATINIB": "PHASE_3", "TRASTUZUMAB": "APPROVAL", "TRASTUZUMAB BOTIDOTIN": "PHASE_3", "TRASTUZUMAB DERUXTECAN": "APPROVAL", "TRASTUZUMAB DUOCARMAZINE": "APPROVAL", "TRASTUZUMAB EMTANSINE": "APPROVAL", "TUCATINIB": "APPROVAL", "TUXOBERTINIB": "PHASE_1_2", "VANDETANIB": "APPROVAL", "VARLITINIB": "PHASE_2_3", "ZANIDATAMAB": "APPROVAL", "ZENOCUTUZUMAB": "APPROVAL" }, "approved": [ "AFATINIB", "AFATINIB DIMALEATE", "DACOMITINIB", "LAPATINIB", "LAPATINIB DITOSYLATE", "MARGETUXIMAB", "MASOPROCOL", "NERATINIB", "PERTUZUMAB", "TRASTUZUMAB", "TRASTUZUMAB DERUXTECAN", "TRASTUZUMAB DUOCARMAZINE", "TRASTUZUMAB EMTANSINE", "TUCATINIB", "VANDETANIB", "ZANIDATAMAB", "ZENOCUTUZUMAB" ], "n_approved": 17, "approved_for": { "AFATINIB": [ "non-small cell lung carcinoma" ], "AFATINIB DIMALEATE": [ "non-small cell lung carcinoma" ], "DACOMITINIB": [ "non-small cell lung carcinoma" ], "LAPATINIB": [ "breast cancer" ], "LAPATINIB DITOSYLATE": [ "breast cancer", "breast neoplasm", "breast carcinoma" ], "MARGETUXIMAB": [ "HER2 positive breast carcinoma", "breast cancer" ], "MASOPROCOL": [ "prostate cancer" ], "NERATINIB": [ "breast cancer", "breast neoplasm", "breast carcinoma" ], "PERTUZUMAB": [ "breast cancer", "breast carcinoma", "breast neoplasm" ], "TRASTUZUMAB": [ "breast cancer", "breast carcinoma", "gastric cancer", "gastric neoplasm", "breast neoplasm" ], "TRASTUZUMAB DERUXTECAN": [ "breast cancer", "HER2 positive breast carcinoma", "breast neoplasm" ], "TRASTUZUMAB DUOCARMAZINE": [], "TRASTUZUMAB EMTANSINE": [ "breast cancer", "breast carcinoma", "breast neoplasm" ], "TUCATINIB": [ "HER2 positive breast carcinoma", "metastasis", "breast neoplasm", "breast cancer", "colorectal carcinoma", "breast carcinoma" ], "VANDETANIB": [ "thyroid gland carcinoma", "medullary thyroid gland carcinoma", "thyroid tumor" ], "ZANIDATAMAB": [ "biliary tract neoplasm" ], "ZENOCUTUZUMAB": [ "non-small cell lung carcinoma", "pancreatic neoplasm" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "High-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "Approved Drug" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "AB", "bucket": "Human Protein Atlas loc" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Approved Drug" } ] }, { "symbol": "NTRK1", "ensembl": "ENSG00000198400", "n_drug_entries": 17, "n_distinct_drugs": 16, "drugs": { "ALTIRATINIB": "PHASE_1", "AZD-6918": "PHASE_1", "AZD-7451": "PHASE_1", "CENEGERMIN": "APPROVAL", "CEP-2563": "PHASE_1", "ENTRECTINIB": "APPROVAL", "GZ-389988": "PHASE_2", "LAROTRECTINIB": "APPROVAL", "LESTAURTINIB": "APPROVAL", "MILCICLIB": "PHASE_2", "PEGCANTRATINIB": "PHASE_2", "PLX-7486": "PHASE_1", "REGORAFENIB": "APPROVAL", "REPOTRECTINIB": "APPROVAL", "SELITRECTINIB": "PHASE_1", "TALETRECTINIB": "PHASE_3" }, "approved": [ "CENEGERMIN", "ENTRECTINIB", "LAROTRECTINIB", "LESTAURTINIB", "REGORAFENIB", "REPOTRECTINIB" ], "n_approved": 6, "approved_for": { "CENEGERMIN": [ "keratitis", "eye disorder" ], "ENTRECTINIB": [ "non-small cell lung carcinoma" ], "LAROTRECTINIB": [ "metastasis" ], "LESTAURTINIB": [ "acute myeloid leukemia by FAB classification" ], "REGORAFENIB": [ "colorectal cancer", "metastatic colorectal cancer", "colorectal neoplasm" ], "REPOTRECTINIB": [ "non-small cell lung carcinoma" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "High-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Approved Drug" } ] }, { "symbol": "TP53", "ensembl": "ENSG00000141510", "n_drug_entries": 9, "n_distinct_drugs": 8, "drugs": { "ALRIZOMADLIN": "PHASE_2", "CENERSEN": "PHASE_2", "CONTUSUGENE LADENOVEC": "PHASE_3", "EPRENETAPOPT": "PHASE_3", "IDASANUTLIN": "PHASE_3", "NAVTEMADLIN": "PHASE_3", "SIREMADLIN": "PHASE_2", "TEPRASIRAN": "PHASE_3" }, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "Advanced Clinical" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Med-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Advanced Clinical" } ] }, { "symbol": "STK11", "ensembl": "ENSG00000118046", "n_drug_entries": 0, "n_distinct_drugs": 0, "drugs": {}, "approved": [], "n_approved": 0, "approved_for": {}, "tractability": [ { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Med-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "KEAP1", "ensembl": "ENSG00000079999", "n_drug_entries": 4, "n_distinct_drugs": 4, "drugs": { "BARDOXOLONE METHYL": "PHASE_3", "DIMETHYL": "APPROVAL", "DIROXIMEL": "APPROVAL", "MONOMETHYL": "APPROVAL" }, "approved": [ "DIMETHYL", "DIROXIMEL", "MONOMETHYL" ], "n_approved": 3, "approved_for": { "DIMETHYL": [ "multiple sclerosis", "psoriasis", "relapsing-remitting multiple sclerosis", "immune system disorder" ], "DIROXIMEL": [ "multiple sclerosis", "relapsing-remitting multiple sclerosis", "immune system disorder" ], "MONOMETHYL": [ "multiple sclerosis" ] }, "tractability": [ { "modality": "SM", "bucket": "Approved Drug" }, { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "High-Quality Pocket" }, { "modality": "SM", "bucket": "Druggable Family" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Database Ubiquitination" }, { "modality": "PR", "bucket": "Half-life Data" }, { "modality": "PR", "bucket": "Small Molecule Binder" } ] }, { "symbol": "CD274", "ensembl": "ENSG00000120217", "n_drug_entries": 13, "n_distinct_drugs": 13, "drugs": { "ADEBRELIMAB": "PHASE_3", "ATEZOLIZUMAB": "APPROVAL", "AVELUMAB": "APPROVAL", "BINTRAFUSP ALFA": "PHASE_3", "COSIBELIMAB": "APPROVAL", "DANBURSTOTUG": "PHASE_2", "DURVALUMAB": "APPROVAL", "ENVAFOLIMAB": "PHASE_3", "ERFONRILIMAB": "PHASE_3", "INCB-086550": "PHASE_2", "PACMILIMAB": "PHASE_2", "SOCAZOLIMAB": "PHASE_3", "SUGEMALIMAB": "APPROVAL" }, "approved": [ "ATEZOLIZUMAB", "AVELUMAB", "COSIBELIMAB", "DURVALUMAB", "SUGEMALIMAB" ], "n_approved": 5, "approved_for": { "ATEZOLIZUMAB": [ "urothelial carcinoma", "non-small cell lung carcinoma", "breast cancer", "small cell lung carcinoma", "breast neoplasm", "transitional cell carcinoma" ], "AVELUMAB": [ "Merkel cell skin cancer", "urothelial carcinoma", "neuroendocrine neoplasm" ], "COSIBELIMAB": [ "head and neck squamous cell carcinoma" ], "DURVALUMAB": [ "non-small cell lung carcinoma", "small cell lung carcinoma", "urothelial carcinoma", "hepatocellular carcinoma" ], "SUGEMALIMAB": [ "non-small cell lung carcinoma" ] }, "tractability": [ { "modality": "SM", "bucket": "Structure with Ligand" }, { "modality": "SM", "bucket": "High-Quality Ligand" }, { "modality": "SM", "bucket": "Med-Quality Pocket" }, { "modality": "AB", "bucket": "Approved Drug" }, { "modality": "AB", "bucket": "UniProt loc high conf" }, { "modality": "AB", "bucket": "GO CC high conf" }, { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "PR", "bucket": "Literature" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "PR", "bucket": "Small Molecule Binder" }, { "modality": "OC", "bucket": "Advanced Clinical" } ] }, { "symbol": "DLL3", "ensembl": "ENSG00000090932", "n_drug_entries": 2, "n_distinct_drugs": 2, "drugs": { "ROVALPITUZUMAB TESIRINE": "PHASE_3", "TARLATAMAB": "APPROVAL" }, "approved": [ "TARLATAMAB" ], "n_approved": 1, "approved_for": { "TARLATAMAB": [ "small cell lung carcinoma" ] }, "tractability": [ { "modality": "AB", "bucket": "UniProt SigP or TMHMM" }, { "modality": "AB", "bucket": "GO CC med conf" }, { "modality": "AB", "bucket": "Human Protein Atlas loc" }, { "modality": "PR", "bucket": "UniProt Ubiquitination" }, { "modality": "OC", "bucket": "Advanced Clinical" } ] } ], "trials": { "by_antigen": { "PD-L1": { "n": 574, "n_observational": 85, "n_active": 273, "n_withdrawn": 21, "trials": [ { "nct": "NCT03556228", "title": "VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma", "status": "RECRUITING", "last_update": "2025-12-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04105270", "title": "RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial", "status": "RECRUITING", "last_update": "2025-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04165070", "title": "KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-na\u00efve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)", "status": "RECRUITING", "last_update": "2026-08-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04253964", "title": "Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy", "status": "RECRUITING", "last_update": "2026-08-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04273061", "title": "Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity", "status": "RECRUITING", "last_update": "2025-09-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04302025", "title": "A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04467723", "title": "Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC", "status": "RECRUITING", "last_update": "2026-01-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04539977", "title": "PD-L1 Antibody (TQB2450) Plus Chemotherapy for Previously Untreated Limited- Stage Small-cell Lung Cancer", "status": "RECRUITING", "last_update": "2023-05-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04550104", "title": "A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC", "status": "RECRUITING", "last_update": "2025-12-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04585490", "title": "Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC", "status": "RECRUITING", "last_update": "2026-05-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04686305", "title": "Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04865250", "title": "Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC", "status": "RECRUITING", "last_update": "2024-05-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04892953", "title": "Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04919382", "title": "Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-04-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04951947", "title": "JS-201 Combined With Lenvatinib in the Treatment of Small-cell Lung Cancer", "status": "RECRUITING", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04992780", "title": "Comparing Hypo-fractionated Intensity- Modulated Radiation Therapy to Standard- Fractionated IMRT Along With Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2023-12-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04996017", "title": "Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)", "status": "RECRUITING", "last_update": "2025-03-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05039632", "title": "Phase I/II Randomized Study of NBTXR3 Activated by Abscopal or RadScopal Radiation in Combination With Immunotherapy (Anti-PD-1/L-1) for Patients With Advanced Solid Malignancies", "status": "RECRUITING", "last_update": "2026-07-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05068232", "title": "Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)", "status": "RECRUITING", "last_update": "2026-03-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05136846", "title": "Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-06-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05142189", "title": "Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-07-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05284539", "title": "Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer", "status": "RECRUITING", "last_update": "2024-06-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05317858", "title": "Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets", "status": "RECRUITING", "last_update": "2026-08-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05344209", "title": "Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2023-11-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05431270", "title": "Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)", "status": "RECRUITING", "last_update": "2026-05-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05501665", "title": "Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer", "status": "RECRUITING", "last_update": "2024-10-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05568212", "title": "Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab", "status": "RECRUITING", "last_update": "2025-12-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05624996", "title": "Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05632809", "title": "REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)", "status": "RECRUITING", "last_update": "2026-07-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05652686", "title": "A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)", "status": "RECRUITING", "last_update": "2026-07-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05696782", "title": "Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-07-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05703971", "title": "Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05718323", "title": "Niraparib Added to Anti-PD-L1 Antibody Maintenance in SLFN11-positive, Extensive-disease SCLC", "status": "RECRUITING", "last_update": "2026-05-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05751798", "title": "Dose-finding and Dose Expansion Study of OSE-279 in Subjects With Advanced Solid Tumors or Lymphomas", "status": "RECRUITING", "last_update": "2026-06-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05754203", "title": "Efficacy and Safety of Super-hyperfractionation Pulse Radiotherapy Combined With ICIs for Advanced NSCLC", "status": "RECRUITING", "last_update": "2025-07-14", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05765084", "title": "Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma", "status": "RECRUITING", "last_update": "2026-06-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05886439", "title": "LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer", "status": "RECRUITING", "last_update": "2025-12-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05913089", "title": "A Clinical Study of TQB2450 Injection Combined With Chemotherapy or Anlotinib Hydrochloride Capsule in the Treatment of Non Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2023-06-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05920356", "title": "A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05937906", "title": "Clinical Trial Evaluating the Safety and Efficacy of Chemoimmunotherapy Plus Short Course of Mek Inhibitor in First Line of Treatment of Metastatic Non Squamous Non Small Cell Lung Adenocarcinoma With PDL1 < 50 %.", "status": "RECRUITING", "last_update": "2026-07-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05944237", "title": "HTL0039732 in Participants With Advanced Solid Tumours", "status": "RECRUITING", "last_update": "2025-06-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06066138", "title": "A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06088771", "title": "Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC", "status": "RECRUITING", "last_update": "2026-07-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06090266", "title": "A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents", "status": "RECRUITING", "last_update": "2025-01-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06102057", "title": "PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC", "status": "RECRUITING", "last_update": "2025-12-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06110572", "title": "Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation", "status": "RECRUITING", "last_update": "2024-06-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06141226", "title": "Phase II Clinical Trial to Evaluate the Safety and Efficacy of TQB2450 Injection Combined With Anlotinib Capsule and Chemotherapy in the Treatment of Immunoresistant Advanced Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06170788", "title": "Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) \u2265 50% (MK-2870-007)", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06171750", "title": "Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-03-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06223711", "title": "Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC", "status": "RECRUITING", "last_update": "2024-04-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06228066", "title": "Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)", "status": "RECRUITING", "last_update": "2026-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06284317", "title": "A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.", "status": "RECRUITING", "last_update": "2026-05-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06287775", "title": "Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06332755", "title": "Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC", "status": "RECRUITING", "last_update": "2025-11-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06345729", "title": "A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) \u226550% (MK-1084-004/KANDLELIT-004)", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06362252", "title": "A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)", "status": "RECRUITING", "last_update": "2026-02-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06371482", "title": "Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01)", "status": "RECRUITING", "last_update": "2024-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06388031", "title": "ICI Rechallenge for Advanced NSCLC With Long-Term Response to First-Line ICI", "status": "RECRUITING", "last_update": "2024-11-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06444815", "title": "A Study of VET3-TGI in Patients With Solid Tumors", "status": "RECRUITING", "last_update": "2026-04-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06449313", "title": "Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features", "status": "RECRUITING", "last_update": "2026-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06463665", "title": "Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer", "status": "RECRUITING", "last_update": "2026-06-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06475209", "title": "Adebrelimab + Apatinib in SCLC Maintenance Therapy", "status": "RECRUITING", "last_update": "2024-06-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06492421", "title": "Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.", "status": "RECRUITING", "last_update": "2024-07-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06492954", "title": "Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma", "status": "RECRUITING", "last_update": "2026-06-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06498635", "title": "Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06562920", "title": "Adebrelimab Combined With Chemotherapy and Concurrent SBRT for Neoadjuvant Treatment of Limited-stage Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2024-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06610734", "title": "Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined With Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC)", "status": "RECRUITING", "last_update": "2026-02-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06616584", "title": "Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)", "status": "RECRUITING", "last_update": "2026-05-05", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06616623", "title": "Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-02-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06623422", "title": "A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)", "status": "RECRUITING", "last_update": "2026-08-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06623656", "title": "Preoperative Radioimmunotherapy Versus Chemoimmunotherapy in NSCLC", "status": "RECRUITING", "last_update": "2026-04-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06646276", "title": "A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06656598", "title": "Adjuvant Chemotherapy +/- Cemiplimab and Sequential Hypofractionated Radiotherapy in Unfit or Elderly Patients With Stage III Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06680050", "title": "Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen", "status": "RECRUITING", "last_update": "2025-12-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06692738", "title": "A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)", "status": "RECRUITING", "last_update": "2026-08-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06712316", "title": "Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06712355", "title": "Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-09-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06731270", "title": "Diclofenac for the Treatment of Patients With Metastatic Non-small Cell Lung Cancer on Single Agent Immunotherapy", "status": "RECRUITING", "last_update": "2026-02-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06743581", "title": "Study of Neoadjuvant Cemiplimab and Dupilumab in Early-Stage Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-17", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06768307", "title": "Assessment of Adebelizumab Combined With Chemotherapy in Concurrent Radiotherapy Versus Sequential Radiotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06769126", "title": "Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study", "status": "RECRUITING", "last_update": "2026-03-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06773910", "title": "BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)", "status": "RECRUITING", "last_update": "2026-08-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06780085", "title": "A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)", "status": "RECRUITING", "last_update": "2026-08-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06788912", "title": "Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)", "status": "RECRUITING", "last_update": "2026-09-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06807632", "title": "A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06810609", "title": "Immunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA/B NSCLC", "status": "RECRUITING", "last_update": "2026-01-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06840782", "title": "First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.", "status": "RECRUITING", "last_update": "2025-09-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06841055", "title": "Safety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Chemotherapy as First-line or Second-line Treatment", "status": "RECRUITING", "last_update": "2026-04-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06865339", "title": "Thoracic Radiotherapy and Inhibition of PD-1 and LAG-3 for Locally Advanced Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06868277", "title": "A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06892548", "title": "A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06907615", "title": "A Phase II Clinical Study to Evaluate HLX43 in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC)", "status": "RECRUITING", "last_update": "2025-08-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06908304", "title": "A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC", "status": "RECRUITING", "last_update": "2026-01-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06917573", "title": "PALACE: Cemiplimab Trial According to ctDNA Levels", "status": "RECRUITING", "last_update": "2025-11-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06918132", "title": "Cemiplimab and Fianlimab Before Surgery for the Treatment of Stage IB-IIIB Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-02-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06923761", "title": "EMITT-1 (ERAP Mediated Immunopeptidome Targeting Trial - 1)", "status": "RECRUITING", "last_update": "2026-01-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06931717", "title": "A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Received Prior Chemotherapy", "status": "RECRUITING", "last_update": "2026-07-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06996782", "title": "A Platform Study in Non-Small Cell Lung Cancer (NSCLC)", "status": "RECRUITING", "last_update": "2026-07-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07001618", "title": "Oral Pooled Fecal Microbiotherapy (MaaT033) Concomitant to Cemiplimab Versus Best Investigator's Choice in Patients With Resistance to Treatment Due to Antibiotics Uptake With Advanced Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-04-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07020065", "title": "Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50%", "status": "RECRUITING", "last_update": "2026-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07034391", "title": "A Study Evaluating the Efficacy of PD-1 Inhibitor Combined With Denosumab and Chemotherapy in Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Patients With Driver Gene-Negative Status", "status": "RECRUITING", "last_update": "2025-06-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07070232", "title": "A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07071103", "title": "Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid Tumors", "status": "RECRUITING", "last_update": "2025-11-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07098338", "title": "A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)", "status": "RECRUITING", "last_update": "2026-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07111520", "title": "A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)", "status": "RECRUITING", "last_update": "2026-08-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07113691", "title": "Iadademstat + SBRT With Atezo in ES-SCLC", "status": "RECRUITING", "last_update": "2026-03-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07130032", "title": "Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade", "status": "RECRUITING", "last_update": "2025-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07153445", "title": "Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC)", "status": "RECRUITING", "last_update": "2025-11-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07155174", "title": "A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07171606", "title": "A Phase II Study of SSGJ-706 Monotherapy and Combination Therapy in Advanced Non-Small Cell Lung Cancer\uff08NSCLC\uff09 Patients", "status": "RECRUITING", "last_update": "2025-12-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07174583", "title": "A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-07-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07195695", "title": "Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07217301", "title": "A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07224971", "title": "Impact of Circadian Rhythm on Immunotherapy", "status": "RECRUITING", "last_update": "2025-12-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07226999", "title": "Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-17", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07227597", "title": "A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)", "status": "RECRUITING", "last_update": "2026-08-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07234058", "title": "Trial Assessing Fianlimab Plus Cemiplimab Plus Chemotherapy or Cemiplimab Plus Chemotherapy in Patients With Pleural Mesothelioma", "status": "RECRUITING", "last_update": "2026-08-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07250477", "title": "Risk-adapted, Proteomic-guided Systemic Therapy for Previously Untreated Advanced Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07252739", "title": "KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07264647", "title": "Neoadjuvant Chemo-immunotherapy for Stage III PD-L1 Positive Non-Small Cell Lung Cancer (NSCLC)", "status": "RECRUITING", "last_update": "2025-12-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07288034", "title": "Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial", "status": "RECRUITING", "last_update": "2026-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07322341", "title": "SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07339059", "title": "Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-07-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07361510", "title": "A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 \u2265 50%. (ROSETTA Lung-202)", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07388524", "title": "Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07391670", "title": "A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab", "status": "RECRUITING", "last_update": "2026-08-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07472517", "title": "DAREON \u00ae -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy", "status": "RECRUITING", "last_update": "2026-08-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07531095", "title": "Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)", "status": "RECRUITING", "last_update": "2026-08-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07545954", "title": "DSP-0390 in Combination With Atezolizumab for Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07554339", "title": "A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07603856", "title": "A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-06-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07632365", "title": "Induction Chemoimmunotherapy in Combination With Chemoradiotherapy and Consolidation Immunotherapy in Unresectable Locally Advanced Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-07-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07654400", "title": "A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07744698", "title": "Metronomic Oral Paclitaxel Plus PD-1/ PD-L1 Inhibitor Maintenance in Advanced Lung Cancer (PULSE Study)", "status": "RECRUITING", "last_update": "2026-08-04", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07759856", "title": "NK Cells Plus ICI for SCLC Maintenance", "status": "RECRUITING", "last_update": "2026-08-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01295827", "title": "Study of Pembrolizumab (MK-3475) in Participants With Progressive Locally Advanced or Metastatic Carcinoma, Melanoma, or Non-small Cell Lung Carcinoma (P07990/MK-3475-001/KEYNOTE-001)", "status": "COMPLETED", "last_update": "2019-12-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01772004", "title": "Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)", "status": "COMPLETED", "last_update": "2021-12-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01846416", "title": "A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]", "status": "COMPLETED", "last_update": "2019-01-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01905657", "title": "Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010)", "status": "COMPLETED", "last_update": "2021-10-06", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01993810", "title": "Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02000947", "title": "A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2019-10-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02031458", "title": "A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2020-01-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02087423", "title": "A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-04-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02088112", "title": "MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).", "status": "COMPLETED", "last_update": "2022-04-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02142738", "title": "Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)", "status": "COMPLETED", "last_update": "2022-06-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02220894", "title": "Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)", "status": "COMPLETED", "last_update": "2026-06-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02264678", "title": "Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02314481", "title": "Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity", "status": "COMPLETED", "last_update": "2026-05-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02366143", "title": "A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2021-09-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02367794", "title": "A Study of Atezolizumab in Combination With Carboplatin + Paclitaxel or Carboplatin + Nab-Paclitaxel Compared With Carboplatin + Nab-Paclitaxel in Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower131]", "status": "COMPLETED", "last_update": "2022-03-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02403193", "title": "Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2022-01-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02409342", "title": "A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]", "status": "COMPLETED", "last_update": "2023-03-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02409355", "title": "A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111)", "status": "TERMINATED", "last_update": "2019-02-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02452463", "title": "Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy", "status": "TERMINATED", "last_update": "2020-04-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02453282", "title": "Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02454933", "title": "Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours", "status": "COMPLETED", "last_update": "2024-09-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02484404", "title": "Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02492867", "title": "A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2024-09-03", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02495636", "title": "Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2017-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02525757", "title": "MPDL3280A With Chemoradiation for Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02542293", "title": "Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02543645", "title": "A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer", "status": "TERMINATED", "last_update": "2018-04-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02554812", "title": "A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)", "status": "TERMINATED", "last_update": "2024-07-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02572687", "title": "A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies", "status": "COMPLETED", "last_update": "2021-01-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02572843", "title": "Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2025-10-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02576574", "title": "Avelumab in First-line NSCLC (JAVELIN Lung 100)", "status": "COMPLETED", "last_update": "2025-01-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02599454", "title": "Atezolizumab and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2025-10-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02628067", "title": "Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02630186", "title": "A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC", "status": "TERMINATED", "last_update": "2019-07-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02657434", "title": "A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)", "status": "COMPLETED", "last_update": "2023-11-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02658214", "title": "Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2020-08-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02664935", "title": "National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-04-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02669914", "title": "MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors", "status": "TERMINATED", "last_update": "2018-11-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02673814", "title": "Phase 2 Trial of Durvalumab With or Without Bavituximab in Patients With Previously Treated Metastatic Non-small-cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2016-08-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02701400", "title": "Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2021-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02740985", "title": "A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies", "status": "COMPLETED", "last_update": "2023-05-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02748889", "title": "Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2018-07-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02763579", "title": "A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)", "status": "COMPLETED", "last_update": "2023-07-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02766335", "title": "Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers", "status": "COMPLETED", "last_update": "2023-05-25", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02775435", "title": "A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)", "status": "COMPLETED", "last_update": "2024-10-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02805660", "title": "Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC", "status": "TERMINATED", "last_update": "2021-04-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02813785", "title": "A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing Chemotherapy", "status": "COMPLETED", "last_update": "2023-01-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02848651", "title": "A Study of Atezolizumab as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2020-04-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02862457", "title": "Study of Epacadostat (INCB024360) Alone and In Combination With Pembrolizumab (MK-3475) With Chemotherapy and Pembrolizumab Without Chemotherapy in Participants With Advanced Solid Tumors (MK-3475-434)", "status": "COMPLETED", "last_update": "2022-08-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02864394", "title": "Study of Pembrolizumab Versus Docetaxel in Participants Previously Treated for Non-Small Cell Lung Cancer (MK-3475-033/KEYNOTE-033)", "status": "COMPLETED", "last_update": "2024-09-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02869685", "title": "Consistency Analysis of PD-L1s in Advanced NSCLC Tissues and in Plasma Exosomes Before and After Radiotherapy", "status": "COMPLETED", "last_update": "2024-02-23", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02876510", "title": "ACTolog in Patients With Solid Cancers", "status": "COMPLETED", "last_update": "2025-02-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02879617", "title": "A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients", "status": "COMPLETED", "last_update": "2024-01-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02888743", "title": "Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02898116", "title": "Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2022-10-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02899195", "title": "Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma", "status": "COMPLETED", "last_update": "2023-07-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02903914", "title": "Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors", "status": "COMPLETED", "last_update": "2025-08-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02904954", "title": "Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2023-10-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02919449", "title": "Dose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus in Combination With Atezolizumab", "status": "TERMINATED", "last_update": "2023-07-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02927301", "title": "A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3)", "status": "COMPLETED", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02937818", "title": "A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer", "status": "COMPLETED", "last_update": "2024-06-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02952989", "title": "A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2019-07-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02973789", "title": "Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)", "status": "COMPLETED", "last_update": "2026-03-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02978196", "title": "99mTc/68Ga Labeled Anti-PD-L1 sdAb in Assessment of PD-L1 Expression in NSCLC", "status": "COMPLETED", "last_update": "2024-05-17", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02983578", "title": "Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02992912", "title": "Atezolizumab With Stereotactic Ablative Radiotherapy in Patients With Metastatic Tumours", "status": "COMPLETED", "last_update": "2026-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02994576", "title": "Atezolizumab as Induction Therapy in Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-08-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03022500", "title": "Pulmonary sarcomatoid_MEDI4736+Treme", "status": "COMPLETED", "last_update": "2024-05-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03023423", "title": "A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2019-11-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03030131", "title": "Immune Neoadjuvant Therapy Study of Durvalumab in Early Stage Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2023-03-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03043872", "title": "Durvalumab \u00b1 Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03050060", "title": "Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer", "status": "TERMINATED", "last_update": "2022-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03050554", "title": "SBRT Combined With Avelumab (Anti-PD-L1) for Management of Early Stage Non-Small Cell Lung Cancer (NSCLC)", "status": "TERMINATED", "last_update": "2024-08-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03057106", "title": "Durvalumab and Tremelimumab \u00b1 Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03066778", "title": "A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)", "status": "COMPLETED", "last_update": "2022-10-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03083808", "title": "Phase II Trial of Continuation Therapy in Advanced NSCLC", "status": "COMPLETED", "last_update": "2023-08-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03088540", "title": "Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2026-06-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03102242", "title": "Atezolizumab Immunotherapy in Patients With Advanced NSCLC", "status": "COMPLETED", "last_update": "2023-05-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03134872", "title": "A Study of SHR-1210 in Combination With Pemetrexed and Carboplatin in Subjects With Non-squamous NSCLC", "status": "COMPLETED", "last_update": "2020-06-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03141359", "title": "Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03158883", "title": "UCDCC#270: Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients", "status": "COMPLETED", "last_update": "2021-10-20", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03169738", "title": "QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors", "status": "WITHDRAWN", "last_update": "2025-02-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03170960", "title": "Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03176173", "title": "Radical RADiotherapy and Immunotherapy for Metastatic CAncer of the Lung (RRADICAL)", "status": "COMPLETED", "last_update": "2025-11-05", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03191786", "title": "A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Na\u00efve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy", "status": "COMPLETED", "last_update": "2024-10-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03212469", "title": "A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer", "status": "COMPLETED", "last_update": "2025-05-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03237377", "title": "Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2026-05-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03241173", "title": "A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies", "status": "COMPLETED", "last_update": "2022-09-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03262454", "title": "Sequential Hypofractionated Radiotherapy Followed by Anti-PD-L1 Atezolizumab for SCLC", "status": "UNKNOWN", "last_update": "2022-04-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03275597", "title": "Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition", "status": "TERMINATED", "last_update": "2023-05-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03285763", "title": "A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2025-01-23", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03289962", "title": "A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors", "status": "COMPLETED", "last_update": "2026-06-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03308942", "title": "Effects of Single Agent Niraparib and Niraparib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Non-Small Cell Lung Cancer Participants", "status": "COMPLETED", "last_update": "2023-10-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03313804", "title": "Priming Immunotherapy in Advanced Disease With Radiation", "status": "COMPLETED", "last_update": "2026-03-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03322540", "title": "Pembrolizumab Plus Epacadostat vs Pembrolizumab Plus Placebo in Metastatic Non-Small Cell Lung Cancer (KEYNOTE-654-05/ECHO-305-05)", "status": "COMPLETED", "last_update": "2025-08-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03334617", "title": "Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03345810", "title": "Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)", "status": "COMPLETED", "last_update": "2023-06-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03365791", "title": "PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies", "status": "COMPLETED", "last_update": "2022-05-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03367819", "title": "Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies", "status": "TERMINATED", "last_update": "2022-05-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03373760", "title": "Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer", "status": "COMPLETED", "last_update": "2023-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03380871", "title": "A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer", "status": "COMPLETED", "last_update": "2021-02-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03382912", "title": "Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2020-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03409614", "title": "Combinations of Cemiplimab (Anti-PD-1 Antibody) and Platinum-based Doublet Chemotherapy in Patients With Lung Cancer", "status": "COMPLETED", "last_update": "2026-05-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03412058", "title": "Identifying the Predictive Factors of Response to PD-1 or PD-L1 Antagonists", "status": "TERMINATED", "last_update": "2026-08-03", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03417882", "title": "GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLC", "status": "TERMINATED", "last_update": "2023-08-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03419559", "title": "Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2019-04-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03421353", "title": "AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer", "status": "COMPLETED", "last_update": "2024-08-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03425006", "title": "Pembrolizumab and Itacitinib (INCB039110) for Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2023-09-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03430063", "title": "A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer", "status": "TERMINATED", "last_update": "2022-11-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03438318", "title": "Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2022-08-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03446547", "title": "Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736)", "status": "COMPLETED", "last_update": "2026-04-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03447678", "title": "Pembrolizumab in First Line Treatment of Advanced NSCLC Patients With PD-L1 Low Tumors.", "status": "UNKNOWN", "last_update": "2021-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03468426", "title": "A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours", "status": "COMPLETED", "last_update": "2025-11-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03469960", "title": "Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr", "status": "COMPLETED", "last_update": "2025-11-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03509012", "title": "Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2025-01-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03511391", "title": "CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors", "status": "COMPLETED", "last_update": "2024-01-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03515629", "title": "REGN2810 (Anti-PD-1 Antibody), Platinum-based Doublet Chemotherapy, and Ipilimumab (Anti-CTLA-4 Antibody) Versus Pembrolizumab Monotherapy in Patients With Lung Cancer", "status": "TERMINATED", "last_update": "2022-11-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03516981", "title": "A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495/KEYNOTE-495)", "status": "COMPLETED", "last_update": "2026-06-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03523702", "title": "The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial", "status": "COMPLETED", "last_update": "2026-04-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03526900", "title": "Atezolizumab in Combination With Carboplatin Plus Pemetrexed in Chemotherapy-na\u00efve Patients With Asymptomatic Brain Metastasis", "status": "COMPLETED", "last_update": "2024-10-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03540420", "title": "Atezolizumab After Concurrent Chemo-radiotherapy Versus Chemo-radiotherapy Alone in Limited Disease Small-cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03544723", "title": "Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.", "status": "UNKNOWN", "last_update": "2020-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03549000", "title": "A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.", "status": "TERMINATED", "last_update": "2024-12-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03574402", "title": "Phase II Umbrella Study Directed by Next Generation Sequencing", "status": "UNKNOWN", "last_update": "2022-12-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03580694", "title": "Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)", "status": "TERMINATED", "last_update": "2020-03-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03581487", "title": "Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-07-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03585998", "title": "Chemoradiation With Durvalumab Followed by Durvalumab Maintenance for Limited Disease Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2020-03-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03589547", "title": "Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung", "status": "COMPLETED", "last_update": "2026-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03620669", "title": "1st Line Durvalumab in PS 2 NSCLC Patients", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03631199", "title": "Study of Efficacy and Safety of Pembrolizumab Plus Platinum-based Doublet Chemotherapy With or Without Canakinumab in Previously Untreated Locally Advanced or Metastatic Non-squamous and Squamous NSCLC Subjects", "status": "TERMINATED", "last_update": "2026-06-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03631706", "title": "M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2025-04-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03631784", "title": "A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799)", "status": "COMPLETED", "last_update": "2025-03-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03647956", "title": "Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors", "status": "UNKNOWN", "last_update": "2019-04-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03654833", "title": "Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma", "status": "COMPLETED", "last_update": "2026-08-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03664024", "title": "Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782)", "status": "COMPLETED", "last_update": "2024-08-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03673332", "title": "Elderly Cancer PatIents, Safety and qualiTy of Life Under immunOtheraPies", "status": "TERMINATED", "last_update": "2026-01-22", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03689855", "title": "Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC", "status": "COMPLETED", "last_update": "2024-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03703297", "title": "Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03713944", "title": "Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-na\u00efve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2023-03-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03715205", "title": "Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593)", "status": "COMPLETED", "last_update": "2025-08-29", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03732664", "title": "ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer", "status": "COMPLETED", "last_update": "2023-03-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03735121", "title": "A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2025-12-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03775486", "title": "Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03801902", "title": "Testing the Safety of Adding Either Monalizumab (IPH2201) or Oleclumab (MEDI9447) to Durvalumab (MEDI4736) Plus Standard Radiation Therapy for Locally Advanced Non-small Cell Lung Cancer (NSCLC), ARCHON-1 Trial", "status": "COMPLETED", "last_update": "2025-09-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03809624", "title": "Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer", "status": "TERMINATED", "last_update": "2024-10-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03811002", "title": "Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03811652", "title": "A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors", "status": "COMPLETED", "last_update": "2019-12-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03818776", "title": "Proton Based Cardiac Sparing Accelerated Fractionated RadioTherapy in Unresectable NSCLC", "status": "TERMINATED", "last_update": "2024-02-15", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03819465", "title": "A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03829332", "title": "Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-na\u00efve Nonsmall Cell Lung Cancer (NSCLC) (MK-7902-007/E7080-G000-314/LEAP-007)", "status": "COMPLETED", "last_update": "2026-02-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03829501", "title": "A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies", "status": "TERMINATED", "last_update": "2025-04-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03832348", "title": "Dynamics of 18-FDG Uptake in Stage III/IV Non Small Cell Lung Cancer During First Line Pembrolizumab Treatment", "status": "COMPLETED", "last_update": "2026-01-02", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03833154", "title": "Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03833440", "title": "Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance", "status": "UNKNOWN", "last_update": "2024-05-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03836066", "title": "Atezolizumab Plus Bevacizumab in First Line NSCLC Patients", "status": "COMPLETED", "last_update": "2025-12-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03838848", "title": "KN046 in Patients With Advanced Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2023-03-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03850444", "title": "Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)-China Extension Study", "status": "COMPLETED", "last_update": "2023-09-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03853187", "title": "Imaging Tumor-infiltrating T-cells in Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2022-12-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03871153", "title": "Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2023-11-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03875092", "title": "A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)-China Extension Study", "status": "COMPLETED", "last_update": "2024-10-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03896074", "title": "Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients (BEAT)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03915678", "title": "Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03916419", "title": "Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2025-11-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03916627", "title": "Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03922997", "title": "A Study to Investigate the Safety and Efficacy of Atezolizumab in Previously-Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2022-09-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03923270", "title": "Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03924869", "title": "Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or II Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867)", "status": "TERMINATED", "last_update": "2025-12-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03944772", "title": "Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-01-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03950674", "title": "Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study", "status": "COMPLETED", "last_update": "2024-06-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03975114", "title": "A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5)", "status": "UNKNOWN", "last_update": "2023-03-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03976323", "title": "Study of Pembrolizumab With Maintenance Olaparib or Maintenance Pemetrexed in First-line (1L) Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC) (MK-7339-006, KEYLYNK-006)", "status": "COMPLETED", "last_update": "2026-07-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03976362", "title": "A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)", "status": "COMPLETED", "last_update": "2026-02-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03977194", "title": "Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03977467", "title": "Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor", "status": "COMPLETED", "last_update": "2025-08-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03989362", "title": "Vopratelimab and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Subjects With NSCLC or Urothelial Cancer", "status": "COMPLETED", "last_update": "2022-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03991403", "title": "Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC", "status": "UNKNOWN", "last_update": "2023-04-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03994393", "title": "Non Small Cell Lung Cancer Trial of Durvalumab and Tremelimumab in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Disease.", "status": "UNKNOWN", "last_update": "2023-04-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03999710", "title": "Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04003246", "title": "Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2025-03-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04028050", "title": "A Study of Atezolizumab in Combination With Carboplatin Plus Etoposide to Investigate Safety and Efficacy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2024-07-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04042558", "title": "A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies", "status": "COMPLETED", "last_update": "2026-05-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04059887", "title": "Evaluation of Blood TMB for the Efficacy of Atezolizumab [BUDDY]", "status": "COMPLETED", "last_update": "2023-02-08", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04062708", "title": "CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04081688", "title": "Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC", "status": "TERMINATED", "last_update": "2026-02-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04092283", "title": "Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04101357", "title": "Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411", "status": "TERMINATED", "last_update": "2025-03-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04115111", "title": "Diadem to Investigate the Activity and Safety of Durvalumab", "status": "COMPLETED", "last_update": "2023-03-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04116320", "title": "Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-07-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04153734", "title": "Pembrolizumab + Platinum Doublets Without Radiation for Programmed Death-ligand 1 (PD-L1) \u226550% Locally Advanced NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2019-11-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04159025", "title": "EBUS-Miniforceps Biopsy Specimen Acquisition for PD-L1 Testing in Nonsmall Cell Lung Cancer", "status": "COMPLETED", "last_update": "2023-03-01", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04181788", "title": "Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies", "status": "COMPLETED", "last_update": "2026-06-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04203485", "title": "Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)", "status": "UNKNOWN", "last_update": "2020-05-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04214262", "title": "Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04224337", "title": "Phase II Study of Durvalumab ,Doxorubicin, and Ifosfamide in Pulmonary Sarcomatoid Carcinoma", "status": "COMPLETED", "last_update": "2025-12-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04230408", "title": "Intensified Chemo-immuno-radiotherapy With Durvalumab for Stage III Non-Small Cell Lung Cancers", "status": "COMPLETED", "last_update": "2025-02-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04245085", "title": "ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma", "status": "COMPLETED", "last_update": "2026-07-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04245514", "title": "Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04252365", "title": "Sintilimab Versus Pembrolizumab for Advanced-stage Non-Small-Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2020-02-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04253145", "title": "Study to Assess Safety,Tolerability,Efficacy of PM01183 and Atezolizumab in Patients w/ Advanced Small Cell Lung Cancer.", "status": "UNKNOWN", "last_update": "2023-11-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04255836", "title": "Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC)", "status": "UNKNOWN", "last_update": "2020-02-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04262375", "title": "A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION", "status": "WITHDRAWN", "last_update": "2020-11-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04262869", "title": "Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2021-10-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04267237", "title": "A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2021-02-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04287894", "title": "Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the Treatment", "status": "TERMINATED", "last_update": "2024-11-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04291079", "title": "SRK-181 Alone or in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)", "status": "COMPLETED", "last_update": "2025-04-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04310020", "title": "Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04334759", "title": "DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma", "status": "COMPLETED", "last_update": "2026-01-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04348292", "title": "Sirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2024-08-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04356222", "title": "Efficacy and Safety of Durvalumab in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis", "status": "UNKNOWN", "last_update": "2020-05-27", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04361825", "title": "Durvalumab(MEDI4736) and AZD6738 Combination Therapy in Relapsed Small Cell Lung Cancer Subjects", "status": "COMPLETED", "last_update": "2024-01-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04364048", "title": "Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2024-12-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04372927", "title": "ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy", "status": "TERMINATED", "last_update": "2023-06-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04373369", "title": "Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2025-11-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04381494", "title": "Mobile Devices to Detect Early Pneumonitis in Stage III NSCLC Patients on Durvalumab.", "status": "TERMINATED", "last_update": "2023-06-22", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04385368", "title": "Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2024-08-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04402788", "title": "Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial", "status": "SUSPENDED", "last_update": "2026-09-04", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04422210", "title": "A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).", "status": "TERMINATED", "last_update": "2021-11-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04426825", "title": "A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2024-05-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04432207", "title": "A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2026-03-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04441138", "title": "Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLC", "status": "TERMINATED", "last_update": "2025-05-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04442126", "title": "A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-05-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04449861", "title": "Durvalumab Plus Chemotherapy in ES-SCLC (Oriental)", "status": "COMPLETED", "last_update": "2024-11-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04460456", "title": "A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors", "status": "UNKNOWN", "last_update": "2022-06-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04462276", "title": "Thoracic RadiothErapy With Atezolizumab in Small Cell lUng canceR Extensive Disease", "status": "COMPLETED", "last_update": "2025-01-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04465968", "title": "Efficacy and Safety of CRT, Durvalumab and Surgery for SST", "status": "NOT_YET_RECRUITING", "last_update": "2020-07-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04471415", "title": "Study to Investigate DRP-104 in Adults With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-06-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04471428", "title": "Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy", "status": "COMPLETED", "last_update": "2025-12-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04471727", "title": "A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04472949", "title": "Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC).", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04487756", "title": "Combination of Atezolizumab With Dendritic Cell Vaccine in Patients With Lung Cancer", "status": "COMPLETED", "last_update": "2026-07-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04513925", "title": "A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2026-06-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04517526", "title": "Efficacy and Safety of Platinum-based Chemotherapy + Bevacizumab + Durvalumab, and Salvage SBRT for IV Non-Small Cell Lung Cancer Patients With EGFR Mutations After Failure of First Line Osimertinib: A Multicenter, Prospective, Phase II Clinical Study", "status": "UNKNOWN", "last_update": "2020-08-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04525391", "title": "AZD2811 and Durvalumab (MEDI4736) Combination Therapy in Relapsed Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2022-02-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04549428", "title": "Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC", "status": "TERMINATED", "last_update": "2025-11-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04560686", "title": "Bintrafusp Alfa Before Surgery for the Treatment of Untreated Resectable Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2022-07-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04560972", "title": "LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04563338", "title": "An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04585477", "title": "Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)", "status": "SUSPENDED", "last_update": "2026-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04590781", "title": "Safety and Efficacy of XmAb18087 \u00b1 Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2023-04-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04602533", "title": "Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04607954", "title": "Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04610684", "title": "Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases", "status": "TERMINATED", "last_update": "2024-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04622007", "title": "Tomivosertib Combined With Pembrolizumab in Subjects With PD-L1 Positive NSCLC (KICKSTART)", "status": "UNKNOWN", "last_update": "2024-04-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04622228", "title": "Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2024-07-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04624204", "title": "Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Na\u00efve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04631731", "title": "Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity", "status": "UNKNOWN", "last_update": "2023-06-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04636762", "title": "A Study of Concurrent Chemoradiation With Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)", "status": "COMPLETED", "last_update": "2022-06-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04639245", "title": "Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2023-08-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04642469", "title": "Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.", "status": "COMPLETED", "last_update": "2024-06-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04665856", "title": "Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04696939", "title": "Combined Atezolizumab and Chemotherapy (Carboplatin Plus Etoposide) in Neoadjuvant Treating Limited-Stage Small Cell Lung Cancer Patients", "status": "UNKNOWN", "last_update": "2021-01-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04699838", "title": "Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Na\u00efve Patients With Extensive Stage Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04726215", "title": "Imaging of T-cell Activation With [18F]F-AraG in Advanced Non Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2023-09-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04728230", "title": "Olaparib and Durvalumab With Carboplatin, Etoposide, and/or Radiation Therapy for the Treatment of Extensive-Stage Small Cell Lung Cancer, PRIO Trial", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04730999", "title": "Efficacy and Safety Study of a New Therapeutic Strategy in the Treatment of Extended-Disease Small-Cell Lung Cancer", "status": "COMPLETED", "last_update": "2024-07-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04738487", "title": "Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)", "status": "COMPLETED", "last_update": "2026-06-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04745689", "title": "Study of AZD2811 + Durvalumab in ES-SCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04748419", "title": "Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Lung Cancer With Durvalumab", "status": "TERMINATED", "last_update": "2026-06-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04762030", "title": "Neoadjuvant Durvalumab/Anlotinib /Chemotherapy Plus Curative Resection in Stage III Non-Small-Cell Lung Cancer : A Single-arm Phase II Study", "status": "UNKNOWN", "last_update": "2021-02-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04774380", "title": "Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2025-05-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04776447", "title": "Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO)", "status": "COMPLETED", "last_update": "2026-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04786093", "title": "Durvalumab and Stereotactic Radiotherapy for Advanced NSCLC", "status": "TERMINATED", "last_update": "2026-05-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04789668", "title": "Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases", "status": "TERMINATED", "last_update": "2026-03-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04791839", "title": "Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04795713", "title": "Study of MT-6402 in Subjects With Advanced Solid Cancer That Expresses PD-L1", "status": "TERMINATED", "last_update": "2024-11-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04832854", "title": "A Study Evaluating the Safety and Efficacy of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab, With or Without Platinum-Based Chemotherapy, in Participants With Previously Untreated Locally Advanced Resectable Stage II, IIIA, or Select IIIB Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2026-03-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04841538", "title": "A Study of ES101 (PD-L1x4-1BB Bispecific Antibody) in Patients With Advanced Malignant Thoracic Tumors", "status": "WITHDRAWN", "last_update": "2022-04-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04866017", "title": "A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2024-10-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04870112", "title": "A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2025-04-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04881045", "title": "Study to Test the Safety and Tolerability of PF-07257876 in Participants With Selected Advanced Tumors.", "status": "COMPLETED", "last_update": "2026-06-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04889066", "title": "Durvalumab (MEDI4736) and Radiosurgery (fSRT Vs. PULSAR) for the Treatment of Non-Small Cell Lung Cancer Brain Metastases", "status": "WITHDRAWN", "last_update": "2024-12-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04902040", "title": "Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies", "status": "TERMINATED", "last_update": "2026-04-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04905316", "title": "A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung Cancer", "status": "COMPLETED", "last_update": "2026-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04916002", "title": "A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer", "status": "TERMINATED", "last_update": "2026-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04924101", "title": "Efficacy and Safety of Pembrolizumab Plus Investigational Agents in Combination With Chemotherapy as First-Line Treatment in Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (MK-3475-B99/ KEYNOTE-B99)", "status": "COMPLETED", "last_update": "2026-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04933695", "title": "A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment", "status": "TERMINATED", "last_update": "2026-07-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04951115", "title": "A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly Diagnosed Stage IV Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2024-11-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04956692", "title": "Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-12-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04958811", "title": "Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04971187", "title": "Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2023-08-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04982224", "title": "Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer", "status": "TERMINATED", "last_update": "2025-11-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04985851", "title": "To Evaluate the Efficacy of Durvalumab + Anlotinib in Terms of OS and PFS.", "status": "UNKNOWN", "last_update": "2023-12-01", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04989283", "title": "Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2023-09-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04992715", "title": "PD-L1 Expression in Lung Cancer", "status": "UNKNOWN", "last_update": "2023-03-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04995523", "title": "A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04997382", "title": "Chemotherapy Combined with ICIs in First-line Alectinib Failed Patients with ALK-rearranged NSCLC", "status": "COMPLETED", "last_update": "2025-02-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05005429", "title": "Study of the Efficacy and Safety of the Bintrafusp Alfa in Previously Treated Advanced Malignant Pleural Mesothelioma", "status": "COMPLETED", "last_update": "2025-12-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05008861", "title": "Gut Microbiota Reconstruction for NSCLC Immunotherapy", "status": "UNKNOWN", "last_update": "2021-08-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05013450", "title": "Dupilumab_Metastatic NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-31", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05020457", "title": "SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05034055", "title": "Study of Stereotactic Ablative Radiotherapy(SBRT) Followed by Atezolizumab / Tiragolumab in Treatment-naive Patients With Metastatic Non-small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2021-09-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05034133", "title": "Durvalumab With Chemotherapy Followed by Sequential Radiotherapy for Limited Stage Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2021-09-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05042375", "title": "A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Na\u00efve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2022-11-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05061537", "title": "Study of PF-07263689 in Participants With Selected Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2024-04-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05061823", "title": "Bintrafusp Alfa Program Rollover Study", "status": "COMPLETED", "last_update": "2026-02-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05069935", "title": "FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05077709", "title": "IO102-IO103 in Combination With Pembrolizumab as First-line Treatment for Patients With Metastatic NSCLC, SCCHN, or mUBC", "status": "COMPLETED", "last_update": "2026-04-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05091567", "title": "A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05094804", "title": "A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents", "status": "UNKNOWN", "last_update": "2023-11-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05117372", "title": "ANALYSIS OF INFLAMMATORY REACTIONS OBSERVED IN BRONCHOALVEOLAR LAVAGES (BALS)", "status": "UNKNOWN", "last_update": "2021-11-11", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05142696", "title": "A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05156515", "title": "PD-L1 Targeting Nanobody Probe for PET Imaging of Solid Tumor", "status": "UNKNOWN", "last_update": "2023-03-29", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05157542", "title": "Neoadjuvant LDRT Combined With Durvalumab in Potentially Resectable Stage III NSCLC", "status": "UNKNOWN", "last_update": "2021-12-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05161533", "title": "Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial", "status": "WITHDRAWN", "last_update": "2023-10-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05170204", "title": "A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05171777", "title": "A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2025-12-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05191797", "title": "Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2024-09-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05195619", "title": "Personalized DC Vaccines in Non Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-07-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05198830", "title": "Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05203276", "title": "Envafolimab Combined With Endostar in the First-line Treatment of Advanced NSCLC", "status": "UNKNOWN", "last_update": "2023-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05206812", "title": "Window of Opportunity Trial of Durvalumab (MEDI4736) to Identify Immune Dynamics in Operable Non-small Cell Lung Cancer (NSCLC) (MIRACLE)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05208944", "title": "THIO Sequenced With Cemiplimab in Advanced NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05211895", "title": "A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05221840", "title": "A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05224141", "title": "Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-07-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05234606", "title": "A Safety and Preliminary Efficacy Study of SBT6290 Alone and in Combination With PD-(L)1 Inhibitors in Select Advanced Solid Tumors", "status": "WITHDRAWN", "last_update": "2022-04-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05245994", "title": "An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese", "status": "UNKNOWN", "last_update": "2022-02-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05253053", "title": "To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2025-06-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05259696", "title": "Glycan Mediated Immune Regulation With a Bi-Sialidase Fusion Protein (GLIMMER-01)", "status": "COMPLETED", "last_update": "2025-08-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05267392", "title": "Neoadjuvant Immunotherapy With Durvalumab (MEDI4736) in Non-Surgical Early Stage or Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Followed by Radical Radiotherapy or Chemoradiotherapy", "status": "UNKNOWN", "last_update": "2022-03-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05296603", "title": "Efficacy and Biomarker Explanation of IBI-322 Plus Lenvatinib on Extensive Stage Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2024-01-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05298423", "title": "Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)", "status": "COMPLETED", "last_update": "2026-08-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05334329", "title": "Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05340309", "title": "Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05346952", "title": "A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC).", "status": "UNKNOWN", "last_update": "2022-04-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05358691", "title": "A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC Participants", "status": "WITHDRAWN", "last_update": "2025-04-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05361395", "title": "First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05374603", "title": "Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05380713", "title": "......SMARTEST Trial......", "status": "COMPLETED", "last_update": "2025-12-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05395052", "title": "FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05401786", "title": "Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05403723", "title": "Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC", "status": "SUSPENDED", "last_update": "2026-02-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05420220", "title": "Study of KN046 in Subjects With Advanced Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-05-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05429866", "title": "Immunological Variables Associated to ICI Toxicity in Cancer Patients", "status": "UNKNOWN", "last_update": "2023-03-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05443971", "title": "Durvalumab and Grid Therapy for Non-small Cell Lung Cancer in Progression During or After Treatment With PACIFIC Regimen", "status": "TERMINATED", "last_update": "2026-02-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05445843", "title": "Study of Efficacy and Safety of JDQ443 Single-agent as First-line Treatment for Patients With Locally Advanced or Metastatic KRAS G12C- Mutated Non-small Cell Lung Cancer With a PD-L1 Expression < 1% or a PD-L1 Expression \u2265 1% and an STK11 Co-mutation.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05450692", "title": "A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05451173", "title": "Combining ICI With SBRT or HypoFrx-RT for ES NSCLC", "status": "UNKNOWN", "last_update": "2023-10-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05468489", "title": "To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05484583", "title": "Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment in Extensive Stage Small Cell Lung Cancer With Oligometastases", "status": "NOT_YET_RECRUITING", "last_update": "2022-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05499390", "title": "AK112 in Advanced Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05527808", "title": "A Single-arm Exploratory Study of Neoadjuvant Therapy", "status": "UNKNOWN", "last_update": "2023-06-08", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05553834", "title": "PCSK9 Inhibitor and PD-1 Inhibitor in Patients With Metastatic, Refractory To Prior Anti PD-1 Non-small Cell Lung", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05557591", "title": "A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05565378", "title": "A Platform Study of Novel Immunotherapy Combinations in Participants With Previously Untreated, Advanced/Metastatic Non-Small-Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05572476", "title": "Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2024-06-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05576077", "title": "A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-03-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05595460", "title": "Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05599789", "title": "Pembrolizumab in Combination With Plinabulin and Docetaxel For Metastatic NSCLC After ICIs (KeyPemls-004)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05603013", "title": "Vinorelbine Metronomic Chemotherapy Combined With Hypofractionated Radiotherapy, PD-1/PD-L1 Sequential GM-CSF and IL-2 for Treatment of Advanced Refractory Non-small Cell Lung Cancer and Breast Cancer(PRaG 6.0)", "status": "UNKNOWN", "last_update": "2022-11-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05609968", "title": "Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) \u226550% (MK-3475-D46)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-12-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05617963", "title": "Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Disease is Limited to the Thorax", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05655663", "title": "Evaluation of Vascular Toxicity of Immune Checkpoint Inhibitors in Patients Head and Neck or Lung Cancer", "status": "UNKNOWN", "last_update": "2022-12-19", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05668767", "title": "Surufatinib in Combination of Durvalumab and EP/EC in the Firstly-line Treatment of ES-SCLC", "status": "UNKNOWN", "last_update": "2022-12-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05687266", "title": "Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05689671", "title": "Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-10", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05703997", "title": "FASTing-like Approach and Maintenance IMMunotherapy in ES-SCLC Patients Not Progressing on Chemoimmunotherapy Induction", "status": "NOT_YET_RECRUITING", "last_update": "2023-01-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05704634", "title": "A Phase Ib Study to Evaluate the Safety and Preliminary Efficacy of IL6-receptor Antibody Sarilumab in Combination With antiPD1 Antibody Cemiplimab for Patients With Non-small Cell Lung Cancer.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05718167", "title": "TQB2450 Injection Combined With Chemotherapy Followed by Sequential Combination With Anlotinib Hydrochloride Capsule for First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer.", "status": "UNKNOWN", "last_update": "2023-02-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05718297", "title": "Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2024-10-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05735028", "title": "The Efficacy and Safety of PD-1/PD-L1 Inhibitors Combined With Centipeda Minima (CM) in Lung Cancer", "status": "UNKNOWN", "last_update": "2024-04-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05757843", "title": "Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab", "status": "WITHDRAWN", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05781308", "title": "Combination of Paclitaxel-bevacizumab \u00b1 Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05785767", "title": "A Study to Learn if a Combination of Fianlimab and Cemiplimab Versus Cemiplimab Alone is More Effective for Adult Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-02", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05792995", "title": "Foundation and Clinical About the Expression of PD-1 in Peripheral Blood T Lymphocytes", "status": "COMPLETED", "last_update": "2023-03-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05796089", "title": "Chemotherapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer With Thoracic Radiotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05800015", "title": "A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-15", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05825625", "title": "NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05840770", "title": "Cemiplimab for the Treatment of Untreated Brain Metastases From PD-L1 >= 50% Non-Small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2025-05-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05848843", "title": "A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations", "status": "WITHDRAWN", "last_update": "2024-01-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05856695", "title": "Durvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cancer (SCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05859217", "title": "A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)", "status": "NOT_YET_RECRUITING", "last_update": "2024-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05864144", "title": "A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2026-09-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05882734", "title": "Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05911308", "title": "Abequolixron (RGX-104) and Durvalumab in Lung Cancer", "status": "TERMINATED", "last_update": "2025-03-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05925530", "title": "Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05935774", "title": "OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2023-08-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05941897", "title": "A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged \u2265 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06008093", "title": "A Study to Investigate the Efficacy of Durvalumab Plus Tremelimumab in Combination With Chemotherapy Compared With Pembrolizumab in Combination With Chemotherapy in Metastatic NSCLC Patients With Non-squamous Histology Who Have Mutations and/or Co-mutations in STK11, KEAP1, or KRAS", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06049966", "title": "Atezolizumab in Large Cell Neuroendocrine Carcinoma", "status": "COMPLETED", "last_update": "2026-07-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06052852", "title": "Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies", "status": "TERMINATED", "last_update": "2025-11-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06064279", "title": "Harnessing Allo-immunity to Enhance Immune Checkpoint Inhibitor Responses in Advanced NSCLC", "status": "WITHDRAWN", "last_update": "2024-09-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06077500", "title": "DAREON\u1d40\u1d39-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06161441", "title": "A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06162572", "title": "Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06195683", "title": "Serplulimab for Patients With Non-small Cell Lung Cancer (NSCLC) With TPS \u2265 50%: a Prospective, Single-center, Single-arm Phase 2 Study.", "status": "UNKNOWN", "last_update": "2024-01-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06211036", "title": "Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-12-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06219317", "title": "Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06267001", "title": "A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy", "status": "TERMINATED", "last_update": "2026-06-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06331455", "title": "Treatment of Pulmonary SUlcus, Pancoast and Chest Wall Non-small Cell Lung Cancer Employing Radiation, Immuno-oncology and Resection", "status": "UNKNOWN", "last_update": "2024-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06333678", "title": "A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC)", "status": "TERMINATED", "last_update": "2026-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06356701", "title": "Tumor Nutritional Therapy in the First-line Treatment of Stage IV NSCLC", "status": "UNKNOWN", "last_update": "2024-04-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06382129", "title": "A Study Comparing BL-B01D1 With Docetaxel in Patients With Unresectable Locally Advanced or Metastatic EGFR Wild-type Non-small Cell Lung Cancer(PANKU-Lung02)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06385262", "title": "TOP 2301: Neoadjuvant Chemo for NSCLC", "status": "SUSPENDED", "last_update": "2026-08-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06405230", "title": "Evaluation of Programmed Death Ligand 1 (PDL1) Response to Treatment in Extracellular Vesicles (EVs), Patient-derived Organoid (PDOs)s and Immune-marker Positron Emission Tomography (PET) Scanning in Non-small Cell Lung Cancer (NSCLC)", "status": "TERMINATED", "last_update": "2026-09-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06419179", "title": "Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)", "status": "ENROLLING_BY_INVITATION", "last_update": "2025-05-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06446570", "title": "Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid Carcinoma", "status": "COMPLETED", "last_update": "2024-06-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06449209", "title": "Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06465329", "title": "A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06472076", "title": "A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06572722", "title": "Perioperative Immunotherapy for NSCLC (ECTOP-1030)", "status": "WITHDRAWN", "last_update": "2026-04-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06586697", "title": "First-line Treatment for ES-SCLC with Chemotherapy Combined with PD-1/PD-L1 Inhibitor Sequential Thoracic Radiotherapy", "status": "UNKNOWN", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06606847", "title": "A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06632327", "title": "Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06644768", "title": "A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06685653", "title": "Personalized Neoantigen MRNA Vaccine Combined with Adebrelimab in Non-Small Cell Lung Cancer Patients", "status": "NOT_YET_RECRUITING", "last_update": "2024-11-12", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06690216", "title": "Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors", "status": "ENROLLING_BY_INVITATION", "last_update": "2025-03-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06700421", "title": "Phase II Clinical Study of Adebrelimab Combined with Apatinib in the Treatment of Locally Advanced Non-small Cell Lung Cancer Patients with Radiation Pneumonitis", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-11-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06732401", "title": "Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06735508", "title": "MRNA Neoantigen Vaccine in Non-Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-12-16", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06739252", "title": "Perioperative Treatment of High-risk Resectable CCA With HAIC Plus A+T: Neobrave CCA", "status": "TERMINATED", "last_update": "2026-01-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06851169", "title": "This is a Two-cohort, Exploratory Clinical Study Assessing the Activity of Benmelstobart Alone or Combined with Anlotinib Administered Prior to Surgery in Terms of Pathological Complete Response", "status": "NOT_YET_RECRUITING", "last_update": "2025-02-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06897579", "title": "Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2026-04-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06898957", "title": "Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06925048", "title": "SHR0302 Combined With PD-1/PD-L1 Inhibition for Treatment na\u00efve or Acquired Resistant to Immunology NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2025-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06939036", "title": "Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )", "status": "TERMINATED", "last_update": "2026-02-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06943664", "title": "Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06992609", "title": "Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06998719", "title": "Neoadjuvant Durvalumab and Chemotherapy Followed by Surgery/CRT and Durvalumab in Borderline Resectable Stage III NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2025-05-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07092137", "title": "Nano-crystalline Megestrol Acetate for Anorexia-Cachexia Syndrome in Advanced Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-07-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07172412", "title": "Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07247786", "title": "Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT)", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07274384", "title": "Hyperprogression in PD-L1 \u2265 50% NSCLC: a Biomarker Guided Phase 2 Trial", "status": "NOT_YET_RECRUITING", "last_update": "2025-12-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07283198", "title": "A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-12-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07353476", "title": "Radiotherapy Plus Anti-PD-1 Versus Anti-PD-1 Alone in ypTanyN\u207aM0 NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07360743", "title": "Immunotherapy Without Chemotherapy for Advanced Lung Cancer Patients With High PD-L1 Levels", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07416058", "title": "PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 \u226550% Non-Squamous NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07418931", "title": "A Multicenter Open-label Phase II Study of Cemiplimab Plus Chemotherapy, Selected on the Basis of Baseline Cytidine Deaminase Activity, in Advanced Squamous Non-small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07450183", "title": "Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07538271", "title": "A Study of Benmelstobart, Anlotinib, Chemotherapy and Thoracic Radiotherapy for People With Extensive-stage Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07551778", "title": "Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07579221", "title": "Ph1/2 Trial Of Navlimetostat With Pumitamig In MTAP-Deficient Advanced Non-Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07603791", "title": "Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK202 for Injection in Combination With Drugs in NSCLC Participants.", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07630168", "title": "Effects of Infusion Timing on Treatment Response in Solid Tumors", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07720167", "title": "Cemiplimab for Clinical Stage I, 2-3.9cm, Non-Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07742956", "title": "Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK201 for Injection in Combination With Ivonescimab Injection in sqNSCLC Participants.", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07746388", "title": "Adaptive Chemotherapy for Pd-l1 High REsEctablE NSCLC: A Chemo-PHREE Trial", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07796100", "title": "A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07808138", "title": "RADICAL-IO: thRee Cycles of immunotherApy Without raDical Therapy In mediCALly InOperable Stage I Non-small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 7, "n_observational": 2, "n_active": 3, "n_withdrawn": 1, "trials": [ { "nct": "NCT05632809", "title": "REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)", "status": "RECRUITING", "last_update": "2026-07-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07759856", "title": "NK Cells Plus ICI for SCLC Maintenance", "status": "RECRUITING", "last_update": "2026-08-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03419559", "title": "Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2019-04-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03853187", "title": "Imaging Tumor-infiltrating T-cells in Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2022-12-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04639245", "title": "Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2023-08-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05792995", "title": "Foundation and Clinical About the Expression of PD-1 in Peripheral Blood T Lymphocytes", "status": "COMPLETED", "last_update": "2023-03-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07551778", "title": "Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "PD-L1", "PDL1", "CD274", "B7-H1", "atezolizumab", "durvalumab", "cemiplimab" ] }, "DLL3": { "n": 69, "n_observational": 3, "n_active": 54, "n_withdrawn": 2, "trials": [ { "nct": "NCT04199741", "title": "PET/CT Imaging of Small Cell Lung Cancer Using 89Zr-DFO-SC16.56", "status": "RECRUITING", "last_update": "2026-08-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05652686", "title": "A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)", "status": "RECRUITING", "last_update": "2026-07-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05882058", "title": "DAREON\u2122-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers", "status": "RECRUITING", "last_update": "2026-07-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06179069", "title": "A Study of ZL-1310 in Subjects With Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06348797", "title": "Phase I Clinical Study of \u03b1-PD-L1/DLL3 CAR-T in Patients With R/R SCLC", "status": "RECRUITING", "last_update": "2026-07-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06598306", "title": "Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)", "status": "RECRUITING", "last_update": "2026-06-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06814496", "title": "Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors", "status": "RECRUITING", "last_update": "2026-07-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06830694", "title": "Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06937905", "title": "Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)", "status": "RECRUITING", "last_update": "2026-02-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06957314", "title": "A Study of Hospital-at-Home for People Receiving Tarlatamab", "status": "RECRUITING", "last_update": "2026-06-12", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07006727", "title": "Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07016230", "title": "Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07037758", "title": "A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)", "status": "RECRUITING", "last_update": "2026-05-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07174583", "title": "A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-07-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07203053", "title": "A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07218146", "title": "A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07242547", "title": "Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients", "status": "RECRUITING", "last_update": "2026-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07246304", "title": "TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC", "status": "RECRUITING", "last_update": "2025-11-24", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07249879", "title": "This Study is an Open-lable, Early Study to Evaluate the Safety, Feasibility, Cytokinetics, and Preliminary Efficacy of GC511B in DLL3+ Relapsed/Refractory Small Cell Lung Cancer.", "status": "RECRUITING", "last_update": "2026-05-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07278479", "title": "Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors", "status": "RECRUITING", "last_update": "2026-05-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07402343", "title": "Tarlatamab for SCLC Brain Metastases", "status": "RECRUITING", "last_update": "2026-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07416695", "title": "A Phase I Clinical Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HLX3901 in Patients With Advanced SCLC or NEC", "status": "RECRUITING", "last_update": "2026-07-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07423585", "title": "Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-07-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07480213", "title": "Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)", "status": "RECRUITING", "last_update": "2026-03-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07488923", "title": "A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)", "status": "RECRUITING", "last_update": "2026-08-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07508852", "title": "68Ga-PFD3 PET Imaging for the Diagnosis and Evaluation of Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-06-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07531095", "title": "Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)", "status": "RECRUITING", "last_update": "2026-08-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07564401", "title": "A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07677787", "title": "DLL3-Targeted PET/CT in Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-07-01", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07744256", "title": "Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)", "status": "RECRUITING", "last_update": "2026-08-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07778316", "title": "Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)", "status": "RECRUITING", "last_update": "2026-08-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07783477", "title": "A Study of Armored CAR T Cells in People With Cancer", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07803848", "title": "Study to Confirm Efficacy and Feasibility of Tarlatamab Treatment in Patients With Extensive Stage Small-cell Lung Cancer With Poor Performance Status", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01901653", "title": "Rovalpituzumab Tesirine (SC16LD6.5) in Recurrent Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2018-08-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02674568", "title": "Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2021-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02819999", "title": "A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2020-03-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02874664", "title": "A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2018-09-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03000257", "title": "A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2022-04-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03026166", "title": "A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2020-07-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03033511", "title": "A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)", "status": "TERMINATED", "last_update": "2021-07-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03061812", "title": "Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)", "status": "COMPLETED", "last_update": "2021-02-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03086239", "title": "A Study on the Safety and Tolerability of Rovalpituzumab Tesirine in Japanese Patients With Advanced, Recurrent Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2021-08-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03319940", "title": "Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03334487", "title": "Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2018-12-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03392064", "title": "A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects With RR SCLC", "status": "SUSPENDED", "last_update": "2025-10-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04429087", "title": "A Study to Test Different Doses of Obrixtamig in Patients With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04471727", "title": "A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04885998", "title": "AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)", "status": "COMPLETED", "last_update": "2025-09-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05060016", "title": "A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05361395", "title": "First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05507593", "title": "Study of DLL3-CAR-NK Cells in the Treatment of Extensive Stage Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2022-08-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05680922", "title": "DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05740566", "title": "Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05879978", "title": "A Study to Test How Well Different Doses of Obrixtamig (BI 764532) in Combination With Ezabenlimab Are Tolerated by People With Small Cell Lung Cancer and Other Neuroendocrine Tumours That Are Positive for DLL3", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06117774", "title": "Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06211036", "title": "Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-12-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06384482", "title": "SNC115 Injections in Patients With Recurrent/Refractory Small Cell Lung Cancer and Lung Large Cell Neuroendocrine Carcinoma", "status": "UNKNOWN", "last_update": "2024-04-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06502977", "title": "Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06736418", "title": "Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06745323", "title": "A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06898957", "title": "Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06941480", "title": "A Study of 177Lu-DTPA-SC16.56 in People With Neuroendocrine Carcinomas of the Lung and Prostate", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07005128", "title": "A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07172412", "title": "Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07328490", "title": "Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer", "status": "WITHDRAWN", "last_update": "2026-04-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07625644", "title": "BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07637513", "title": "Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07699237", "title": "A Multicenter Phase II Trial to Evaluate Rechallenge With Platinum-based Chemotherapy (Carboplatin, Etoposide) for Progression During Tarlatamab Therapy in Relapsed Extensive Disease Small-cell Lung Cancer (SCLC)", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07796100", "title": "A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 9, "n_observational": 0, "n_active": 8, "n_withdrawn": 0, "trials": [ { "nct": "NCT06348797", "title": "Phase I Clinical Study of \u03b1-PD-L1/DLL3 CAR-T in Patients With R/R SCLC", "status": "RECRUITING", "last_update": "2026-07-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07246304", "title": "TC-D101 Cell Therapy for Patients With DLL3-Positive SCLC", "status": "RECRUITING", "last_update": "2025-11-24", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07480213", "title": "Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)", "status": "RECRUITING", "last_update": "2026-03-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07488923", "title": "A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)", "status": "RECRUITING", "last_update": "2026-08-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07564401", "title": "A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07744256", "title": "Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)", "status": "RECRUITING", "last_update": "2026-08-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07783477", "title": "A Study of Armored CAR T Cells in People With Cancer", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05507593", "title": "Study of DLL3-CAR-NK Cells in the Treatment of Extensive Stage Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2022-08-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05680922", "title": "DLL3-Directed Chimeric Antigen Receptor T-cells in Subjects With Extensive Stage Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "DLL3", "delta-like ligand 3", "delta-like 3", "tarlatamab", "Imdelltra", "rovalpituzumab" ] }, "TROP2": { "n": 81, "n_observational": 3, "n_active": 73, "n_withdrawn": 2, "trials": [ { "nct": "NCT05061550", "title": "Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05627960", "title": "First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies", "status": "RECRUITING", "last_update": "2022-11-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05941507", "title": "A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2025-09-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05969041", "title": "Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors", "status": "RECRUITING", "last_update": "2024-01-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06170788", "title": "Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) \u2265 50% (MK-2870-007)", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06312137", "title": "A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06350097", "title": "Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06357533", "title": "Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC \u2265 50%) and Without Actionable Genomic Alterations", "status": "RECRUITING", "last_update": "2026-08-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06401824", "title": "Sacituzumab Govitecan and Bevacizumab for NSCLC Brain Metastases", "status": "RECRUITING", "last_update": "2025-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06417814", "title": "A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-05-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06422143", "title": "Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06431633", "title": "Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.", "status": "RECRUITING", "last_update": "2026-05-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06477419", "title": "A Study of Sacituzumab Govitecan in People With Mesothelioma", "status": "RECRUITING", "last_update": "2026-05-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06667167", "title": "First Line Therapy for Extensive SCLC Patients, Treated with Chemo+Keytruda Followed by Keytuda+Trodelvy", "status": "RECRUITING", "last_update": "2025-01-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06788912", "title": "Pembrolizumab (MK-3475) Plus Investigational Agents in Resectable Non-small Cell Lung Cancer (NSCLC) (MK-3475-01E/KEYMAKER-U01)", "status": "RECRUITING", "last_update": "2026-09-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06801834", "title": "Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06822543", "title": "A Single Arm, Phase 2 Study of Datopotamab Deruxtecan, Carboplatin, and Pembrolizumab for Treatment-naive Brain Metastases From NSCLC (Non-small Cell Lung Cancer)", "status": "RECRUITING", "last_update": "2026-08-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06851663", "title": "Trop2-targeted immunoPET Imaging of Solid Tumors", "status": "RECRUITING", "last_update": "2026-05-29", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06953089", "title": "DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06974604", "title": "Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM", "status": "RECRUITING", "last_update": "2025-10-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06992739", "title": "Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC)", "status": "RECRUITING", "last_update": "2026-04-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07026110", "title": "Clinical Application Study of PET/CT for Differential Diagnosis of Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2025-06-18", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07252739", "title": "KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07259226", "title": "Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers", "status": "RECRUITING", "last_update": "2025-12-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07286149", "title": "A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07291037", "title": "Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07323056", "title": "Neoadjuvant Sacituzumab Tirumotecan and Limertinib for Potentially Resectable Stage \u2162 EGFR-mutant Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-01-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07329322", "title": "Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07339059", "title": "Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-07-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07357597", "title": "An Open-label, Single-arm Study of Prophylaxis for Datopotamab Deruxtecan (Dato-DXd) -Related Stomatitis in Eligible Patients With Metastatic or Inoperable Locally Recurrent Breast Cancer or Locally Advanced or Metastatic Epidermal Growth Factor Receptor-Mutated Non-small Cell Lung Cancer.", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07375316", "title": "A ctDNA-guided Phase II Trial of Osimertinib in Combination With Sacituzumab Tirumotecan in EGFR-mutated Advanced NSCLC Patients With Positive ctDNA After lead-in Osimertinib Monotherapy", "status": "RECRUITING", "last_update": "2026-05-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07548060", "title": "A Phase II Study of Sacituzumab Tirumotecan in Combination With Furmonertinib in Patients With Non-squamous Non-Small Cell Lung Cancer Who Have Progressed After EGFR-TKI and Platinum-Based Chemotherapy", "status": "RECRUITING", "last_update": "2026-04-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07669779", "title": "A Phase II Study of AK146D1 in Combination With AK112 in Advanced Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-07-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07697586", "title": "SKB264 in Combination With SKB118 for Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01631552", "title": "Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer", "status": "COMPLETED", "last_update": "2021-08-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03337698", "title": "A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer)", "status": "TERMINATED", "last_update": "2026-05-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03401385", "title": "First-in-human Study of DS-1062a for Advanced Solid Tumors (TROPION-PanTumor01)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03944772", "title": "Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-01-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04143711", "title": "Study of DF1001 in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2026-03-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04152499", "title": "Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (KL264-01)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04484142", "title": "Study of DS-1062a in Advanced or Metastatic Non-small Cell Lung Cancer With Actionable Genomic Alterations (TROPION-Lung05)", "status": "COMPLETED", "last_update": "2026-03-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04526691", "title": "Datopotamab Deruxtecan (Dato-DXd) in Combination With Pembrolizumab With or Without Platinum Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer (TROPION-Lung02)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04612751", "title": "Phase 1b Study of Dato-DXd in Combination With Immunotherapy With or Without Carboplatin in Advanced or Metastatic Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04644068", "title": "Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04656652", "title": "Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04794699", "title": "Study of IDE397 in Participants With Solid Tumors Harboring MTAP Deletion", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04826341", "title": "A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer, Extra-Pulmonary Small Cell Neuroendocrine Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors", "status": "COMPLETED", "last_update": "2026-07-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04916002", "title": "A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer", "status": "TERMINATED", "last_update": "2026-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04940325", "title": "Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05089734", "title": "Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05186974", "title": "Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05215340", "title": "Study of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in the First-line Treatment of Subjects With Advanced or Metastatic NSCLC Without Actionable Genomic Alterations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05460273", "title": "A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-31", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05555732", "title": "Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in 1L Non-Small Cell Lung Cancer (TROPION-Lung07)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05609968", "title": "Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) \u226550% (MK-3475-D46)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-12-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05633667", "title": "Study of Novel Treatment Combinations in Patients With Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05687266", "title": "Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05816252", "title": "A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06049212", "title": "Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06055465", "title": "Neoadjuvant Sacituzumab Govitecan Plus Pembrolizumab in Resectable Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06074588", "title": "Sacituzumab Tirumotecan (MK-2870) Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06305754", "title": "Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06454890", "title": "Clinical Study of Trop2 CAR-NK in the Treatment of Relapsed/Refractory Non-Small Cell Lung Cancer (NSCLC)", "status": "NOT_YET_RECRUITING", "last_update": "2024-06-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06564844", "title": "A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06676917", "title": "Datopotamab Deruxtecan (Dato-DXd) for Non-Small Cell Lung Cancer (NSCLC) Patients With Active Brain Metastases", "status": "WITHDRAWN", "last_update": "2025-08-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06706219", "title": "Efficacy and Safety of Sacituzumab Tirumotecan (SKB264) in Combination With Toripalimab in Patients With Initially Unresectable Stage III NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07108816", "title": "A Single-center, Phase II Clinical Trial Evaluating the Efficacy of Sacituzumab Tirumotecan in Combination With Tagitanlimab as Neoadjuvant Therapy for PD-L1-positive, Resectable Stage II to IIIB Non-small Cell Lung Cancer (NSCLC)", "status": "NOT_YET_RECRUITING", "last_update": "2025-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07193160", "title": "Sacituzumab Tirumotecan in Combination With Furmonertinib as Second-line Treatment for EGFR-mutant Advanced or Metastatic NSCLC After Failure of First-line Third-generation EGFR-TKI Therapy", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07197008", "title": "Sacituzumab Tirumotecan (Sac-TMT) Plus Bevacizumab in 3rd Generation EGFR-TKI Treated Advanced EGFR-mutant Nonsquamous NSCLC With Brain Metastasis", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07244926", "title": "Sac-TMT Plus Bevacizumab as Second-Line Treatment for Advanced Non-Squamous Non-Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-11-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07328490", "title": "Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer", "status": "WITHDRAWN", "last_update": "2026-04-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07343479", "title": "Sacituzumab Tirumotecan Plus Third-Generation TKI With/Without Radiotherapy for EGFR-Mutant NSCLC Brain Metastases", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07388875", "title": "Sacituzumab Tirumotecan Plus Anlotinib in Previously Treated ES-SCLC", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07393555", "title": "Treatment for Advanced Non-small Cell Lung Cancer With Actionable Genomic Alterations After Targeted Treatment and Chemotherapy (An Expanded Lung-MAP Treatment Trial)", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07438600", "title": "Study of Sacituzumab Tirumotecan Combined With Toripalimab for Resectable Stage II-IIIB NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2026-03-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07501169", "title": "Sacituzumab Tirumotecan in Combination With Anlotinib in Previously Treated Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC)", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07685197", "title": "Comparative \u00b9\u2078F-FDG and \u2076\u2078Ga-MY6349 PET/CT Imaging for Assessing TROP2 ADC Therapeutic Efficacy in EGFR-TKI Resistant Advanced NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07702305", "title": "Safety and Efficacy of Intrathecal Sacituzumab Tirumotecan for Leptomeningeal Metastasis in EGFR-TKI-Resistant Non-Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07703228", "title": "Second-Line Sacituzumab Tirumotecan Plus Anlotinib for Advanced Driver Gene-Negative Non-Squamous NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07750704", "title": "Lorlatinib Plus Sacituzumab Tirumotecan With Peripheral ctDNA Guidance as First-Line Therapy for ALK Fusion-Positive NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07789444", "title": "Sacituzumab Tirumotecan\uff08Sac-TMT\uff09 and Brain Radotherapy for EGFR+ NSCLC With Brain Mets", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 0, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [] }, "synonyms_searched": [ "TROP2", "TROP-2", "TACSTD2", "sacituzumab", "datopotamab" ] }, "HER2": { "n": 184, "n_observational": 21, "n_active": 91, "n_withdrawn": 8, "trials": [ { "nct": "NCT03198052", "title": "GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGF\u03b2/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers", "status": "RECRUITING", "last_update": "2024-06-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03740256", "title": "Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors", "status": "RECRUITING", "last_update": "2026-02-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04025541", "title": "Analysis of Circulating Tumor Markers in Blood", "status": "RECRUITING", "last_update": "2025-04-02", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04322890", "title": "Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation", "status": "RECRUITING", "last_update": "2024-10-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04389632", "title": "A Study of Sigvotatug Vedotin in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04686305", "title": "Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04842812", "title": "Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2024-06-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04899908", "title": "Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05150691", "title": "A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05482568", "title": "A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-04-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05579366", "title": "Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)", "status": "RECRUITING", "last_update": "2026-08-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05681780", "title": "Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC", "status": "RECRUITING", "last_update": "2026-03-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05751018", "title": "Phase II Clinical Study of Pyrotinib in First-line Treatment of Primary HER2-amplified/Mutated Advanced Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2025-12-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05785741", "title": "A Study of DB-1310 in Advanced/Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-04-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05969041", "title": "Study of MT-302 in Adults With Advanced or Metastatic Epithelial Tumors", "status": "RECRUITING", "last_update": "2024-01-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06043817", "title": "First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR or HER2 Exon 20 Insertion Mutations", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06253871", "title": "A Phase 1/1b Study of IAM1363 in HER2 Cancers", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06293898", "title": "Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06430437", "title": "A Study of SHR-A1811 in First-line Treatment of Patients With Advanced or Metastatic Non-small Cell Lung Cancer With HER2 Mutations", "status": "RECRUITING", "last_update": "2026-01-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06452277", "title": "A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06472245", "title": "Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor", "status": "RECRUITING", "last_update": "2026-07-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06563999", "title": "Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.", "status": "RECRUITING", "last_update": "2026-04-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06616766", "title": "A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946", "status": "RECRUITING", "last_update": "2026-08-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06625775", "title": "Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06632262", "title": "A Phase 2 Clinical Study of ABSK061 and ABSK043", "status": "RECRUITING", "last_update": "2024-11-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06695845", "title": "A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors", "status": "RECRUITING", "last_update": "2026-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06706076", "title": "A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations", "status": "RECRUITING", "last_update": "2026-08-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06726148", "title": "Study of ECI830 Single Agent or in Combination in Patients With Advanced HR+/HER2- Breast Cancer and in Patients With Other Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06734182", "title": "Neoadjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resectable HER2-Mutant Non-Small-Cell Lung Cancer", "status": "RECRUITING", "last_update": "2024-12-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06749860", "title": "Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression", "status": "RECRUITING", "last_update": "2024-12-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06750185", "title": "Safety and Preliminary Effectiveness of BNT317, an Investigational Therapy for Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06899126", "title": "Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-07-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06974370", "title": "Avoiding Radiation Therapy Due to Intracranial Response to Chemotherapy, Targeted Therapy and/or Immuno-ONcology Therapy for Brain Metastases: Pilot Pragmatic Trial", "status": "RECRUITING", "last_update": "2026-05-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06974604", "title": "Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM", "status": "RECRUITING", "last_update": "2025-10-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07012031", "title": "Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07070232", "title": "A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07178795", "title": "A Study of BL-M07D1 vs Pembrolizumab-platinum Chemotherapy in First-line Treatment of HER2-mutant Advanced or Metastatic Non-squamous NSCLC", "status": "RECRUITING", "last_update": "2025-11-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07192068", "title": "Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.", "status": "RECRUITING", "last_update": "2025-12-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07195695", "title": "Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07259226", "title": "Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers", "status": "RECRUITING", "last_update": "2025-12-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07264816", "title": "A Study of BL-M07D1 in Combination With Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic HER2-Overexpressing Non-Squamous NSCLC", "status": "RECRUITING", "last_update": "2026-03-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07334119", "title": "Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-304 in Adults With Advanced HER2-Expressing Solid Tumors", "status": "RECRUITING", "last_update": "2026-05-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07361562", "title": "A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07424547", "title": "Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-04-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07428044", "title": "A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-02-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07486817", "title": "Beamion 44: A Study to Test How Well Zongertinib is Tolerated by People With Advanced Non-small Cell Lung Cancer With HER2 Mutations When Given in Combination With Chemotherapy With or Without Pembrolizumab", "status": "RECRUITING", "last_update": "2026-09-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07540572", "title": "A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-06-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07613424", "title": "A Study of MET Concordance and Gene Profiling in 1L NSCLC (Genomet)", "status": "RECRUITING", "last_update": "2026-07-14", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07630961", "title": "Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07641023", "title": "Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC", "status": "RECRUITING", "last_update": "2026-06-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07660055", "title": "Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07801508", "title": "A Study of [68Ga]Ga-DWJ155 in Adult Patients With Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003002", "title": "HER-2/Neu Vaccine Plus GM-CSF in Treating Patients With Stage III or Stage IV Breast, Ovarian, or Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2019-02-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00004883", "title": "Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer That Overexpresses HER2", "status": "COMPLETED", "last_update": "2013-01-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00005023", "title": "Vaccine Therapy Plus Sargramostim in Treating Patients With Stage III or Stage IV Cancer", "status": "COMPLETED", "last_update": "2017-11-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00014430", "title": "Chemotherapy Plus Trastuzumab in Treating Patients With Breast Cancer", "status": "COMPLETED", "last_update": "2013-03-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00017537", "title": "Vaccine Therapy in Treating Patients With Metastatic or Recurrent Cancer", "status": "WITHDRAWN", "last_update": "2013-08-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00028535", "title": "Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors", "status": "COMPLETED", "last_update": "2013-06-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00031681", "title": "7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)", "status": "COMPLETED", "last_update": "2013-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00063154", "title": "Safety and Effect of Pertuzumab in Patients With Advanced Non-Small Cell Lung Cancer, Which Has Progressed After Prior Chemotherapy", "status": "COMPLETED", "last_update": "2015-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00291473", "title": "Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers", "status": "COMPLETED", "last_update": "2009-03-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00433407", "title": "T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors", "status": "COMPLETED", "last_update": "2012-10-04", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00758134", "title": "Trastuzumab Therapy in Non-Small Cell Lung Cancer Patients", "status": "TERMINATED", "last_update": "2013-05-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00818441", "title": "Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung", "status": "COMPLETED", "last_update": "2019-01-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01386580", "title": "An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.", "status": "COMPLETED", "last_update": "2015-01-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01542437", "title": "Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2024-02-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01679743", "title": "GRN1005 for Brain Metastases From Breast or Lung Cancer", "status": "WITHDRAWN", "last_update": "2019-11-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01827267", "title": "Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2018-07-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01862081", "title": "A Dose-escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer or Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2017-11-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01913067", "title": "Evaluation of Cabazitaxel in Patients With Brain Metastasis Secondary to Breast Cancer and NSCLC", "status": "WITHDRAWN", "last_update": "2014-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01953926", "title": "Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations", "status": "TERMINATED", "last_update": "2024-03-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02226276", "title": "Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-13", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02264678", "title": "Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02289833", "title": "A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor (HER)2 Immunohistochemistry (IHC)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2019-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02314481", "title": "Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity", "status": "COMPLETED", "last_update": "2026-05-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02442414", "title": "A Phase 1 Study of KBP-5209 in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2022-03-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02535507", "title": "Efficacy and Safety of Pyrotinib in Patients With HER2 Mutation Advanced Non-Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2015-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02597946", "title": "Afatinib in NSCLC With HER2 Mutation", "status": "COMPLETED", "last_update": "2025-02-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02675829", "title": "Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers", "status": "COMPLETED", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02713984", "title": "A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer", "status": "WITHDRAWN", "last_update": "2020-03-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02716116", "title": "A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02779751", "title": "A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02834936", "title": "A Clinica Study of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 Mutation", "status": "COMPLETED", "last_update": "2025-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02892123", "title": "Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers", "status": "COMPLETED", "last_update": "2024-11-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02912949", "title": "A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02952729", "title": "Study of Antibody Drug Conjugate in Patients With Advanced Breast Cancer Expressing HER2", "status": "COMPLETED", "last_update": "2021-02-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02983045", "title": "A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2023-03-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03066206", "title": "Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC", "status": "TERMINATED", "last_update": "2026-02-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03099174", "title": "This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer", "status": "COMPLETED", "last_update": "2025-06-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03125200", "title": "Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression", "status": "TERMINATED", "last_update": "2021-02-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03169738", "title": "QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors", "status": "WITHDRAWN", "last_update": "2025-02-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03318939", "title": "Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation", "status": "TERMINATED", "last_update": "2026-06-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03319459", "title": "FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2021-11-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03334617", "title": "Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03420079", "title": "A Phase I Study of FCN-411 in Advanced Non-small Cell Lung Cancer Chinese Patients With EGFR Positive Mutation", "status": "UNKNOWN", "last_update": "2020-07-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03505710", "title": "DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2025-05-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03574402", "title": "Phase II Umbrella Study Directed by Next Generation Sequencing", "status": "UNKNOWN", "last_update": "2022-12-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03602079", "title": "Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene", "status": "COMPLETED", "last_update": "2023-08-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03721120", "title": "Evaluation of the Feasibility and Clinical Relevance of Liquid Biopsy in Patients With Suspicious Metastatic Lung Cancer", "status": "COMPLETED", "last_update": "2025-08-08", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03784599", "title": "T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLC", "status": "TERMINATED", "last_update": "2022-11-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03805841", "title": "Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions", "status": "TERMINATED", "last_update": "2023-06-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03807778", "title": "A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03810872", "title": "An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR, a HER2 or a HER3 Mutation", "status": "UNKNOWN", "last_update": "2019-01-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03821233", "title": "A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers", "status": "COMPLETED", "last_update": "2025-01-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03845270", "title": "Her2-positive Lung Cancer Treated With Dedicated Drug", "status": "COMPLETED", "last_update": "2023-12-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03924466", "title": "Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients", "status": "UNKNOWN", "last_update": "2024-02-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03970382", "title": "A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors", "status": "SUSPENDED", "last_update": "2022-08-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03974022", "title": "Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04042480", "title": "A Study of SGN-CD228A in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-03-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04042701", "title": "DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04044170", "title": "Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation", "status": "TERMINATED", "last_update": "2020-11-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04063462", "title": "Phase 2 Study of Pyrotinib in Previously Treated Patients With NSCLC Having EGFR or ERBB2 Exon 20 Insertion Mutation", "status": "UNKNOWN", "last_update": "2019-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04143711", "title": "Study of DF1001 in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2026-03-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04209465", "title": "A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors.", "status": "TERMINATED", "last_update": "2025-04-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04225117", "title": "A Study to Evaluate Enfortumab Vedotin in Subjects With Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04247126", "title": "A Study of SY 5609, a Selective CDK7 Inhibitor, in Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2023-10-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04278144", "title": "A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors", "status": "TERMINATED", "last_update": "2025-09-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04285671", "title": "Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04311034", "title": "A Study of RC48-ADC in Subjects With Advanced Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2023-12-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04319757", "title": "ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors", "status": "COMPLETED", "last_update": "2024-12-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04336098", "title": "Study of SRF617 in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2024-06-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04436120", "title": "Treatment Resistance Following Anti-cancer Therapies", "status": "TERMINATED", "last_update": "2024-12-03", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04447118", "title": "Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy", "status": "COMPLETED", "last_update": "2025-12-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04450732", "title": "Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors", "status": "UNKNOWN", "last_update": "2023-12-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04460456", "title": "A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors", "status": "UNKNOWN", "last_update": "2022-06-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04464967", "title": "Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers", "status": "WITHDRAWN", "last_update": "2021-05-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04485013", "title": "TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04553133", "title": "PF-07104091 as a Single Agent and in Combination Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04644068", "title": "Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04644237", "title": "Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2025-11-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04660929", "title": "CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors", "status": "UNKNOWN", "last_update": "2024-12-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04706949", "title": "Pyrotinib Combined With Pemetrexed Plus Carboplatin in the First-line Treatment", "status": "UNKNOWN", "last_update": "2021-01-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04818333", "title": "A Study of SHR-A1811 in Subjects With Advanced Non-small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2024-06-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04884282", "title": "Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04886804", "title": "Beamion LUNG-1: A Study to Test Different Doses of Zongertinib in People With Different Types of Advanced Cancer (Solid Tumours With Changes in the HER2 Gene)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04916002", "title": "A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer", "status": "TERMINATED", "last_update": "2026-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04982926", "title": "A Study of TAS2940 in Participants With Locally Advanced or Metastatic Solid Tumor Cancer", "status": "TERMINATED", "last_update": "2025-10-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05013554", "title": "Dose Escalation and Expansion Study of SAR443216 in Participants With Relapsed/Refractory HER2 Expressing Solid Tumors", "status": "TERMINATED", "last_update": "2025-09-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05016544", "title": "Inetetamab in Combination With Pyrotinib in HER2 Mutant or Amplified Advanced Non-small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2021-08-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05041972", "title": "ARX788 in Selected HER2-mutated or HER2-amplified/Overexpressed Solid Tumors (ACE-Pan Tumor-02)", "status": "WITHDRAWN", "last_update": "2022-09-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05048797", "title": "A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05068024", "title": "A Study of FWD1509 in Adults With Non-Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2022-07-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05069935", "title": "FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05091528", "title": "A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers", "status": "TERMINATED", "last_update": "2022-08-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05141786", "title": "A Study of MRG002 in the Treatment of Patients With HER2-mutated Unresectable/Metastatic Non-small Cell Lung Cancer (NSCLC).", "status": "UNKNOWN", "last_update": "2021-12-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05159518", "title": "A Study of PRT2527 in Participants With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2023-12-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05194072", "title": "A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2026-01-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05246514", "title": "A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05364073", "title": "Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05395052", "title": "FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05435274", "title": "Phase 1/2 Study of HS-10376 in Patients With Non-Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2022-06-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05472532", "title": "Evaluation of an Automated System to Culture Metastatic Patient Circulating Tumor Cells in Embryonated Chicken Eggs (in Ovo Culture)", "status": "COMPLETED", "last_update": "2025-11-20", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05514717", "title": "A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2", "status": "TERMINATED", "last_update": "2026-06-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05546268", "title": "Study of Oral MRT-2359 in Selected Cancer Patients", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05576077", "title": "A Study of TBio-4101 (TIL) and Pembrolizumab in Patients With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-03-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05650879", "title": "ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-07-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05745740", "title": "A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation", "status": "UNKNOWN", "last_update": "2023-11-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05805956", "title": "IMM2902 in Patients With Advanced Solid Tumors Expressing HER2", "status": "UNKNOWN", "last_update": "2023-04-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05847764", "title": "Disitamab Vedotin Combined Therapy for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations", "status": "UNKNOWN", "last_update": "2023-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05905341", "title": "Study of PF-07224826, as a Single Agent or in Combination With Endocrine Therapy in Participants With Breast Cancer and Other Advanced Solid Tumors.", "status": "WITHDRAWN", "last_update": "2023-11-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05926180", "title": "Assessing the Effect of DZD9008 on the Pharmacokinetics of the Cocktail Probes Representative for CYP3A4, P-gp, BCRP and OATP1B1 in Patients with EGFR or HER2 Mutant Advanced Non-small Cell Lung Cancer (WU-KONG19)", "status": "COMPLETED", "last_update": "2024-12-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06003231", "title": "A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06151574", "title": "Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06185400", "title": "RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations", "status": "NOT_YET_RECRUITING", "last_update": "2023-12-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06250777", "title": "Efficacy and Safety of T-DXd in HER2-mutant Advanced Lung Cancer Patients With Asymptomatic Brain Metastases", "status": "ENROLLING_BY_INVITATION", "last_update": "2026-02-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06257264", "title": "A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06329895", "title": "A Study to Learn About How BAY2927088 Affects the Level of Dabigatran or Rosuvastatin in the Blood When These Drugs Are Taken Together in Healthy Participants", "status": "COMPLETED", "last_update": "2024-07-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06348888", "title": "A Study to Learn About How Itraconazole and Carbamazepine Affect the Level of BAY2927088 in the Blood When These Drugs Are Taken Together by Healthy Participants", "status": "COMPLETED", "last_update": "2024-06-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06360211", "title": "A Study to Learn About How BAY2927088 Affects the Level of Midazolam in the Blood When Both Drugs Are Taken Together in Healthy Participants", "status": "COMPLETED", "last_update": "2024-07-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06378658", "title": "A Study to Learn About How Food and Esomeprazole Affect the Level of BAY2927088 in the Blood When Taken Together in Healthy Participants", "status": "COMPLETED", "last_update": "2024-07-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06519110", "title": "Neratinib Tablets Monotherapy for Advanced Solid Tumors With HER2 Mutations", "status": "UNKNOWN", "last_update": "2024-07-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07036185", "title": "A Clinical Trail of KJ015 in Patients With HER2-Expressing Solid Tumors", "status": "NOT_YET_RECRUITING", "last_update": "2025-06-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07191405", "title": "Clinical Study of Chemotherapy and Immunotherapy Combined With Lactobacillus Johnsonii in Patients With Multiple Irresectable Solid Tumors", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-24", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07281209", "title": "A Study of SHR-A1811 Combined With Adebelimumab as Neoadjuvant Therapy for Resectable HER2-Altered Non-Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-12-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07283198", "title": "A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-12-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07377916", "title": "Clinical Study of SHR-A1811 Combined With Pertuzumab as Second-Line Therapy in Patients With HER2-Altered Advanced NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-30", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07416058", "title": "PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 \u226550% Non-Squamous NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07436858", "title": "Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER2-overexpressing Metastatic Non-small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07489703", "title": "SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2026-03-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07630077", "title": "Trastuzumab Rezetecan(SHR-A1811) Combined With Ivonescimab (AK112) in Locally Advanced or Metastatic Non-small Cell Lung Cancer Harboring HER2 Gene Abnormalities", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07631884", "title": "Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07671092", "title": "Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-16", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07699952", "title": "First-line Therapy With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor(EGFR-TKI) Combined With Trastuzumab Rezetecan for Advanced Non-small Cell Lung Cancer(NSCLC) Harboring EGFR Mutations Concomitant With Human Epidermal Growth Factor Receptor 2(HER2) Alterations", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 6, "n_observational": 0, "n_active": 3, "n_withdrawn": 1, "trials": [ { "nct": "NCT03198052", "title": "GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGF\u03b2/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers", "status": "RECRUITING", "last_update": "2024-06-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04842812", "title": "Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2024-06-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07641023", "title": "Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC", "status": "RECRUITING", "last_update": "2026-06-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02713984", "title": "A Clinical Research of CAR T Cells Targeting HER2 Positive Cancer", "status": "WITHDRAWN", "last_update": "2020-03-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02983045", "title": "A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2023-03-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03970382", "title": "A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors", "status": "SUSPENDED", "last_update": "2022-08-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "HER2", "ERBB2", "trastuzumab deruxtecan" ] }, "c-MET": { "n": 227, "n_observational": 34, "n_active": 104, "n_withdrawn": 3, "trials": [ { "nct": "NCT01639508", "title": "Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity", "status": "RECRUITING", "last_update": "2026-08-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03175224", "title": "APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2025-06-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03785574", "title": "Study of Different Therapeutic Strategies in Hydatidiform Mole With Lung Nodule", "status": "RECRUITING", "last_update": "2026-03-16", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04270591", "title": "Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2022-08-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04322890", "title": "Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation", "status": "RECRUITING", "last_update": "2024-10-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04916990", "title": "Improving Care for Rural Patients With Solid Tumors", "status": "RECRUITING", "last_update": "2026-02-05", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04928846", "title": "A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04930432", "title": "Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors", "status": "RECRUITING", "last_update": "2026-02-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05005403", "title": "Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan", "status": "RECRUITING", "last_update": "2026-06-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05642572", "title": "Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)", "status": "RECRUITING", "last_update": "2026-06-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05777278", "title": "Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression", "status": "RECRUITING", "last_update": "2023-10-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05967689", "title": "A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.", "status": "RECRUITING", "last_update": "2026-09-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06031688", "title": "Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)", "status": "RECRUITING", "last_update": "2026-05-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06102928", "title": "A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation", "status": "RECRUITING", "last_update": "2023-10-26", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06106802", "title": "Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06109558", "title": "The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC", "status": "RECRUITING", "last_update": "2024-05-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06116682", "title": "Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)", "status": "RECRUITING", "last_update": "2026-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06119581", "title": "A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06203210", "title": "A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06343064", "title": "Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI", "status": "RECRUITING", "last_update": "2025-05-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06422143", "title": "Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06481813", "title": "Prospective, Longitudinal Biocollection in Thoracic Oncology, Including Newly Diagnosed Lung Cancer Patients", "status": "RECRUITING", "last_update": "2026-01-21", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06517953", "title": "Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations", "status": "RECRUITING", "last_update": "2024-07-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06561685", "title": "A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06563999", "title": "Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.", "status": "RECRUITING", "last_update": "2026-04-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06568939", "title": "A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06621563", "title": "Phase Ib Trial of HS-20117 in Combination With Other Drugs in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2025-04-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06669117", "title": "FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations", "status": "RECRUITING", "last_update": "2025-07-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06680050", "title": "Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen", "status": "RECRUITING", "last_update": "2025-12-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06731907", "title": "A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)", "status": "RECRUITING", "last_update": "2026-08-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06772623", "title": "Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06814496", "title": "Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors", "status": "RECRUITING", "last_update": "2026-07-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06930794", "title": "A Study of Vebreltinib and Platinum-Containing Double Agents in Subjects With MET-Positive", "status": "RECRUITING", "last_update": "2026-05-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06954246", "title": "A Study of MHB088C Injection Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2025-06-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07005102", "title": "A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-06-08", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07087223", "title": "Phase Ib/II Study of Vebreltinib With Furmonertinib in NSCLC Patients With c-Met Amplification After EGFR-TKI Failure", "status": "RECRUITING", "last_update": "2025-07-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07089199", "title": "Tislelizumab Combined With Anlotinib and Nab-paclitaxel in III Resectable Non-small Cell Lung Cancer : A Prospective, Single-Arm, Phase II Study", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07120698", "title": "Adaptive Adjuvant Sintilimab Therapy Guided by MRD (ADAPT Lung)", "status": "RECRUITING", "last_update": "2026-01-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07155187", "title": "A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-07-09", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07322783", "title": "Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification", "status": "RECRUITING", "last_update": "2026-01-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07323641", "title": "Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-04-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07439094", "title": "A First-in-Human Study of CKD-703 in Advanced Solid Tumors and Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-04-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07589205", "title": "Study of IBI3028 in Participants With Locally Advanced, Unresectable, or Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00062439", "title": "S0220: Chemoradiotherapy Followed By Surgery and Docetaxel in Treating Patients With Pancoast Tumors", "status": "COMPLETED", "last_update": "2013-11-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00449033", "title": "A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients With Stage IIIb With Effusion and Stage IV Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2015-04-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00585195", "title": "A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer", "status": "COMPLETED", "last_update": "2023-02-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00606502", "title": "Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment", "status": "COMPLETED", "last_update": "2021-03-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00652561", "title": "Phase 2 Study of S-1 as 2nd Line Therapy in Advanced Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2024-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00870870", "title": "A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before", "status": "COMPLETED", "last_update": "2018-06-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00935896", "title": "High Tidal Volume Induces Inflammation In Normal Lungs", "status": "COMPLETED", "last_update": "2009-07-09", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01039948", "title": "A Phase 1b/2 Study in Asian Subjects With Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2015-04-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01044290", "title": "Outlook Quality of Life Intervention Study", "status": "COMPLETED", "last_update": "2015-11-20", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01107444", "title": "Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2019-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01115790", "title": "A Phase 1 Study in Participants With Advanced Cancer", "status": "COMPLETED", "last_update": "2016-05-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01121575", "title": "A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2015-10-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01126346", "title": "Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC)", "status": "COMPLETED", "last_update": "2018-07-03", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01190527", "title": "Using FDG-PET During Radiation Therapy in Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2017-06-02", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01232452", "title": "A Study in Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2019-09-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01244191", "title": "Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer", "status": "TERMINATED", "last_update": "2021-04-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01306045", "title": "Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies", "status": "COMPLETED", "last_update": "2024-10-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01324479", "title": "Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2020-12-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01336634", "title": "Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.", "status": "COMPLETED", "last_update": "2022-04-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01423760", "title": "Common Safety Follow-up Trial of Tecemotide (L-BLP25)", "status": "TERMINATED", "last_update": "2016-10-06", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01441128", "title": "-02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2019-12-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01456325", "title": "A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)", "status": "COMPLETED", "last_update": "2016-11-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01570296", "title": "A Trial of Gefitinib in Combination With BKM120 in Patients With Advanced Non-Small Cell Lung Cancer, With Enrichment for Patients Whose Tumours Harbour Molecular Alterations of PI3K Pathway and Known to Overexpress EGFR", "status": "COMPLETED", "last_update": "2023-03-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01580735", "title": "ARQ 197 Plus Erlotinib in Patient With Locally Advanced or Metastatic EGFR Mutation-positive Non-small-cell Lung Cancer", "status": "COMPLETED", "last_update": "2015-08-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01602289", "title": "A Study of LY2875358 in Japanese Participants With Advanced Cancer", "status": "COMPLETED", "last_update": "2015-06-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01610336", "title": "A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment", "status": "COMPLETED", "last_update": "2021-04-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01654965", "title": "Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors", "status": "COMPLETED", "last_update": "2018-04-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01861301", "title": "Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma", "status": "TERMINATED", "last_update": "2016-10-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01887886", "title": "A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation", "status": "COMPLETED", "last_update": "2016-11-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01900652", "title": "A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants", "status": "COMPLETED", "last_update": "2019-09-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01904253", "title": "A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung Cancer Following Platinum-Based Chemotherapy", "status": "TERMINATED", "last_update": "2024-09-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01911507", "title": "INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2021-10-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01913067", "title": "Evaluation of Cabazitaxel in Patients With Brain Metastasis Secondary to Breast Cancer and NSCLC", "status": "WITHDRAWN", "last_update": "2014-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02006043", "title": "Evaluate Erlotinib Efficacy and Safety as the 2nd/3rd Treatment in NSCLC With EGFR M(-) and C-met(-)", "status": "UNKNOWN", "last_update": "2015-07-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02014116", "title": "A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body", "status": "TERMINATED", "last_update": "2019-12-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02080650", "title": "Characterization of Circulating Tumor Cells Captured by c-MET (CTC-MET)", "status": "COMPLETED", "last_update": "2017-08-01", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02132598", "title": "Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases", "status": "TERMINATED", "last_update": "2021-03-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02134912", "title": "S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib", "status": "TERMINATED", "last_update": "2020-02-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02175017", "title": "ONO-4538 Study in Patients With Advanced Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2024-12-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02194738", "title": "Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02201992", "title": "Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-12-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02219711", "title": "Phase 1/1b Study of MGCD516 in Patients With Advanced Cancer", "status": "COMPLETED", "last_update": "2023-03-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02276027", "title": "A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2020-12-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02308020", "title": "A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain", "status": "COMPLETED", "last_update": "2020-12-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02320123", "title": "End-of-Life Care for African Americans", "status": "COMPLETED", "last_update": "2020-08-12", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02335944", "title": "Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.", "status": "TERMINATED", "last_update": "2023-06-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02411448", "title": "A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02423343", "title": "A Study of Galunisertib (LY2157299) in Combination With Nivolumab in Advanced Refractory Solid Tumors and in Recurrent or Refractory NSCLC, or Hepatocellular Carcinoma", "status": "COMPLETED", "last_update": "2021-09-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02440906", "title": "Evaluation of the Texas Wellness Incentives and Navigation (WIN) Project", "status": "COMPLETED", "last_update": "2017-10-03", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02498665", "title": "A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies", "status": "COMPLETED", "last_update": "2023-11-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02499614", "title": "Crizotinib in Pretreated Metastatic Non-small-cell Lung Cancer With MET Amplification or ROS1 Translocation (METROS)", "status": "UNKNOWN", "last_update": "2017-10-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02571036", "title": "A Safety, Tolerability and PK Study of DCC-2618 in Patients With Advanced Malignancies", "status": "COMPLETED", "last_update": "2023-12-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02572687", "title": "A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies", "status": "COMPLETED", "last_update": "2021-01-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02609776", "title": "Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02639767", "title": "Concurrent Pemetrexed/Cisplatin With Pleural Intensity Modulated Radiation Therapy for Patients With Unresectable Malignant Pleural Mesothelioma", "status": "WITHDRAWN", "last_update": "2016-12-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02664935", "title": "National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-04-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02676050", "title": "Visualising c-MET and Activated Neutrophils in Lung Cancer", "status": "TERMINATED", "last_update": "2026-06-03", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02687958", "title": "Study of Everolimus as Maintenance Therapy for Metastatic NEC With Pulmonary or Gastroenteropancreatic Origin", "status": "UNKNOWN", "last_update": "2023-05-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02864992", "title": "Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02871115", "title": "Pilot Study of a Pharmacy Intervention for Older Adults With Cancer", "status": "COMPLETED", "last_update": "2021-11-12", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02896231", "title": "First-in-human Phase I Study of a Selective c-Met Inhibitor PLB1001", "status": "COMPLETED", "last_update": "2019-11-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02920996", "title": "Merestinib In Non-Small Cell Lung Cancer And Solid Tumors", "status": "TERMINATED", "last_update": "2024-04-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02926638", "title": "Lung-MAP: Rilotumumab and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches", "status": "TERMINATED", "last_update": "2020-03-19", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02929290", "title": "Safety, Efficacy and Pharmacokinetic of BPI-9016M in Patients With c-Met- Dysregulated Advanced NSCLC", "status": "UNKNOWN", "last_update": "2021-09-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02938104", "title": "Multimodal Prehabilitation to Enhance Functional Recovery After Lung Surgery", "status": "COMPLETED", "last_update": "2018-03-22", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02946359", "title": "A+C in Metastatic Lung Adenocarcinoma Cancer", "status": "UNKNOWN", "last_update": "2016-11-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03023423", "title": "A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2019-11-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03066778", "title": "A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)", "status": "COMPLETED", "last_update": "2022-10-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03088930", "title": "Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2022-02-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03101839", "title": "Phase I Dose-Escalation Study of AZD4785 in Patients With Advanced Solid Tumours", "status": "COMPLETED", "last_update": "2019-10-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03115398", "title": "A Simple Walking Program to Enhance Concurrent Chemoradiotherapy Delivery", "status": "COMPLETED", "last_update": "2026-04-13", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03128008", "title": "Locally Advanced NSCLC Hyperfractionated RT", "status": "COMPLETED", "last_update": "2021-05-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03128060", "title": "Expanding Access to Home-Based Palliative Care", "status": "TERMINATED", "last_update": "2025-09-22", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03159585", "title": "To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors", "status": "COMPLETED", "last_update": "2020-01-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03318939", "title": "Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation", "status": "TERMINATED", "last_update": "2026-06-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03333343", "title": "Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03334617", "title": "Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03337399", "title": "Stepped Palliative Care Versus Early Integrated Palliative Care in Patients With Advanced Lung Cancer", "status": "COMPLETED", "last_update": "2026-08-03", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03375489", "title": "Early Integrated Telehealth Versus In-Person Palliative Care for Patients With Lung Cancer", "status": "COMPLETED", "last_update": "2025-05-16", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03420742", "title": "A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid Tumors", "status": "COMPLETED", "last_update": "2023-01-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03468985", "title": "Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2023-10-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03539536", "title": "Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03574402", "title": "Phase II Umbrella Study Directed by Next Generation Sequencing", "status": "UNKNOWN", "last_update": "2022-12-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03574753", "title": "Lung-MAP S1400K: c-MET Positive", "status": "COMPLETED", "last_update": "2021-10-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03600233", "title": "Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-12-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03721120", "title": "Evaluation of the Feasibility and Clinical Relevance of Liquid Biopsy in Patients With Suspicious Metastatic Lung Cancer", "status": "COMPLETED", "last_update": "2025-08-08", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03785808", "title": "Reducing Insulin, Growth Hormones, and Tumors", "status": "TERMINATED", "last_update": "2019-08-12", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03793894", "title": "Inpatient Smokers and LDCT Screening Part 2", "status": "COMPLETED", "last_update": "2020-07-07", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03797391", "title": "A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors", "status": "UNKNOWN", "last_update": "2023-05-31", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03847519", "title": "Study of ADXS-503 With or Without Pembro in Subjects With Metastatic Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2024-06-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03865511", "title": "MEchanisms of Resistance in EGFR Mutated Nonpretreated Advanced Lung Cancer Receiving OSimErtib", "status": "UNKNOWN", "last_update": "2024-02-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03911193", "title": "CABozantinib in Non-Small Cell Lung Cancer (NSCLC) Patients With MET Deregulation", "status": "UNKNOWN", "last_update": "2019-04-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03944772", "title": "Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-01-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04036682", "title": "A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04052971", "title": "To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of ABN401 in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer Harboring c-MET Dysregulation", "status": "COMPLETED", "last_update": "2025-01-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04084717", "title": "Study of Crizotinib for ROS1 and MET Activated Lung Cancer", "status": "COMPLETED", "last_update": "2026-06-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04148937", "title": "A Study of the CD73 Inhibitor LY3475070 Alone or in Combination With Pembrolizumab in Participants With Advanced Cancer", "status": "COMPLETED", "last_update": "2024-04-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04255836", "title": "Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC)", "status": "UNKNOWN", "last_update": "2020-02-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04258033", "title": "A Study of PLB1001 in Non-small Cell Lung Cancer With c-Met Dysregulation(KUNPENG)", "status": "COMPLETED", "last_update": "2026-06-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04258813", "title": "Onco-primary Care Networking to Support TEAM-based Care", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-20", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04292119", "title": "Lorlatinib Combinations in Lung Cancer", "status": "UNKNOWN", "last_update": "2021-03-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04323436", "title": "Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations", "status": "TERMINATED", "last_update": "2024-10-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04325776", "title": "A Study of AL2846 Versus Zoledronic Acid in Subjects With Advanced Non-Small Cell Lung Cancer With Bone Metastasis", "status": "UNKNOWN", "last_update": "2020-10-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04338243", "title": "Glumetinib Combined With Osimertinib in the Treatment of Relapsed and Metastatic Non-small Cell Lung Cancer Patients Who Failed to Receive EGFR Inhibitors", "status": "UNKNOWN", "last_update": "2020-04-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04398940", "title": "A Study of TQ-B3139 Capsules in Subjects With MET-Altered Advanced Non-small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2020-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04465968", "title": "Efficacy and Safety of CRT, Durvalumab and Surgery for SST", "status": "NOT_YET_RECRUITING", "last_update": "2020-07-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04606771", "title": "A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04624204", "title": "Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Na\u00efve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04647838", "title": "Tepotinib in Solid Tumors Harboring MET Alterations", "status": "UNKNOWN", "last_update": "2020-12-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04677595", "title": "Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation", "status": "COMPLETED", "last_update": "2026-03-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04738487", "title": "Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)", "status": "COMPLETED", "last_update": "2026-06-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04762459", "title": "Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection", "status": "ENROLLING_BY_INVITATION", "last_update": "2022-02-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04768296", "title": "Berzosertib + Topotecan in Relapsed Platinum-Resistant Small-Cell Lung Cancer (DDRiver SCLC 250)", "status": "COMPLETED", "last_update": "2024-09-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04774380", "title": "Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2025-05-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04808752", "title": "Almonertinib as First-line Treatment in Patients With EGFR Mutations Positive in Advanced NSCLC With Brain Metastases", "status": "UNKNOWN", "last_update": "2024-04-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04816214", "title": "Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy", "status": "TERMINATED", "last_update": "2024-03-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04868877", "title": "Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04870333", "title": "PROphylaxis for paTiEnts at Risk of COVID-19 infecTion -V", "status": "COMPLETED", "last_update": "2025-06-20", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04922138", "title": "Aumolertinib Adjuvant Therapy of Resectable Stage I EGFRm+ NSCLC With High-grade Patterns", "status": "UNKNOWN", "last_update": "2023-04-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04982224", "title": "Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer", "status": "TERMINATED", "last_update": "2025-11-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05007938", "title": "Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer", "status": "UNKNOWN", "last_update": "2024-08-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05009836", "title": "Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05067738", "title": "Same Day Discharge for Wedge Resection", "status": "COMPLETED", "last_update": "2024-05-31", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05089734", "title": "Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05110196", "title": "Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.", "status": "COMPLETED", "last_update": "2026-04-07", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05120349", "title": "A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05180851", "title": "Safety and Efficacy of Recombinant Oncolytic Adenovirus L-IFN Injection in Relapsed/Refractory Solid Tumors Clinical Study", "status": "UNKNOWN", "last_update": "2022-02-01", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05261399", "title": "Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05270395", "title": "Piloting 'mPal,' a Multilevel Strategy for Palliative Care Implementation", "status": "COMPLETED", "last_update": "2025-05-13", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05299125", "title": "Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor Mutations", "status": "COMPLETED", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05360979", "title": "A Clinical Study of Immunotherapy Combined With Chemotherapy and Anti-angiogenic Therapy in Operable NSCLC", "status": "UNKNOWN", "last_update": "2022-05-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05374603", "title": "Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05430386", "title": "Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC", "status": "UNKNOWN", "last_update": "2023-02-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05513703", "title": "A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)", "status": "TERMINATED", "last_update": "2025-10-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05555342", "title": "A Novel Method for Treating Lung Met w/Combo of Electric Fields & Rad Therapy: A Single-Arm", "status": "COMPLETED", "last_update": "2025-05-14", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05585320", "title": "A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05652868", "title": "Clinical Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2025-12-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05663866", "title": "Premedication to Reduce Amivantamab Associated Infusion Related Reactions", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05668988", "title": "A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05722015", "title": "A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05731076", "title": "Self-Management Support for Lung Cancer Patients With Cachexia", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-13", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05767892", "title": "YK-029A as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations", "status": "NOT_YET_RECRUITING", "last_update": "2023-04-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05782361", "title": "POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05784142", "title": "Chemo-immunotherapy Induction Followed by Hypo-radiotherapy in LA-NSCLC(CHIC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2023-03-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05801029", "title": "A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05812534", "title": "Study of Cadonilimab Combined With Bevacizumab and Chemotherapy for Advanced Nonsquamous Non-small Cell Lung Cancer Patients With Untreated Brain Metastases", "status": "UNKNOWN", "last_update": "2023-11-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05925530", "title": "Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05930418", "title": "Cardiovascular Magnetic Resonance Prognosticators in Pediatric Oncology Patients With Sepsis", "status": "COMPLETED", "last_update": "2026-06-17", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06015568", "title": "Study of MCLA-129 Combined With Befotertinib in the Treatment of Advanced Non-small Cell Lung Cancer With EGFR Sensitive Mutation", "status": "NOT_YET_RECRUITING", "last_update": "2023-08-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06093503", "title": "Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein", "status": "WITHDRAWN", "last_update": "2024-06-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06212752", "title": "A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06234735", "title": "Physical Activity Behavioral Change Intervention in Lung Cancer", "status": "UNKNOWN", "last_update": "2024-02-09", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06289192", "title": "Testing C-Raven, a Virtual Tobacco Cessation Intervention, in the Community", "status": "COMPLETED", "last_update": "2025-09-10", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06305754", "title": "Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06339242", "title": "A Study of Furmonertinib Combined With Chemotherapy in the Treatment of NSCLC With Leptomeningeal Metastasis", "status": "UNKNOWN", "last_update": "2024-04-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06370416", "title": "the Prevention of Bone Marrow Suppression Caused by Chemotherapy in Advanced NSCLC With Trilaciclib", "status": "ENROLLING_BY_INVITATION", "last_update": "2026-01-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06525350", "title": "A Study to Evaluate the Efficacy and Safety of the Combination of Glumetinib and Docetaxel\uff08Albumin Bound\uff09Verse Docetaxel for the Treatment of MET-overexpressed Non-small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-07-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06530719", "title": "A Study to Evaluate the Efficacy of Osimertinib in Patients With EGFR-sensitive Mutated Non-small Cell Lung Cancer Progression After Receiving Adjuvant Targeted Therapy Following Radical Surgery", "status": "NOT_YET_RECRUITING", "last_update": "2024-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06532032", "title": "A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-07-31", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06545669", "title": "C-Raven, a Virtual Tobacco Cessation Intervention in the Community", "status": "COMPLETED", "last_update": "2026-02-02", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06594874", "title": "A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors", "status": "NOT_YET_RECRUITING", "last_update": "2024-09-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06644313", "title": "Vebreltinib for Neoadjuvant in MET-altered Stage IIIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)", "status": "NOT_YET_RECRUITING", "last_update": "2024-10-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06762327", "title": "Ensartinib in the Treatment of ALK Positive or MET Exon 14 Skipping Anvanced Solid Tumors Excluded Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-01-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06885840", "title": "Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.", "status": "NOT_YET_RECRUITING", "last_update": "2025-03-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06908772", "title": "Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients", "status": "NOT_YET_RECRUITING", "last_update": "2025-04-03", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06931145", "title": "Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-04-23", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06998719", "title": "Neoadjuvant Durvalumab and Chemotherapy Followed by Surgery/CRT and Durvalumab in Borderline Resectable Stage III NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2025-05-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07153770", "title": "Bozitinib Combined With Chemotherapy as Radical Treatment for Stage IIA-IIIC MET-Altered Non-Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07220356", "title": "C-Raven, a Virtual Tobacco Cessation Intervention in Residency Clinics", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-06", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07232394", "title": "Early Feeding and Mobilization in Thoracic Surgery", "status": "COMPLETED", "last_update": "2026-09-11", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07244926", "title": "Sac-TMT Plus Bevacizumab as Second-Line Treatment for Advanced Non-Squamous Non-Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-11-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07254650", "title": "Combination Versus Alone Liposomal Bupivacaine Blocks in Minimally Invasive Thoracic Surgery-1", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-26", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07285148", "title": "A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-12-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07489703", "title": "SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2026-03-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07502963", "title": "Effectiveness of a Multimodal Outpatient Supervised Physical Activity Program to Improve Tolerance and Efficacy of Chemotherapy in Adults With Breast, Lung and Colon Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-03-31", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07538973", "title": "A Clinical Study to Evaluate the Pharmacokinetics and Safety of Anecatibin Fumarate Capsules in Subjects With Impaired Liver Function Versus Normal Liver Function", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07549061", "title": "Vebreltinib Plus Chemotherapy as First-line Treatment for MET-overexpressing NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07558200", "title": "Phase Ia/Ib Study of FXB0871 Monotherapy in Locally Advanced/Metastatic Solid Tumors", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07603791", "title": "Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK202 for Injection in Combination With Drugs in NSCLC Participants.", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07625644", "title": "BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07703228", "title": "Second-Line Sacituzumab Tirumotecan Plus Anlotinib for Advanced Driver Gene-Negative Non-Squamous NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07739966", "title": "A Study of DS-3939a in Participants With Solid Tumors", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07782359", "title": "Impact of Using a GLP1 on Treatment Related Side Effects of Lung Cancer Patients Receiving Lorlatinib", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 0, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [] }, "synonyms_searched": [ "c-Met", "MET", "telisotuzumab", "Emrelis" ] }, "CEACAM5": { "n": 47, "n_observational": 6, "n_active": 15, "n_withdrawn": 4, "trials": [ { "nct": "NCT06010862", "title": "Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors", "status": "RECRUITING", "last_update": "2023-11-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06043466", "title": "A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors", "status": "RECRUITING", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06126406", "title": "Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes\uff08CAR-T\uff09 for CEA Positive Advanced Malignant Solid Tumors", "status": "RECRUITING", "last_update": "2023-11-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06472245", "title": "Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor", "status": "RECRUITING", "last_update": "2026-07-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06768151", "title": "A Clinical Trial of CEA Targeting CAR-T for CEA Positive Advanced Lung Cancer", "status": "RECRUITING", "last_update": "2025-01-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06903117", "title": "Anti-CEA CAR-T for Advanced CEA-Positive Lung Carcinoma", "status": "RECRUITING", "last_update": "2025-04-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06945523", "title": "Clinical Study on Chimeric Antigen Receptor T Lymphocyte (CAR-T) Targeting CEA for the Treatment of CEA - Positive Advanced Lung Cancer", "status": "RECRUITING", "last_update": "2025-06-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06992583", "title": "Targeted Anti-CEA CAR-T Immunotherapy for Advanced Lung Cancer", "status": "RECRUITING", "last_update": "2025-05-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07179692", "title": "CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2025-10-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07250386", "title": "A Study of CEA-Targeted CAR-T Therapy in Patients With CEA-Positive Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2025-11-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003125", "title": "Vaccine Therapy, Interleukin-2, and Sargramostim in Treating Patients With Advanced Tumors", "status": "COMPLETED", "last_update": "2011-03-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00004604", "title": "Biological Therapy in Treating Patients With Metastatic Cancer", "status": "COMPLETED", "last_update": "2013-02-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00006347", "title": "Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2009-03-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00006458", "title": "Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2009-03-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00088933", "title": "Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or Metastatic Colorectal Cancer", "status": "TERMINATED", "last_update": "2014-03-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00091039", "title": "Vaccine Therapy, Chemotherapy, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed With Surgery", "status": "COMPLETED", "last_update": "2013-06-20", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00103142", "title": "Vaccine Therapy in Treating Patients With Liver or Lung Metastases From Colorectal Cancer", "status": "COMPLETED", "last_update": "2015-10-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00128622", "title": "Denileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic Cancer", "status": "COMPLETED", "last_update": "2012-11-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00529984", "title": "A Phase I/II Study With CEA(6D) VRP Vaccine in Patients With Advanced or Metastatic CEA-Expressing Malignancies", "status": "COMPLETED", "last_update": "2012-07-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00738452", "title": "Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Stage I-IIIB Non-Small Cell Lung Cancer After Completion of Radiation Therapy Alone or Combined Radiation Therapy and Chemotherapy", "status": "COMPLETED", "last_update": "2018-02-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00924092", "title": "An Open Label Phase I Study to Eval the Safety and Tolerability of a Vaccine (GI-6207) Consisting of Whole, Heat-killed Recombinant Saccharomyces Cerevisiae (Yeast) Genetically Modified to Express CEA Protein in Adults With Metastatic CEA-expressing ...", "status": "COMPLETED", "last_update": "2019-12-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01147965", "title": "QUILT-3.038: Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA", "status": "COMPLETED", "last_update": "2025-11-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01212887", "title": "Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating Patients With Cancer", "status": "TERMINATED", "last_update": "2012-02-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01221675", "title": "TF2- Small Cell Lung Cancer Radio Immunotherapy", "status": "COMPLETED", "last_update": "2016-08-31", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01603849", "title": "Prophylactic Cranial Irradiation in Patients With Lung Adenocarcinoma With High Risk of Brain Metastasis", "status": "COMPLETED", "last_update": "2023-04-27", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01723306", "title": "Phase II/Pilot Study of 2nd Generation Anti-CEA Designer T Cells in Adenocarcinomas", "status": "SUSPENDED", "last_update": "2016-06-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02293954", "title": "Copper Cu 64 Anti-CEA Monoclonal Antibody M5A PET in Diagnosing Patients With CEA Positive Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-14", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02346955", "title": "Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)", "status": "TERMINATED", "last_update": "2020-08-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02349724", "title": "A Clinical Research of CAR T Cells Targeting CEA Positive Cancer", "status": "UNKNOWN", "last_update": "2017-04-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03127098", "title": "QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer", "status": "TERMINATED", "last_update": "2024-08-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03169738", "title": "QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors", "status": "WITHDRAWN", "last_update": "2025-02-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03384316", "title": "Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer", "status": "COMPLETED", "last_update": "2020-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03574649", "title": "QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2025-02-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04154956", "title": "SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small-cell Lung Cancer Patients", "status": "TERMINATED", "last_update": "2026-05-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04315467", "title": "Intraoperative Imaging of Pulmonary Nodules by SGM-101", "status": "COMPLETED", "last_update": "2022-06-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04348643", "title": "Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer", "status": "WITHDRAWN", "last_update": "2026-07-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04394624", "title": "Tusamitamab Ravtansine (SAR408701) in Combination With Ramucirumab or Ramucirumab and Pembrolizumab in Pretreated Patients With NSQ NSCLC (CARMEN-LC04)", "status": "TERMINATED", "last_update": "2025-06-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04524689", "title": "Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC", "status": "TERMINATED", "last_update": "2025-10-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04737213", "title": "SGM-101 in Colorectal Lung Metastases", "status": "UNKNOWN", "last_update": "2021-02-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04884282", "title": "Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05245071", "title": "Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA", "status": "TERMINATED", "last_update": "2025-08-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05703555", "title": "INTRUSION: Unraveling the INTRatUmoral PK/PD relatION for SAR408701", "status": "WITHDRAWN", "last_update": "2024-02-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05736731", "title": "A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-04-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05849246", "title": "The Study of Tusamitamab Ravtansine (IBI126) Combined With Sintilimab and Tusamitamab Ravtansine (IBI126) Combined With Sintilimab Plus Platinum-based Chemotherapy and Pemetrexed in Subjects With CEACAM5 Positive Expression Advanced/Metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC)", "status": "TERMINATED", "last_update": "2024-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06006390", "title": "CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors", "status": "UNKNOWN", "last_update": "2024-08-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06710132", "title": "Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07153770", "title": "Bozitinib Combined With Chemotherapy as Radical Treatment for Stage IIA-IIIC MET-Altered Non-Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 14, "n_observational": 0, "n_active": 10, "n_withdrawn": 1, "trials": [ { "nct": "NCT06010862", "title": "Clinical Study of CEA-targeted CAR-T Therapy for CEA-positive Advanced/Metastatic Malignant Solid Tumors", "status": "RECRUITING", "last_update": "2023-11-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06043466", "title": "A Clinical Trial Targeting CEA Chimeric Antigen Receptor T (CAR-T) for CEA Positive Advanced Malignant Solid Tumors", "status": "RECRUITING", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06126406", "title": "Clinical Study of CEA Targeting Chimeric Antigen Receptor T Lymphocytes\uff08CAR-T\uff09 for CEA Positive Advanced Malignant Solid Tumors", "status": "RECRUITING", "last_update": "2023-11-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06768151", "title": "A Clinical Trial of CEA Targeting CAR-T for CEA Positive Advanced Lung Cancer", "status": "RECRUITING", "last_update": "2025-01-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06903117", "title": "Anti-CEA CAR-T for Advanced CEA-Positive Lung Carcinoma", "status": "RECRUITING", "last_update": "2025-04-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06945523", "title": "Clinical Study on Chimeric Antigen Receptor T Lymphocyte (CAR-T) Targeting CEA for the Treatment of CEA - Positive Advanced Lung Cancer", "status": "RECRUITING", "last_update": "2025-06-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06992583", "title": "Targeted Anti-CEA CAR-T Immunotherapy for Advanced Lung Cancer", "status": "RECRUITING", "last_update": "2025-05-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07179692", "title": "CEA-Targeted CAR-T Therapy in CEA-Positive Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2025-10-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07250386", "title": "A Study of CEA-Targeted CAR-T Therapy in Patients With CEA-Positive Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2025-11-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01723306", "title": "Phase II/Pilot Study of 2nd Generation Anti-CEA Designer T Cells in Adenocarcinomas", "status": "SUSPENDED", "last_update": "2016-06-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02349724", "title": "A Clinical Research of CAR T Cells Targeting CEA Positive Cancer", "status": "UNKNOWN", "last_update": "2017-04-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04348643", "title": "Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer", "status": "WITHDRAWN", "last_update": "2026-07-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05736731", "title": "A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-04-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06006390", "title": "CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors", "status": "UNKNOWN", "last_update": "2024-08-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "CEACAM5", "CEA", "carcinoembryonic antigen", "tusamitamab" ] }, "B7-H3": { "n": 27, "n_observational": 1, "n_active": 21, "n_withdrawn": 1, "trials": [ { "nct": "NCT03198052", "title": "GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGF\u03b2/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers", "status": "RECRUITING", "last_update": "2024-06-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04165070", "title": "KEYMAKER-U01 Substudy 01A: Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Chemotherapy When Used With Investigational Agents in Treatment-na\u00efve Participants With Stage IV Non-small Cell Lung Cancer (NSCLC) (MK-3475-01A/KEYMAKER-U01A)", "status": "RECRUITING", "last_update": "2026-08-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04842812", "title": "Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2024-06-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05142189", "title": "Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-07-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05914116", "title": "A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2025-11-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06203210", "title": "A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06242470", "title": "A Study of MGC026 in Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06362252", "title": "A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)", "status": "RECRUITING", "last_update": "2026-02-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06780085", "title": "A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)", "status": "RECRUITING", "last_update": "2026-08-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06780098", "title": "Substudy 01I: A Study of Investigational Agents in Participants With Previously Treated Stage IV Squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01I/KEYMAKER-U01I)", "status": "RECRUITING", "last_update": "2026-08-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06780137", "title": "A Study to Evaluate the Safety and Efficacy of Gocatamig (MK-6070) and Ifinatamab Deruxtecan (I-DXd) in Participants With Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer (MK-6070-002)", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06953089", "title": "DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07099898", "title": "A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC)", "status": "RECRUITING", "last_update": "2026-08-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07181473", "title": "A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of TJ101 in Patients With Advanced/Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-01-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07189871", "title": "177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-03-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07227597", "title": "A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)", "status": "RECRUITING", "last_update": "2026-08-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07503808", "title": "A Study of IDE034 in Adult Participants With Locally Advanced/Metastatic Solid Tumors Types", "status": "RECRUITING", "last_update": "2026-06-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02381314", "title": "Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer", "status": "COMPLETED", "last_update": "2022-02-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02628535", "title": "Safety Study of MGD009 in B7-H3-expressing Tumors", "status": "TERMINATED", "last_update": "2022-02-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03729596", "title": "MGC018 With or Without MGA012 in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-07-31", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04471727", "title": "A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04864821", "title": "Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid Tumor", "status": "UNKNOWN", "last_update": "2021-05-06", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05190185", "title": "A Clinical Trial of TAA06 Injection in Advanced Solid Tumors", "status": "UNKNOWN", "last_update": "2022-01-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05280470", "title": "Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06052423", "title": "ARTEMIS-007: HS-20093 in Patients With Extensive Stage Small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2024-03-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07076095", "title": "A Phase II/III Study of IBB0979 in Combination With Topotecan Versus Topotecan in Relapsed Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-07-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07509034", "title": "Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 4, "n_observational": 0, "n_active": 3, "n_withdrawn": 0, "trials": [ { "nct": "NCT03198052", "title": "GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGF\u03b2/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers", "status": "RECRUITING", "last_update": "2024-06-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04842812", "title": "Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2024-06-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04864821", "title": "Clinical Study of CD276 Targeted Autologous Chimeric Antigen Receptor T Cell Infusion in Patients With CD276 Positive Advanced Solid Tumor", "status": "UNKNOWN", "last_update": "2021-05-06", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07509034", "title": "Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory Disease", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "B7-H3", "CD276", "ifinatamab" ] }, "mesothelin": { "n": 39, "n_observational": 4, "n_active": 16, "n_withdrawn": 1, "trials": [ { "nct": "NCT03198052", "title": "GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGF\u03b2/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers", "status": "RECRUITING", "last_update": "2024-06-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04842812", "title": "Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2024-06-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05403554", "title": "A Study of NI-1801 in Patients with Mesothelin Expressing Solid Cancers", "status": "RECRUITING", "last_update": "2024-10-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05568680", "title": "SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma", "status": "RECRUITING", "last_update": "2026-06-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06051695", "title": "A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression", "status": "RECRUITING", "last_update": "2026-06-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06196294", "title": "GPC3/Mesothelin-CAR-\u03b3\u03b4T Cells Against Cancers", "status": "RECRUITING", "last_update": "2024-06-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06756035", "title": "CT-95 in Advanced Cancers Associated With Mesothelin Expression", "status": "RECRUITING", "last_update": "2026-06-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06885697", "title": "Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma", "status": "RECRUITING", "last_update": "2026-08-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07467863", "title": "Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC", "status": "RECRUITING", "last_update": "2026-03-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07510815", "title": "Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma", "status": "RECRUITING", "last_update": "2026-04-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07641023", "title": "Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC", "status": "RECRUITING", "last_update": "2026-06-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00006981", "title": "Immunotoxin Therapy in Treating Patients With Advanced Cancer", "status": "COMPLETED", "last_update": "2015-04-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00066651", "title": "Immunotoxin Therapy in Treating Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2015-04-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00325494", "title": "A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer", "status": "COMPLETED", "last_update": "2014-07-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00585845", "title": "Study of Safety and Tolerability of Intravenous CRS-207 in Adults With Selected Advanced Solid Tumors Who Have Failed or Who Are Not Candidates for Standard Treatment", "status": "TERMINATED", "last_update": "2009-02-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01355965", "title": "Autologous Redirected RNA Meso-CIR T Cells", "status": "COMPLETED", "last_update": "2017-09-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01413451", "title": "Amatuximab for High Mesothelin Cancers", "status": "TERMINATED", "last_update": "2019-12-17", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01521325", "title": "A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers", "status": "COMPLETED", "last_update": "2016-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01583686", "title": "CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer", "status": "TERMINATED", "last_update": "2019-10-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01675765", "title": "Safety and Efficacy of Listeria in Combination With Chemotherapy as Front-line Treatment for Malignant Pleural Mesothelioma", "status": "COMPLETED", "last_update": "2020-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02414269", "title": "Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02485119", "title": "Phase I Dose Escalation Study of BAY94-9343 Given by Intravenous Infusion Every 3 Weeks in Japanese Subjects With Advanced Malignancies", "status": "COMPLETED", "last_update": "2018-06-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02580747", "title": "Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso", "status": "UNKNOWN", "last_update": "2015-10-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02639091", "title": "Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors", "status": "COMPLETED", "last_update": "2019-11-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02839681", "title": "Anti-Mesothelin Antibody Drug Conjugate Anetumab Ravtansine for Mesothelin Expressing Lung Adenocarcinoma", "status": "TERMINATED", "last_update": "2019-05-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03054298", "title": "CAR T Cells in Mesothelin Expressing Cancers", "status": "COMPLETED", "last_update": "2025-04-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03102320", "title": "Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2022-06-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03126630", "title": "Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03356808", "title": "Antigen-specific T Cells Against Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03455556", "title": "Anetumab Ravtansine and Atezolizumab in Treating Participants With Advanced Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2023-01-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03507452", "title": "First-in-human Study of BAY2287411 Injection, a Thorium-227 Labeled Antibody-chelator Conjugate, in Patients With Tumors Known to Express Mesothelin", "status": "COMPLETED", "last_update": "2023-03-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03907852", "title": "Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04027946", "title": "LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC)", "status": "TERMINATED", "last_update": "2024-04-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04489862", "title": "\u03b1PD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors", "status": "UNKNOWN", "last_update": "2020-07-28", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04577326", "title": "Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05375825", "title": "Phase I Evaluation of Immunotoxin LMB-100 Administered by Normothermic, Intrapleural Perfusion Following Cytoreductive Surgery in Participants With Pleural Mesotheliomas, or Pleural Effusions From Cancers Expressing Mesothelin", "status": "WITHDRAWN", "last_update": "2024-02-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05451849", "title": "A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer", "status": "TERMINATED", "last_update": "2026-07-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06256055", "title": "Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors", "status": "UNKNOWN", "last_update": "2024-07-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06523803", "title": "A Study of ZW171 in Participants With Advanced or Metastatic Mesothelin-expressing Cancers", "status": "TERMINATED", "last_update": "2025-10-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 16, "n_observational": 0, "n_active": 11, "n_withdrawn": 0, "trials": [ { "nct": "NCT03198052", "title": "GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGF\u03b2/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers", "status": "RECRUITING", "last_update": "2024-06-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04842812", "title": "Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2024-06-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06051695", "title": "A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With Solid Tumors That Express MSLN and Have Lost HLA-A*02 Expression", "status": "RECRUITING", "last_update": "2026-06-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06196294", "title": "GPC3/Mesothelin-CAR-\u03b3\u03b4T Cells Against Cancers", "status": "RECRUITING", "last_update": "2024-06-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06885697", "title": "Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma", "status": "RECRUITING", "last_update": "2026-08-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07467863", "title": "Dual-Target CAR-NK Cells Directed Against MSLN, EGFR, or HER2 in Advanced NSCLC", "status": "RECRUITING", "last_update": "2026-03-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07510815", "title": "Dual-Target MSLN/FAP CAR-NK Cells for Pleural and Peritoneal Mesothelioma", "status": "RECRUITING", "last_update": "2026-04-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07641023", "title": "Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC", "status": "RECRUITING", "last_update": "2026-06-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01355965", "title": "Autologous Redirected RNA Meso-CIR T Cells", "status": "COMPLETED", "last_update": "2017-09-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01583686", "title": "CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer", "status": "TERMINATED", "last_update": "2019-10-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02414269", "title": "Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen Mesothelin", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02580747", "title": "Treatment of Relapsed and/or Chemotherapy Refractory Advanced Malignancies by CART-meso", "status": "UNKNOWN", "last_update": "2015-10-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03054298", "title": "CAR T Cells in Mesothelin Expressing Cancers", "status": "COMPLETED", "last_update": "2025-04-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03356808", "title": "Antigen-specific T Cells Against Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04489862", "title": "\u03b1PD1-MSLN-CAR T Cells for the Treatment of MSLN-positive Advanced Solid Tumors", "status": "UNKNOWN", "last_update": "2020-07-28", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04577326", "title": "Mesothelin-targeted CAR T-cell Therapy in Patients With Mesothelioma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "mesothelin", "MSLN" ] }, "MUC1": { "n": 33, "n_observational": 2, "n_active": 9, "n_withdrawn": 4, "trials": [ { "nct": "NCT01720836", "title": "Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2025-10-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03198052", "title": "GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGF\u03b2/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers", "status": "RECRUITING", "last_update": "2024-06-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04842812", "title": "Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2024-06-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07166601", "title": "M0324 as Monotherapy and in Combination With Pembrolizumab or Chemotherapy in Participants With Selected Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00103142", "title": "Vaccine Therapy in Treating Patients With Liver or Lung Metastases From Colorectal Cancer", "status": "COMPLETED", "last_update": "2015-10-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00157196", "title": "Safety Study of Tecemotide (L-BLP25) in Non-Small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease", "status": "COMPLETED", "last_update": "2015-08-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00157209", "title": "Phase 2b Randomized Controlled Study of Tecemotide (L-BLP25) for Immunotherapy of NSCLC (Non-Small Cell Lung Cancer)", "status": "COMPLETED", "last_update": "2015-11-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00409188", "title": "Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)", "status": "COMPLETED", "last_update": "2015-11-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00415818", "title": "Immunotherapy With TG4010 in Patients With Advanced Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2014-07-16", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00828009", "title": "BLP25 Liposome Vaccine and Bevacizumab After Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery", "status": "COMPLETED", "last_update": "2023-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00960115", "title": "Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy", "status": "COMPLETED", "last_update": "2015-10-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01015443", "title": "Cancer Vaccine Study for Stage III, Unresectable, Non-small Cell Lung Cancer (NSCLC) in the Asian Population", "status": "TERMINATED", "last_update": "2016-10-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01423760", "title": "Common Safety Follow-up Trial of Tecemotide (L-BLP25)", "status": "TERMINATED", "last_update": "2016-10-06", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01731587", "title": "Anti-cancer MUC1-specific Immunotherapy for Unresectable Stage III Non-small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2017-02-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02049151", "title": "Tecemotide Following Concurrent Chemo-radiotherapy for Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2017-08-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02132403", "title": "(PM-01) IMPRIME PGG\u00ae With BTH1704 and Gemcitabine for Advanced Pancreatic Cancer", "status": "TERMINATED", "last_update": "2015-05-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02140996", "title": "Safety Study of Human MUC-1 (Mucin-1) Adenoviral Vector Vaccine for Immunotherapy of Epithelial Cancers", "status": "UNKNOWN", "last_update": "2016-10-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02587689", "title": "Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor", "status": "UNKNOWN", "last_update": "2016-12-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02823990", "title": "TG4010 and Nivolumab in Patients With Lung Cancer", "status": "COMPLETED", "last_update": "2025-11-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02839954", "title": "CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor", "status": "UNKNOWN", "last_update": "2016-12-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03164772", "title": "Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC", "status": "COMPLETED", "last_update": "2022-10-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03169738", "title": "QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors", "status": "WITHDRAWN", "last_update": "2025-02-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03300817", "title": "MUC1 Vaccine in Preventing Lung Cancer in Current and Former Smokers at High Risk for Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03356808", "title": "Antigen-specific T Cells Against Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03384316", "title": "Multi-Targeted Recombinant Ad5 (CEA/MUC1/Brachyury) Based Immunotherapy Vaccine Regimen in People With Advanced Cancer", "status": "COMPLETED", "last_update": "2020-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03501056", "title": "Study of Activated Cytokine-induced Killer Armed With Bispecific Antibody for Advanced Lung Cancer", "status": "WITHDRAWN", "last_update": "2020-10-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03525782", "title": "Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC", "status": "UNKNOWN", "last_update": "2018-05-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03574649", "title": "QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2025-02-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03652077", "title": "A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies", "status": "COMPLETED", "last_update": "2021-11-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03970746", "title": "Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-05-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04695847", "title": "M1231 in Participants With Solid Tumors", "status": "COMPLETED", "last_update": "2023-07-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05239143", "title": "P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07670312", "title": "Evaluation of XYA02 in Patients With Advanced Solid Tumors", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 7, "n_observational": 0, "n_active": 4, "n_withdrawn": 0, "trials": [ { "nct": "NCT03198052", "title": "GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGF\u03b2/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers", "status": "RECRUITING", "last_update": "2024-06-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04842812", "title": "Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2024-06-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02587689", "title": "Phase I/II Study of Anti-Mucin1 (MUC1) CAR T Cells for Patients With MUC1+ Advanced Refractory Solid Tumor", "status": "UNKNOWN", "last_update": "2016-12-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02839954", "title": "CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor", "status": "UNKNOWN", "last_update": "2016-12-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03356808", "title": "Antigen-specific T Cells Against Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03525782", "title": "Anti-MUC1 CAR T Cells and PD-1 Knockout Engineered T Cells for NSCLC", "status": "UNKNOWN", "last_update": "2018-05-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05239143", "title": "P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "MUC1", "mucin-1", "tecemotide" ] }, "NY-ESO-1": { "n": 26, "n_observational": 3, "n_active": 5, "n_withdrawn": 2, "trials": [ { "nct": "NCT05296564", "title": "Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers", "status": "RECRUITING", "last_update": "2025-10-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05492682", "title": "START: Safety and Anti-Tumor Activity of PeptiCRAd-1 in Treatment of Cancer", "status": "RECRUITING", "last_update": "2026-05-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06942143", "title": "An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2025-09-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00199849", "title": "NY-ESO-1 Plasmid DNA (pPJV7611) Cancer Vaccine", "status": "COMPLETED", "last_update": "2022-10-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00291473", "title": "Safety and Immunogenicity of CHP-HER2 and CHP-NY-ESO-1 Protein With OK-432 in Antigen-Expressing Cancers", "status": "COMPLETED", "last_update": "2009-03-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00948961", "title": "A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1", "status": "COMPLETED", "last_update": "2016-06-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01159288", "title": "Trial of a Vaccination With Tumor Antigen-loaded Dendritic Cell-derived Exosomes", "status": "COMPLETED", "last_update": "2026-08-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01522820", "title": "Vaccine Therapy With or Without Sirolimus in Treating Patients With NY-ESO-1 Expressing Solid Tumors", "status": "COMPLETED", "last_update": "2016-10-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01584115", "title": "Clinical Trial of a Therapeutic Vaccine With NY-ESO-1 in Combination With the Adjuvant Monophosphoryl Lipid A (MPLA)", "status": "UNKNOWN", "last_update": "2012-04-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01967823", "title": "T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer", "status": "COMPLETED", "last_update": "2021-03-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02015416", "title": "A Phase 1 Trial of NY-ESO-1 With GLA-SE in Patients With Unresectable or Metastatic Cancer", "status": "COMPLETED", "last_update": "2017-08-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02122861", "title": "Phase 1 Study of Intradermal LV305 in Patients With Locally Advanced, Relapsed or Metastatic Cancer Expressing NY-ESO-1", "status": "COMPLETED", "last_update": "2019-03-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02387125", "title": "Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1", "status": "TERMINATED", "last_update": "2020-07-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02457650", "title": "T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies", "status": "UNKNOWN", "last_update": "2016-08-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02495636", "title": "Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2017-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02588612", "title": "Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2021-09-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02661100", "title": "A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients", "status": "WITHDRAWN", "last_update": "2016-12-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02869217", "title": "Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-12-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03029273", "title": "NY-ESO-1 TCR \uff08TAEST16001\uff09for Patients With Advanced NSCLC", "status": "UNKNOWN", "last_update": "2019-01-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03159585", "title": "To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors", "status": "COMPLETED", "last_update": "2020-01-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03164772", "title": "Phase 1/2 Study of Combination Immunotherapy and Messenger Ribonucleic Acid (mRNA) Vaccine in Subjects With NSCLC", "status": "COMPLETED", "last_update": "2022-10-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03709706", "title": "Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab", "status": "TERMINATED", "last_update": "2024-02-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03970746", "title": "Safety, Immunogenicity and Preliminary Clinical Activity Study of PDC*lung01 Cancer Vaccine in NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-05-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04526509", "title": "Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2024-11-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04908111", "title": "A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1", "status": "SUSPENDED", "last_update": "2026-04-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06048705", "title": "Study of GSK3901961 In Previously Treated Advanced (Metastatic OR Unresectable) Synovial Sarcoma/ Myxoid/Round Cell Liposarcoma, and Previously Treated Metastatic Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2024-11-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ], "cell_therapy": { "n": 8, "n_observational": 0, "n_active": 3, "n_withdrawn": 0, "trials": [ { "nct": "NCT05296564", "title": "Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers", "status": "RECRUITING", "last_update": "2025-10-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06942143", "title": "An Open-label, Phase I Clinical Trial of Super1 TCR-T in NY-ESO-1-positive Patients With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2025-09-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02457650", "title": "T Cell Receptor-transduced T Cells Targeting NY-ESO-1 for Treatment of Patients With NY-ESO-1- Expressing Malignancies", "status": "UNKNOWN", "last_update": "2016-08-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02588612", "title": "Letetresgene Autoleucel Engineered T Cells in NY-ESO -1 Positive Advanced Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2021-09-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02869217", "title": "Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-12-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03029273", "title": "NY-ESO-1 TCR \uff08TAEST16001\uff09for Patients With Advanced NSCLC", "status": "UNKNOWN", "last_update": "2019-01-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03709706", "title": "Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab", "status": "TERMINATED", "last_update": "2024-02-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04526509", "title": "Master Protocol to Assess Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2024-11-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "synonyms_searched": [ "NY-ESO-1", "CTAG1B" ] } }, "by_drug": { "ABIVERTINIB": { "n": 8, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02274337", "title": "Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AC0010 in Advanced Non Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2016-11-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02330367", "title": "Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010 in Patients With EGFR T790M Positive NSCLC", "status": "UNKNOWN", "last_update": "2021-09-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02448251", "title": "Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010MA in Advanced Non Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2019-10-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03001609", "title": "Study to Investigate the Absorption, Metabolism and Excretion of [14C] AC0010 in Patients With Advanced NSCLC", "status": "COMPLETED", "last_update": "2017-10-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03053219", "title": "Preliminary Evaluation of Safety and Efficacy by [14C] AC0010 Trail and Subsequent AC0010 Treatment", "status": "COMPLETED", "last_update": "2019-02-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03300115", "title": "Clinical Trial of the Efficacy and Safety of AC0010 in the Treatment of EGFR T790M Patients With Advanded NSCLC", "status": "UNKNOWN", "last_update": "2019-02-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03574402", "title": "Phase II Umbrella Study Directed by Next Generation Sequencing", "status": "UNKNOWN", "last_update": "2022-12-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03856697", "title": "Abivertinib Maleate Versus Geifitinib in Patients With Advanced Non-small Cell Lung Cancer With Sensitive EGFR Mutation", "status": "UNKNOWN", "last_update": "2019-02-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "ADAGRASIB": { "n": 24, "n_observational": 0, "n_active": 14, "n_withdrawn": 2, "trials": [ { "nct": "NCT04613596", "title": "Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7", "status": "RECRUITING", "last_update": "2026-08-25", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06026410", "title": "KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-06-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06248606", "title": "Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases", "status": "RECRUITING", "last_update": "2026-04-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06481813", "title": "Prospective, Longitudinal Biocollection in Thoracic Oncology, Including Newly Diagnosed Lung Cancer Patients", "status": "RECRUITING", "last_update": "2026-01-21", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06764771", "title": "A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors", "status": "RECRUITING", "last_update": "2026-07-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06875310", "title": "A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)", "status": "RECRUITING", "last_update": "2026-09-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07288034", "title": "Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial", "status": "RECRUITING", "last_update": "2026-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07382726", "title": "Phase 1 Study Of Izalontamab Brengitecan + Adagrasib In NSCLC - The IZA-A Trial", "status": "RECRUITING", "last_update": "2026-08-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04330664", "title": "Adagrasib in Combination With TNO155 in Patients With Cancer (KRYSTAL 2)", "status": "COMPLETED", "last_update": "2025-04-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04685135", "title": "Phase 3 Study of MRTX849 (Adagrasib) vs Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04975256", "title": "Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)", "status": "TERMINATED", "last_update": "2024-12-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05375994", "title": "Study of Avutometinib (VS-6766) + Adagrasib in KRAS G12C NSCLC Patients", "status": "COMPLETED", "last_update": "2026-07-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05472623", "title": "Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab", "status": "WITHDRAWN", "last_update": "2025-09-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05578092", "title": "A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway", "status": "TERMINATED", "last_update": "2026-02-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05609578", "title": "Combination Therapies With Adagrasib in Patients With Advanced NSCLC With KRAS G12C Mutation", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05673187", "title": "Adagrasib in Patients With KRASG12C-mutant NSCLC Who Are Elderly or Have Poor Performance Status", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05840510", "title": "Adagrasib in Combination With Nab-Sirolimus in Patients With Advanced Solid Tumors and Non-Small Cell Lung Cancer With a KRAS G12C Mutation (KRYSTAL -19)", "status": "TERMINATED", "last_update": "2025-04-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05848843", "title": "A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations", "status": "WITHDRAWN", "last_update": "2024-01-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05853575", "title": "Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06024174", "title": "A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors", "status": "TERMINATED", "last_update": "2025-07-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06039384", "title": "A Study of INCB099280 in Combination With Adagrasib in Adults With Advanced Solid Tumors Harboring a KRASG12C Mutation", "status": "TERMINATED", "last_update": "2026-09-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06130254", "title": "Phase Ib Trial of the KRAS G12C Inhibitor Adagrasib (MRTX849) in Combination With the PARP Inhibitor Olaparib in Patients With KRAS G12C Mutated Advanced Solid Tumors, With a Focus on Gynecological, Breast, Pancreatic and KEAP1 Mutated Non-small Cell Lung Cancers", "status": "TERMINATED", "last_update": "2026-04-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06497556", "title": "A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07543172", "title": "CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ADEBRELIMAB": { "n": 68, "n_observational": 8, "n_active": 62, "n_withdrawn": 1, "trials": [ { "nct": "NCT04770207", "title": "Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs", "status": "RECRUITING", "last_update": "2024-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06177925", "title": "A Phase \u2161 Clinical Study of Adebrelimab Combined With Chemotherapy and Concurrent Radiotherapy for Extensive-Stage Oligometastatic SCLC", "status": "RECRUITING", "last_update": "2023-12-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06188650", "title": "The Efficacy and Safety of Drug Loaded Microsphere Bronchial Artery Chemoembolization (DEB-BACE) Combined With Anlotinib and Adebelimumab in the Third Line Treatment of Advanced NSCLC: a Prospective, Single Arm, Single Center, Exploratory Clinical Study", "status": "RECRUITING", "last_update": "2024-01-03", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06424899", "title": "A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC", "status": "RECRUITING", "last_update": "2024-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06467617", "title": "Adebrelimab Plus Chemo and Recaticimab in Perioperative Treatment of Resectable NSCLC", "status": "RECRUITING", "last_update": "2024-12-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06475209", "title": "Adebrelimab + Apatinib in SCLC Maintenance Therapy", "status": "RECRUITING", "last_update": "2024-06-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06480864", "title": "Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2025-01-06", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06483282", "title": "A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06485544", "title": "Neoadjuvant Adebrelimab in Resectable SCLC: A Randomized Trial", "status": "RECRUITING", "last_update": "2024-07-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06512051", "title": "A Trial of SHR-A2102 With Adebrelimab With or Without Other Antitumor Therapy in Advanced or Metastatic Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2025-12-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06527898", "title": "Hypofractionated Radiotherapy Combined with Immunotherapy for Limited-stage Small-cell Lung Cancer", "status": "RECRUITING", "last_update": "2024-09-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06562920", "title": "Adebrelimab Combined With Chemotherapy and Concurrent SBRT for Neoadjuvant Treatment of Limited-stage Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2024-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06589778", "title": "A Study of SHR-A2102 in Combination With Adebrelimab and SHR-8068 in Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2024-11-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06610734", "title": "Multicenter, Phase II Randomized Controlled Study of Adebrelimab Combined With Chemotherapy and Concurrent Low-Dose Radiotherapy (LDRT) for the Treatment of Extensive-Stage Small Cell Lung Cancer (SCLC)", "status": "RECRUITING", "last_update": "2026-02-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06739928", "title": "Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC", "status": "RECRUITING", "last_update": "2024-12-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06768307", "title": "Assessment of Adebelizumab Combined With Chemotherapy in Concurrent Radiotherapy Versus Sequential Radiotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06775275", "title": "A Study of Adebrelimab in Combination with Chemo with or Without Bevacizumab Neoadjuvant Therapy for Resectable NSCLC", "status": "RECRUITING", "last_update": "2025-01-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06853678", "title": "Second-line Immunotherapy for ES-SCLC", "status": "RECRUITING", "last_update": "2025-03-03", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06925516", "title": "A Trial of Apatinib and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable ICC", "status": "RECRUITING", "last_update": "2026-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06936735", "title": "A Phase I Study of HS-20108 in Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-06-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06943235", "title": "Study of Probiotics Combined With Concurrent Hyperfractionated ChemoRadiotherapy and Adebrelimab Immunomaintenance in the Treatment of Limited-stage Small Cell Lung Cancer (LS-SCLC)", "status": "RECRUITING", "last_update": "2026-02-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07141264", "title": "Adebrelimab Combine With Etoposide Capsules in ES-SCLC Maintenance Therapy", "status": "RECRUITING", "last_update": "2025-12-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07170995", "title": "Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2025-11-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07229729", "title": "A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2025-12-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07232849", "title": "A Trial of HRS-4508 Combined With Other Antitumor Therapies in Subjects With Locally Advanced or Metastatic Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2025-12-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07559786", "title": "A Multicenter, Open-label, Randomized, Prospective Clinical Study of Adebrelimab Consolidation Therapy for Limited-Stage Small-Cell Lung Cancer (LS-SCLC) Without Progression After Concurrent Chemoradiotherapy", "status": "RECRUITING", "last_update": "2026-07-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07759856", "title": "NK Cells Plus ICI for SCLC Maintenance", "status": "RECRUITING", "last_update": "2026-08-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04562337", "title": "SHR-1316 Combined With Chemotherapy and Chest Radiotherapy in ES-SCLC", "status": "UNKNOWN", "last_update": "2024-07-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05416775", "title": "Phase Ib/II Study of SHR-8068 Injection in the Treatment of Advanced Non-small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2022-08-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05496166", "title": "The Efficiency of Surgery and Radiotherapy After SHR-1316 (Adebrelimab) and Platinum-containing Doublet Induction Therapy for Limited-stage Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2023-05-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05738317", "title": "Adebrelimab Combined With Bevacizumab and Albumin Paclitaxel in Non-squamous NSCLC After First-line Treatment", "status": "UNKNOWN", "last_update": "2023-02-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05932264", "title": "Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2023-07-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06182800", "title": "Adebrelimab Combined With Bevacizumab and Docetaxel for Advanced Non-Squamous Non-small Cell Lung Cancer After Progression on First-line Immunotherapy", "status": "UNKNOWN", "last_update": "2023-12-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06236997", "title": "Adebrelimab and Concurrent Radiochemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-02-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06299371", "title": "Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations", "status": "NOT_YET_RECRUITING", "last_update": "2024-03-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06300424", "title": "Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06306560", "title": "A Study of Adebrelimab Combined With Famitinib and Chemotherapy in the Treatment of ES-SCLC.", "status": "NOT_YET_RECRUITING", "last_update": "2024-03-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06332950", "title": "Safety and Efficacy of Adebrelimab Plus Irinotecan Liposome (II) With or Without Famitinib in ES-SCLC Pre-treated With Immunotherapy", "status": "NOT_YET_RECRUITING", "last_update": "2024-03-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06335355", "title": "A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients", "status": "NOT_YET_RECRUITING", "last_update": "2024-03-28", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06434103", "title": "Clinical Study of SHR-A1921 Combined With Adebrelimab and SHR-8068 With or Without Carboplatin in the Treatment of Advanced NSCLC", "status": "WITHDRAWN", "last_update": "2026-04-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06594874", "title": "A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Participants with KRAS G12C Mutation Advanced Solid Tumors", "status": "NOT_YET_RECRUITING", "last_update": "2024-09-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06597513", "title": "Auto-HSCT-Supported Dose-Dense Chemotherapy with Adebrelimab As First-Line Treatment for ES-SCLC", "status": "NOT_YET_RECRUITING", "last_update": "2024-10-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06614621", "title": "A Study of Adebelimab Combined With Chemotherapy as a First-line Treatment Sequential Treatment for Extensive-stage Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-09-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06648525", "title": "Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF \u00b1 Lenvatinib As First-line Treatment for Advanced ICC", "status": "NOT_YET_RECRUITING", "last_update": "2024-10-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06685653", "title": "Personalized Neoantigen MRNA Vaccine Combined with Adebrelimab in Non-Small Cell Lung Cancer Patients", "status": "NOT_YET_RECRUITING", "last_update": "2024-11-12", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06700421", "title": "Phase II Clinical Study of Adebrelimab Combined with Apatinib in the Treatment of Locally Advanced Non-small Cell Lung Cancer Patients with Radiation Pneumonitis", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-11-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06735508", "title": "MRNA Neoantigen Vaccine in Non-Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-12-16", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06764368", "title": "Phase II Study of Adebrelimab, Chemotherapy, and Apatinib for Advanced Pulmonary Neuroendocrine Tumors", "status": "NOT_YET_RECRUITING", "last_update": "2025-01-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06773156", "title": "Adjuvant Adebrelimab Plus Apatinib After Chemoradiation in Limited-Stage Small Cell Lung Cancer", "status": "ENROLLING_BY_INVITATION", "last_update": "2025-01-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06784206", "title": "Adebrelimab Maintenance Therapy After Concurrent Chemoradiotherapy with Hyperfractionated Radiotherapy in Limited-Stage Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-01-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06786312", "title": "A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-01-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06914050", "title": "Hypofractionated Radiotherapy Followed by Chemo-immunotherapy Induction Therapy", "status": "NOT_YET_RECRUITING", "last_update": "2025-04-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06963502", "title": "A Phase Ib Study of HS-10370 in Addition to Other Anti-cancer Therapies in Patients With Advanced Solid Tumors", "status": "NOT_YET_RECRUITING", "last_update": "2025-05-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07031154", "title": "A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07035392", "title": "Adebrelimab + Chemotherapy as Neoadjuvant Therapy for Resectable NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2025-06-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07063407", "title": "Phase 1 Study of HS-20093 Combinations in Patients With Extensive Stage Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-07-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07069270", "title": "A Study on the First-line Treatment of Small Cell Lung Cancer With Adebrelimab and Vunakizumab and Chemotherapy", "status": "NOT_YET_RECRUITING", "last_update": "2025-07-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07200154", "title": "Adebrelimab Plus Chemoradiotherapy Followed by Adebrelimab Maintenance in Limited-Stage SCLC", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07281209", "title": "A Study of SHR-A1811 Combined With Adebelimumab as Neoadjuvant Therapy for Resectable HER2-Altered Non-Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-12-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07357532", "title": "Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRD", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07381543", "title": "Adebrelimab Maintenance Therapy for LS-SCLC Post Induction Chemo-Adebrelimab Plus CRT or CRT Alone", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07398560", "title": "Adebrelimab Combined With Oral Etoposide for Elderly Patients and Patients With Poor Performance Status in Small Cell Lung Cancer: An Exploratory Clinical Study", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07464327", "title": "A Phase III Study of HS-20093 Injection Combined With Adebrelimab Versus Docetaxel in Previously Treated Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations", "status": "NOT_YET_RECRUITING", "last_update": "2026-03-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07560358", "title": "Adebrelimab Combined With Chemoradiotherapy in Patients With Large Bulky Stage III Unresectable Non-Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07567326", "title": "Adebrelimab or Retlirafusp Alfa Plus Recaticimab and Chemotherapy for Resectable NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07583550", "title": "Low-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy, and Then Sequential Maintenance Therapy With Adebrelimab for Extensive-stage Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07704645", "title": "The Clinical Study of Adalimumab Combined With Other Anti-tumor Therapy as a Treatment for Resectable Non-small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07798947", "title": "A Phase II Clinical Study of SHR-7787 Injection Combined With SHR-1316 Injection in Patients With LS-SCLC", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "AFATINIB": { "n": 87, "n_observational": 25, "n_active": 12, "n_withdrawn": 3, "trials": [ { "nct": "NCT05445791", "title": "Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations", "status": "RECRUITING", "last_update": "2026-04-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06071013", "title": "Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients", "status": "RECRUITING", "last_update": "2025-01-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06486142", "title": "EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study", "status": "RECRUITING", "last_update": "2026-05-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06709859", "title": "Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC", "status": "RECRUITING", "last_update": "2025-07-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07185997", "title": "Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations", "status": "RECRUITING", "last_update": "2026-09-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00525148", "title": "LUX Lung 2 Phase II Single Arm BIBW 2992 \"Afatinib\" in NSCLC With EGFR Activating Mutations", "status": "COMPLETED", "last_update": "2016-09-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00656136", "title": "BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1)", "status": "COMPLETED", "last_update": "2016-07-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00711594", "title": "LUX-Lung 4: BIBW 2992 (Afatinib) Phase I Trial in Advanced Non Small Cell Lung Cancer Patients & Phase II Trial in Non Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib", "status": "COMPLETED", "last_update": "2015-01-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00730925", "title": "Single-arm Trial of BIBW 2992 (Afatinib) in Demographically and Genotypically Selected NSCLC Patients", "status": "COMPLETED", "last_update": "2014-03-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00796549", "title": "BIBW2992 (Afatinib) in Advanced (EGFR-FISH +) NSCLC (Non Small Cell Lung Cancer) Patients", "status": "COMPLETED", "last_update": "2014-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00949650", "title": "BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation", "status": "COMPLETED", "last_update": "2018-04-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00993499", "title": "Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 (Afatinib) Plus Sirolimus (Rapamune\u00ae) in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or Gefitinib", "status": "COMPLETED", "last_update": "2015-10-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01003899", "title": "A Phase II Trial of Afatinib(BIBW 2992) in Third-line Treatment for Patients With Stage IIIB/IV Adenocarcinoma of the Lung Harbouring Wild-type Epidermal Growth Factor Receptor[EGFR]", "status": "COMPLETED", "last_update": "2013-12-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01074177", "title": "Understanding Mechanisms of Acquired Resistance to BIBW2992", "status": "COMPLETED", "last_update": "2018-03-09", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01085136", "title": "LUX-Lung 5: Afatinib Plus Weekly Paclitaxel Versus Investigator's Choice of Single Agent Chemotherapy Following Afatinib Monotherapy in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib", "status": "COMPLETED", "last_update": "2017-04-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01090011", "title": "Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2015-10-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01121393", "title": "BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2018-12-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01156545", "title": "BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC", "status": "COMPLETED", "last_update": "2022-04-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01288430", "title": "A Study of DS-2248 in Participants With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2021-10-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01415011", "title": "Efficacy and Safety Study of Afatinib to Treat Lung Cancer Patients", "status": "COMPLETED", "last_update": "2019-01-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01466660", "title": "LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung", "status": "COMPLETED", "last_update": "2020-04-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01480141", "title": "A Window of Opportunity Trial of Afatinib In Early Stage Non-Small Cell Lung Cancer (NSCLC)", "status": "WITHDRAWN", "last_update": "2013-03-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01523587", "title": "LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy", "status": "COMPLETED", "last_update": "2019-02-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01542437", "title": "Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2024-02-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01553942", "title": "Afatinib With CT and RT for EGFR-Mutant NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-11-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01647711", "title": "A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations", "status": "COMPLETED", "last_update": "2017-01-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01746251", "title": "Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation", "status": "UNKNOWN", "last_update": "2020-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01776684", "title": "Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis", "status": "UNKNOWN", "last_update": "2013-01-28", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01814553", "title": "ADAM-Afatinib Diarrhea Assessment and Management", "status": "COMPLETED", "last_update": "2016-10-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01836341", "title": "Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation", "status": "WITHDRAWN", "last_update": "2013-12-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01853826", "title": "An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)", "status": "COMPLETED", "last_update": "2025-04-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01861223", "title": "Afatinib Plus Nimotuzumb for NSCLC", "status": "UNKNOWN", "last_update": "2014-02-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01880515", "title": "Tetracycline as a Prophylaxis for Rash in Patients With NSCLC Receiving Treatment With BIBW2992 (Afatinib)", "status": "COMPLETED", "last_update": "2025-05-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01932229", "title": "An Open Label Study of BIBW 2992/Afatinib in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib", "status": "UNKNOWN", "last_update": "2013-08-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01953913", "title": "Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation", "status": "COMPLETED", "last_update": "2019-08-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01999985", "title": "Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2020-11-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02044380", "title": "Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations", "status": "COMPLETED", "last_update": "2017-03-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02145637", "title": "Phase I Study of the Combination of Afatinib and Ruxolitinib in Patients With Treatment-refractory Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2019-03-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02183883", "title": "Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity", "status": "COMPLETED", "last_update": "2023-11-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02191891", "title": "Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2025-06-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02208843", "title": "Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation", "status": "COMPLETED", "last_update": "2018-12-17", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02271906", "title": "The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting", "status": "TERMINATED", "last_update": "2019-04-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02364609", "title": "Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib", "status": "COMPLETED", "last_update": "2024-10-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02424617", "title": "A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2025-02-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02438722", "title": "S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-05-18", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02450656", "title": "Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2018-08-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02470065", "title": "Neoadjuvant Afatinib in Early Stage Non Small Cell Lung Cancer.", "status": "SUSPENDED", "last_update": "2016-01-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02488694", "title": "Maintaining ERBB Blockade in EGFR-mutated Lung Cancer", "status": "TERMINATED", "last_update": "2018-01-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02514174", "title": "Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older", "status": "COMPLETED", "last_update": "2020-03-30", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02595840", "title": "Biomarker Study Accompanying the AIO-TRK-0114 Study (MARBLE)", "status": "TERMINATED", "last_update": "2019-04-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02597946", "title": "Afatinib in NSCLC With HER2 Mutation", "status": "COMPLETED", "last_update": "2025-02-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02625168", "title": "Afatinib vs Erlotinib as 2nd TKI After Failure to 1st TKI and Chemotherapy for Metastatic NSCLC", "status": "COMPLETED", "last_update": "2015-12-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02629523", "title": "Afatinib in Lung Cancer With EGFR Mutation From Circulating Tumor DNA", "status": "COMPLETED", "last_update": "2021-08-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02695290", "title": "Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)", "status": "TERMINATED", "last_update": "2017-09-18", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02716311", "title": "Combination of Cetuximab With Afatinib for Patient With EGFR Mutated Lung Cancer", "status": "COMPLETED", "last_update": "2022-08-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02736513", "title": "Intracranial Activity of AZD9291 (TAGRISSO) in Advanced EGFRm NSCLC Patients With Asymptomatic Brain Metastases", "status": "UNKNOWN", "last_update": "2021-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02747953", "title": "Gilotrif (Afatinib) in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib", "status": "COMPLETED", "last_update": "2021-03-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02768337", "title": "Cambridge Brain Mets Trial 1", "status": "TERMINATED", "last_update": "2024-01-31", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02795156", "title": "Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations", "status": "COMPLETED", "last_update": "2023-12-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02805530", "title": "Radical Treatment of Synchronous Oligometastatic Non-Small Cell Lung Carcinoma", "status": "COMPLETED", "last_update": "2023-05-06", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02876081", "title": "Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV Bronchial Adenocarcinoma, Harboring Wild-type EGFR, Expressing the Neurotensin - Neurotensin Receptor Complex", "status": "WITHDRAWN", "last_update": "2017-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02906163", "title": "First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy", "status": "UNKNOWN", "last_update": "2016-09-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03054038", "title": "Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2022-04-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03071705", "title": "Metformin Plus TKI Use in Patients With Non-Small Cell Lung Carcinoma", "status": "UNKNOWN", "last_update": "2017-03-07", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03157089", "title": "Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung", "status": "COMPLETED", "last_update": "2021-02-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03486509", "title": "Afatinib Plus Chemotherapy Against Esophageal or Lung Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2018-04-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03574402", "title": "Phase II Umbrella Study Directed by Next Generation Sequencing", "status": "UNKNOWN", "last_update": "2022-12-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03623750", "title": "E GFR TKI and EGF-P TI C Ombination in EGFR mutA nt NSCL C", "status": "COMPLETED", "last_update": "2022-06-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03711422", "title": "Afatinib on CNS Metastases and LMD in EGFR Mutation Positive NSCLC", "status": "TERMINATED", "last_update": "2022-06-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03727724", "title": "Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung Cancer", "status": "COMPLETED", "last_update": "2023-10-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03810872", "title": "An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR, a HER2 or a HER3 Mutation", "status": "UNKNOWN", "last_update": "2019-01-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03827070", "title": "Dry Pleurodesis With Talcum and Afatinib is Used to Treat Patients With Non-Small Cell Lung Carcinoma", "status": "UNKNOWN", "last_update": "2023-04-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04201756", "title": "Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma", "status": "COMPLETED", "last_update": "2022-12-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04356118", "title": "Efficacy and Safety of Recombinant Human Endostatin in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis", "status": "UNKNOWN", "last_update": "2020-05-27", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04448379", "title": "Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2020-12-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04470076", "title": "Neoadjuvant Afatinib Combination With Chemotherapy for Stage \u2161a-\u2162b NSCLC With EGFR Activating Mutation", "status": "UNKNOWN", "last_update": "2020-07-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04497584", "title": "Phase 2 Trial of Afatinib Plus Prednisone for Advanced Squamous NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04814056", "title": "To Evaluate the Efficacy of Afatinib in the Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer With NRG1 Fusion", "status": "UNKNOWN", "last_update": "2021-04-01", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05215548", "title": "Primary Tumor Resection With EGFR TKI for Stage IV NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-02-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05267288", "title": "Phase II Study of Afatinib Plus Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon G719X, S768I, and L861Q Mutation Metastatic Non-Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2023-03-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05298176", "title": "Combining Afatinib and Concurrent Chemotherapy, Followed by Osimertinib and Concurrent Chemotherapy, in Untreated EGFR Positive NSCLC Tumors", "status": "COMPLETED", "last_update": "2025-03-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05364073", "title": "Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06385483", "title": "Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06759857", "title": "FHND9041 Versus Afatinib for Non-small Cell Lung Cancer", "status": "ENROLLING_BY_INVITATION", "last_update": "2025-01-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06897735", "title": "Exploratory Study of Inhaled Afatinib Dimaleate PK Profile", "status": "TERMINATED", "last_update": "2026-06-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07271446", "title": "An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer", "status": "COMPLETED", "last_update": "2025-12-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "AFATINIB DIMALEATE": { "n": 87, "n_observational": 25, "n_active": 12, "n_withdrawn": 3, "trials": [ { "nct": "NCT05445791", "title": "Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations", "status": "RECRUITING", "last_update": "2026-04-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06071013", "title": "Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients", "status": "RECRUITING", "last_update": "2025-01-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06486142", "title": "EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study", "status": "RECRUITING", "last_update": "2026-05-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06709859", "title": "Afatinib Combined With Chemotherapy as Conversion Therapy in Unresectable EGFR Sensitive Mutation-positive Stage III NSCLC", "status": "RECRUITING", "last_update": "2025-07-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07185997", "title": "Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations", "status": "RECRUITING", "last_update": "2026-09-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00525148", "title": "LUX Lung 2 Phase II Single Arm BIBW 2992 \"Afatinib\" in NSCLC With EGFR Activating Mutations", "status": "COMPLETED", "last_update": "2016-09-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00656136", "title": "BIBW 2992 and BSC Versus Placebo and BSC in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib (LUX-LUNG 1)", "status": "COMPLETED", "last_update": "2016-07-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00711594", "title": "LUX-Lung 4: BIBW 2992 (Afatinib) Phase I Trial in Advanced Non Small Cell Lung Cancer Patients & Phase II Trial in Non Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib", "status": "COMPLETED", "last_update": "2015-01-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00730925", "title": "Single-arm Trial of BIBW 2992 (Afatinib) in Demographically and Genotypically Selected NSCLC Patients", "status": "COMPLETED", "last_update": "2014-03-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00796549", "title": "BIBW2992 (Afatinib) in Advanced (EGFR-FISH +) NSCLC (Non Small Cell Lung Cancer) Patients", "status": "COMPLETED", "last_update": "2014-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00949650", "title": "BIBW 2992 (Afatinib) Versus Chemotherapy as First Line Treatment in NSCLC With EGFR Mutation", "status": "COMPLETED", "last_update": "2018-04-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00993499", "title": "Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 (Afatinib) Plus Sirolimus (Rapamune\u00ae) in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or Gefitinib", "status": "COMPLETED", "last_update": "2015-10-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01003899", "title": "A Phase II Trial of Afatinib(BIBW 2992) in Third-line Treatment for Patients With Stage IIIB/IV Adenocarcinoma of the Lung Harbouring Wild-type Epidermal Growth Factor Receptor[EGFR]", "status": "COMPLETED", "last_update": "2013-12-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01074177", "title": "Understanding Mechanisms of Acquired Resistance to BIBW2992", "status": "COMPLETED", "last_update": "2018-03-09", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01085136", "title": "LUX-Lung 5: Afatinib Plus Weekly Paclitaxel Versus Investigator's Choice of Single Agent Chemotherapy Following Afatinib Monotherapy in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib", "status": "COMPLETED", "last_update": "2017-04-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01090011", "title": "Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2015-10-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01121393", "title": "BIBW 2992 (Afatinib) vs Gemcitabine-cisplatin in 1st Line Non-small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2018-12-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01156545", "title": "BIBW 2992 Plus Simvastatin vs. BIBW 2992 in Previously Treated Patients With Advanced Non-adenocarcinomatous NSCLC", "status": "COMPLETED", "last_update": "2022-04-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01288430", "title": "A Study of DS-2248 in Participants With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2021-10-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01415011", "title": "Efficacy and Safety Study of Afatinib to Treat Lung Cancer Patients", "status": "COMPLETED", "last_update": "2019-01-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01466660", "title": "LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung", "status": "COMPLETED", "last_update": "2020-04-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01480141", "title": "A Window of Opportunity Trial of Afatinib In Early Stage Non-Small Cell Lung Cancer (NSCLC)", "status": "WITHDRAWN", "last_update": "2013-03-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01523587", "title": "LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy", "status": "COMPLETED", "last_update": "2019-02-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01542437", "title": "Treatment With BIBW 2992, Irreversible Inhibitor of EGFR and HER-2 in Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2024-02-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01553942", "title": "Afatinib With CT and RT for EGFR-Mutant NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-11-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01647711", "title": "A Study of Intermittent, High-dose Afatinib to Determine the Maximal Tolerated Dose and Assess Activity of This Dose Against Non-small Cell Lung Cancer With T790M Mutations", "status": "COMPLETED", "last_update": "2017-01-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01746251", "title": "Adjuvant Afatinib in Stage I-III NSCLC With EGFR Mutation", "status": "UNKNOWN", "last_update": "2020-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01776684", "title": "Evaluation of EGFR TKI Resistance Mechanism Using Plasma DNA Analysis", "status": "UNKNOWN", "last_update": "2013-01-28", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01814553", "title": "ADAM-Afatinib Diarrhea Assessment and Management", "status": "COMPLETED", "last_update": "2016-10-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01836341", "title": "Afatinib In Combination With Cisplatin Or Carboplatin + Pemetrexed In Patients With EGFR-Mutant Lung Cancers Undergoing Definitive Chemoradiation", "status": "WITHDRAWN", "last_update": "2013-12-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01853826", "title": "An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)", "status": "COMPLETED", "last_update": "2025-04-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01861223", "title": "Afatinib Plus Nimotuzumb for NSCLC", "status": "UNKNOWN", "last_update": "2014-02-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01880515", "title": "Tetracycline as a Prophylaxis for Rash in Patients With NSCLC Receiving Treatment With BIBW2992 (Afatinib)", "status": "COMPLETED", "last_update": "2025-05-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01932229", "title": "An Open Label Study of BIBW 2992/Afatinib in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib", "status": "UNKNOWN", "last_update": "2013-08-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01953913", "title": "Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation", "status": "COMPLETED", "last_update": "2019-08-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01999985", "title": "Phase I Trial of Afatinib (BIBW 2992) and Dasatinib in Non-small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2020-11-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02044380", "title": "Afatinib in Patients With Non Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Mutations", "status": "COMPLETED", "last_update": "2017-03-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02145637", "title": "Phase I Study of the Combination of Afatinib and Ruxolitinib in Patients With Treatment-refractory Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2019-03-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02183883", "title": "Deciphering Afatinib Response and Resistance With INtratumour Heterogeneity", "status": "COMPLETED", "last_update": "2023-11-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02191891", "title": "Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2025-06-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02208843", "title": "Afatinib as Second-line Therapy for Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation", "status": "COMPLETED", "last_update": "2018-12-17", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02271906", "title": "The ATTAIN Study: A Therapeutic Trial of Afatinib In the Neoadjuvant Setting", "status": "TERMINATED", "last_update": "2019-04-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02364609", "title": "Pembrolizumab and Afatinib in Patients With Non-small Cell Lung Cancer With Resistance to Erlotinib", "status": "COMPLETED", "last_update": "2024-10-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02424617", "title": "A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2025-02-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02438722", "title": "S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-05-18", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02450656", "title": "Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2018-08-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02470065", "title": "Neoadjuvant Afatinib in Early Stage Non Small Cell Lung Cancer.", "status": "SUSPENDED", "last_update": "2016-01-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02488694", "title": "Maintaining ERBB Blockade in EGFR-mutated Lung Cancer", "status": "TERMINATED", "last_update": "2018-01-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02514174", "title": "Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or Older", "status": "COMPLETED", "last_update": "2020-03-30", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02595840", "title": "Biomarker Study Accompanying the AIO-TRK-0114 Study (MARBLE)", "status": "TERMINATED", "last_update": "2019-04-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02597946", "title": "Afatinib in NSCLC With HER2 Mutation", "status": "COMPLETED", "last_update": "2025-02-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02625168", "title": "Afatinib vs Erlotinib as 2nd TKI After Failure to 1st TKI and Chemotherapy for Metastatic NSCLC", "status": "COMPLETED", "last_update": "2015-12-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02629523", "title": "Afatinib in Lung Cancer With EGFR Mutation From Circulating Tumor DNA", "status": "COMPLETED", "last_update": "2021-08-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02695290", "title": "Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)", "status": "TERMINATED", "last_update": "2017-09-18", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02716311", "title": "Combination of Cetuximab With Afatinib for Patient With EGFR Mutated Lung Cancer", "status": "COMPLETED", "last_update": "2022-08-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02736513", "title": "Intracranial Activity of AZD9291 (TAGRISSO) in Advanced EGFRm NSCLC Patients With Asymptomatic Brain Metastases", "status": "UNKNOWN", "last_update": "2021-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02747953", "title": "Gilotrif (Afatinib) in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib", "status": "COMPLETED", "last_update": "2021-03-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02768337", "title": "Cambridge Brain Mets Trial 1", "status": "TERMINATED", "last_update": "2024-01-31", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02795156", "title": "Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations", "status": "COMPLETED", "last_update": "2023-12-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02805530", "title": "Radical Treatment of Synchronous Oligometastatic Non-Small Cell Lung Carcinoma", "status": "COMPLETED", "last_update": "2023-05-06", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02876081", "title": "Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV Bronchial Adenocarcinoma, Harboring Wild-type EGFR, Expressing the Neurotensin - Neurotensin Receptor Complex", "status": "WITHDRAWN", "last_update": "2017-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02906163", "title": "First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy", "status": "UNKNOWN", "last_update": "2016-09-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03054038", "title": "Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2022-04-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03071705", "title": "Metformin Plus TKI Use in Patients With Non-Small Cell Lung Carcinoma", "status": "UNKNOWN", "last_update": "2017-03-07", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03157089", "title": "Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung", "status": "COMPLETED", "last_update": "2021-02-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03486509", "title": "Afatinib Plus Chemotherapy Against Esophageal or Lung Squamous Cell Carcinoma", "status": "UNKNOWN", "last_update": "2018-04-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03574402", "title": "Phase II Umbrella Study Directed by Next Generation Sequencing", "status": "UNKNOWN", "last_update": "2022-12-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03623750", "title": "E GFR TKI and EGF-P TI C Ombination in EGFR mutA nt NSCL C", "status": "COMPLETED", "last_update": "2022-06-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03711422", "title": "Afatinib on CNS Metastases and LMD in EGFR Mutation Positive NSCLC", "status": "TERMINATED", "last_update": "2022-06-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03727724", "title": "Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung Cancer", "status": "COMPLETED", "last_update": "2023-10-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03810872", "title": "An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR, a HER2 or a HER3 Mutation", "status": "UNKNOWN", "last_update": "2019-01-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03827070", "title": "Dry Pleurodesis With Talcum and Afatinib is Used to Treat Patients With Non-Small Cell Lung Carcinoma", "status": "UNKNOWN", "last_update": "2023-04-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04201756", "title": "Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung Adenocarcinoma", "status": "COMPLETED", "last_update": "2022-12-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04356118", "title": "Efficacy and Safety of Recombinant Human Endostatin in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis", "status": "UNKNOWN", "last_update": "2020-05-27", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04448379", "title": "Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2020-12-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04470076", "title": "Neoadjuvant Afatinib Combination With Chemotherapy for Stage \u2161a-\u2162b NSCLC With EGFR Activating Mutation", "status": "UNKNOWN", "last_update": "2020-07-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04497584", "title": "Phase 2 Trial of Afatinib Plus Prednisone for Advanced Squamous NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04814056", "title": "To Evaluate the Efficacy of Afatinib in the Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer With NRG1 Fusion", "status": "UNKNOWN", "last_update": "2021-04-01", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05215548", "title": "Primary Tumor Resection With EGFR TKI for Stage IV NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-02-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05267288", "title": "Phase II Study of Afatinib Plus Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon G719X, S768I, and L861Q Mutation Metastatic Non-Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2023-03-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05298176", "title": "Combining Afatinib and Concurrent Chemotherapy, Followed by Osimertinib and Concurrent Chemotherapy, in Untreated EGFR Positive NSCLC Tumors", "status": "COMPLETED", "last_update": "2025-03-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05364073", "title": "Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06385483", "title": "Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06759857", "title": "FHND9041 Versus Afatinib for Non-small Cell Lung Cancer", "status": "ENROLLING_BY_INVITATION", "last_update": "2025-01-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06897735", "title": "Exploratory Study of Inhaled Afatinib Dimaleate PK Profile", "status": "TERMINATED", "last_update": "2026-06-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07271446", "title": "An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer", "status": "COMPLETED", "last_update": "2025-12-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "ALECTINIB": { "n": 46, "n_observational": 15, "n_active": 20, "n_withdrawn": 0, "trials": [ { "nct": "NCT04302025", "title": "A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04322890", "title": "Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation", "status": "RECRUITING", "last_update": "2024-10-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05014464", "title": "ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2024-09-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05266846", "title": "Pembrolizumab Plus Bevacizumab and Chemotherapy for ALK-rearranged NSCLC With Persistent 5'ALK", "status": "RECRUITING", "last_update": "2024-05-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05525338", "title": "Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels", "status": "RECRUITING", "last_update": "2024-05-13", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05713006", "title": "Alectinib Pharmacokinetic in Patients With NSCLC", "status": "RECRUITING", "last_update": "2026-04-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05724004", "title": "Alectinib Followed by Concomitant Consolidation Radiation Therapy in Advanced NSCLC With ALK-rearrangement (A-SAB)", "status": "RECRUITING", "last_update": "2023-10-10", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05987644", "title": "Delayed or Upfront Brain RAdiotherapy in Treatment na\u00efve Lung Cancer Patients With Asymptomatic or Minimally Symptomatic Brain Metastases and ALK rEarrangements", "status": "RECRUITING", "last_update": "2026-04-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06765109", "title": "Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC", "status": "RECRUITING", "last_update": "2026-08-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01801111", "title": "A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment", "status": "COMPLETED", "last_update": "2018-11-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01871805", "title": "A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2018-08-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02013219", "title": "A Phase 1b Study of Atezolizumab in Combination With Erlotinib or Alectinib in Participants With Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2020-04-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02075840", "title": "A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants", "status": "COMPLETED", "last_update": "2026-05-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02314481", "title": "Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity", "status": "COMPLETED", "last_update": "2026-05-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02450903", "title": "LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.", "status": "COMPLETED", "last_update": "2021-03-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02521051", "title": "Phase I/II Trial of Alectinib and Bevacizumab in Patients With Advanced, Anaplastic Lymphoma Kinase (ALK)-Positive, Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2025-05-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02604342", "title": "Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib", "status": "COMPLETED", "last_update": "2019-10-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02706626", "title": "Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors", "status": "TERMINATED", "last_update": "2023-01-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02838420", "title": "A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2026-06-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03131206", "title": "A Study of Alectinib in RET-rearranged Non-small Cell Lung Cancer or RET-mutated Thyroid Cancer", "status": "TERMINATED", "last_update": "2021-09-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03155009", "title": "A Study of the Efficacy and Safety of Alectinib in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2020-02-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03178552", "title": "A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03194893", "title": "A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer", "status": "COMPLETED", "last_update": "2026-06-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03202940", "title": "A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03445000", "title": "ALEctinib for the Treatment of Pretreated RET-rearranged Advanced Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2026-07-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03456076", "title": "A Study Comparing Adjuvant Alectinib Versus Adjuvant Platinum-Based Chemotherapy in Patients With ALK Positive Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03535740", "title": "A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib", "status": "COMPLETED", "last_update": "2025-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03596866", "title": "A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer", "status": "COMPLETED", "last_update": "2025-09-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03737994", "title": "Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2026-04-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03779191", "title": "Alectinib in Combination With Bevacizumab in ALK Positive NSCLC", "status": "COMPLETED", "last_update": "2023-07-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03944772", "title": "Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-01-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04356118", "title": "Efficacy and Safety of Recombinant Human Endostatin in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis", "status": "UNKNOWN", "last_update": "2020-05-27", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04591431", "title": "The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy", "status": "UNKNOWN", "last_update": "2023-10-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04634110", "title": "Brigatinib Before Brain Irradiation Trial (B3i Trial)", "status": "TERMINATED", "last_update": "2022-10-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04644315", "title": "A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors", "status": "TERMINATED", "last_update": "2023-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04997382", "title": "Chemotherapy Combined with ICIs in First-line Alectinib Failed Patients with ALK-rearranged NSCLC", "status": "COMPLETED", "last_update": "2025-02-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05015010", "title": "Alectinib in Neo-adjuvant Treatment of Stage III NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-08-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05081674", "title": "Brazilian Lung Immunotherapy Study", "status": "COMPLETED", "last_update": "2023-10-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05170204", "title": "A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05195619", "title": "Personalized DC Vaccines in Non Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-07-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05296278", "title": "Efficacy and Biomarker Explanation of IBI-323 + Bevacizumab Plus Platinum Based Chemotherapy on ALK-Rearranged NSCLC", "status": "UNKNOWN", "last_update": "2024-01-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05987956", "title": "Pharmacogenomics IND SNP Clinical Trial - Alectinib and Single Nucleotide Polymorphisms", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-24", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06624059", "title": "A Study to See How Well and How Safely Different Treatments Work in a Group of Participants With Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2026-08-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06709274", "title": "Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2024-11-29", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07573696", "title": "Multidisciplinary Treatment of Stage III ALK+ NSCLC With Neoadjuvant Alectinib and Chemotherapy", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07771764", "title": "A Multicenter Exploratory Clinical Study of Iruplaltinib Combined With Pemetrexed as Neoadjuvant Therapy for Resectable ALK-Positive Non-Squamous Non-Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ALRIZOMADLIN": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 1, "trials": [ { "nct": "NCT06654050", "title": "Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma", "status": "WITHDRAWN", "last_update": "2026-03-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "AMIVANTAMAB": { "n": 33, "n_observational": 5, "n_active": 27, "n_withdrawn": 0, "trials": [ { "nct": "NCT05498428", "title": "A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06116682", "title": "Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has Increased Copies of the MET Gene (An Expanded Lung-MAP Treatment Trial)", "status": "RECRUITING", "last_update": "2026-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06247826", "title": "Mechanisms of Resistance to Amivantamab in Patients With NSCLC With EGFR Exon 20 Insertion", "status": "RECRUITING", "last_update": "2026-04-29", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06667076", "title": "A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)", "status": "RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06784791", "title": "Preoperative Amivantamab or Amivantamab and Carboplatin/Pemetrexed Treatment in Patients With Resectable Non-small-cell Lung Cancer Harboring Oncogenic EGFR Mutations (NEOpredict-EGFR)", "status": "RECRUITING", "last_update": "2025-08-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07227025", "title": "A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07392658", "title": "Phase II Trial of Amivantamab Plus Monochemotherapy in Platinum Unfit NSCLC Patients With EGFR exon20 Insertion Mutations.", "status": "RECRUITING", "last_update": "2026-02-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07586202", "title": "A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC", "status": "RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07744529", "title": "Amivantamab Combined With Intrathecal Pemetrexed for LM From EGFR-Mutated Lung Adenocarcinoma", "status": "RECRUITING", "last_update": "2026-08-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02609776", "title": "Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04077463", "title": "A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04085315", "title": "Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer", "status": "COMPLETED", "last_update": "2026-08-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04487080", "title": "A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04538664", "title": "A Study of Combination Amivantamab and Carboplatin-Pemetrexed Therapy, Compared With Carboplatin-Pemetrexed, in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Characterized by Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04965090", "title": "A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2025-12-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04988295", "title": "A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05241873", "title": "(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations", "status": "TERMINATED", "last_update": "2025-02-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05299125", "title": "Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor Mutations", "status": "COMPLETED", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05388669", "title": "A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05395052", "title": "FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05488314", "title": "A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05601973", "title": "Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05663866", "title": "Premedication to Reduce Amivantamab Associated Infusion Related Reactions", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05801029", "title": "A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05845671", "title": "Amivantamab With Tyrosine Kinase Inhibitors (TKI) for Advanced NSCLC With ALK, ROS1, or RET Alterations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05908734", "title": "A Study of Combination Therapy With Amivantamab and Cetrelimab in Participants With Metastatic Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06083857", "title": "PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06120140", "title": "Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06532032", "title": "A Study of Combination Therapy With Amivantamab and Docetaxel in Participants With Metastatic Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-07-31", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06585059", "title": "Clinical Trial of TQB2928 in Combination With a Third-Generation Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Patients With Advanced Non-Small Cell Lung Cancers", "status": "NOT_YET_RECRUITING", "last_update": "2024-09-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07469488", "title": "A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving Amivantamab-Based Regimens", "status": "NOT_YET_RECRUITING", "last_update": "2026-03-13", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07507188", "title": "Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients With EGFR-mutant, Locally Advanced or Metastatic/Recurrent Non-Small Cell Lung Cancer (INSTAR Study)", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07798921", "title": "JIN-A02 Plus Amivantamab in EGFR-Mutant NSCLC After Third-Generation EGFR-TKI Failure", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "AMUVATINIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01357395", "title": "A Phase 2, Open-Label Study of Amuvatinib in Combination With Platinum-Etoposide Chemotherapy in Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2024-08-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ATEZOLIZUMAB": { "n": 170, "n_observational": 30, "n_active": 75, "n_withdrawn": 5, "trials": [ { "nct": "NCT04253964", "title": "Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy", "status": "RECRUITING", "last_update": "2026-08-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04273061", "title": "Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity", "status": "RECRUITING", "last_update": "2025-09-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04467723", "title": "Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC", "status": "RECRUITING", "last_update": "2026-01-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04865250", "title": "Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC", "status": "RECRUITING", "last_update": "2024-05-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04919382", "title": "Temozolomide and Atezolizumab for Subsequent Line for the Treatment of Metastatic or Recurrent Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-04-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04996017", "title": "Atezolizumab Versus Placebo for the Adjuvant Treatment of Malignant Pleural Mesothelioma (Atezomeso)", "status": "RECRUITING", "last_update": "2025-03-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05284539", "title": "Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer", "status": "RECRUITING", "last_update": "2024-06-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05317858", "title": "Blood-brain Barrier (BBB) Opening Using Exablate Focused Ultrasound With Standard of Care Treatment of NSCLC Brain Mets", "status": "RECRUITING", "last_update": "2026-08-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05344209", "title": "Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2023-11-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05652686", "title": "A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)", "status": "RECRUITING", "last_update": "2026-07-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05703971", "title": "Quaratusugene Ozeplasmid (Reqorsa) and Atezolizumab Maintenance Therapy in ES-SCLC Patients", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05765084", "title": "Integration of the PD-L1 Inhibitor Atezolizumab and WT1/DC Vaccination Into Platinum/Pemetrexed-based First-line Treatment for Epithelioid Malignant Pleural Mesothelioma", "status": "RECRUITING", "last_update": "2026-06-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05944237", "title": "HTL0039732 in Participants With Advanced Solid Tumours", "status": "RECRUITING", "last_update": "2025-06-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06066138", "title": "A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06110572", "title": "Phase I/II Trial in ES-SCLC to Enhance Response to Atezolizumab Plus Chemotherapy With Total Body Irradiation", "status": "RECRUITING", "last_update": "2024-06-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06287775", "title": "Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06332755", "title": "Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC", "status": "RECRUITING", "last_update": "2025-11-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06362252", "title": "A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)", "status": "RECRUITING", "last_update": "2026-02-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06444815", "title": "A Study of VET3-TGI in Patients With Solid Tumors", "status": "RECRUITING", "last_update": "2026-04-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06475209", "title": "Adebrelimab + Apatinib in SCLC Maintenance Therapy", "status": "RECRUITING", "last_update": "2024-06-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06492954", "title": "Atezolizumab in Combination With Stereotactic Body Radiation Therapy (SBRT) and Surgery for Relapsed Osteosarcoma", "status": "RECRUITING", "last_update": "2026-06-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06562920", "title": "Adebrelimab Combined With Chemotherapy and Concurrent SBRT for Neoadjuvant Treatment of Limited-stage Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2024-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06616623", "title": "Vismodegib and Atezolizumab for the Treatment of Recurrent or Metastatic Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-02-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06646276", "title": "A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS).", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06712355", "title": "Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-09-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06768307", "title": "Assessment of Adebelizumab Combined With Chemotherapy in Concurrent Radiotherapy Versus Sequential Radiotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06807632", "title": "A Study of Valemetostat in Combination With Atezolizumab in People With Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06840782", "title": "First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.", "status": "RECRUITING", "last_update": "2025-09-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07113691", "title": "Iadademstat + SBRT With Atezo in ES-SCLC", "status": "RECRUITING", "last_update": "2026-03-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07130032", "title": "Efficacy And Safety Of Anti-PD-1/PD-L1 Antibodies In Combination With Bevacizumab And Metronomic Cyclophosphamide In Patients With Non-Small Cell Lung Cancer And Cutaneous Melanoma Previously Treated With Immune Checkpoint Blockade", "status": "RECRUITING", "last_update": "2025-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07153445", "title": "Neoadjuvant Treatment With Atezolizumab and Atezolizumab as Maintenance for the Treatment of Stage III Non Small-Cell Lung Cancer (NSCLC)", "status": "RECRUITING", "last_update": "2025-11-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07155174", "title": "A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07195695", "title": "Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07224971", "title": "Impact of Circadian Rhythm on Immunotherapy", "status": "RECRUITING", "last_update": "2025-12-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07226999", "title": "Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-17", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07227597", "title": "A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)", "status": "RECRUITING", "last_update": "2026-08-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07322341", "title": "SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07339059", "title": "Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-07-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07388524", "title": "Testing the Impact of an Anti-Cancer Drug, Atezolizumab, After Surgery to Prevent Early Stage Non-small Cell Lung Cancer From Returning, AASI-NSCLC Trial", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07472517", "title": "DAREON \u00ae -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy", "status": "RECRUITING", "last_update": "2026-08-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07545954", "title": "DSP-0390 in Combination With Atezolizumab for Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07654400", "title": "A Study of BL-M14D1 in Combination With Atezolizumab in Patients With Extensive-stage Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07759856", "title": "NK Cells Plus ICI for SCLC Maintenance", "status": "RECRUITING", "last_update": "2026-08-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01846416", "title": "A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]", "status": "COMPLETED", "last_update": "2019-01-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02314481", "title": "Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity", "status": "COMPLETED", "last_update": "2026-05-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02366143", "title": "A Study of Atezolizumab in Combination With Carboplatin Plus (+) Paclitaxel With or Without Bevacizumab Compared With Carboplatin+Paclitaxel+Bevacizumab in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2021-09-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02409342", "title": "A Study of Atezolizumab (MPDL3280A) Compared With a Platinum Agent (Cisplatin or Carboplatin) + (Pemetrexed or Gemcitabine) in Participants With Stage IV Non-Squamous or Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower110]", "status": "COMPLETED", "last_update": "2023-03-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02409355", "title": "A Study of Atezolizumab Compared With Gemcitabine Plus (+) Cisplatin or Carboplatin for PD-L1-Selected Participants With Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower111)", "status": "TERMINATED", "last_update": "2019-02-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02495636", "title": "Phase 2 Study of MPDL3280A Combined With CDX-1401 in NY-ESO 1 (+) IIIB, IV or Recurrent Non-Small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2017-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02525757", "title": "MPDL3280A With Chemoradiation for Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02543645", "title": "A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer", "status": "TERMINATED", "last_update": "2018-04-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02599454", "title": "Atezolizumab and Stereotactic Body Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2025-10-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02630186", "title": "A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC", "status": "TERMINATED", "last_update": "2019-07-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02657434", "title": "A Study of Atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed Compared With Carboplatin or Cisplatin + Pemetrexed in Participants Who Are Chemotherapy-Naive and Have Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) (IMpower 132)", "status": "COMPLETED", "last_update": "2023-11-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02664935", "title": "National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-04-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02748889", "title": "Carboplatin Plus Etoposide With or Without MPDL3280A in Untreated Extensive Stage Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2018-07-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02763579", "title": "A Study of Carboplatin Plus Etoposide With or Without Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)", "status": "COMPLETED", "last_update": "2023-07-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02813785", "title": "A Study of Atezolizumab Compared With Docetaxel in Non-Small Cell Lung Cancer (NSCLC) After Failure With Platinum-Containing Chemotherapy", "status": "COMPLETED", "last_update": "2023-01-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02848651", "title": "A Study of Atezolizumab as First-line Monotherapy for Advanced or Metastatic Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2020-04-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02876510", "title": "ACTolog in Patients With Solid Cancers", "status": "COMPLETED", "last_update": "2025-02-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02919449", "title": "Dose Escalation Trial of Intra-Tumoral Injection of NIS Measles Virus in Combination With Atezolizumab", "status": "TERMINATED", "last_update": "2023-07-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02927301", "title": "A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3)", "status": "COMPLETED", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02992912", "title": "Atezolizumab With Stereotactic Ablative Radiotherapy in Patients With Metastatic Tumours", "status": "COMPLETED", "last_update": "2026-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02994576", "title": "Atezolizumab as Induction Therapy in Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-08-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03023423", "title": "A Study of Daratumumab in Combination With Atezolizumab Compared With Atezolizumab Alone in Participants With Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2019-11-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03050060", "title": "Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer", "status": "TERMINATED", "last_update": "2022-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03102242", "title": "Atezolizumab Immunotherapy in Patients With Advanced NSCLC", "status": "COMPLETED", "last_update": "2023-05-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03170960", "title": "Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03191786", "title": "A Study of Atezolizumab Compared With a Single-Agent Chemotherapy in Treatment Na\u00efve Participants With Locally Advanced or Recurrent or Metastatic Non-Small Cell Lung Cancer Who Are Deemed Unsuitable For Platinum-Doublet Chemotherapy", "status": "COMPLETED", "last_update": "2024-10-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03212469", "title": "A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer", "status": "COMPLETED", "last_update": "2025-05-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03262454", "title": "Sequential Hypofractionated Radiotherapy Followed by Anti-PD-L1 Atezolizumab for SCLC", "status": "UNKNOWN", "last_update": "2022-04-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03285763", "title": "A Study of Atezolizumab (Tecentriq) to Investigate Long-term Safety and Efficacy in Previously-treated Participants With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2025-01-23", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03289962", "title": "A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors", "status": "COMPLETED", "last_update": "2026-06-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03313804", "title": "Priming Immunotherapy in Advanced Disease With Radiation", "status": "COMPLETED", "last_update": "2026-03-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03438318", "title": "Study Evaluating CMP-001 in Combination With Atezolizumab in Participants With Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2022-08-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03468426", "title": "A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours", "status": "COMPLETED", "last_update": "2025-11-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03511391", "title": "CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors", "status": "COMPLETED", "last_update": "2024-01-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03526900", "title": "Atezolizumab in Combination With Carboplatin Plus Pemetrexed in Chemotherapy-na\u00efve Patients With Asymptomatic Brain Metastasis", "status": "COMPLETED", "last_update": "2024-10-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03540420", "title": "Atezolizumab After Concurrent Chemo-radiotherapy Versus Chemo-radiotherapy Alone in Limited Disease Small-cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03544723", "title": "Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.", "status": "UNKNOWN", "last_update": "2020-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03647956", "title": "Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors", "status": "UNKNOWN", "last_update": "2019-04-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03654833", "title": "Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma", "status": "COMPLETED", "last_update": "2026-08-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03689855", "title": "Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC", "status": "COMPLETED", "last_update": "2024-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03713944", "title": "Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-na\u00efve Patients With Stage IV Non-squamous Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2023-03-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03735121", "title": "A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2025-12-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03811002", "title": "Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03829501", "title": "A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab (KY1044) as Single Agent and in Combination With Anti-PD-L1 (Atezolizumab) in Adult Patients With Selected Advanced Malignancies", "status": "TERMINATED", "last_update": "2025-04-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03836066", "title": "Atezolizumab Plus Bevacizumab in First Line NSCLC Patients", "status": "COMPLETED", "last_update": "2025-12-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03896074", "title": "Atezolizumab Versus Atezolizumab Plus Bevacizumab as First Line in NSCLC Patients (BEAT)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03915678", "title": "Atezolizumab Combined With BDB001 AnD Immunogenic Radiotherapy in Patients With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03922997", "title": "A Study to Investigate the Safety and Efficacy of Atezolizumab in Previously-Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2022-09-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03977194", "title": "Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03977467", "title": "Atezolizumab and Tiragolumab in Patients With NSCLC or Advanced Solid Tumors Having Had Prior Treatment With a PD-1 Inhibitor", "status": "COMPLETED", "last_update": "2025-08-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03991403", "title": "Study of Atezolizumab Combination Carboplatin + Paclitaxel + Bevacizumab in EGRF Mutation or ALK Translocation NSCLC", "status": "UNKNOWN", "last_update": "2023-04-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04028050", "title": "A Study of Atezolizumab in Combination With Carboplatin Plus Etoposide to Investigate Safety and Efficacy in Patients With Untreated Extensive-Stage Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2024-07-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04042558", "title": "A Study Evaluating Platinum-Pemetrexed-Atezolizumab (+/-Bevacizumab) for Patients With Stage IIIB/IV Non-squamous Non-small Cell Lung Cancer With EGFR Mutations, ALK Rearrangement or ROS1 Fusion Progressing After Targeted Therapies", "status": "COMPLETED", "last_update": "2026-05-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04059887", "title": "Evaluation of Blood TMB for the Efficacy of Atezolizumab [BUDDY]", "status": "COMPLETED", "last_update": "2023-02-08", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04081688", "title": "Atezolizumab and Varlilumab in Combination With Radiation Therapy for NSCLC", "status": "TERMINATED", "last_update": "2026-02-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04101357", "title": "Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT411", "status": "TERMINATED", "last_update": "2025-03-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04116320", "title": "Focused Ultrasound Ablation and PD-1 Antibody Blockade in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-07-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04214262", "title": "Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04245085", "title": "ABC-lung: Atezolizumab, Bevacizumab and Chemotherapy in EGFR-mutant Non-small Cell Lung Carcinoma", "status": "COMPLETED", "last_update": "2026-07-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04253145", "title": "Study to Assess Safety,Tolerability,Efficacy of PM01183 and Atezolizumab in Patients w/ Advanced Small Cell Lung Cancer.", "status": "UNKNOWN", "last_update": "2023-11-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04267237", "title": "A Study of the Efficacy and Safety of RO7198457 in Combination With Atezolizumab Versus Atezolizumab Alone Following Adjuvant Platinum-Doublet Chemotherapy in Participants Who Are ctDNA Positive After Surgical Resection of Stage II-III Non-Small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2021-02-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04310020", "title": "Study of Radiation Therapy Followed by Atezolizumab in Stage II or III Non-small Cell Lung Cancer Patients", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04373369", "title": "Vorolanib + Atezolizumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2025-11-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04402788", "title": "Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial", "status": "SUSPENDED", "last_update": "2026-09-04", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04422210", "title": "A Study Evaluating The Safety, Tolerability, Pharmacokinetics, And Efficacy Of Venetoclax In Combination With Atezolizumab, Carboplatin, And Etoposide In Participants With Untreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC).", "status": "TERMINATED", "last_update": "2021-11-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04426825", "title": "A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2024-05-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04432207", "title": "A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2026-03-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04442126", "title": "A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2025-05-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04462276", "title": "Thoracic RadiothErapy With Atezolizumab in Small Cell lUng canceR Extensive Disease", "status": "COMPLETED", "last_update": "2025-01-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04471415", "title": "Study to Investigate DRP-104 in Adults With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-06-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04471428", "title": "Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy", "status": "COMPLETED", "last_update": "2025-12-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04471727", "title": "A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04487756", "title": "Combination of Atezolizumab With Dendritic Cell Vaccine in Patients With Lung Cancer", "status": "COMPLETED", "last_update": "2026-07-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04513925", "title": "A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2026-06-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04549428", "title": "Atezolizumab Plus 8 Gy Single-fraction Radiotherapy for Advanced Oligoprogressive NSCLC", "status": "TERMINATED", "last_update": "2025-11-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04560686", "title": "Bintrafusp Alfa Before Surgery for the Treatment of Untreated Resectable Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2022-07-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04560972", "title": "LB-100, Carboplatin, Etoposide, and Atezolizumab for the Treatment of Untreated Extensive-Stage Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04563338", "title": "An Exploratory Study of Atezolizumab and Bevacizumab in Hepatocellular Carcinoma and Non-Small Cell Lung Cancer With Liver Metastases (INTEGRATE)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04610684", "title": "Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases", "status": "TERMINATED", "last_update": "2024-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04622228", "title": "Study of Low-Dose Radiotherapy (LDRT) Concurrent Cisplatin/Carboplatin Plus Etoposide With Atezolizumab for Patients With Extensive-Stage Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2024-07-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04631731", "title": "Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity", "status": "UNKNOWN", "last_update": "2023-06-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04636762", "title": "A Study of Concurrent Chemoradiation With Atezolizumab in Participants With Untreated Extensive-Stage (ES) Small Cell Lung Cancer (SCLC)", "status": "COMPLETED", "last_update": "2022-06-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04639245", "title": "Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2023-08-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04665856", "title": "Study of Atezolizumab Plus Carboplatin and Etoposide With or Without Tiragolumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04696939", "title": "Combined Atezolizumab and Chemotherapy (Carboplatin Plus Etoposide) in Neoadjuvant Treating Limited-Stage Small Cell Lung Cancer Patients", "status": "UNKNOWN", "last_update": "2021-01-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04730999", "title": "Efficacy and Safety Study of a New Therapeutic Strategy in the Treatment of Extended-Disease Small-Cell Lung Cancer", "status": "COMPLETED", "last_update": "2024-07-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04776447", "title": "Atezolizumab Plus Induction Chemotherapy Plus CT-radiotherapy. (APOLO)", "status": "COMPLETED", "last_update": "2026-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04789668", "title": "Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases", "status": "TERMINATED", "last_update": "2026-03-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04902040", "title": "Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies", "status": "TERMINATED", "last_update": "2026-04-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04958811", "title": "Tiragolumab With Atezolizumab Plus Bevacizumab in Previously-Treated Advanced Non-squamous NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04971187", "title": "Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2023-08-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04989283", "title": "Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2023-09-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04992715", "title": "PD-L1 Expression in Lung Cancer", "status": "UNKNOWN", "last_update": "2023-03-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04997382", "title": "Chemotherapy Combined with ICIs in First-line Alectinib Failed Patients with ALK-rearranged NSCLC", "status": "COMPLETED", "last_update": "2025-02-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05034055", "title": "Study of Stereotactic Ablative Radiotherapy(SBRT) Followed by Atezolizumab / Tiragolumab in Treatment-naive Patients With Metastatic Non-small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2021-09-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05069935", "title": "FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05091567", "title": "A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05142696", "title": "A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05171777", "title": "A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2025-12-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05191797", "title": "Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive Stage Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2024-09-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05195619", "title": "Personalized DC Vaccines in Non Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-07-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05224141", "title": "Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-07-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05253053", "title": "To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2025-06-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05334329", "title": "Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05340309", "title": "Subcutaneous Atezolizumab for the Treatment of Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05361395", "title": "First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05395052", "title": "FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05468489", "title": "To Evaluate Efficacy and Safety of Serplulimab + Chemotherapy (Carboplatin- Etoposide) in US Patients With ES-SCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05595460", "title": "Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05655663", "title": "Evaluation of Vascular Toxicity of Immune Checkpoint Inhibitors in Patients Head and Neck or Lung Cancer", "status": "UNKNOWN", "last_update": "2022-12-19", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05689671", "title": "Pemetrexed-free vs. Pemetrexed-based Immunochemotherapy in Metastatic TTF-1 Negative Lung Adenocarcinoma", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-10", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05703997", "title": "FASTing-like Approach and Maintenance IMMunotherapy in ES-SCLC Patients Not Progressing on Chemoimmunotherapy Induction", "status": "NOT_YET_RECRUITING", "last_update": "2023-01-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05781308", "title": "Combination of Paclitaxel-bevacizumab \u00b1 Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05825625", "title": "NeoTRACK - Dissection of IO Efficacy in NSCLC by Longitudinal tracKing", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05859217", "title": "A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)", "status": "NOT_YET_RECRUITING", "last_update": "2024-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05935774", "title": "OT-101 in Combination With Atezolizumab for the Treatment of Metastatic or Recurrent Non-Small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2023-08-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06049966", "title": "Atezolizumab in Large Cell Neuroendocrine Carcinoma", "status": "COMPLETED", "last_update": "2026-07-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06077500", "title": "DAREON\u1d40\u1d39-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06195683", "title": "Serplulimab for Patients With Non-small Cell Lung Cancer (NSCLC) With TPS \u2265 50%: a Prospective, Single-center, Single-arm Phase 2 Study.", "status": "UNKNOWN", "last_update": "2024-01-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06267001", "title": "A Study of Tiragolumab Plus Atezolizumab Compared With Placebo Plus Atezolizumab in Participants With Completely Resected Non-small Cell Lung Cancer Who Have Received Adjuvant Platinum-based Chemotherapy", "status": "TERMINATED", "last_update": "2026-06-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06356701", "title": "Tumor Nutritional Therapy in the First-line Treatment of Stage IV NSCLC", "status": "UNKNOWN", "last_update": "2024-04-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06572722", "title": "Perioperative Immunotherapy for NSCLC (ECTOP-1030)", "status": "WITHDRAWN", "last_update": "2026-04-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06632327", "title": "Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06739252", "title": "Perioperative Treatment of High-risk Resectable CCA With HAIC Plus A+T: Neobrave CCA", "status": "TERMINATED", "last_update": "2026-01-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06939036", "title": "Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )", "status": "TERMINATED", "last_update": "2026-02-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07172412", "title": "Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07796100", "title": "A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "AUMOLERTINIB": { "n": 63, "n_observational": 4, "n_active": 28, "n_withdrawn": 1, "trials": [ { "nct": "NCT04322890", "title": "Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation", "status": "RECRUITING", "last_update": "2024-10-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04951635", "title": "A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2022-06-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05800223", "title": "Armatinib Alone or in Combination With SRT for Brain Metastases EGFR-mutated Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2023-04-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06043973", "title": "Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance", "status": "RECRUITING", "last_update": "2023-09-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06102928", "title": "A Clinical Study of the Combination of Anlotinib and Aumolertinib in the First-line Treatment of Advanced NSCLC With EGFR 21L858R Mutation", "status": "RECRUITING", "last_update": "2023-10-26", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06417008", "title": "A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2025-08-01", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06926413", "title": "A Study Evaluating the Effect of Aumolertinib on the Pharmacokinetics of Midazolam in Patients With NSCLC", "status": "RECRUITING", "last_update": "2025-04-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06951464", "title": "A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC", "status": "RECRUITING", "last_update": "2025-07-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07130916", "title": "A Study of Aumolertinib in European Participants With Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2025-08-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07183189", "title": "A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC", "status": "RECRUITING", "last_update": "2026-04-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07398599", "title": "Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study", "status": "RECRUITING", "last_update": "2026-04-23", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07624487", "title": "Aumolertinib Combined With Phased Chemotherapy for EGFR L858R Lung Adenocarcinoma", "status": "RECRUITING", "last_update": "2026-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07637448", "title": "EGFR-TKIs Plus PD-1 in EGFR-Mutant Advanced NSCLC", "status": "RECRUITING", "last_update": "2026-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07645222", "title": "PHASE 1b STUDY OF HS-20122 COMBINED THERAPY IN NSCLC", "status": "RECRUITING", "last_update": "2026-07-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07699328", "title": "A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-07-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02981108", "title": "A Study to Evaluate Safety, PK and Efficacy of HS-10296 in Patients With NSCLC", "status": "UNKNOWN", "last_update": "2023-01-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03849768", "title": "A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients", "status": "UNKNOWN", "last_update": "2023-01-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04401059", "title": "Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC\uff1aProspective Study", "status": "UNKNOWN", "last_update": "2023-12-27", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04455594", "title": "Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC", "status": "UNKNOWN", "last_update": "2020-07-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04500704", "title": "Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Non-EGFR Driver Gene Mutant, Locally Advanced or Metastatic NSCLC", "status": "UNKNOWN", "last_update": "2020-08-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04500717", "title": "Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Tumor Suppressor Gene Mutation", "status": "UNKNOWN", "last_update": "2020-08-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04519983", "title": "Efficacy of SRT as Salvage Therapy in Patients With Brain Oligo-progression of EGFR-mutant Non-small Cell Lung Cancer After Failure of the Third-generation EGFR-TKIs", "status": "UNKNOWN", "last_update": "2023-03-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04553887", "title": "Almonertinib as Upfront Treatment for Uncommon EGFR Mutation Harboring Non-Small-Cell Lung Cancer Patients: A Multicenter, Open-Label, Phase II Trial", "status": "UNKNOWN", "last_update": "2020-10-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04592666", "title": "Almonertinib/Pemetrexed/Carboplatin in EGFR T790M+ Advanced Lung Cancer", "status": "UNKNOWN", "last_update": "2020-10-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04636593", "title": "A Phase 2 Trial of Almonertinib With Concurrent Radiotherapy in The Treatment of Local Advanced EGFR-mutant NSCLC", "status": "UNKNOWN", "last_update": "2021-01-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04643847", "title": "A Phase II Trial of Upfront Radiotherapy Plus Almonertinib for Epidermal Growth Factor Receptor(EGFR)-Mutant Non-small-cell Lung Cancer(NSCLC) Patients With Brain Metastases", "status": "UNKNOWN", "last_update": "2020-11-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04646824", "title": "Almonertinib With Chemotherapy in mEGFR NSCLC", "status": "UNKNOWN", "last_update": "2020-12-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04685070", "title": "Neoadjuvant HS-10296 (Almonertinib) Therapy for Potential Resectable Stage III EGFR Mutation-Positive Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-08-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04687241", "title": "Almonertinib Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB Non-Small Cell Lung Cancer With EGFR-sensitive Mutations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-11-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04755738", "title": "Almonertinib Plus Microwave Ablation in Advanced Non-small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2021-09-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04762459", "title": "Efficacy and Safety of Almonertinib Combined With or Without Chemotherapy as an Adjuvant Treatment for Stage II-IIIA Non-small Cell Lung Carcinoma Following Complete Tumour Resection", "status": "ENROLLING_BY_INVITATION", "last_update": "2022-02-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04778800", "title": "A Dose Exploration Study of Almonertinib for EGFRm NSCLC Patients With Brain/Leptomeningeal Metastasis (ARTISTRY)", "status": "UNKNOWN", "last_update": "2021-08-31", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04808752", "title": "Almonertinib as First-line Treatment in Patients With EGFR Mutations Positive in Advanced NSCLC With Brain Metastases", "status": "UNKNOWN", "last_update": "2024-04-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04841811", "title": "MDT-bridged Radical Therapy After Aumolertinib With MRD-guided Maintenance in EGFRm+ Unresectable Stage III NSCLC (APPROACH)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04882345", "title": "Almonertinib Treats Advanced NSCLC Patients With EGFR Mutations Who Are Safety Intolerant After Osimertinib Treatment", "status": "UNKNOWN", "last_update": "2021-05-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04905550", "title": "Almonertinib Combined With Cerebral Radiation Treat Brain Metastases From EGFR Positive NSCLC", "status": "UNKNOWN", "last_update": "2021-06-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04922138", "title": "Aumolertinib Adjuvant Therapy of Resectable Stage I EGFRm+ NSCLC With High-grade Patterns", "status": "UNKNOWN", "last_update": "2023-04-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04923906", "title": "Aumolertinib with or Without Chemotherapy As 1st Line Treatment in Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Sensitizing EGFR Mutations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-11-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04944069", "title": "Almonertinib With Bevacizumab for EGFR-Mutant NSCLC Patients With Leptomeningeal Metastasis", "status": "UNKNOWN", "last_update": "2021-06-29", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04951648", "title": "A Phase III Study to Assess the Efficacy and Safety of Almonertinib Versus Platinum-based Chemotherapy as First-line Therapy in Patients With Locally Advanced or Metastatic NSCLC Harbouring Uncommon EGFR Mutation", "status": "UNKNOWN", "last_update": "2021-07-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04952168", "title": "Combination of Almonertinib and Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC", "status": "UNKNOWN", "last_update": "2021-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04978753", "title": "the Efficacy and Safety of Anlotinib Combined With Almonertinib in the First-line Treatment of Patients With Brain Metastases From EGFR Mutation-positive Non-small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2021-07-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05223595", "title": "A Study of Gentuximab in Combination With Almonertinib in EGFR Mutation-positive Metastatic NSCLC", "status": "UNKNOWN", "last_update": "2022-02-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05430386", "title": "Study of HS-10241 in Combination With Almonertinib in Patients With Locally Advanced or Metastatic NSCLC", "status": "UNKNOWN", "last_update": "2023-02-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05493501", "title": "Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2024-05-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05503888", "title": "Phase Ib/II Study of Almonertinib Combined With SHR-1701 in the Treatment of Relapsed or Advanced Non-small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2022-08-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05534113", "title": "Envafolimab Immunotherapy After ctDNA EGFR Clearance by Treatment With Almonertinib in EGFR-Mutant, PD-LI Positive NSCLC", "status": "UNKNOWN", "last_update": "2022-09-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05662813", "title": "Almonertinib Therapy in Patients With Abnormal Liver Function After EGFR-TKI Treatment, or Almonertinib First-line Therapy in Patients With Basic Hepatopathy", "status": "UNKNOWN", "last_update": "2022-12-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05778149", "title": "Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation", "status": "NOT_YET_RECRUITING", "last_update": "2023-03-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05810350", "title": "Aumolertinib Combined Intrathecal Chemotherapy for Leptomeningeal Metastasis From EGFR-Mutated NSCLC and Prognostic Value of Dynamic Changes in cfDNA Profiles", "status": "UNKNOWN", "last_update": "2023-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05826483", "title": "Almonertinib in the First-line Treatment of Patients of NSCLC With Poor Performance Status", "status": "UNKNOWN", "last_update": "2023-04-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05946460", "title": "Neoadjuvant Aumolertinib in Patients With AI-diagnosed EGFR-mutant High-risk Pulmonary Ground-glass Opacity.", "status": "UNKNOWN", "last_update": "2024-02-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05994339", "title": "Radiotherapy Combined With Almonertinib for Stage III EGFR-Mutated Lung Cancer", "status": "UNKNOWN", "last_update": "2023-08-29", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06110663", "title": "A Study of HS-10241 Combined With Almonertinib Versus Platinum-based Chemotherapy in Treatment of Advanced NSCLC With MET Amplification After Failure of EGFR-TKI Therapy", "status": "UNKNOWN", "last_update": "2023-11-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06185400", "title": "RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations", "status": "NOT_YET_RECRUITING", "last_update": "2023-12-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06227897", "title": "Aumolertinib in EGFR-Mutant Resected Stage IB-IIIA NSCLC (AERESA).", "status": "WITHDRAWN", "last_update": "2024-12-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06300424", "title": "Neoadjuvant Almonertinib Followed by Chemo-immunotherapy in II-IIIB EGFR-mutant NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06452433", "title": "Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.", "status": "NOT_YET_RECRUITING", "last_update": "2024-06-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06463171", "title": "Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2024-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06481566", "title": "Efficacy and Safety of Almonertinib Combined With Stereotactic Body Radiotherapy (SBRT) in the Treatment of Non-small Cell Lung Cancer With EGFR Sensitive Mutation: a Single-arm, Open-label Clinical Trial", "status": "UNKNOWN", "last_update": "2024-09-04", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06585059", "title": "Clinical Trial of TQB2928 in Combination With a Third-Generation Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor (TKI) in Patients With Advanced Non-Small Cell Lung Cancers", "status": "NOT_YET_RECRUITING", "last_update": "2024-09-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06752408", "title": "Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-12-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07699952", "title": "First-line Therapy With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor(EGFR-TKI) Combined With Trastuzumab Rezetecan for Advanced Non-small Cell Lung Cancer(NSCLC) Harboring EGFR Mutations Concomitant With Human Epidermal Growth Factor Receptor 2(HER2) Alterations", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "AVELUMAB": { "n": 38, "n_observational": 1, "n_active": 5, "n_withdrawn": 2, "trials": [ { "nct": "NCT05267626", "title": "Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2R\u03b1 Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer", "status": "RECRUITING", "last_update": "2026-07-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06228066", "title": "Lurbinectedin With or Without Avelumab in Small Cell Carcinoma of the Bladder (LASER)", "status": "RECRUITING", "last_update": "2026-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07224971", "title": "Impact of Circadian Rhythm on Immunotherapy", "status": "RECRUITING", "last_update": "2025-12-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01772004", "title": "Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor)", "status": "COMPLETED", "last_update": "2021-12-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02222922", "title": "A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2020-12-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02349633", "title": "Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)", "status": "TERMINATED", "last_update": "2021-06-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02395172", "title": "Avelumab in Non-Small Cell Lung Cancer (JAVELIN Lung 200)", "status": "COMPLETED", "last_update": "2020-08-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02554812", "title": "A Study Of Avelumab In Combination With Other Cancer Immunotherapies In Advanced Malignancies (JAVELIN Medley)", "status": "TERMINATED", "last_update": "2024-07-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02576574", "title": "Avelumab in First-line NSCLC (JAVELIN Lung 100)", "status": "COMPLETED", "last_update": "2025-01-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02584634", "title": "Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)", "status": "TERMINATED", "last_update": "2023-07-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03050554", "title": "SBRT Combined With Avelumab (Anti-PD-L1) for Management of Early Stage Non-Small Cell Lung Cancer (NSCLC)", "status": "TERMINATED", "last_update": "2024-08-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03158883", "title": "UCDCC#270: Avelumab and Stereotactic Ablative Radiotherapy in Non-responding and Progressing NSCLC Patients", "status": "COMPLETED", "last_update": "2021-10-20", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03169738", "title": "QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors", "status": "WITHDRAWN", "last_update": "2025-02-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03228667", "title": "QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03268057", "title": "VX15/2503 in Combination With Avelumab in Advanced Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2022-05-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03270176", "title": "A Dose-Finding Study of the Second Mitochondrial Activator of Caspases (SMAC) Mimetic Debio 1143 When Given in Combination With Avelumab to Participants With Advanced Solid Malignancies and to Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) After Platinum-Based Therapy", "status": "COMPLETED", "last_update": "2022-06-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03317496", "title": "Safety And Efficacy Study Of Avelumab Plus Chemotherapy With Or Without Other Anti-Cancer Immunotherapy Agents In Patients With Advanced Malignancies", "status": "TERMINATED", "last_update": "2023-08-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03330405", "title": "Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid Tumors", "status": "TERMINATED", "last_update": "2023-10-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03386929", "title": "Survival Prolongation by Rationale Innovative Genomics", "status": "TERMINATED", "last_update": "2023-12-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03399552", "title": "Stereotactic Body Radiation Therapy and Avelumab Immunotherapy for Treatment of Malignant Mesothelioma", "status": "COMPLETED", "last_update": "2023-10-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03409458", "title": "A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab", "status": "COMPLETED", "last_update": "2023-11-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03472560", "title": "A Study of Avelumab in Combination With Axitinib In Non-Small Cell Lung Cancer (NSCLC) or Urothelial Cancer (Javelin Medley VEGF)", "status": "TERMINATED", "last_update": "2024-04-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03475953", "title": "A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors", "status": "UNKNOWN", "last_update": "2023-03-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03514719", "title": "PD-L1 Imaging in Non Small Cell Lung Cancer' (PINNACLE)", "status": "COMPLETED", "last_update": "2022-01-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03568097", "title": "Immunotherapy in Combination With Chemotherapy in Small-cell Lung Cancer", "status": "UNKNOWN", "last_update": "2023-06-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03574649", "title": "QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2025-02-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03717155", "title": "Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC", "status": "COMPLETED", "last_update": "2022-06-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03815643", "title": "Avelumab Program Rollover Study", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04173507", "title": "Combination Treatment (Talazoparib Plus Avelumab) for Stage IV or Recurrent Non-Squamous Non-Small Cell Lung Cancer With STK11 Gene Mutation (A LUNG-MAP Treatment Trial)", "status": "COMPLETED", "last_update": "2024-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04260802", "title": "A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers", "status": "TERMINATED", "last_update": "2026-01-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04551885", "title": "FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04571632", "title": "Clinical Trial of SBRT and Systemic Pembrolizumab With or Without Avelumab/Ipilimumab+ Dendritic Cells in Solid Tumors", "status": "UNKNOWN", "last_update": "2022-09-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04601402", "title": "GEN-001 (Live Biotherapeutic Product) and Avelumab Combination Study for Patients With Solid Tumors Who Have Progressed on Anti-PD-(L)1 Therapy", "status": "COMPLETED", "last_update": "2023-08-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04902040", "title": "Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies", "status": "TERMINATED", "last_update": "2026-04-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05069935", "title": "FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05395052", "title": "FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05429866", "title": "Immunological Variables Associated to ICI Toxicity in Cancer Patients", "status": "UNKNOWN", "last_update": "2023-03-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06939036", "title": "Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )", "status": "TERMINATED", "last_update": "2026-02-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "AZD-3759": { "n": 5, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT07361705", "title": "Zorifertinib With Osimertinib for NSCLC With Meningeal Progression", "status": "RECRUITING", "last_update": "2026-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02228369", "title": "Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2021-01-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03360929", "title": "Evaluate Safety, Tolerability, Pharmacokinetics and Anti-tumor Activity of AZD3759", "status": "COMPLETED", "last_update": "2022-11-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03574402", "title": "Phase II Umbrella Study Directed by Next Generation Sequencing", "status": "UNKNOWN", "last_update": "2022-12-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03653546", "title": "First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases", "status": "COMPLETED", "last_update": "2025-09-10", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" } ] }, "BINTRAFUSP ALFA": { "n": 11, "n_observational": 0, "n_active": 0, "n_withdrawn": 1, "trials": [ { "nct": "NCT03631706", "title": "M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2025-04-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03840902", "title": "M7824 With cCRT in Unresectable Stage III Non-small Cell Lung Cancer (NSCLC)", "status": "TERMINATED", "last_update": "2024-01-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03840915", "title": "M7824 in Combination With Chemotherapy in Stage IV Non-small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2023-08-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04297748", "title": "Bioimaging Study of 89Zr-M7824 in NSCLC", "status": "TERMINATED", "last_update": "2023-01-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04396535", "title": "Docetaxel With or Without Bintrafusp Alfa for the Treatment of Advanced Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2025-11-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04560686", "title": "Bintrafusp Alfa Before Surgery for the Treatment of Untreated Resectable Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2022-07-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04648826", "title": "Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies", "status": "WITHDRAWN", "last_update": "2021-12-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04789668", "title": "Bintrafusp Alfa and Pimasertib for the Treatment of Patients With Brain Metastases", "status": "TERMINATED", "last_update": "2026-03-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04971187", "title": "Bintrafusp Alfa With Chemotherapy for Tyrosine Kinase Inhibitor-Resistant EGFR-Mutant Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2023-08-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05005429", "title": "Study of the Efficacy and Safety of the Bintrafusp Alfa in Previously Treated Advanced Malignant Pleural Mesothelioma", "status": "COMPLETED", "last_update": "2025-12-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05061823", "title": "Bintrafusp Alfa Program Rollover Study", "status": "COMPLETED", "last_update": "2026-02-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "BMS-690514": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00743938", "title": "A Comparison Between BMS-690514 and Erlotinib in Patients Who Were Previously Treated for NSCLC", "status": "COMPLETED", "last_update": "2015-10-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01167244", "title": "Trial of BMS-690514 in Non-Small Cell Lung Cancer Subjects Who Have Been Treated With Gefitinib or Erlotinib and Are Genotypically EGFR Mutation Positive or Who Have Had a Prior Response", "status": "COMPLETED", "last_update": "2015-10-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "BPI-9016": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02929290", "title": "Safety, Efficacy and Pharmacokinetic of BPI-9016M in Patients With c-Met- Dysregulated Advanced NSCLC", "status": "UNKNOWN", "last_update": "2021-09-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "BRIGATINIB": { "n": 27, "n_observational": 13, "n_active": 9, "n_withdrawn": 3, "trials": [ { "nct": "NCT04322890", "title": "Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation", "status": "RECRUITING", "last_update": "2024-10-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05014464", "title": "ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2024-09-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06620835", "title": "Trial for Local Ablative Treatment (LAT) Optimization in Patients With Advanced Non-Small Cells Lung Cancer (NSCLC) Presenting an Anaplastic Lymphoma Kinase (ALK) Rearrangement Treated by Brigatinib", "status": "RECRUITING", "last_update": "2026-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01449461", "title": "A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-Tumor Activity of the Oral Anaplastic Lymphoma Kinase (ALK)/Epidermal Growth Factor Receptor (EGFR) Inhibitor Brigatinib (AP26113)", "status": "COMPLETED", "last_update": "2021-08-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02094573", "title": "A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib", "status": "COMPLETED", "last_update": "2021-03-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02706626", "title": "Trial of Brigatinib After Treatment With Next-Generation ALK Inhibitors", "status": "TERMINATED", "last_update": "2023-01-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02737501", "title": "ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants", "status": "COMPLETED", "last_update": "2021-08-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03410108", "title": "Phase 2 Study of Brigatinib in Japanese Participants With Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2024-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03420742", "title": "A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate, Midazolam, in Participants With ALK-Positive or ROS1-Positive Solid Tumors", "status": "COMPLETED", "last_update": "2023-01-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03535740", "title": "A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib", "status": "COMPLETED", "last_update": "2025-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03596866", "title": "A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer", "status": "COMPLETED", "last_update": "2025-09-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03707938", "title": "Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03737994", "title": "Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2026-04-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03868423", "title": "Brigatinib in Treating Patients With ALK and ROS1 Gene Alterations and Locally Advanced or Metastatic Solid Cancers", "status": "WITHDRAWN", "last_update": "2022-02-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04005144", "title": "Brigatinib and Binimetinib in Treating Patients With Stage IIIB-IV ALK or ROS1-Rearranged Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2022-10-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04074993", "title": "Brigatinib in ALK-positive NSCLC Identified Via Blood-based Assays", "status": "UNKNOWN", "last_update": "2023-09-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04223596", "title": "Clinical Utility of Liquid Biopsy in Brigatinib ALK+ Patients", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04227028", "title": "Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04318938", "title": "Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping", "status": "COMPLETED", "last_update": "2026-06-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04591431", "title": "The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy", "status": "UNKNOWN", "last_update": "2023-10-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04634110", "title": "Brigatinib Before Brain Irradiation Trial (B3i Trial)", "status": "TERMINATED", "last_update": "2022-10-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05195619", "title": "Personalized DC Vaccines in Non Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-07-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05200481", "title": "Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05361564", "title": "A Window of Opportunity Study for Investigating Drug Tolerant Persister (DTP) to Preoperative Brigatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Fusions.", "status": "UNKNOWN", "last_update": "2022-05-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05718297", "title": "Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2024-10-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06522360", "title": "Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2)", "status": "WITHDRAWN", "last_update": "2025-04-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07771764", "title": "A Multicenter Exploratory Clinical Study of Iruplaltinib Combined With Pemetrexed as Neoadjuvant Therapy for Resectable ALK-Positive Non-Squamous Non-Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "CABOZANTINIB": { "n": 25, "n_observational": 0, "n_active": 11, "n_withdrawn": 1, "trials": [ { "nct": "NCT01639508", "title": "Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity", "status": "RECRUITING", "last_update": "2026-08-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04893785", "title": "A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM)", "status": "RECRUITING", "last_update": "2024-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05613413", "title": "A Pilot Phase II Study of Maintenance Cabozantinib Plus Pembrolizumab for Patients With Metastatic Squamous Non-Small Cell Lung Cancer (sqNSCLC)", "status": "RECRUITING", "last_update": "2026-01-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06026410", "title": "KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-06-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00596648", "title": "A Study of XL184 (Cabozantinib) With or Without Erlotinib in Subjects With Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2026-01-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00940225", "title": "Study of Cabozantinib (XL184) in Adults With Advanced Malignancies", "status": "COMPLETED", "last_update": "2024-04-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01588821", "title": "Cabozantinib in Advanced Solid Malignancies", "status": "COMPLETED", "last_update": "2020-09-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01708954", "title": "Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01834651", "title": "A Phase II Study of Cabozantinib (XL184) Therapy in Castrate Resistant Prostate Cancer (CRPC) With Visceral Metastases", "status": "COMPLETED", "last_update": "2017-09-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01866410", "title": "Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2019-05-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02071862", "title": "Study of the Glutaminase Inhibitor CB-839 in Solid Tumors", "status": "COMPLETED", "last_update": "2022-07-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02132598", "title": "Trial of Cabozantinib (XL184) in Non-Small Cell Lung Cancer With Brain Metastases", "status": "TERMINATED", "last_update": "2021-03-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02795156", "title": "Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations", "status": "COMPLETED", "last_update": "2023-12-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03170960", "title": "Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03375320", "title": "Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03468985", "title": "Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2023-10-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03911193", "title": "CABozantinib in Non-Small Cell Lung Cancer (NSCLC) Patients With MET Deregulation", "status": "UNKNOWN", "last_update": "2019-04-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04079712", "title": "Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04131543", "title": "Phase II Study With Cabozantinib in Patients With RET Positive NSCLC", "status": "UNKNOWN", "last_update": "2019-10-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04151563", "title": "A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy", "status": "WITHDRAWN", "last_update": "2023-12-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04173338", "title": "Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant Mesothelioma", "status": "TERMINATED", "last_update": "2022-06-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04310007", "title": "Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04471428", "title": "Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy", "status": "COMPLETED", "last_update": "2025-12-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04514484", "title": "Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05859217", "title": "A Study of Combining Cabozantinib and Atezolizumab for Advanced/Metastatic NSCLC (Cabatezo-1)", "status": "NOT_YET_RECRUITING", "last_update": "2024-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "CABOZANTINIB S-MALATE": { "n": 7, "n_observational": 0, "n_active": 5, "n_withdrawn": 0, "trials": [ { "nct": "NCT01708954", "title": "Erlotinib Hydrochloride and Cabozantinib-s-Malate Alone or in Combination as Second or Third Line Therapy in Treating Patients With Stage IV Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01866410", "title": "Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2019-05-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03375320", "title": "Testing Cabozantinib in Patients With Advanced Pancreatic Neuroendocrine and Carcinoid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03468985", "title": "Nivolumab, Cabozantinib S-Malate, and Ipilimumab in Treating Patients With Recurrent Stage IV Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2023-10-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04079712", "title": "Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04310007", "title": "Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04514484", "title": "Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "CANERTINIB": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00050830", "title": "A Phase 2, Randomized, Open-Label Study Of Single Agent CI-1033 In Patients With Advanced Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2006-11-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00174356", "title": "PH 1 Evaluation Of Oral CI-1033 In Combination With Paclitaxel/ Carboplatin As 1st Line Chemotherapy In NSCLC Patients", "status": "COMPLETED", "last_update": "2006-11-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "CAPMATINIB": { "n": 26, "n_observational": 8, "n_active": 4, "n_withdrawn": 3, "trials": [ { "nct": "NCT05642572", "title": "Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)", "status": "RECRUITING", "last_update": "2026-06-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01324479", "title": "Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2020-12-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01610336", "title": "A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment", "status": "COMPLETED", "last_update": "2021-04-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01911507", "title": "INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2021-10-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02276027", "title": "A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2020-12-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02323126", "title": "Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2022-02-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02335944", "title": "Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.", "status": "TERMINATED", "last_update": "2023-06-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02414139", "title": "Study of Oral cMET Inhibitor INC280 in Patients With EGFR Wild-type (wt), Advanced Non-small Cell Lung Cancer (NSCLC) (Geometry Mono-1)", "status": "COMPLETED", "last_update": "2024-03-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02468661", "title": "A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification", "status": "TERMINATED", "last_update": "2020-02-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02750215", "title": "A Study of Capmatinib (INC280) in NSCLC Patients With MET Exon 14 Alterations Who Have Received Prior MET Inhibitor", "status": "COMPLETED", "last_update": "2022-03-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03040973", "title": "Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03240393", "title": "Study of Oral cMET Inhibitor INC280 in Chinese Patients With EGFR Wild-type Advanced Non-small Cell Lung Cancer (NSCLC)", "status": "WITHDRAWN", "last_update": "2018-07-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03333343", "title": "Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03647488", "title": "Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2022-01-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03693339", "title": "Capmatinib in Patients With Non-small Cell Lung Cancer Harboring cMET exon14 Skipping Mutation", "status": "UNKNOWN", "last_update": "2018-10-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04139317", "title": "Safety and Efficacy of Capmatinib (INC280) Plus Pembrolizumab vs Pembrolizumab Alone in NSCLC With PD-L1\u2265 50%", "status": "TERMINATED", "last_update": "2024-10-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04323436", "title": "Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations", "status": "TERMINATED", "last_update": "2024-10-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04427072", "title": "Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation", "status": "TERMINATED", "last_update": "2025-05-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04460729", "title": "A Phase II, Open-Label, Multicenter Study of Capmatinib in Subjects With MET Exon 14 Skipping Mutation Positive, Advanced, NSCLC With Brain Metastases", "status": "WITHDRAWN", "last_update": "2020-12-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04677595", "title": "Study of Capmatinib in Chinese Adult Patients With Advanced Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation", "status": "COMPLETED", "last_update": "2026-03-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04816214", "title": "Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy", "status": "TERMINATED", "last_update": "2024-03-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04926831", "title": "Phase II of Neoadjuvant and Adjuvant Capmatinib in NSCLC", "status": "TERMINATED", "last_update": "2025-10-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05110196", "title": "Study of Capmatinib in Indian Patients With MET Exon 14 Skipping Mutation Positive Advanced NSCLC.", "status": "COMPLETED", "last_update": "2026-04-07", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05435846", "title": "Capmatinib Plus Trametinib for the Treatment of Metastatic Non-small Cell Lung Cancer With MET Exon 14 Skipping Mutation", "status": "TERMINATED", "last_update": "2024-06-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05488314", "title": "A Study of Amivantamab and Capmatinib Combination Therapy in Unresectable Metastatic Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05567055", "title": "Central Nervous System Efficacy of Capmatinib in NSCLC With Brain Metastases With cfDNA Positive MET Alterations", "status": "WITHDRAWN", "last_update": "2024-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "CEP-32496": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01877811", "title": "Study of RXDX-105, Potent RET Inhibitor in Patients With Advanced Lung Cancer and Other Solid Tumors", "status": "COMPLETED", "last_update": "2019-04-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "CERITINIB": { "n": 25, "n_observational": 7, "n_active": 4, "n_withdrawn": 0, "trials": [ { "nct": "NCT04322890", "title": "Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation", "status": "RECRUITING", "last_update": "2024-10-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01283516", "title": "A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase", "status": "COMPLETED", "last_update": "2019-03-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01685060", "title": "LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib", "status": "COMPLETED", "last_update": "2017-06-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01685138", "title": "LDK378 in Crizotinib na\u00efve Adult Patients With ALK-activated Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2019-03-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01772797", "title": "Phase Ib Study of LDK378 and AUY922 in ALK-rearranged Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2020-12-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01828099", "title": "LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2025-01-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01828112", "title": "LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib", "status": "COMPLETED", "last_update": "2025-02-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01964157", "title": "An Open-label, Multicenter, Phase II Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement", "status": "COMPLETED", "last_update": "2026-07-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02040870", "title": "LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib", "status": "COMPLETED", "last_update": "2019-02-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02276027", "title": "A Phase II, Open Label, Multiple Arm Study of AUY922, BYL719, INC280, LDK378 and MEK162 in Chinese Patients With Advanced Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2020-12-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02292550", "title": "Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.", "status": "COMPLETED", "last_update": "2020-12-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02299505", "title": "Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2022-02-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02321501", "title": "Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02336451", "title": "A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges", "status": "COMPLETED", "last_update": "2020-04-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02393625", "title": "Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02422589", "title": "A Phase I, Multi-center, Open Label, Drug-drug Interaction Study to Assess the Effect of Ceritinib on the Pharmacokinetics of Warfarin and Midazolam in Patients With ALK-positive Advanced Tumors", "status": "COMPLETED", "last_update": "2020-12-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02450903", "title": "LDK378 in Patients With ALK Positive NSCLC Previously Treated With Alectinib.", "status": "COMPLETED", "last_update": "2021-03-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02513667", "title": "Ceritinib in Combination With Stereotactic Ablative Radiation Metastatic Lung Adenocarcinoma", "status": "TERMINATED", "last_update": "2023-02-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03087448", "title": "Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)", "status": "TERMINATED", "last_update": "2022-12-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03399487", "title": "A Study of LDK378 in Patients With Non-small Cell Lung Cancer Harboring ROS1 Rearrangement", "status": "UNKNOWN", "last_update": "2019-01-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03535740", "title": "A Study of Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib", "status": "COMPLETED", "last_update": "2025-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03611738", "title": "Ceritinib Plus Docetaxel in ALK-Negative, EGFR WT Advanced NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03737994", "title": "Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2026-04-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04356118", "title": "Efficacy and Safety of Recombinant Human Endostatin in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis", "status": "UNKNOWN", "last_update": "2020-05-27", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04634110", "title": "Brigatinib Before Brain Irradiation Trial (B3i Trial)", "status": "TERMINATED", "last_update": "2022-10-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "CETUXIMAB": { "n": 127, "n_observational": 2, "n_active": 33, "n_withdrawn": 4, "trials": [ { "nct": "NCT05504278", "title": "Efficacy and Safety of IBI351 in Combination With Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation", "status": "RECRUITING", "last_update": "2025-01-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05786924", "title": "Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies", "status": "RECRUITING", "last_update": "2026-06-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05910827", "title": "A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers", "status": "RECRUITING", "last_update": "2026-05-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06179160", "title": "A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation", "status": "RECRUITING", "last_update": "2026-07-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06385925", "title": "A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation", "status": "RECRUITING", "last_update": "2026-04-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06586515", "title": "MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06764771", "title": "A Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors", "status": "RECRUITING", "last_update": "2026-07-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06835569", "title": "A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations", "status": "RECRUITING", "last_update": "2026-06-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06917079", "title": "BBO-11818 in Adult Subjects With KRAS Mutant Cancer", "status": "RECRUITING", "last_update": "2026-06-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06943820", "title": "AK129 Combination Therapy for Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2025-06-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07020221", "title": "A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors", "status": "RECRUITING", "last_update": "2026-04-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07198841", "title": "IBI351 Plus Cetuximab \u03b2 in Untreated Advanced Non-small Cell Lung Cancer With KRAS G12C Mutation", "status": "RECRUITING", "last_update": "2026-03-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07216105", "title": "FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07223047", "title": "A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies", "status": "RECRUITING", "last_update": "2026-05-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07252739", "title": "KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07286149", "title": "A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07300150", "title": "A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07349537", "title": "Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07397338", "title": "Study of RAS(ON) Inhibitors in Combination With Ivonescimab in Patients With Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07468071", "title": "Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit From Opnurasib as a Single Agent or in Combination With Other Study Treatments", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00034541", "title": "Study of Cetuximab in Combination With Carboplatin-Paclitaxel in Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2010-04-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00063388", "title": "Phase II Study in Patients With Recurrent Non-Small-Cell Lung Cancer", "status": "COMPLETED", "last_update": "2010-04-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00081302", "title": "Cetuximab, Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients With Unresectable Stage IIIA or Stage IIIB Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2015-11-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00085501", "title": "S0342: Paclitaxel, Carboplatin, and Cetuximab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2012-11-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00095199", "title": "Docetaxel or Pemetrexed With or Without Cetuximab in Patients With Recurrent or Progressive Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2012-10-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00097214", "title": "Carboplatin Plus Cetuximab for Treatment of Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2010-04-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00097227", "title": "Trial of Carboplatin/Paclitaxel/Cetuximab in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2010-04-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00101348", "title": "Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2014-06-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00103207", "title": "Cetuximab in Treating Patients With Recurrent or Stage IIIB or Stage IV Lung Cancer", "status": "COMPLETED", "last_update": "2023-06-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00112294", "title": "Study of Taxane/Carboplatin +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2015-12-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00112346", "title": "Study of Gemcitabine/Platinum +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2015-10-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00115518", "title": "Radiation Plus Cetuximab in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2011-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00117962", "title": "Pemetrexed Disodium, Carboplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Stage III Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2016-10-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00118183", "title": "Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2013-06-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00124618", "title": "Cetuximab and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2016-07-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00148798", "title": "Study of Cisplatin/Vinorelbine +/- Cetuximab as First-line Treatment of Advanced Non Small Cell Lung Cancer (FLEX)", "status": "COMPLETED", "last_update": "2014-06-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00162318", "title": "A Phase I Study of Cetuximab in Combination With Gefitinib in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2015-10-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00165334", "title": "Cetuximab and Vinorelbine in Elderly Subjects With Lung Cancer", "status": "COMPLETED", "last_update": "2009-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00193453", "title": "Gemcitabine, Docetaxel, and Cetuximab in Patients With Unresectable Advanced Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2012-11-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00203931", "title": "Trial Comparing Cetuximab With Pemetrexed/Cetuximab Therapy for Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2014-03-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00207116", "title": "An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma", "status": "COMPLETED", "last_update": "2015-10-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00216203", "title": "Pemetrexed Plus Cetuximab in Patients With Recurrent Non Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2016-09-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00251498", "title": "Phase II Study of Cetuximab in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2008-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00288054", "title": "S0429: Docetaxel, Cetuximab, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2013-01-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00315185", "title": "Study of Paclitaxel, Carboplatin, and Cetuximab for Advanced Lung Cancer", "status": "COMPLETED", "last_update": "2010-09-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00323869", "title": "Phase II Bevacizumab, Gemcitabine and Carboplatin in Newly Diagnosed Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2016-09-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00330746", "title": "CALC-1 (Cetuximab in Advanced Lung Cancer): Study of 2 Methods of Combining Cetuximab and Gemcitabine in Patients With Advanced Non Small-cell Lung Cancer", "status": "COMPLETED", "last_update": "2012-05-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00343291", "title": "A Study of Cetuximab and Bevacizumab in Combination With Paclitaxel and Carboplatin in Stage IIIb/IV NSCLC", "status": "COMPLETED", "last_update": "2011-06-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00368992", "title": "S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2015-09-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00397384", "title": "Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer", "status": "COMPLETED", "last_update": "2015-09-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00406302", "title": "Immune Response on Neoadjuvant Therapy in Non-small-cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2014-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00408499", "title": "Erlotinib and Cetuximab in Treating Patients With Advanced Solid Tumors With Emphasis on Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2017-05-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00492206", "title": "Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLC", "status": "COMPLETED", "last_update": "2017-02-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00513266", "title": "Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer With Liver Metastases or Lung Metastases That Are Potentially Removable by Surgery", "status": "UNKNOWN", "last_update": "2009-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00519831", "title": "Ph II of Vinflunine and Cetuximab in Second Line Treatment of NSCLC", "status": "TERMINATED", "last_update": "2017-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00522886", "title": "Phase I Cetuximab and Concurrent Radio-chemotherapy", "status": "COMPLETED", "last_update": "2011-07-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00533949", "title": "High-Dose or Standard-Dose Radiation Therapy and Chemotherapy With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery", "status": "COMPLETED", "last_update": "2022-06-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00557102", "title": "Cetuximab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and/or Lung", "status": "COMPLETED", "last_update": "2012-12-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00561054", "title": "Efficacy and Safety of Cetuximab in Combination With Cisplatin Gemcitabine as First-Line Therapy in Advanced NSCLC", "status": "UNKNOWN", "last_update": "2007-11-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00569296", "title": "Laboratory-Treated Autologous Lymphocytes, Aldesleukin, and GM-CSF in Treating Patients With Recurrent, Refractory, or Metastatic Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2015-03-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00622674", "title": "Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2017-12-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00673738", "title": "Cetuximab Plus Conformal Thoracic Radiotherapy in Patients (Pts) With Inoperable or Unresectable Locally Advanced Non-Small Cell Lung Cancer (LA - NSCLC)", "status": "COMPLETED", "last_update": "2015-10-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00694603", "title": "Cetuximab as Therapy for Recurrent Non-Small Cell Lung Cancer Patients Who Have Received Prior Therapy", "status": "TERMINATED", "last_update": "2012-09-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00716456", "title": "Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed \"Acquired Resistance\" to Erlotinib", "status": "COMPLETED", "last_update": "2015-04-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00768131", "title": "A Study to Determine Whether EGFR Status by FISH Can Predict Results in Non Small Cell Lung Cancer (NSCLC) Patients Treated With Cetuximab, Carboplatin and Paclitaxel", "status": "WITHDRAWN", "last_update": "2015-10-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00820417", "title": "Pharmocokinetic/Pharmacodynamic (PK/PD) Study of the Combination Cetuximab/Gefitinib", "status": "COMPLETED", "last_update": "2009-01-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00820755", "title": "Trial With Cetuximab in Maintenance Therapy After Platinum Based Chemotherapy in First Line Treatment of Non-small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2014-05-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00828841", "title": "Phase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLC", "status": "COMPLETED", "last_update": "2013-11-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00842712", "title": "Cilengitide and Cetuximab in Combination With Platinum-based Chemotherapy as First-line Treatment for Subjects With Advanced Non Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2017-01-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00867009", "title": "A Study of Induction and Maintenance Treatment of Advanced or Metastatic Non Squamous Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2015-06-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00870870", "title": "A Study of IMC-A12 (Cixutumumab) With and Without Other Standard Chemotherapies in Participants With Lung Cancer Who Have Not Received Chemotherapy Before", "status": "COMPLETED", "last_update": "2018-06-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00874848", "title": "Efficacy/Safety of Imprime PGG With Cetuximab & Paclitaxel/Carboplatin Therapy in Pts With Untreated Advanced Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2016-11-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00910676", "title": "Study About Preventive Treatment of Folliculitis Induced by Epidermal Growth Factor Receptor Inhibitors", "status": "COMPLETED", "last_update": "2012-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00946712", "title": "S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2023-05-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00985855", "title": "Feasibility of Cetuximab Associated With Concomitant Radio-Chemotherapy in Patients With Locally Advanced Non Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2017-09-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00986674", "title": "Carboplatin and Paclitaxel Combined With Cetuximab and/or IMC-A12 in Patients With Advanced Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2014-09-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00996567", "title": "A Study of Cetuximab Combined With Cisplatin or Carboplatin/Pemetrexed as First Line Treatment in Patients With Malignant Pleural Mesothelioma.", "status": "COMPLETED", "last_update": "2017-02-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00998101", "title": "Carboplatin, Ixabepilone, and Cetuximab in Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Untreated With Chemotherapy", "status": "WITHDRAWN", "last_update": "2012-03-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01004731", "title": "Study of Anti-Epidermal Growth Factor Receptor (EGFr) Antibody, Cetuximab, in Combination With Gemcitabine/Carboplatin in Patients With Stage IV Lung Cancer", "status": "COMPLETED", "last_update": "2023-05-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01059188", "title": "Neo-adjuvant Treatment in Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2022-03-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01090011", "title": "Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2015-10-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01102231", "title": "Chemoradiotherapy in Stage III Non-small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2021-02-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01109524", "title": "Safety Study of Cetuximab in Combination With Cisplatin and Vinorelbine to Treat Advanced Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2015-12-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01166035", "title": "Lenalidomide and Cetuximab in Patients With Advanced Solid Tumors", "status": "UNKNOWN", "last_update": "2010-07-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01178411", "title": "An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols", "status": "COMPLETED", "last_update": "2021-03-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01184482", "title": "Lapatinib and Cetuximab in Patients With Solid Tumors", "status": "COMPLETED", "last_update": "2013-10-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01212627", "title": "Ridaforolimus With Cetuximab: Adv Non-Small Cell Lung, Colorectal, Head & Neck Cancer", "status": "TERMINATED", "last_update": "2021-02-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01451632", "title": "A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers", "status": "COMPLETED", "last_update": "2016-09-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01923987", "title": "Short Course Radiotherapy Followed Intensive Chemotherapy With Delayed Surgery for Rectal Cancer With Synchronous Distant Metastasis", "status": "UNKNOWN", "last_update": "2019-09-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02438722", "title": "S1403, Afatinib Dimaleate With or Without Cetuximab in Treating Patients With Newly Diagnosed Stage IV or Recurrent, EGFR Mutation Positive Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-05-18", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02716311", "title": "Combination of Cetuximab With Afatinib for Patient With EGFR Mutated Lung Cancer", "status": "COMPLETED", "last_update": "2022-08-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02845856", "title": "Combination of Cetuximab and NK Immunotherapy for Recurrent Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2019-09-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02857270", "title": "A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer", "status": "COMPLETED", "last_update": "2022-11-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03009058", "title": "Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer", "status": "TERMINATED", "last_update": "2024-11-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03319459", "title": "FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2021-11-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03693612", "title": "GSK3359609 Plus Tremelimumab for the Treatment of Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2024-08-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03717155", "title": "Study of Avelumab and Cetuximab Plus Gemcitabine and Cisplatin in Participants With NSCLC", "status": "COMPLETED", "last_update": "2022-06-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03727724", "title": "Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung Cancer", "status": "COMPLETED", "last_update": "2023-10-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04165031", "title": "A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation", "status": "TERMINATED", "last_update": "2021-11-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04349267", "title": "Study of BMS-986315 Alone and in Combination With Nivolumab or Cetuximab in Participants With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2025-12-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04449874", "title": "A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04464967", "title": "Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers", "status": "WITHDRAWN", "last_update": "2021-05-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04485013", "title": "TTX-080 HLA-G Antagonist in Subjects With Advanced Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04648189", "title": "Cetuxibab to Reduce Circulating Tumor Cells in Early Stage NSCLC", "status": "WITHDRAWN", "last_update": "2023-10-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04800822", "title": "PF-07284892 in Participants With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2026-06-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04872634", "title": "A Study to Evaluate the Safety and Anti-tumor Activity of SNK01 (NK Cells) Administered in Combination With Chemotherapy or Chemotherapy / Cetuximab in Local Advanced or Metastatic Non-small Cell Lung Cancer Patients Who Failed Tyrosine Kinase Inhibitor Treatment", "status": "UNKNOWN", "last_update": "2021-07-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04956640", "title": "Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05002270", "title": "JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation", "status": "COMPLETED", "last_update": "2026-01-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05069935", "title": "FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05355701", "title": "A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05358249", "title": "Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05395052", "title": "FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05756153", "title": "A Study of GFH925 in Combination With Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation", "status": "COMPLETED", "last_update": "2025-08-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05954871", "title": "Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer", "status": "COMPLETED", "last_update": "2025-11-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06024174", "title": "A Study of BMS-986466 With Adagrasib With or Without Cetuximab in Participants With Kirsten Rat Sarcoma Virus Glycine 12 to Cysteine (KRAS G12C)-Mutant Solid Tumors", "status": "TERMINATED", "last_update": "2025-07-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06067776", "title": "Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2023-10-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06101394", "title": "Development of a Fluorescent Visualization System for Non-visible Lung Cancer Nodules", "status": "UNKNOWN", "last_update": "2024-01-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06447662", "title": "A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06585488", "title": "A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification", "status": "TERMINATED", "last_update": "2026-07-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06599502", "title": "A Phase I/IIa Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD0022 as Monotherapy and in Combination With Anti-cancer Agents in Adult Participants With Tumours Harbouring a KRASG12D Mutation", "status": "TERMINATED", "last_update": "2026-03-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06607185", "title": "A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06704724", "title": "A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.", "status": "TERMINATED", "last_update": "2026-05-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06943664", "title": "Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07294261", "title": "Garsorasib In KRAS G12C Mutant Locally Advanced and Metastatic NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2025-12-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07463677", "title": "Tunlametinib Combination Therapy in KRAS-Mutated Unresectable Locally Advanced or Metastatic Non-Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-03-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07551778", "title": "Allogeneic NK Cell Therapy Combined With Standard Maintenance Treatment in Advanced Solid Tumors", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07554859", "title": "GFH375 Monotherapy and Combination Therapy as First-Line Treatment for Advanced KRAS G12D-Mutant Non-Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "CETUXIMAB SAROTALOCAN": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT06943664", "title": "Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "CLN-081": { "n": 5, "n_observational": 0, "n_active": 5, "n_withdrawn": 0, "trials": [ { "nct": "NCT05967689", "title": "A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.", "status": "RECRUITING", "last_update": "2026-09-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04036682", "title": "A Phase 1/2 Trial of CLN-081 in Patients With Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05973773", "title": "REZILIENT3 (REsearching ZIpaLertinib In Egfr Non-small Cell Lung Cancer Tumors)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07128199", "title": "A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07229339", "title": "Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "CONTELTINIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02695550", "title": "Study of Safety, Efficacy and Pharmacokinetics of CT-707 in Patients With ALK-positive Non-small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2017-03-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "CONTUSUGENE LADENOVEC": { "n": 6, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT00003649", "title": "Gene Therapy in Treating Patients With Non-small Cell Lung Cancer That Cannot Be Surgically Removed", "status": "COMPLETED", "last_update": "2023-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00004225", "title": "Gene Therapy Plus Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2010-07-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00049218", "title": "Chemotherapy Followed By Vaccine Therapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2014-05-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00776295", "title": "Autologous SCT Followed by Dendritic Cell p53 Vaccination in Patients With Limited Stage Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2013-01-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03544723", "title": "Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.", "status": "UNKNOWN", "last_update": "2020-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07150416", "title": "Nebulized Inhalation of Recombinant Human p53 Adenovirus Injection for Treatment of Multiple Ground-Glass Lung Nodules: A Single-Arm Clinical Study", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "COSIBELIMAB": { "n": 2, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT03212404", "title": "Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-02-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04786964", "title": "Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab in First Line Metastatic Non-squamous NSCLC", "status": "TERMINATED", "last_update": "2025-04-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "CRIZOTINIB": { "n": 82, "n_observational": 21, "n_active": 22, "n_withdrawn": 2, "trials": [ { "nct": "NCT04322890", "title": "Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation", "status": "RECRUITING", "last_update": "2024-10-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05014464", "title": "ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2024-09-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06563999", "title": "Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.", "status": "RECRUITING", "last_update": "2026-04-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06564324", "title": "A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00585195", "title": "A Study Of Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer", "status": "COMPLETED", "last_update": "2023-02-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00932451", "title": "An Investigational Drug, PF-02341066, Is Being Studied In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene", "status": "COMPLETED", "last_update": "2017-01-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00932893", "title": "An Investigational Drug, PF-02341066 Is Being Studied Versus Standard Of Care In Patients With Advanced Non-Small Cell Lung Cancer With A Specific Gene Profile Involving The Anaplastic Lymphoma Kinase (ALK) Gene", "status": "COMPLETED", "last_update": "2017-01-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00965731", "title": "Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer", "status": "COMPLETED", "last_update": "2015-10-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01121575", "title": "A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2015-10-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01121588", "title": "Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)", "status": "TERMINATED", "last_update": "2025-01-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01154140", "title": "A Clinical Trial Testing The Efficacy Of Crizotinib Versus Standard Chemotherapy Pemetrexed Plus Cisplatin Or Carboplatin In Patients With ALK Positive Non Squamous Cancer Of The Lung", "status": "COMPLETED", "last_update": "2017-11-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01441128", "title": "-02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2019-12-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01500824", "title": "A Clinical Study Testing The Safety And Efficacy Of Crizotinib In East Asian Patients With Anaplastic Lymphoma Kinase (ALK) Positive Advanced Non-Small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2013-02-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01579994", "title": "Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers", "status": "COMPLETED", "last_update": "2020-12-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01639001", "title": "A Study Of Crizotinib Versus Chemotherapy In Previously Untreated ALK Positive East Asian Non-Small Cell Lung Cancer Patients", "status": "COMPLETED", "last_update": "2020-12-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01685060", "title": "LDK378 in Adult Patients With ALK-activated NSCLC Previously Treated With Chemotherapy and Crizotinib", "status": "COMPLETED", "last_update": "2017-06-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01685138", "title": "LDK378 in Crizotinib na\u00efve Adult Patients With ALK-activated Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2019-03-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01712217", "title": "A Study of AT13387 in Patients With Non-Small Cell Lung Cancer (NSCLC) Alone and in Combination With Crizotinib", "status": "COMPLETED", "last_update": "2024-08-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01801111", "title": "A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment", "status": "COMPLETED", "last_update": "2018-11-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01822496", "title": "Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2019-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01828112", "title": "LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib", "status": "COMPLETED", "last_update": "2025-02-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01871805", "title": "A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2018-08-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01945021", "title": "Phase II Safety and Efficacy Study of Crizotinib in East Asian Patients With ROS1 Positive, ALK Negative Advanced NSCLC", "status": "COMPLETED", "last_update": "2021-02-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01970865", "title": "A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations", "status": "COMPLETED", "last_update": "2024-08-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01998126", "title": "Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2018-04-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02040870", "title": "LDK378 in Adult Chinese Patients With ALK-rearranged (ALK-positive) Advanced Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib", "status": "COMPLETED", "last_update": "2019-02-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02075840", "title": "A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants", "status": "COMPLETED", "last_update": "2026-05-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02094573", "title": "A Study to Evaluate the Efficacy of Brigatinib (AP26113) in Participants With Anaplastic Lymphoma Kinase (ALK)-Positive, Non-small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib", "status": "COMPLETED", "last_update": "2021-03-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02134912", "title": "S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib", "status": "TERMINATED", "last_update": "2020-02-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02183870", "title": "EUCROSS: European Trial on Crizotinib in ROS1 Translocated Lung Cancer", "status": "COMPLETED", "last_update": "2022-06-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02194738", "title": "Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02201992", "title": "Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-12-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02277457", "title": "Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver Mutations", "status": "WITHDRAWN", "last_update": "2016-06-24", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02336451", "title": "A Phase II Study to Evaluate the Efficacy and Safety of Oral Ceritinib in Patients With ALK-positive NSCLC Metastatic to the Brain and/or to Leptomeninges", "status": "COMPLETED", "last_update": "2020-04-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02499614", "title": "Crizotinib in Pretreated Metastatic Non-small-cell Lung Cancer With MET Amplification or ROS1 Translocation (METROS)", "status": "UNKNOWN", "last_update": "2017-10-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02511184", "title": "Crizotinib Plus Pembrolizumab In Alk-Positive Advanced Non Small Cell Lung Cancer Patients", "status": "TERMINATED", "last_update": "2019-07-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02568267", "title": "Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02574078", "title": "A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2021-05-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02584634", "title": "Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)", "status": "TERMINATED", "last_update": "2023-07-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02604342", "title": "Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC) Participants Previously Treated With Platinum-Based Chemotherapy and Crizotinib", "status": "COMPLETED", "last_update": "2019-10-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02664935", "title": "National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-04-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02695550", "title": "Study of Safety, Efficacy and Pharmacokinetics of CT-707 in Patients With ALK-positive Non-small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2017-03-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02701231", "title": "Low-frequency Rotating Magnetic System Combined With Systemic Anti-tumor Therapy for Advanced Lung Cancer", "status": "UNKNOWN", "last_update": "2016-03-09", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02737501", "title": "ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants", "status": "COMPLETED", "last_update": "2021-08-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02767804", "title": "eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02838420", "title": "A Study to Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2026-06-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02946359", "title": "A+C in Metastatic Lung Adenocarcinoma Cancer", "status": "UNKNOWN", "last_update": "2016-11-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03052608", "title": "A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03088930", "title": "Evaluating Crizotinib in the Neoadjuvant Setting in Patients With Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2022-02-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03194893", "title": "A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer", "status": "COMPLETED", "last_update": "2026-06-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03215693", "title": "X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib", "status": "UNKNOWN", "last_update": "2023-08-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03439215", "title": "PF-06463922 for Crizotinib Pretreated ROS1 Positive Non-small-cell Lung Cancer", "status": "UNKNOWN", "last_update": "2021-07-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03574402", "title": "Phase II Umbrella Study Directed by Next Generation Sequencing", "status": "UNKNOWN", "last_update": "2022-12-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03596866", "title": "A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer", "status": "COMPLETED", "last_update": "2025-09-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03607188", "title": "Study of Alkotinib in Patients With Advanced Non Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2024-03-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03672643", "title": "Long Term Safety Observation of Crizotinib in Chinese NSCLC Population", "status": "TERMINATED", "last_update": "2024-11-08", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03737994", "title": "Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2026-04-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04009317", "title": "Study of TQ-B3139 Versus Crizotinib in the First Line Treatment of Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC)", "status": "UNKNOWN", "last_update": "2019-10-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04056572", "title": "Study of TQ-B3139 in Subjects With Anaplastic Lymphoma Kinase (ALK) Positive Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Crizotinib", "status": "UNKNOWN", "last_update": "2019-10-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04084717", "title": "Study of Crizotinib for ROS1 and MET Activated Lung Cancer", "status": "COMPLETED", "last_update": "2026-06-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04148066", "title": "ctDNA Guided Treatment of Early Resistance to Targeted Treatment", "status": "COMPLETED", "last_update": "2023-10-10", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04193007", "title": "The Role of Brain Radiotherapy in Patients With Asymptomatic Brain Metastasis in the Era of Targeted Therapy for NSCLC", "status": "UNKNOWN", "last_update": "2019-12-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04211922", "title": "Alkotinib Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib", "status": "TERMINATED", "last_update": "2024-04-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04292119", "title": "Lorlatinib Combinations in Lung Cancer", "status": "UNKNOWN", "last_update": "2021-03-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04322578", "title": "Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC", "status": "UNKNOWN", "last_update": "2024-06-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04439253", "title": "Testing Crizotinib as a Potential Targeted Treatment in Cancers With ROS1 Genetic Changes (MATCH-Subprotocol G)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04439266", "title": "Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04603807", "title": "A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04632758", "title": "Study Comparing WX-0593 to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients", "status": "UNKNOWN", "last_update": "2023-11-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04634110", "title": "Brigatinib Before Brain Irradiation Trial (B3i Trial)", "status": "TERMINATED", "last_update": "2022-10-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04641754", "title": "A Study Evaluates the Safety and Efficacy of WX-0593 in ALK -Positive, or ROS1-positive Non-small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2020-11-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05160922", "title": "Crizotinib Continuation Clinical Study", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-30", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05195619", "title": "Personalized DC Vaccines in Non Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-07-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05204628", "title": "A Study to Evaluate and Compare the Efficacy and Safety of XZP-3621 Versus Crizotinib", "status": "UNKNOWN", "last_update": "2022-01-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05297890", "title": "A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06082635", "title": "TGRX-326 Chinese Phase III for Advanced Non-small Cell Lung Cancer (NSCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-05-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06140836", "title": "A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-na\u00efve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06254599", "title": "A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2024-02-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06569420", "title": "Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-08-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07538973", "title": "A Clinical Study to Evaluate the Pharmacokinetics and Safety of Anecatibin Fumarate Capsules in Subjects With Impaired Liver Function Versus Normal Liver Function", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07816380", "title": "A Phase III Study to Evaluate the Efficacy and Safety of JYP0322 Versus Crizotinib in Previously Untreated ROS1-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "CUDC-101": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01171924", "title": "A Phase Ib Expansion Study Investigating the Safety, Efficacy, and Pharmacokinetics of Intravenous CUDC-101 in Subjects With Advanced Head and Neck, Gastric, Breast, Liver and Non-small Cell Lung Cancer Tumors", "status": "COMPLETED", "last_update": "2016-03-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "DABRAFENIB": { "n": 13, "n_observational": 4, "n_active": 7, "n_withdrawn": 1, "trials": [ { "nct": "NCT03340506", "title": "Dabrafenib and/or Trametinib Rollover Study", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06563999", "title": "Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.", "status": "RECRUITING", "last_update": "2026-04-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07440290", "title": "DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers.", "status": "RECRUITING", "last_update": "2026-08-17", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01336634", "title": "Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.", "status": "COMPLETED", "last_update": "2022-04-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02124772", "title": "Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations", "status": "COMPLETED", "last_update": "2021-07-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02672358", "title": "Study of Efficacy and Safety of Dabrafenib and Trametinib Combination Therapy in Japanese Patients With BRAF V600E Stage IV NSCLC", "status": "WITHDRAWN", "last_update": "2018-08-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03543306", "title": "Dabrafenib and Trametinib in Patients With Non-small Cell Lung Cancer Harboring V600E BRAF Mutation", "status": "UNKNOWN", "last_update": "2018-06-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03975829", "title": "Pediatric Long-Term Follow-up and Rollover Study", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-27", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04418167", "title": "JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations", "status": "SUSPENDED", "last_update": "2025-09-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04439292", "title": "Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04452877", "title": "A Study of Dabrafenib in Combination With Trametinib in Chinese Patients With BRAF V600E Mutant Metastatic NSCLC", "status": "COMPLETED", "last_update": "2026-01-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05585320", "title": "A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "DACOMITINIB": { "n": 27, "n_observational": 10, "n_active": 5, "n_withdrawn": 0, "trials": [ { "nct": "NCT05271916", "title": "First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations", "status": "RECRUITING", "last_update": "2023-04-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06486142", "title": "EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study", "status": "RECRUITING", "last_update": "2026-05-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00548093", "title": "PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib", "status": "COMPLETED", "last_update": "2019-05-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00553254", "title": "Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer", "status": "COMPLETED", "last_update": "2020-10-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00728390", "title": "A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks", "status": "COMPLETED", "last_update": "2024-04-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00769067", "title": "A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen", "status": "COMPLETED", "last_update": "2015-10-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00818441", "title": "Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung", "status": "COMPLETED", "last_update": "2019-01-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00971191", "title": "A Study In Patients Who Will Undergo Surgical Removal Of Non-Small Cell Lung Cancer To Evaluate Molecular Changes That Occur In Tumor Tissue After Short Term Exposure To PF-00299804", "status": "TERMINATED", "last_update": "2012-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01000025", "title": "PF-00299804 in Stage IIIB or Stage IV Non-Small Cell Lung Cancer Not Responding to Standard Therapy for Advanced or Metastatic Cancer", "status": "COMPLETED", "last_update": "2023-08-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01034748", "title": "A Radiolabeled Mass Balance Study Of [14C]PF-00299804 In Healthy Male Volunteers", "status": "COMPLETED", "last_update": "2010-03-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01121575", "title": "A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2015-10-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01360554", "title": "ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2017-05-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01441128", "title": "-02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2019-12-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01465802", "title": "Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO", "status": "COMPLETED", "last_update": "2019-01-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01774721", "title": "ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.", "status": "COMPLETED", "last_update": "2023-11-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01858389", "title": "A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2017-07-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01918761", "title": "Dacomitinib + Pemetrexed for Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)", "status": "TERMINATED", "last_update": "2019-12-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02039336", "title": "Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC", "status": "COMPLETED", "last_update": "2025-07-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03755102", "title": "A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.", "status": "COMPLETED", "last_update": "2025-05-15", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03810807", "title": "Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer", "status": "COMPLETED", "last_update": "2025-12-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04027647", "title": "Phase 2 Study of Dacomitinib in NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-06-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04339829", "title": "An Open Label, Multicenter, Phase II Study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases", "status": "UNKNOWN", "last_update": "2020-04-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04504071", "title": "Dacomitinib in Lung Cancer With Uncommon EGFR Mutations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04511533", "title": "Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations", "status": "COMPLETED", "last_update": "2024-04-05", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04675008", "title": "Central Nervous System(CNS) Efficacy of Dacomitinib", "status": "UNKNOWN", "last_update": "2021-01-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04811001", "title": "Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations", "status": "UNKNOWN", "last_update": "2023-02-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04946968", "title": "Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging Biomarkers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-06-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "DEPATUXIZUMAB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02365662", "title": "A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor", "status": "TERMINATED", "last_update": "2018-03-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "DEPATUXIZUMAB MAFODOTIN": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02365662", "title": "A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor", "status": "TERMINATED", "last_update": "2018-03-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "DIMETHYL": { "n": 11, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT00006229", "title": "Paclitaxel + Carboplatin With/ut BMS-275291 in Advanced or Metastatic Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2020-04-06", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00676507", "title": "Phase III Lucanix\u2122 Vaccine Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Following Front-line Chemotherapy", "status": "COMPLETED", "last_update": "2015-05-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01070927", "title": "An Exploratory Study of RO4929097 in Patients With Recurrent or Refractory Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2016-11-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01131234", "title": "Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2014-12-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01193868", "title": "RO4929097 in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Recently Completed Treatment With Front-Line Chemotherapy", "status": "TERMINATED", "last_update": "2015-11-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01193881", "title": "RO4929097 and Erlotinib Hydrochloride in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2015-09-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01217411", "title": "RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer", "status": "TERMINATED", "last_update": "2024-11-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01336634", "title": "Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.", "status": "COMPLETED", "last_update": "2022-04-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01578551", "title": "Study of Metformin Plus Paclitaxel/Carboplatin/Bevacizumab in Patients With Adenocarcinoma.", "status": "TERMINATED", "last_update": "2018-12-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03715985", "title": "Personalized Neo-antigen Vaccine in Advanced Solid Tumors (NeoPepVac)", "status": "UNKNOWN", "last_update": "2022-01-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04439292", "title": "Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "DISITAMAB VEDOTIN": { "n": 5, "n_observational": 0, "n_active": 4, "n_withdrawn": 0, "trials": [ { "nct": "NCT06734182", "title": "Neoadjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resectable HER2-Mutant Non-Small-Cell Lung Cancer", "status": "RECRUITING", "last_update": "2024-12-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06749860", "title": "Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or Metastatic Non-small Cell Lung Cancer with HER2 Mutation/amplification/expression", "status": "RECRUITING", "last_update": "2024-12-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05847764", "title": "Disitamab Vedotin Combined Therapy for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations", "status": "UNKNOWN", "last_update": "2023-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06003231", "title": "A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06185400", "title": "RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations", "status": "NOT_YET_RECRUITING", "last_update": "2023-12-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "DURVALUMAB": { "n": 179, "n_observational": 21, "n_active": 81, "n_withdrawn": 11, "trials": [ { "nct": "NCT04105270", "title": "RMT in Combination With Durvalumab + Chemo in Untreated Adenocarcinoma NSCLC. A Randomized Double Blind Phase II Trial", "status": "RECRUITING", "last_update": "2025-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04550104", "title": "A Platform Study of Novel Agents in Combination With Radiotherapy in NSCLC", "status": "RECRUITING", "last_update": "2025-12-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04585490", "title": "Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC", "status": "RECRUITING", "last_update": "2026-05-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04686305", "title": "Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04892953", "title": "Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04992780", "title": "Comparing Hypo-fractionated Intensity- Modulated Radiation Therapy to Standard- Fractionated IMRT Along With Chemotherapy and Immunotherapy for Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2023-12-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05068232", "title": "Durvalumab and Ablative Radiation in Small Cell Lung Cancer (DARES)", "status": "RECRUITING", "last_update": "2026-03-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05136846", "title": "Papaverine in Combination With Chemoradiation for the Treatment of Stage II-III Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-06-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05568212", "title": "Randomized Trial Comparing Standard of Care Versus Immune- Based Combination in Relapsed Stage III Non-small-cell Lung Cancer (NSCLC) Pretreated With Chemoradiotherapy and Durvalumab", "status": "RECRUITING", "last_update": "2025-12-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05624996", "title": "Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05632809", "title": "REStoring lymphoCytes Using NKTR-255* After chemoradiothErapy in Solid Tumors (RESCUE)", "status": "RECRUITING", "last_update": "2026-07-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05696782", "title": "Quick Start Durvalumab Following Chemoradiation for Stage III Nonsmall Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-07-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05886439", "title": "LK101 Combined With PD-1 or PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer", "status": "RECRUITING", "last_update": "2025-12-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06102057", "title": "PACCELIO - FDG-PET Based Small Volume Accelerated Immuno Chemoradiotherapy in Locally Advanced NSCLC", "status": "RECRUITING", "last_update": "2025-12-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06223711", "title": "Durvalumab With Consolidative Radiochemotherapy and Ablative Stereotactic Radiotherapy in Oligometastatic ES-SCLC", "status": "RECRUITING", "last_update": "2024-04-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06284317", "title": "A Study to Evaluate the Benefit of Adding Durvalumab After Chemotherapy, Durvalumab and Surgery in Patients With Early-stage, Operable, Non-small Cell Lung Cancer.", "status": "RECRUITING", "last_update": "2026-05-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06287775", "title": "Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06371482", "title": "Durvalumab Combined With Chemoradiotherapy for Limited Stage Small Cell Lung Cancer (Camel-01)", "status": "RECRUITING", "last_update": "2024-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06492421", "title": "Neoadjuvant Intra-tumor Double Immunotherapy for Lung Cancer.", "status": "RECRUITING", "last_update": "2024-07-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06680050", "title": "Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC Regimen", "status": "RECRUITING", "last_update": "2025-12-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06773910", "title": "BMS-986489 (Atigotatug + Nivolumab) vs Durvalumab in Limited-stage Small-cell Lung Cancer (TIGOS-LS)", "status": "RECRUITING", "last_update": "2026-08-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06810609", "title": "Immunochemotherapy, Surgery or Chemoradiation, and Durvalumab for Stage IIIA/B NSCLC", "status": "RECRUITING", "last_update": "2026-01-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06840782", "title": "First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.", "status": "RECRUITING", "last_update": "2025-09-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07174583", "title": "A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-07-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07195695", "title": "Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07224971", "title": "Impact of Circadian Rhythm on Immunotherapy", "status": "RECRUITING", "last_update": "2025-12-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07288034", "title": "Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial", "status": "RECRUITING", "last_update": "2026-04-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07339059", "title": "Study of Sacituzumab Govitecan With Atezolizumab/Durvalumab as Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-07-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07391670", "title": "A Phase I Dose Escalation and Dose Expansion Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Durvalumab", "status": "RECRUITING", "last_update": "2026-08-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07554339", "title": "A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015/KANDLELIT-015)", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07603856", "title": "A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-06-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07759856", "title": "NK Cells Plus ICI for SCLC Maintenance", "status": "RECRUITING", "last_update": "2026-08-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02000947", "title": "A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2019-10-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02087423", "title": "A Global Study to Assess the Effects of MEDI4736 (Durvalumab) in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-04-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02088112", "title": "MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).", "status": "COMPLETED", "last_update": "2022-04-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02264678", "title": "Ascending Doses of Ceralasertib in Combination With Chemotherapy and/or Novel Anti Cancer Agents", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02452463", "title": "Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy", "status": "TERMINATED", "last_update": "2020-04-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02453282", "title": "Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02454933", "title": "Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours", "status": "COMPLETED", "last_update": "2024-09-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02484404", "title": "Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02492867", "title": "A Pilot Study of Response-Driven Adaptive Radiation Therapy for Patients With Locally Advanced Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2024-09-03", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02542293", "title": "Study of Durvalumab With Tremelimumab Versus SoC as 1st Line Therapy in Metastatic Non Small-Cell Lung Cancer (NSCLC) (NEPTUNE)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02572687", "title": "A Study of Ramucirumab (LY3009806) Plus MEDI4736 in Participants With Advanced Gastrointestinal or Thoracic Malignancies", "status": "COMPLETED", "last_update": "2021-01-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02572843", "title": "Anti-PD-L1 in Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2025-10-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02658214", "title": "Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2020-08-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02664935", "title": "National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-04-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02669914", "title": "MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors", "status": "TERMINATED", "last_update": "2018-11-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02673814", "title": "Phase 2 Trial of Durvalumab With or Without Bavituximab in Patients With Previously Treated Metastatic Non-small-cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2016-08-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02701400", "title": "Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2021-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02740985", "title": "A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies", "status": "COMPLETED", "last_update": "2023-05-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02766335", "title": "Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers", "status": "COMPLETED", "last_update": "2023-05-25", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02805660", "title": "Phase 1/2 Study of Mocetinostat and Durvalumab in Patients With Advanced Solid Tumors and NSCLC", "status": "TERMINATED", "last_update": "2021-04-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02879617", "title": "A Clinical Trial of Durvalumab (MEDI4736) as 1st Line Therapy in Advanced Non-small Cell Lung Cancer Patients", "status": "COMPLETED", "last_update": "2024-01-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02888743", "title": "Durvalumab and Tremelimumab With or Without High or Low-Dose Radiation Therapy in Treating Patients With Metastatic Colorectal or Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02898116", "title": "Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2022-10-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02899195", "title": "Phase II MEDI4736 in Combination With Chemotherapy for First-Line Treatment of Unresectable Mesothelioma", "status": "COMPLETED", "last_update": "2023-07-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02904954", "title": "Durvalumab (MEDI4736) With or Without SBRT in Clinical Stage I, II and IIIA Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2023-10-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02937818", "title": "A Phase II, Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer", "status": "COMPLETED", "last_update": "2024-06-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02983578", "title": "Danvatirsen and Durvalumab in Treating Patients With Advanced and Refractory Pancreatic, Non-Small Cell Lung Cancer, and Mismatch Repair Deficient Colorectal Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-05-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03022500", "title": "Pulmonary sarcomatoid_MEDI4736+Treme", "status": "COMPLETED", "last_update": "2024-05-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03030131", "title": "Immune Neoadjuvant Therapy Study of Durvalumab in Early Stage Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2023-03-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03043872", "title": "Durvalumab \u00b1 Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03057106", "title": "Durvalumab and Tremelimumab \u00b1 Platinum-Based Chemotherapy in Patients With Metastatic Squamous or Non-Squamous NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03141359", "title": "Use of High Dose Radiation Followed by Chemotherapy and Radiation to Treat Locally Advanced NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03212469", "title": "A Trial of Durvalumab and Tremelimumab in Combination With SBRT in Patients With Metastatic Cancer", "status": "COMPLETED", "last_update": "2025-05-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03237377", "title": "Neoadjuvant Immunoradiation for Resectable Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2026-05-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03275597", "title": "Phase Ib Study of Stereotactic Body Radiotherapy (SBRT) in Oligometastatic Non-small Lung Cancer (NSCLC) With Dual Immune Checkpoint Inhibition", "status": "TERMINATED", "last_update": "2023-05-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03334617", "title": "Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03345810", "title": "Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)", "status": "COMPLETED", "last_update": "2023-06-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03419559", "title": "Study of Autologous Tumor Infiltrating Lymphocytes (LN-145) In Combo With Durvalumab in Non-Small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2019-04-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03421353", "title": "AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer", "status": "COMPLETED", "last_update": "2024-08-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03446547", "title": "Ablative STEreotactic RadiOtherapy wIth Durvalumab (MEDI4736)", "status": "COMPLETED", "last_update": "2026-04-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03509012", "title": "Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2025-01-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03544723", "title": "Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.", "status": "UNKNOWN", "last_update": "2020-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03581487", "title": "Durvalumab, Tremelimumab, and Selumetinib in Treating Participants With Recurrent or Stage IV Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-07-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03585998", "title": "Chemoradiation With Durvalumab Followed by Durvalumab Maintenance for Limited Disease Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2020-03-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03589547", "title": "Durvalumab and Consolidation SBRT Following Chemoradiation for Locally Advanced Stage III Non-Small Cell Lung", "status": "COMPLETED", "last_update": "2026-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03620669", "title": "1st Line Durvalumab in PS 2 NSCLC Patients", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03703297", "title": "Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03732664", "title": "ICIs Neoadjuvant Therapy in Resectable Non-Small-Cell Lung Cancer", "status": "COMPLETED", "last_update": "2023-03-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03775486", "title": "Study of Durvalumab+Olaparib or Durvalumab After Treatment With Durvalumab and Chemotherapy in Patients With Lung Cancer (ORION)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03818776", "title": "Proton Based Cardiac Sparing Accelerated Fractionated RadioTherapy in Unresectable NSCLC", "status": "TERMINATED", "last_update": "2024-02-15", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03819465", "title": "A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03833154", "title": "Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03833440", "title": "Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance", "status": "UNKNOWN", "last_update": "2024-05-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03853187", "title": "Imaging Tumor-infiltrating T-cells in Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2022-12-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03871153", "title": "Chemoradiation Plus Durvalumab Followed by Surgery Followed by Adjuvant Durvalumab in Patients With Surgically Resectable Stage III (N2) Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2023-11-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03916419", "title": "Magnetic Resonance-Guided Hypofractionated Adaptive Radiation Therapy With Concurrent Chemotherapy and Consolidation Durvalumab for Inoperable Stage IIB, IIIA, and Select IIIB and IIIC Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2025-11-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03923270", "title": "Radiotherapy and Durvalumab/Durvalumab Combo (Tremelimumab/Olaparid) for Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03944772", "title": "Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-01-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03975114", "title": "A Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5)", "status": "UNKNOWN", "last_update": "2023-03-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03994393", "title": "Non Small Cell Lung Cancer Trial of Durvalumab and Tremelimumab in Advanced Epidermal Growth Factor Receptor (EGFR) Mutant Disease.", "status": "UNKNOWN", "last_update": "2023-04-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03999710", "title": "Determining Whether Durvalumab in Combination With Radiation Therapy Can Prevent the Progression of Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04003246", "title": "Phase II Concurrent Durvalumab and Radiotherapy for for Stage III Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2025-03-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04062708", "title": "CHIO3 Trial: CHemotherapy Combined With Immune Checkpoint Inhibitor for Operable Stage IIIA/B Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04115111", "title": "Diadem to Investigate the Activity and Safety of Durvalumab", "status": "COMPLETED", "last_update": "2023-03-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04224337", "title": "Phase II Study of Durvalumab ,Doxorubicin, and Ifosfamide in Pulmonary Sarcomatoid Carcinoma", "status": "COMPLETED", "last_update": "2025-12-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04230408", "title": "Intensified Chemo-immuno-radiotherapy With Durvalumab for Stage III Non-Small Cell Lung Cancers", "status": "COMPLETED", "last_update": "2025-02-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04245514", "title": "Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04255836", "title": "Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC)", "status": "UNKNOWN", "last_update": "2020-02-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04262375", "title": "A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION", "status": "WITHDRAWN", "last_update": "2020-11-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04262869", "title": "Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2021-10-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04287894", "title": "Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the Treatment", "status": "TERMINATED", "last_update": "2024-11-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04334759", "title": "DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma", "status": "COMPLETED", "last_update": "2026-01-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04356222", "title": "Efficacy and Safety of Durvalumab in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis", "status": "UNKNOWN", "last_update": "2020-05-27", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04361825", "title": "Durvalumab(MEDI4736) and AZD6738 Combination Therapy in Relapsed Small Cell Lung Cancer Subjects", "status": "COMPLETED", "last_update": "2024-01-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04364048", "title": "Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2024-12-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04372927", "title": "ADMIRAL Trial: Adaptive Mediastinal Radiation With Chemo-Immunotherapy", "status": "TERMINATED", "last_update": "2023-06-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04381494", "title": "Mobile Devices to Detect Early Pneumonitis in Stage III NSCLC Patients on Durvalumab.", "status": "TERMINATED", "last_update": "2023-06-22", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04385368", "title": "Phase III Study to Determine the Efficacy of Durvalumab in Combination With Chemotherapy in Completely Resected Stage II-III Non-small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2024-08-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04441138", "title": "Chemoradiation Followed by Durvalumab in Poor Risk and/or Elderly Patients With Stage III NSCLC", "status": "TERMINATED", "last_update": "2025-05-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04449861", "title": "Durvalumab Plus Chemotherapy in ES-SCLC (Oriental)", "status": "COMPLETED", "last_update": "2024-11-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04465968", "title": "Efficacy and Safety of CRT, Durvalumab and Surgery for SST", "status": "NOT_YET_RECRUITING", "last_update": "2020-07-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04472949", "title": "Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC).", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04513925", "title": "A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2026-06-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04517526", "title": "Efficacy and Safety of Platinum-based Chemotherapy + Bevacizumab + Durvalumab, and Salvage SBRT for IV Non-Small Cell Lung Cancer Patients With EGFR Mutations After Failure of First Line Osimertinib: A Multicenter, Prospective, Phase II Clinical Study", "status": "UNKNOWN", "last_update": "2020-08-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04525391", "title": "AZD2811 and Durvalumab (MEDI4736) Combination Therapy in Relapsed Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2022-02-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04585477", "title": "Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)", "status": "SUSPENDED", "last_update": "2026-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04602533", "title": "Efficacy and Safety of Standard of Care Plus Durvalumab in Patients With Limited Disease Small Cell Lung Cancer (DOLPHIN)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04607954", "title": "Durvalumab and Lurbinectedin for the Treatment of Relapsed or Refractory Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04610684", "title": "Chemotherapy and Atezolizumab for Patients With Extensive Stage Small Cell Lung Cancer (SCLC) With Untreated, Asymptomatic Brain Metastases", "status": "TERMINATED", "last_update": "2024-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04642469", "title": "Phase III Study to Determine Efficacy of Durvalumab in Stage II-III Non-small Cell Lung Cancer (NSCLC) After Curative Intent Therapy.", "status": "COMPLETED", "last_update": "2024-06-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04699838", "title": "Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Na\u00efve Patients With Extensive Stage Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04745689", "title": "Study of AZD2811 + Durvalumab in ES-SCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04748419", "title": "Safety & Efficacy of Consolidative Hypofractionated Radiation Therapy for Boosting Residual Lung Cancer With Durvalumab", "status": "TERMINATED", "last_update": "2026-06-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04762030", "title": "Neoadjuvant Durvalumab/Anlotinib /Chemotherapy Plus Curative Resection in Stage III Non-Small-Cell Lung Cancer : A Single-arm Phase II Study", "status": "UNKNOWN", "last_update": "2021-02-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04774380", "title": "Study of Durvalumab in Combination With Platinum and Etoposide for the First Line Treatment of Patients With Extensive-stage Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2025-05-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04866017", "title": "A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2024-10-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04870112", "title": "A Study to Evaluate Subcutaneous Durvalumab in Patients With Non-Small Cell Lung Cancer and Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2025-04-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04889066", "title": "Durvalumab (MEDI4736) and Radiosurgery (fSRT Vs. PULSAR) for the Treatment of Non-Small Cell Lung Cancer Brain Metastases", "status": "WITHDRAWN", "last_update": "2024-12-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04902040", "title": "Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies", "status": "TERMINATED", "last_update": "2026-04-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04905316", "title": "A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung Cancer", "status": "COMPLETED", "last_update": "2026-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04951115", "title": "A Trial With Chemotherapy, Immunotherapy, and Radiotherapy for Patients With Newly Diagnosed Stage IV Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2024-11-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04985851", "title": "To Evaluate the Efficacy of Durvalumab + Anlotinib in Terms of OS and PFS.", "status": "UNKNOWN", "last_update": "2023-12-01", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05008861", "title": "Gut Microbiota Reconstruction for NSCLC Immunotherapy", "status": "UNKNOWN", "last_update": "2021-08-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05034133", "title": "Durvalumab With Chemotherapy Followed by Sequential Radiotherapy for Limited Stage Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2021-09-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05157542", "title": "Neoadjuvant LDRT Combined With Durvalumab in Potentially Resectable Stage III NSCLC", "status": "UNKNOWN", "last_update": "2021-12-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05161533", "title": "Hypofractionated Radiation Therapy After Durvalumab and Chemotherapy for the Treatment of Stage IV Extensive Stage Small Cell Lung Cancer, CASPIAN-RT Trial", "status": "WITHDRAWN", "last_update": "2023-10-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05170204", "title": "A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05198830", "title": "Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05206812", "title": "Window of Opportunity Trial of Durvalumab (MEDI4736) to Identify Immune Dynamics in Operable Non-small Cell Lung Cancer (NSCLC) (MIRACLE)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05211895", "title": "A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05221840", "title": "A Global Study to Assess the Effects of Durvalumab With Oleclumab or Durvalumab With Monalizumab Following Concurrent Chemoradiation in Patients With Stage III Unresectable Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05245994", "title": "An Open Label, Multicenter Phase 2 Study of Durvalumab (MEDI4736) + Olaparib as Maintenance Therapy in Chinese", "status": "UNKNOWN", "last_update": "2022-02-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05267392", "title": "Neoadjuvant Immunotherapy With Durvalumab (MEDI4736) in Non-Surgical Early Stage or Locally Advanced Non-Small Cell Lung Cancer (NSCLC) Followed by Radical Radiotherapy or Chemoradiotherapy", "status": "UNKNOWN", "last_update": "2022-03-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05358691", "title": "A Trial of AN0025 With Chemoradiation Therapy in Stage III NSCLC Participants", "status": "WITHDRAWN", "last_update": "2025-04-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05374603", "title": "Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05380713", "title": "......SMARTEST Trial......", "status": "COMPLETED", "last_update": "2025-12-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05403723", "title": "Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC", "status": "SUSPENDED", "last_update": "2026-02-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05443971", "title": "Durvalumab and Grid Therapy for Non-small Cell Lung Cancer in Progression During or After Treatment With PACIFIC Regimen", "status": "TERMINATED", "last_update": "2026-02-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05450692", "title": "A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05451173", "title": "Combining ICI With SBRT or HypoFrx-RT for ES NSCLC", "status": "UNKNOWN", "last_update": "2023-10-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05484583", "title": "Durvalumab Combined With Consolidation Radiotherapy After First-line Treatment in Extensive Stage Small Cell Lung Cancer With Oligometastases", "status": "NOT_YET_RECRUITING", "last_update": "2022-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05572476", "title": "Lurbinectedin Combined With Durvalumab in Pre-treated Patients With Extensive Stage Small-cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2024-06-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05617963", "title": "Durvalumab Maintenance After Thoracic Chemoradiotherapy in Frail Small Cell Lung Cancer Patients Whose Disease is Limited to the Thorax", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05668767", "title": "Surufatinib in Combination of Durvalumab and EP/EC in the Firstly-line Treatment of ES-SCLC", "status": "UNKNOWN", "last_update": "2022-12-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05687266", "title": "Phase III, Open-label, First-line Study of Dato-DXd in Combination With Durvalumab and Carboplatin for Advanced NSCLC Without Actionable Genomic Alterations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05718297", "title": "Brigatinib Post Definitive Chemo-radiotherapy in Patients with ALK-fusion Non-small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2024-10-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05757843", "title": "Using Circulating Tumor DNA to Personalize Duration of Consolidation Durvalumab", "status": "WITHDRAWN", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05792995", "title": "Foundation and Clinical About the Expression of PD-1 in Peripheral Blood T Lymphocytes", "status": "COMPLETED", "last_update": "2023-03-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05796089", "title": "Chemotherapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer With Thoracic Radiotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-08-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05848843", "title": "A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations", "status": "WITHDRAWN", "last_update": "2024-01-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05856695", "title": "Durvalumab Plus Etoposide-free Chemotherapy in First-line Treatment of Extensive-disease Small-sell Lung Cancer (SCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05911308", "title": "Abequolixron (RGX-104) and Durvalumab in Lung Cancer", "status": "TERMINATED", "last_update": "2025-03-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05925530", "title": "Study to Assess Neoadjuvant Durvalumab (D) and Platinum-Based Chemotherapy (CT), Followed by Either Surgery and Adjuvant D or CRT and Consolidation D, in Resectable or Borderline Resectable Stage IIB-IIIB NSCLC (MDT-BRIDGE)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05941897", "title": "A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged \u2265 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based Chemotherapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06211036", "title": "Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-12-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06331455", "title": "Treatment of Pulmonary SUlcus, Pancoast and Chest Wall Non-small Cell Lung Cancer Employing Radiation, Immuno-oncology and Resection", "status": "UNKNOWN", "last_update": "2024-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06333678", "title": "A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC)", "status": "TERMINATED", "last_update": "2026-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06419179", "title": "Maintenance Durvalumab (MEDI4736) and Olaparib (AZD2281) After Standard 1st Line Treatment (Carboplatin/Cisplatin, Etoposide, Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC)", "status": "ENROLLING_BY_INVITATION", "last_update": "2025-05-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06446570", "title": "Phase II Study of Durvalumab(MEDI4736) + Tremelimumab in Pulmonary Sarcomatoid Carcinoma", "status": "COMPLETED", "last_update": "2024-06-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06606847", "title": "A Study to Investigate the Effects of Durvalumab With Oleclumab Following Chemoradiation in Participants With Locally Advanced Unresectable Non-Small Cell Lung Cancer (LADOGA)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06732401", "title": "Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06939036", "title": "Study of 225Ac-SS0110 in Subjects With ES-SCLC or MCC (SANTANA-225 )", "status": "TERMINATED", "last_update": "2026-02-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06992609", "title": "Durvalumab After Chemoradiotherapy in Limited Stage Small Cell Lung Cancer.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06998719", "title": "Neoadjuvant Durvalumab and Chemotherapy Followed by Surgery/CRT and Durvalumab in Borderline Resectable Stage III NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2025-05-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07172412", "title": "Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07247786", "title": "Study for Evaluating the Safety and Feasibility of Fecal Microbiota Transplant in Stage II-III NSCLC Patients Using ICI Responders as Donors (MIGRANT)", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07796100", "title": "A Study of ZL-1310 in Combination With a Checkpoint Inhibitor Versus Standard of Care Platinum Based Chemotherapy With a Checkpoint Inhibitor as First-line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "EMIBETUZUMAB": { "n": 4, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01602289", "title": "A Study of LY2875358 in Japanese Participants With Advanced Cancer", "status": "COMPLETED", "last_update": "2015-06-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01897480", "title": "A Study of LY2875358 in Participants With Non-Small Cell Lung Cancer With Activating Epidermal Growth Factor Receptor Mutations", "status": "COMPLETED", "last_update": "2026-01-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01900652", "title": "A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants", "status": "COMPLETED", "last_update": "2019-09-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02082210", "title": "A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer", "status": "COMPLETED", "last_update": "2020-12-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ENCORAFENIB": { "n": 7, "n_observational": 0, "n_active": 2, "n_withdrawn": 1, "trials": [ { "nct": "NCT02109653", "title": "Efficacy and Safety of LGX818 in Patients With Advanced or Metastatic BRAF V600 Mutant NSCLC", "status": "WITHDRAWN", "last_update": "2020-11-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02857270", "title": "A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer", "status": "COMPLETED", "last_update": "2022-11-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03915951", "title": "An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-03-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04526782", "title": "ENCOrafenib With Binimetinib in bRAF NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04585815", "title": "Study of Immunotherapy (Sasanlimab) in Combination With Targeted Therapies in People With Advanced Non-small Cell Lung Cancer (NSCLC) (Landscape 1011 Study)", "status": "TERMINATED", "last_update": "2026-01-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04800822", "title": "PF-07284892 in Participants With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2026-06-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05195632", "title": "Phase II Study Investigating the Combination of Encorafenib and Binimetinib in BRAF V600E Mutated Chinese Patients With Metastatic Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ENSARTINIB": { "n": 30, "n_observational": 3, "n_active": 17, "n_withdrawn": 0, "trials": [ { "nct": "NCT05241028", "title": "Adjuvant Therapy of Ensartinib in Stage IB-IIIA ALK-positive Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2023-10-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06563999", "title": "Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.", "status": "RECRUITING", "last_update": "2026-04-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07354061", "title": "Neoadjuvant Therapy With Ensartinib Combined With Chemotherapy for ALK-positive Non - Small Cell Lung Cancer (NSCLC)", "status": "RECRUITING", "last_update": "2026-04-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01625234", "title": "Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-04-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02767804", "title": "eXalt3: Study Comparing X-396 (Ensartinib) to Crizotinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) Patients", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02898116", "title": "Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2022-10-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02959619", "title": "Ensartinib in Non-small Cell Lung Cancer Patients With Positive ALK", "status": "COMPLETED", "last_update": "2023-08-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03155620", "title": "Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03213652", "title": "Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03215693", "title": "X-396 Capsule in Patients With ALK-positive Non-small Cell Lung Cancer Previously Treated With Crizotinib", "status": "UNKNOWN", "last_update": "2023-08-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03510611", "title": "A Study to Investigate the Food Effect on the Pharmacokinetics of Ensartinib Capsules in Chinese Healthy Volunteers.", "status": "COMPLETED", "last_update": "2019-07-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03536481", "title": "Bioequivalency Study of Ensartinib Capsules in Healthy Volunteers", "status": "COMPLETED", "last_update": "2019-07-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03574402", "title": "Phase II Umbrella Study Directed by Next Generation Sequencing", "status": "UNKNOWN", "last_update": "2022-12-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03608007", "title": "X-396 Capsule in Advanced NSCLC Patients With ROS1 Gene Rearrangement", "status": "UNKNOWN", "last_update": "2020-01-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03737994", "title": "Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2026-04-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03753685", "title": "X-396(Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-07-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04415320", "title": "X-396 (Ensartinib) Capsules in ALK-Positive NSCLC Patients With Brain Metastases", "status": "UNKNOWN", "last_update": "2020-06-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04837716", "title": "Ensartinib, Carboplatin, Pemetrexed and Bevacizumab for the Treatment of Stage IIIC or IV or Recurrent ALK-Positive Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05178511", "title": "Ensatinib Treat Second-generation ALK-TKI Resistance After Second-generation ALK-TKI Resistance", "status": "UNKNOWN", "last_update": "2022-01-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05186506", "title": "A Study Comparing Ensatinib Versus Platinum-Based Chemotherapy as Adjuvant Treatment for Stage II-IIIA ALK -Positive Non-Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2022-01-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05341583", "title": "Ensartinib as Adjuvant Treatment in Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2024-08-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05380024", "title": "A Study of Ensartinib as Neoadjuvant Therapy for Patients With ALK Positive Resectable Non-Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2022-08-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05491811", "title": "Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 Mutation", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06762327", "title": "Ensartinib in the Treatment of ALK Positive or MET Exon 14 Skipping Anvanced Solid Tumors Excluded Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-01-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06779539", "title": "Neoadjuvant Ensartinib in ALK Positive Resectable Stage II to III Non-Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-01-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06780839", "title": "Adjuvant Treatment of ALK-positive Non-small Cell Lung Cancer with Ensartinib Guided by MRD", "status": "NOT_YET_RECRUITING", "last_update": "2025-01-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06785584", "title": "Efficacy and Safety of Ensartinib in Neoadjuvant Therapy for Stage IIA - IIIB (Operable or Potentially Operable) ALK-Positive Lung Adenocarcinoma \uff1aA Multicenter, Real-World Clinical Study", "status": "NOT_YET_RECRUITING", "last_update": "2025-01-21", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06955325", "title": "Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations", "status": "NOT_YET_RECRUITING", "last_update": "2025-05-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07235306", "title": "Ensartinib After Chemoradiotherapy in Stage III ALK-Mutated NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2025-11-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07671560", "title": "Efficacy and Safety of Ensartinib Combined With Anlotinib in Lorlatinib-Resistant ALK-Positive NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-26", "phase": "PHASE4", "study_type": "INTERVENTIONAL" } ] }, "ENTRECTINIB": { "n": 8, "n_observational": 4, "n_active": 6, "n_withdrawn": 0, "trials": [ { "nct": "NCT04302025", "title": "A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04322890", "title": "Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation", "status": "RECRUITING", "last_update": "2024-10-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02568267", "title": "Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03178552", "title": "A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04591431", "title": "The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy", "status": "UNKNOWN", "last_update": "2023-10-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04603807", "title": "A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04644315", "title": "A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors", "status": "TERMINATED", "last_update": "2023-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05170204", "title": "A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "ENVAFOLIMAB": { "n": 21, "n_observational": 0, "n_active": 9, "n_withdrawn": 0, "trials": [ { "nct": "NCT04770207", "title": "Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs", "status": "RECRUITING", "last_update": "2024-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05024214", "title": "Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors", "status": "RECRUITING", "last_update": "2026-03-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06123754", "title": "Phase III Study of Envafolimab Versus Placebo Plus Chemotherapy in Resectable Stage III NSCLC", "status": "RECRUITING", "last_update": "2026-03-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06698965", "title": "Efficacy and Safety of First-line Treatment for Extensive-stage Small Cell Lung Cancer Using a Combination Therapy of Trilaciclib, Envafolimab, Etoposide, and Carboplatin", "status": "RECRUITING", "last_update": "2024-11-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06734182", "title": "Neoadjuvant Envafolimab Plus Disitamab Vedotin and Carboplatin in Resectable HER2-Mutant Non-Small-Cell Lung Cancer", "status": "RECRUITING", "last_update": "2024-12-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05055167", "title": "Envafolimab as First-line Treatment of Aged Patients in Advanced NSCLC", "status": "UNKNOWN", "last_update": "2021-09-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05068427", "title": "Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC.", "status": "COMPLETED", "last_update": "2024-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05203276", "title": "Envafolimab Combined With Endostar in the First-line Treatment of Advanced NSCLC", "status": "UNKNOWN", "last_update": "2023-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05243355", "title": "Envafolimab Combined With Chemotherapy and Recombinant Human Endostatin in the First-line Treatment of Sq-NSCLC", "status": "UNKNOWN", "last_update": "2022-02-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05360979", "title": "A Clinical Study of Immunotherapy Combined With Chemotherapy and Anti-angiogenic Therapy in Operable NSCLC", "status": "UNKNOWN", "last_update": "2022-05-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05385185", "title": "Clinical Observation of ICI Combined With Recombinant Human Endostatin on Leptomeningeal Metastasis of Lung Cancer", "status": "UNKNOWN", "last_update": "2022-05-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05414630", "title": "A Study of Envafolimab in Subjects With Stage III Non-Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2022-06-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05529355", "title": "Effect and Safety of Envafolimab Combined With Endostar/S-1 in Second-line of Advanced Non-small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2022-09-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05534113", "title": "Envafolimab Immunotherapy After ctDNA EGFR Clearance by Treatment With Almonertinib in EGFR-Mutant, PD-LI Positive NSCLC", "status": "UNKNOWN", "last_update": "2022-09-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05685550", "title": "Safety and Efficacy Analysis of Oral Etoposide Combined With Anlotinib and Envafolimab in First-line Treatment of Elderly Patients With Small Cell Lung Cancer/ Open-label, Single-arm, Exploratory Phase II Clinical Study", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05904015", "title": "The Study of Envafolimab Combined With Concurrent Chemoradiotherapy In LS-SCLC", "status": "NOT_YET_RECRUITING", "last_update": "2023-06-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05910034", "title": "Envafolimab Plus Docetaxel In Combination With or Without Trilaciclib Versus Docetaxel in Advanced NSCLC", "status": "UNKNOWN", "last_update": "2023-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06108726", "title": "A Study of Local Envafolimab Injection Combined With Chemotherapy in Non-small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2023-10-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06279754", "title": "Recombinant Human Endostatin Combined With Envafolimab and Synchronal Radiochemotherapy", "status": "UNKNOWN", "last_update": "2024-02-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06618391", "title": "Local Injection and Systemic Therapy in the Treatment of NSCLC.", "status": "NOT_YET_RECRUITING", "last_update": "2024-10-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07283198", "title": "A Phase II Clinical Study to Evaluate the Safety, Efficacy, Pharmacokinetics/Pharmacodynamics of JSKN033 in Patients With Advanced Non-Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-12-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "EPRENETAPOPT": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT04383938", "title": "Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies", "status": "COMPLETED", "last_update": "2025-05-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ERLOTINIB": { "n": 177, "n_observational": 23, "n_active": 3, "n_withdrawn": 4, "trials": [ { "nct": "NCT04322890", "title": "Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation", "status": "RECRUITING", "last_update": "2024-10-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00039182", "title": "Erlotinib in Treating Patients With Malignant Mesothelioma of the Lung", "status": "COMPLETED", "last_update": "2013-01-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00047736", "title": "A Study With Tarceva and Chemotherapy vs. Chemotherapy Alone in Patients With Advanced Lung Cancer", "status": "COMPLETED", "last_update": "2013-06-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00062101", "title": "Erlotinib and Celecoxib in Treating Patients With Stage IIIB or Stage IV Recurrent Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2013-06-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00072072", "title": "Celecoxib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2013-09-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00072631", "title": "Erlotinib (Tarceva (Trademark), OSI-774) in Treating Patients With Advanced Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2018-02-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00085280", "title": "Erlotinib in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2014-03-31", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00087269", "title": "Erlotinib in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer Undergoing Surgical Resection", "status": "TERMINATED", "last_update": "2013-06-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00095225", "title": "A Study to Evaluate Bevacizumab and Chemotherapy or Tarceva in Treating Recurrent or Refractory NSCLC (Non-Small Cell Lung Cancer)", "status": "COMPLETED", "last_update": "2008-01-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00100854", "title": "Erlotinib With or Without Fulvestrant in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2019-03-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00101348", "title": "Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2014-06-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00125372", "title": "Study of Tarceva and Targretin in Stage I-II Lung Cancer", "status": "COMPLETED", "last_update": "2019-01-08", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00126581", "title": "Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2019-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00130728", "title": "A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2021-01-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00147537", "title": "Combination Study Of CP-751,871 With Paclitaxel And Carboplatin In Advanced Lung Cancer", "status": "COMPLETED", "last_update": "2013-10-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00153803", "title": "Erlotinib or Placebo Following Chemoradiotherapy (Chemo/RT) in Stage III Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2019-09-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00200395", "title": "OSI-774 (Erlotinib, Tarceva) in Elderly Patients", "status": "COMPLETED", "last_update": "2019-12-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00254384", "title": "Docetaxel, Cisplatin, and Erlotinib Hydrochloride in Treating Patients With Stage I-III Non-small Cell Lung Cancer Following Surgery", "status": "COMPLETED", "last_update": "2024-07-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00266877", "title": "Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2018-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00278187", "title": "Volociximab and Erlotinib in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2013-12-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00280150", "title": "Combination Chemotherapy, Bev, RT, and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2017-06-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00283244", "title": "Ph II Gemcitabine, Erlotinib, and Gemcitabine With Erlotinib/Elderly Patients W/ IIIB/IV NSCLC", "status": "COMPLETED", "last_update": "2017-04-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00294736", "title": "A Two-Stage Phase 1 Dose Escalation Pharmacokinetic Study of Tarceva in Patients With Stage IIIB/IV Non-small Cell Lung Cancer Who Continue to Smoke After Failure of One or Two Prior Chemotherapy Regimens", "status": "COMPLETED", "last_update": "2012-08-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00294762", "title": "Erlotinib (Tarceva) as a Single Agent or Intercalated With Combination Chemotherapy in Patients With EGFR Positive NSCLC", "status": "COMPLETED", "last_update": "2012-08-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00298415", "title": "Chemotherapy of Elderly Patients With Non-Small-Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2013-10-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00300586", "title": "IFCT-GFPC 05.02 A Randomized Phase III Trial Assessing in Patients With Advanced Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2019-05-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00305617", "title": "Cerebrospinal Fluid Levels of Erlotinib in Patients Receiving Erlotinib For Stage III Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2011-05-17", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00312728", "title": "A Study of Bevacizumab in Combination With First- or Second-Line Therapy in Subjects With Treated Brain Metastases Due to Non-Squamous NSCLC (PASSPORT)", "status": "COMPLETED", "last_update": "2023-01-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00339586", "title": "First-Line EGFR-1 Tyrosine Kinase Inhibition in Patients With NSCLC With Mutant EGFR Gene", "status": "UNKNOWN", "last_update": "2006-06-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00367601", "title": "Erlotinib + Bevacizumab for PS 2 Chemotherapy Na\u00efve Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2016-02-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00373425", "title": "A Study of Erlotinib (Tarceva) After Surgery With or Without Adjuvant Chemotherapy in Non-Small Cell Lung Carcinoma (NSCLC) Patients Who Have Epidermal Growth Factor Receptor (EGFR) Positive Tumors", "status": "COMPLETED", "last_update": "2015-09-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00384826", "title": "Therapeutic Strategy in Advanced Bronchioloalveolar Carcinoma", "status": "COMPLETED", "last_update": "2015-02-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00391586", "title": "Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung", "status": "TERMINATED", "last_update": "2015-08-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00440414", "title": "Trial of Pemetrexed Versus Erlotinib in Pretreated Patients With Non Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2010-08-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00452413", "title": "A Study of Enzastaurin and Erlotinib in Participants With Solid Tumors and Lung Cancer", "status": "COMPLETED", "last_update": "2021-05-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00473083", "title": "Systemic and Topical Treatments for Rash Secondary to Erlotinib in Lung Cancer", "status": "COMPLETED", "last_update": "2017-04-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00518011", "title": "A Study of Tarceva (Erlotinib) and Gemcitabine in Treatment-Naive Patients With Advanced Non-Small Cell Lung Cancer.", "status": "COMPLETED", "last_update": "2016-05-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00522145", "title": "Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib", "status": "COMPLETED", "last_update": "2022-05-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00536861", "title": "Safety Study of Radiotherapy and Concurrent Erlotinib (Tarceva\u00ae) for Brain Metastases From a Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2008-05-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00550173", "title": "A Study for Non-Smoker Patients With Nonsquamous Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2013-02-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00553254", "title": "Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer", "status": "COMPLETED", "last_update": "2020-10-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00553462", "title": "Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Followed by Radiation Therapy and Erlotinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery", "status": "COMPLETED", "last_update": "2018-01-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00553800", "title": "Study of Bevacizumab and Erlotinib in Patients With Advanced Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2022-07-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00568841", "title": "Erlotinib and Sequential Positron Emission Tomography (PET) in Advanced Non Small Cell Lung Cancer (NSCLC)", "status": "UNKNOWN", "last_update": "2009-09-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00581789", "title": "Erlotinib and Sunitinib in NSCLC", "status": "COMPLETED", "last_update": "2019-11-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00585377", "title": "Bevacizumab (Avastin\u00ae) + Erlotinib as First-line Therapy for Stage IIIB/IV or Recurrent, Non-squamous Cell Lung Cancer", "status": "COMPLETED", "last_update": "2015-09-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00596648", "title": "A Study of XL184 (Cabozantinib) With or Without Erlotinib in Subjects With Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2026-01-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00600496", "title": "A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)", "status": "COMPLETED", "last_update": "2026-05-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00606502", "title": "Study of Pralatrexate vs. Erlotinib for Non-Small Cell Lung Cancer After at Least 1 Prior Platinum-based Treatment", "status": "COMPLETED", "last_update": "2021-03-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00609804", "title": "Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib", "status": "COMPLETED", "last_update": "2016-04-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00619424", "title": "A Phase I Study Of Pazopanib With Either Erlotinib Or Pemetrexed In Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2017-11-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00621049", "title": "Carboplatin, Docetaxel, Bevacizumab, and Erlotinib Versus Chemotherapy Alone in Resected NSCLC", "status": "COMPLETED", "last_update": "2015-06-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00633529", "title": "Safety of Adding IMO-2055 to Erlotinib + Bevacizumab in 2nd Line Treatment for Patients With NSCLC", "status": "COMPLETED", "last_update": "2013-10-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00642473", "title": "A Study of Metronidazole Cream in the Prevention and Treatment of Tarceva (Erlotinib)-Associated Rash", "status": "COMPLETED", "last_update": "2016-05-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00654420", "title": "A Study Evaluating Dalotuzumab (MK-0646) in Combination With Erlotinib for Participants With Non-Small Cell Lung Cancer (MK-0646-007)", "status": "COMPLETED", "last_update": "2018-08-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00660816", "title": "Pemetrexed or Docetaxel With or Without Erlotinib in Stage IIIB or Stage IV Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2015-10-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00702975", "title": "Study of Combination Therapy of Carboplatin -Gemcitabine Plus Bevacizumab Beyond Progression in Patients With Locally Advanced and/or Metastatic Non-small Cell Lung Cancer (NSCLC) Who Have Not Received Prior Systemic Therapy", "status": "COMPLETED", "last_update": "2013-07-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00707252", "title": "Study of Polyphenon E in Addition to Erlotinib in Advanced Non Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2015-04-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00708448", "title": "Early Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB/IV or Recurrent Lung Cancer Patients", "status": "COMPLETED", "last_update": "2025-02-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00711594", "title": "LUX-Lung 4: BIBW 2992 (Afatinib) Phase I Trial in Advanced Non Small Cell Lung Cancer Patients & Phase II Trial in Non Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib", "status": "COMPLETED", "last_update": "2015-01-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00722969", "title": "Erlotinib and Sorafenib in Chemonaive Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2009-03-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00729742", "title": "Phase I Imaging Study Evaluating Dalotuzumab (MK0646) in Combination With Erlotinib for Patients With Non-Small Cell Lung Cancer (MK-0646-008)", "status": "COMPLETED", "last_update": "2016-04-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00738335", "title": "Stereotactic Radiosurgery and Erlotinib in Treating Patients With Non-Small Cell Lung Cancer and Brain Metastases", "status": "WITHDRAWN", "last_update": "2012-10-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00749567", "title": "Combination of Erlotinib and Bevacizumab as Second-line Treatment in Patients With Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2015-09-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00750698", "title": "A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib", "status": "TERMINATED", "last_update": "2023-07-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00760929", "title": "A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC).", "status": "TERMINATED", "last_update": "2021-01-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00773383", "title": "A Study of the Effect of R1507 in Combination With Tarceva (Erlotinib) on Progression-Free Survival in Patients With Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC) Having Received Tarceva Monotherapy.", "status": "TERMINATED", "last_update": "2013-06-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00778167", "title": "Erlotinib Hydrochloride With or Without Cixutumumab in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2014-05-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00783471", "title": "Docetaxel Intermittent-Erlotinib (Tarceva\u00ae) In Metastatic Non Small Cell Lung Cancer (NSCLC)", "status": "TERMINATED", "last_update": "2010-06-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00803842", "title": "Erlotinib Pharmacokinetics During Doxycycline Treatment for Erlotinib-induced Rash", "status": "WITHDRAWN", "last_update": "2015-02-26", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00826449", "title": "Dasatinib and Erlotinib in Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2016-06-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00830245", "title": "A Study to Assess the Efficacy of Erlotinib for Leptomeningeal Carcinomatosis in EGFR Mutation Positive Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2011-07-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00840125", "title": "Study of Erlotinib With Docetaxel in Selected Non Small Cell Lung Cancer Patients in First Line Treatment", "status": "COMPLETED", "last_update": "2012-10-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00883779", "title": "A Study of Tarceva (Erlotinib) or Placebo in Combination With Platinum-Based Therapy as First Line Treatment in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2015-12-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00903292", "title": "Tailored Second Line Treatment by Epidermal Growth Factor Receptor (EGFR) Mutation in Patients With Advanced Lung Adenocarcinoma", "status": "UNKNOWN", "last_update": "2009-05-18", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00940875", "title": "A Study of Tarceva (Erlotinib) in Sequential Combination With Gemcitabine as First Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2015-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00950365", "title": "Pemetrexed Disodium With or Without Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV or Recurrent Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2020-09-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00955695", "title": "Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2013-08-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00965731", "title": "Erlotinib Is Being Studied With Or Without An Investigational Drug, PF-02341066, In Patients With Lung Cancer", "status": "COMPLETED", "last_update": "2015-10-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00973310", "title": "Erlotinib Concurrent With Radiation Therapy in Non-small-cell Lung Cancer", "status": "UNKNOWN", "last_update": "2015-12-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00983307", "title": "A Study of Erlotinib Plus Radiotherapy (RT) for Patients With Advanced or Inoperable Non-Small-Cell Lung Cancer", "status": "COMPLETED", "last_update": "2025-04-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00989690", "title": "Study of Blood and Tissue Samples in Predicting Response to Second-Line Therapy Using Erlotinib Hydrochloride or Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2013-08-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00993499", "title": "Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 (Afatinib) Plus Sirolimus (Rapamune\u00ae) in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or Gefitinib", "status": "COMPLETED", "last_update": "2015-10-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00997334", "title": "Erlotinib Therapy and Subsequent Development of Mechanisms of Secondary Resistance in Patients With NSCLC", "status": "COMPLETED", "last_update": "2018-02-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01026844", "title": "Hydroxychloroquine With or Without Erlotinib in Advanced Non-small Cell Lung Cancer (NSCLC)", "status": "TERMINATED", "last_update": "2017-01-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01027598", "title": "Randomized, Double-Blind Trial of Erlotinib/Pazopanib or Erlotinib/Placebo in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer", "status": "COMPLETED", "last_update": "2016-01-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01069757", "title": "A Study of ARQ 197 in Combination With Erlotinib", "status": "COMPLETED", "last_update": "2017-03-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01090011", "title": "Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2015-10-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01091376", "title": "Erlotinib Combined With Radiotherapy in Patients With Non-resectable Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)", "status": "UNKNOWN", "last_update": "2010-05-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01104155", "title": "Eribulin Mesylate in Combination With Intermittent Erlotinib in Patients With Previously Treated, Advanced Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2023-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01130779", "title": "The Continuation of Erlotinib", "status": "UNKNOWN", "last_update": "2010-05-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01158170", "title": "Prophylactic Cranial Irradiation in Erlotinib/Gefitinib-responders With Non-small Cell Lung Cancer (NSCLC) (RT1001)", "status": "UNKNOWN", "last_update": "2010-07-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01167244", "title": "Trial of BMS-690514 in Non-Small Cell Lung Cancer Subjects Who Have Been Treated With Gefitinib or Erlotinib and Are Genotypically EGFR Mutation Positive or Who Have Had a Prior Response", "status": "COMPLETED", "last_update": "2015-10-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01188707", "title": "A Trial of Belinostat in Combination With Erlotinib in Patients With Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2020-10-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01189435", "title": "Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or Gefitinib", "status": "TERMINATED", "last_update": "2015-11-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01204307", "title": "Influence of Prior Chemotherapy on Clinical Benefit With Erlotinib in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With or Without EGFR Gene Mutation", "status": "COMPLETED", "last_update": "2015-07-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01204697", "title": "A Study of Erlotinib [Tarceva] as Monotherapy or Intermittent Dosing With Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer. (TALISMAN)", "status": "COMPLETED", "last_update": "2015-11-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01211483", "title": "Study of Erlotinib With or Without Investigational Drug (U3-1287) in Subjects With Advanced Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2021-06-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01217619", "title": "Erlotinib as Neoadjuvant Treatment in Patients With Stage \u2162A N2 NSCLC With Activating EGFR Mutation.", "status": "COMPLETED", "last_update": "2017-09-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01244191", "title": "Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer", "status": "TERMINATED", "last_update": "2021-04-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01250119", "title": "A Study to Assess the Incidence of EGFR Mutation in Patients With Newly Diagnosed Locally Advanced or Metastatic Non-Small Cell Lung Cancer in the UK, And of Tarceva (Erlotinib) as First-Line Therapy in EGFR Mutation Positive Patients.", "status": "COMPLETED", "last_update": "2016-03-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01251796", "title": "A Study of ARQ 197 in Combination With Erlotinib", "status": "COMPLETED", "last_update": "2017-03-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01288430", "title": "A Study of DS-2248 in Participants With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2021-10-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01294306", "title": "MK2206 and Erlotinib Hydrochloride in Treating Patients With Advanced Non-Small Cell Lung Cancer Who Have Progressed After Previous Response to Erlotinib Hydrochloride Therapy", "status": "COMPLETED", "last_update": "2016-11-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01306045", "title": "Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies", "status": "COMPLETED", "last_update": "2024-10-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01320501", "title": "Experience of Erlotinib in Patients With Advanced Non-Small Cell Lung Cancer", "status": "SUSPENDED", "last_update": "2016-05-13", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01351415", "title": "A Study of Bevacizumab in Combination With Standard of Care Treatment in Participants With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2017-09-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01377376", "title": "A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib", "status": "TERMINATED", "last_update": "2016-12-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01402089", "title": "Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients", "status": "COMPLETED", "last_update": "2016-02-02", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01407822", "title": "Erlotinib Versus Gemcitabine/Cisplatin as (Neo)Adjuvant Treatment in Non-small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2018-09-11", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01410214", "title": "Erlotinib Versus Vinorelbine/Cisplatin as Adjuvant Treatment in Stage IIIA NSCLC Patients With EGFR Mutations", "status": "UNKNOWN", "last_update": "2011-12-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01455389", "title": "TUSC2-nanoparticles and Erlotinib in Stage IV Lung Cancer", "status": "TERMINATED", "last_update": "2022-03-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01456325", "title": "A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)", "status": "COMPLETED", "last_update": "2016-11-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01487265", "title": "Trial of Erlotinib and BKM120 in Patients With Advanced Non Small Cell Lung Cancer Previously Sensitive to Erlotinib", "status": "COMPLETED", "last_update": "2019-03-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01545947", "title": "Study Assessing Safety, Pharmacokinetics and Efficacy of CC-223 With Either Erlotinib or Oral Azacitidine in Advanced Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2019-11-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01562028", "title": "BELIEF (Bevacizumab and ErLotinib In EGFR Mut+ NSCLC)", "status": "COMPLETED", "last_update": "2026-08-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01565538", "title": "Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma", "status": "COMPLETED", "last_update": "2014-09-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01570296", "title": "A Trial of Gefitinib in Combination With BKM120 in Patients With Advanced Non-Small Cell Lung Cancer, With Enrichment for Patients Whose Tumours Harbour Molecular Alterations of PI3K Pathway and Known to Overexpress EGFR", "status": "COMPLETED", "last_update": "2023-03-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01578668", "title": "Erlotinib Plus Pemetrexed to Treat Lung Adenocarcinoma With Brain Metastases", "status": "COMPLETED", "last_update": "2015-01-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01580735", "title": "ARQ 197 Plus Erlotinib in Patient With Locally Advanced or Metastatic EGFR Mutation-positive Non-small-cell Lung Cancer", "status": "COMPLETED", "last_update": "2015-08-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01602289", "title": "A Study of LY2875358 in Japanese Participants With Advanced Cancer", "status": "COMPLETED", "last_update": "2015-06-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01609543", "title": "A Study of Tarceva (Erlotinib) in First Line in Patients With Locally Advanced or Metastatic Lung Adenocarcinoma With EGFR Mutations", "status": "COMPLETED", "last_update": "2016-02-01", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01610336", "title": "A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment", "status": "COMPLETED", "last_update": "2021-04-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01667562", "title": "A Study of Erlotinib in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2019-12-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01801111", "title": "A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment", "status": "COMPLETED", "last_update": "2018-11-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01802021", "title": "Effect of Astragalus-based Formula: Qingshu-Yiqi-Tang on Modulating Immune Alterations in Lung Cancer Patients", "status": "UNKNOWN", "last_update": "2013-03-01", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01839955", "title": "Erlotinib Hydrochloride and Quinacrine Dihydrochloride in Stage IIIB-IV Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2016-10-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01857271", "title": "Erlotinib Hydrochloride Before Surgery in Treating Patients With Stage III Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2020-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01866410", "title": "Cabozantinib-S-Malate and Erlotinib Hydrochloride in Treating Patients With Previously Treated Metastatic Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2019-05-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01887795", "title": "Phase \u2162 Trial of WBRT Versus Erlotinib Concurrent Whole-brain Radiation Therapy as \ufb01rst-line Treatment for Patients With Multiple Brain Metastases From Non-small-cell Lung Cancer(ENTER): a Multicentre, Open-label, Randomised Study", "status": "COMPLETED", "last_update": "2016-08-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01887886", "title": "A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation", "status": "COMPLETED", "last_update": "2016-11-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01889212", "title": "Imaging With 11C-erlotinib PET/CT to Identify Responders to Erlotinib Treatment in NSCLC", "status": "TERMINATED", "last_update": "2016-10-28", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01900652", "title": "A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants", "status": "COMPLETED", "last_update": "2019-09-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01911507", "title": "INC280 and Erlotinib Hydrochloride in Treating Patients With Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2021-10-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01928160", "title": "Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib", "status": "WITHDRAWN", "last_update": "2015-07-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01965275", "title": "High-Dose,Pulsatile Erlotinib/Gefitinib for Advanced NSCLC Patients After Failure of Standard Dose EGFR-TKIs", "status": "UNKNOWN", "last_update": "2017-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01967095", "title": "Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer", "status": "COMPLETED", "last_update": "2018-11-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02006043", "title": "Evaluate Erlotinib Efficacy and Safety as the 2nd/3rd Treatment in NSCLC With EGFR M(-) and C-met(-)", "status": "UNKNOWN", "last_update": "2015-07-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02034097", "title": "A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2014-05-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02045446", "title": "Maintenance Chemotherapy Versus Consolidative Stereotactic Body Radiation Therapy (SBRT) Plus Maintenance Chemotherapy for Stage IV Non-Small Cell Lung Cancer (NSCLC): A Randomized Phase II Trial", "status": "COMPLETED", "last_update": "2023-05-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02064491", "title": "Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLC", "status": "COMPLETED", "last_update": "2017-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02066038", "title": "Intermittent and Maintenance of Erlotinib in Combination With Pemetrexed/Carboplatin in \u2162b/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation", "status": "UNKNOWN", "last_update": "2014-02-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02069418", "title": "Theranostic Tool During Erlotinib Treatment in Non-small Cell Lung Cancer Patient", "status": "UNKNOWN", "last_update": "2014-02-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02098954", "title": "Erlotinib Combined With Chemotherapy in TKI Resistant Non-Small Cell Lung Cancers", "status": "UNKNOWN", "last_update": "2023-12-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02117024", "title": "A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2020-02-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02134015", "title": "Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)", "status": "TERMINATED", "last_update": "2018-01-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02134886", "title": "Erlotinib Hydrochloride in Treating Non-Small Cell Lung Cancer That is Metastatic or Cannot be Removed by Surgery in Patients With HIV Infection", "status": "TERMINATED", "last_update": "2015-10-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02140333", "title": "Erlotinib 100mg or 150mg in Treating EGFR Mutated NSCLC", "status": "UNKNOWN", "last_update": "2015-02-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02146118", "title": "A Phase II Study to Assess Efficacy of Combined Treatment With Erlotinib (Tarceva) and Silybin-phytosome (Siliphos) in Patients With EGFR Mutant Lung Adenocarcinoma", "status": "UNKNOWN", "last_update": "2014-05-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02152631", "title": "A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02157883", "title": "Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)", "status": "COMPLETED", "last_update": "2025-11-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02178397", "title": "A Multicenter Randomized Phase III Study Comparing Second-line Treatment With Chemotherapy Associated or Not to Erlotinib in NSCLC Patients With Secondary Resistance to TKI-EGFR", "status": "TERMINATED", "last_update": "2017-07-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02194738", "title": "Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02250846", "title": "Study of EGFR-TKI to Asymptomatic Brain Metastases of NSCLC", "status": "UNKNOWN", "last_update": "2014-09-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02296125", "title": "AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-04-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02321293", "title": "A Open-label Prospective Cohort Trial of Curcumin Plus Tyrosine Kinase Inhibitors (TKI) for EGFR -Mutant Advanced NSCLC", "status": "UNKNOWN", "last_update": "2015-09-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02353741", "title": "Concurrent EGFR-TKIs and Thoracic Radiation Therapy in Active EGFR Mutation for 1st Line Treatment of Stage IV NSCLC", "status": "TERMINATED", "last_update": "2018-12-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02399566", "title": "Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma", "status": "UNKNOWN", "last_update": "2015-03-26", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02450591", "title": "Local Therapies for Oligometastatic Non-Small Cell Lung Cancer Harboring Sensitizing EGFR Mutations", "status": "COMPLETED", "last_update": "2018-05-21", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02468661", "title": "A Safety and Efficacy Study of INC280 Alone, and in Combination With Erlotinib, Compared to Chemotherapy, in Advanced/Metastatic Non-small Cell Lung Cancer Patients With EGFR Mutation and cMET Amplification", "status": "TERMINATED", "last_update": "2020-02-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02574078", "title": "A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2021-05-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02625168", "title": "Afatinib vs Erlotinib as 2nd TKI After Failure to 1st TKI and Chemotherapy for Metastatic NSCLC", "status": "COMPLETED", "last_update": "2015-12-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02655536", "title": "Bevacizumab and Erlotinib in Lung Cancer With Brain Metastases, a Phase II Trial", "status": "UNKNOWN", "last_update": "2018-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02701231", "title": "Low-frequency Rotating Magnetic System Combined With Systemic Anti-tumor Therapy for Advanced Lung Cancer", "status": "UNKNOWN", "last_update": "2016-03-09", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02704767", "title": "Tarceva With or Without Apatinib in the Advanced Lung Adenocarcinoma", "status": "UNKNOWN", "last_update": "2016-03-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02714010", "title": "EGFR-TKI Concurrent With/Without WBRT in Brain Metastasis From NSCLC", "status": "UNKNOWN", "last_update": "2017-10-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02714530", "title": "Thoracal Radiotherapy and Tarceva", "status": "TERMINATED", "last_update": "2021-03-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02736513", "title": "Intracranial Activity of AZD9291 (TAGRISSO) in Advanced EGFRm NSCLC Patients With Asymptomatic Brain Metastases", "status": "UNKNOWN", "last_update": "2021-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02774278", "title": "A Study of Erlotinib (Tarceva) in Participants With Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2016-08-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02906163", "title": "First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy", "status": "UNKNOWN", "last_update": "2016-09-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03050411", "title": "Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2017-02-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03119519", "title": "Local Non-salvage Radiotherapy for Synchronous Oligometastatic Non-small-cell Lung Cancer.", "status": "UNKNOWN", "last_update": "2020-03-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03595644", "title": "Maintenance Targeted Therapy With or Without Stereotactic Body Radiation Therapy for Stage IV Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2021-04-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03628521", "title": "First-line Combination Treatment Based on Anlotinib", "status": "UNKNOWN", "last_update": "2018-08-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04356118", "title": "Efficacy and Safety of Recombinant Human Endostatin in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis", "status": "UNKNOWN", "last_update": "2020-05-27", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04874844", "title": "JY025 is a First-line Treatment for EGFR Mutated NSCLC Phase II and III Clinical Trials of Efficacy and Safety", "status": "UNKNOWN", "last_update": "2021-05-10", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07271446", "title": "An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer", "status": "COMPLETED", "last_update": "2025-12-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "FIRMONERTINIB": { "n": 13, "n_observational": 1, "n_active": 13, "n_withdrawn": 0, "trials": [ { "nct": "NCT06668103", "title": "A Phase 2 Clinical Study of Combination Therapy With ABSK043 and Firmonertinib", "status": "RECRUITING", "last_update": "2024-12-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06956001", "title": "Firmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q Mutation", "status": "RECRUITING", "last_update": "2026-08-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06970639", "title": "A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain Metastases", "status": "RECRUITING", "last_update": "2026-08-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07185997", "title": "Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations", "status": "RECRUITING", "last_update": "2026-09-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07314216", "title": "Firmonertinib Combined With Definitive Radiotherapy in Stage III Unresectable EGFR Uncommon Mutant Pulmonary Adenocarcinoma", "status": "RECRUITING", "last_update": "2026-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05607550", "title": "Study to Compare Furmonertinib to Platinum-Based Chemotherapy for Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations (FURVENT)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-06-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06890182", "title": "Firmonertinib Combined With Chemotherapy as Neoadjuvant Therapy for Resectable Stage \u2161-\u2162B EGFR Sensitive Mutanted NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2025-03-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06971406", "title": "High-Dose Firmonertinib Combined With Bevacizumab and Intrathecal Pemetrexed in the Treatment of EGFR-Mutated Non-Small Cell Lung Cancer With Leptomeningeal Metastasis", "status": "NOT_YET_RECRUITING", "last_update": "2025-05-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07182708", "title": "High-Dose Firmonertinib Plus Bevacizumab as Neoadjuvant Therapy for Resectable EGFRm Stage II-IIIB NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07298148", "title": "Firmonertinib 160 mg in Patients With EGFR-Mutant Advanced NSCLC Demonstrating SD After 8 Week Induction With Firmonertinib 80 mg", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07622706", "title": "Firmonertinib in Perioperative Treatment of Resectable Stage II-IIIB EGFR-mutated Lung Adenocarcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07661173", "title": "A Prospective Study of Firmonertinib as First-line Adaptive Therapy Guided by Dynamic ctDNA (MRD) Changes in Locally Advanced or Metastatic EGFR-mutated Non-small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07807722", "title": "Neoadjuvant Therapy With Firmonertinib Combined With Anlotinib and Platinum-Based Doublet Chemotherapy for Resectable EGFR-Mutated NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "FORETINIB": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 1, "trials": [ { "nct": "NCT01068587", "title": "MET/VEGFR2 Inhibitor GSK1363089 and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone in Locally Advanced or Metastatic NSCLC That Has Not Responded to Previous Chemotherapy", "status": "COMPLETED", "last_update": "2023-08-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02034097", "title": "A Study to Evaluate Foretinib in Subjects With Non-Small-Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2014-05-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "FUTUXIMAB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 1, "trials": [ { "nct": "NCT02924233", "title": "Sym004 in Combination With Nivolumab Versus Nivolumab Monotherapy in EGFR-amplified Squamous Non-Small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2017-08-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "GEFITINIB": { "n": 173, "n_observational": 27, "n_active": 10, "n_withdrawn": 6, "trials": [ { "nct": "NCT04322890", "title": "Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation", "status": "RECRUITING", "last_update": "2024-10-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05445791", "title": "Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations", "status": "RECRUITING", "last_update": "2026-04-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06071013", "title": "Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients", "status": "RECRUITING", "last_update": "2025-01-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00005806", "title": "Combination Chemotherapy in Treating Patients With Advanced Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2013-06-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00006048", "title": "ZD 1839 Plus Combination Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2013-12-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00006049", "title": "ZD 1839 Plus Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2013-12-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00020709", "title": "Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery", "status": "COMPLETED", "last_update": "2013-02-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00025207", "title": "Gefitinib in Treating Patients With Malignant Mesothelioma", "status": "COMPLETED", "last_update": "2013-01-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00029003", "title": "Gefitinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2013-02-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00048087", "title": "Iressa/Docetaxel in Non-Small-Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2012-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00049543", "title": "Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery", "status": "COMPLETED", "last_update": "2015-01-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00059722", "title": "This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC.", "status": "COMPLETED", "last_update": "2016-08-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00062062", "title": "Gefitinib With or Without Carboplatin and Paclitaxel in Treating Older Patients With Unresectable or Metastatic Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2016-12-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00068653", "title": "Gefitinib and Celecoxib in Treating Patients With Refractory Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2013-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00076388", "title": "Iressa Versus Docetaxel (Taxotere)", "status": "COMPLETED", "last_update": "2011-05-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00090675", "title": "Maintenance ZD1839 (IRESSA\u00ae) Following Completion of Front Line, Platinum-Based, Double Chemotherapy in Subjects With Advanced or Metastatic Non-Small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2013-01-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00091156", "title": "Gefitinib After Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2012-07-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00096486", "title": "Gefitinib and Everolimus in Treating Patients With Stage IIIB or Stage IV or Recurrent Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2016-01-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00098462", "title": "Gefitinib and Sirolimus in Treating Patients With Recurrent or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2012-10-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00104728", "title": "Neoadjuvant IRESSA As Single Agent PreopTherapy for NSCLC With Molecular Correlates", "status": "TERMINATED", "last_update": "2012-10-31", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00144066", "title": "A Randomized Phase III Trial of Chemotherapy Alone Versus Chemotherapy Followed by Gefitinib in Stage IIIB/IV Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2005-09-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00162318", "title": "A Phase I Study of Cetuximab in Combination With Gefitinib in Patients With Advanced/Metastatic Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2015-10-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00188617", "title": "Phase 2 Study Of Neoadjuvant Iressa Treatment In Stage 1 NSCLC", "status": "COMPLETED", "last_update": "2017-03-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00193336", "title": "Iressa in Poor Performance Status Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2011-05-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00198380", "title": "Treatment of Lung Adenocarcinoma With Bronchioloalveolar Feature", "status": "COMPLETED", "last_update": "2024-03-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00231465", "title": "Phase II Study of Docetaxel + ZD1839 in Elderly Patients With Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2017-03-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00234442", "title": "Iressa in the Treatment of Brain Metastases From Non Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2009-06-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00238628", "title": "A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSA\u00ae) in the Treatment of Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-06-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00252707", "title": "Iressa 2nd Line Phase III Study in Japan", "status": "COMPLETED", "last_update": "2007-12-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00255489", "title": "A Phase I Study of ZD1839 and Palliative Thoracic Radiotherapy in Patients With Non-small-cell Lung Cancer", "status": "COMPLETED", "last_update": "2011-01-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00266877", "title": "Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2018-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00268255", "title": "Gefitinib and Radiation Therapy in Treating Patients With Inoperable Stage I or Stage II Non-Small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2013-04-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00280787", "title": "Induction Chemotherapy Using Paclitaxel, Carboplatin, CPT-11 With Pegfilgrastim", "status": "COMPLETED", "last_update": "2013-02-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00319800", "title": "Second-Line Irinotecan or Gefitinib in Docetaxel Pretreated NSCLC", "status": "UNKNOWN", "last_update": "2008-03-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00328562", "title": "ZD1839 With Hypofractionated Radiation Therapy With an Immobilization Device for Advanced Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2025-05-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00344773", "title": "First-line Treatment for Adenocarcinoma Patients With Epidermal Growth Factor Receptor (EGFR) Mutation", "status": "COMPLETED", "last_update": "2010-06-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00357734", "title": "Iressa Follow-up Trial", "status": "COMPLETED", "last_update": "2016-08-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00372515", "title": "High Dose Gefitinib for the Treatment of Carcinomatous Meningitis in Adult Patients With Non-Small Cell Lung Cancer and Known or Suspected EGFR Mutations", "status": "COMPLETED", "last_update": "2018-01-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00409006", "title": "Chemotherapy for Patients With Non-Small Cell Lung Cancer Who Are Non-Smokers", "status": "COMPLETED", "last_update": "2010-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00411047", "title": "Gefitinib in Treating Patients With Previously Untreated Stage IIIB or Stage IV Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2013-05-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00452244", "title": "Gefitinib With or Without Simvastatin in Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2017-08-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00497250", "title": "Phase I Study of Iressa and CRT/IMRT in Chinese Patients With IIIB/IV NSCLC After Failure of Platinum-Based Chemotherapy", "status": "UNKNOWN", "last_update": "2008-10-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00522145", "title": "Study of XL647 in Subjects With NSCLC Who Have Progressed After Responding to Treatment With Gefitinib or Erlotinib", "status": "COMPLETED", "last_update": "2022-05-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00536107", "title": "Study to Assess Safety/Tolerability/Efficacy of Gefitinib Versus Docetaxel in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)", "status": "TERMINATED", "last_update": "2013-10-01", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00553254", "title": "Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer", "status": "COMPLETED", "last_update": "2020-10-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00588445", "title": "Phase II Trial to Correlate Radiographic Response Induced By Gefitinib With Mutations in the Protein-Tyrosine Kinase Domain of the EGF Receptor Gene", "status": "COMPLETED", "last_update": "2016-01-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00608868", "title": "SELINE: Second-Line Iressa Phase IV Study in NSCLC Patients", "status": "COMPLETED", "last_update": "2012-09-28", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00614809", "title": "Efficacy of Gefitinib for Brain Metastasis of Non-Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2008-02-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00616499", "title": "Gefitinib in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2009-02-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00711594", "title": "LUX-Lung 4: BIBW 2992 (Afatinib) Phase I Trial in Advanced Non Small Cell Lung Cancer Patients & Phase II Trial in Non Small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib", "status": "COMPLETED", "last_update": "2015-01-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00770588", "title": "Assess the Efficacy, Safety and Tolerability of Gefitinib (Iressa\u00ae 250mg) as Maintenance Therapy in Locally Advanced or Metastatic (Stage IIIB/IV) Non Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2016-02-08", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00787410", "title": "An Open-label, Phase II Trial of ZD1839 (IRESSA) in Patients With Malignant Mesothelioma", "status": "COMPLETED", "last_update": "2012-06-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00807066", "title": "Randomized Gefitinib Trial", "status": "COMPLETED", "last_update": "2012-04-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00809237", "title": "Hydroxychloroquine and Gefitinib to Treat Lung Cancer", "status": "UNKNOWN", "last_update": "2013-12-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00820417", "title": "Pharmocokinetic/Pharmacodynamic (PK/PD) Study of the Combination Cetuximab/Gefitinib", "status": "COMPLETED", "last_update": "2009-01-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00824746", "title": "Study of Gefitinib Retreatment in Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2013-02-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00891579", "title": "Study of Pemetrexed Versus Gefitinib in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer Who Have Previously Received Platinum-Based Chemotherapy Without Epidermal Growth Factor Receptor (EGFR) Mutations", "status": "COMPLETED", "last_update": "2012-12-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00955695", "title": "Radiation Therapy to the Brain or Observation in Preventing Brain Metastases in Patients With Advanced Non-Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2013-08-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00986284", "title": "Epidermal Growth Factor Receptor (EGFR) Status Based Gefitinib Neoadjuvant Therapy in Non Small Cell Lung Cancer (NSCLC)", "status": "SUSPENDED", "last_update": "2015-12-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00993499", "title": "Trial of Continuous Once Daily Oral Treatment Using BIBW 2992 (Afatinib) Plus Sirolimus (Rapamune\u00ae) in Patients With Non-small Cell Lung Cancer Harbouring an EGFR Mutation and/or Disease Progression Following Prior Erlotinib or Gefitinib", "status": "COMPLETED", "last_update": "2015-10-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01000740", "title": "A Study on the Long Term Survivals in an Expand Access Program (EAP) of Iressa", "status": "COMPLETED", "last_update": "2010-05-21", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01017679", "title": "Gefitinib 500mg Versus 250mg in Patients With NSCLC With Stable Disease After a Month Treatment of Gefitinib 250mg", "status": "COMPLETED", "last_update": "2013-12-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01017874", "title": "A Study of Alimta/Cisplatin/Gefitinib for Asian Non-smoking Participants With Non Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2015-07-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01027676", "title": "Study of Vorinostat and Gefitinib in Relapsed/ or Refractory Patients With Advanced Non-small Cell Carcinoma (NSCLC)", "status": "UNKNOWN", "last_update": "2013-11-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01037998", "title": "UFUR (Tegafur/Uracil) Plus Iressa in Non-small-cell Lung Cancer", "status": "COMPLETED", "last_update": "2009-12-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01040780", "title": "Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) Patients", "status": "COMPLETED", "last_update": "2014-02-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01090011", "title": "Trial of BIBW 2992 (Afatinib) + Cetuximab in Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2015-10-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01147211", "title": "Dose Defining Study For MK-2206 Combined With Gefitinib In Non Small Cell Lung Cancer (NSCLC)", "status": "UNKNOWN", "last_update": "2013-05-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01158170", "title": "Prophylactic Cranial Irradiation in Erlotinib/Gefitinib-responders With Non-small Cell Lung Cancer (NSCLC) (RT1001)", "status": "UNKNOWN", "last_update": "2010-07-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01167244", "title": "Trial of BMS-690514 in Non-Small Cell Lung Cancer Subjects Who Have Been Treated With Gefitinib or Erlotinib and Are Genotypically EGFR Mutation Positive or Who Have Had a Prior Response", "status": "COMPLETED", "last_update": "2015-10-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01189435", "title": "Erlotinib Re-Challenge for Recurrent EGFR-mutant Lung Cancer in Patients Who Previously Received Adjuvant Erlotinib or Gefitinib", "status": "TERMINATED", "last_update": "2015-11-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01192230", "title": "Study of Endostatin Combined With Docetaxel in the Treatment of Advanced Non-small Cell Lung Cancer Patients", "status": "UNKNOWN", "last_update": "2010-09-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01192243", "title": "Study of Gefitinib Compared With Pemetrexed/Cisplatin in Advanced Non-Small Cell Lung Cancer Patients", "status": "UNKNOWN", "last_update": "2010-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01203917", "title": "Efficacy, Safety, Tolerability of Gefitinib as 1st Line in Caucasian Patients With EGFR Mutation Positive Advanced NSCLC", "status": "COMPLETED", "last_update": "2017-01-02", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01288430", "title": "A Study of DS-2248 in Participants With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2021-10-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01312337", "title": "Iressa for EGFR Mutation Negative Non-small Cell Lung Cancer (NSCLC)", "status": "UNKNOWN", "last_update": "2011-03-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01363557", "title": "Assess the Efficacy of Whole Brain Radiation Therapy in Lung Cancer Patients With Brain Metastasis", "status": "TERMINATED", "last_update": "2014-05-13", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01391260", "title": "Radiotherapy Combined With Iressa for EGFR Mutation Positive Patients With Locally Advanced Non-small Cell Lung Cancer (NSCLC)", "status": "UNKNOWN", "last_update": "2011-08-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01405079", "title": "Gefitinib Versus Vinorelbine/Platinum as Adjuvant Treatment in Stage II-IIIA(N1-N2) NSCLC With EGFR Mutation", "status": "UNKNOWN", "last_update": "2020-02-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01466660", "title": "LUX-Lung 7: A Phase IIb Trial of Afatinib(BIBW2992) Versus Gefitinib for the Treatment of 1st Line EGFR Mutation Positive Adenocarcinoma of the Lung", "status": "COMPLETED", "last_update": "2020-04-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01469000", "title": "A Study of Pemetrexed and Gefitinib Versus Gefitinib in Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2019-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01498562", "title": "Phase II Study of Gefitinib Plus Nimotuzumab Versus Gefitinib in Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2014-12-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01510990", "title": "First Line Gefitinib by FDG-PET Metabolic Response", "status": "UNKNOWN", "last_update": "2013-01-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01513174", "title": "Study With Gefitinib in Combination With Olaparib (AZD2281) Versus Gefitinib Alone", "status": "COMPLETED", "last_update": "2024-06-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01530334", "title": "Iressa Re-Challenge in Advanced NSCLC EGFR M+ Patients Who Responded to Gefitinib USed as 1st Line or Previous Treatment", "status": "COMPLETED", "last_update": "2016-02-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01570296", "title": "A Trial of Gefitinib in Combination With BKM120 in Patients With Advanced Non-Small Cell Lung Cancer, With Enrichment for Patients Whose Tumours Harbour Molecular Alterations of PI3K Pathway and Known to Overexpress EGFR", "status": "COMPLETED", "last_update": "2023-03-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01580735", "title": "ARQ 197 Plus Erlotinib in Patient With Locally Advanced or Metastatic EGFR Mutation-positive Non-small-cell Lung Cancer", "status": "COMPLETED", "last_update": "2015-08-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01602289", "title": "A Study of LY2875358 in Japanese Participants With Advanced Cancer", "status": "COMPLETED", "last_update": "2015-06-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01610336", "title": "A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment", "status": "COMPLETED", "last_update": "2021-04-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01749072", "title": "Vinorelbine-ifosfamide Versus Gefitinib for EGFR Gene Mutation Negative Non-small Cell Lung Cancer Patients", "status": "UNKNOWN", "last_update": "2012-12-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01755923", "title": "Gefitinib or Docetaxel as Second Line Therapy for Wild-type Epidermal Growth Factor Receptor (EGFR) NSCLC", "status": "UNKNOWN", "last_update": "2012-12-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01769066", "title": "Clinical Value of Sequential Gefitinib With Pemetrexed/Platinum for Advanced NSCLC", "status": "COMPLETED", "last_update": "2016-02-23", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01783834", "title": "Gefitinib Versus Pemetrexed for Previously Treated NSCLC Patients", "status": "COMPLETED", "last_update": "2016-02-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01784549", "title": "Customized Neoadjuvant Versus Standard Chemotherapy in NSCL Patients With Resectable Stage IIIA (N2)Disease", "status": "UNKNOWN", "last_update": "2014-11-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01833572", "title": "Preoperative Gefitinib for EGFR Mutant II-IIIa NSCLC (ECTOP-1001)", "status": "COMPLETED", "last_update": "2023-07-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01864681", "title": "Combination of Metformin With Gefitinib to Treat NSCLC", "status": "COMPLETED", "last_update": "2018-06-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01871480", "title": "CIK Cell Transfusion Plus Gefitinib As Second Or Third-Line Treatment for Advanced Adenocarcinoma Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2013-12-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01928160", "title": "Pemetrexed Disodium and Carboplatin or Cisplatin With or Without Erlotinib Hydrochloride in Treating Patient With Stage IV Non-Small Cell Lung Cancer Resistant to First-Line Therapy With Erlotinib Hydrochloride or Gefitinib", "status": "WITHDRAWN", "last_update": "2015-07-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01933347", "title": "Third-line Treatment of Gefitinib in NSCLC Patients", "status": "COMPLETED", "last_update": "2020-02-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01951469", "title": "Gefitinib With or Without Chemotherapy in Brain Metastases From Non-small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2022-03-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01955421", "title": "Erlotinib 100mg qd Versus Gefitinib 250mg qd for EGFR Mutant Nsclc", "status": "UNKNOWN", "last_update": "2015-07-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01965275", "title": "High-Dose,Pulsatile Erlotinib/Gefitinib for Advanced NSCLC Patients After Failure of Standard Dose EGFR-TKIs", "status": "UNKNOWN", "last_update": "2017-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01967095", "title": "Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer", "status": "COMPLETED", "last_update": "2018-11-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01982955", "title": "Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)", "status": "COMPLETED", "last_update": "2022-11-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01997775", "title": "Metformin in Stage IV Lung Adenocarcinoma", "status": "TERMINATED", "last_update": "2016-09-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02025114", "title": "Selumetinib in Combination With Gefitinib in NSCLC Patients", "status": "COMPLETED", "last_update": "2018-07-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02025218", "title": "Iressa Re-challenge in Advanced NSCLC EGFR-mutated Patients", "status": "TERMINATED", "last_update": "2021-04-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02031601", "title": "Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2016-03-29", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02039674", "title": "A Study of Pembrolizumab (MK-3475) in Combination With Chemotherapy or Immunotherapy in Participants With Non-small Cell Lung Cancer (MK-3475-021/KEYNOTE-021)", "status": "COMPLETED", "last_update": "2022-11-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02040064", "title": "Tolerability and Efficacy of Tremelimumab in Combination With Gefitinib in NSCLC Patients", "status": "COMPLETED", "last_update": "2016-06-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02088112", "title": "MEDI4736 (Anti PD-L1) Combined With Gefitinib in Subjects With Non-Small Cell Lung Cancer(NSCLC).", "status": "COMPLETED", "last_update": "2022-04-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02157883", "title": "Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)", "status": "COMPLETED", "last_update": "2025-11-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02179671", "title": "Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer", "status": "COMPLETED", "last_update": "2019-08-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02282267", "title": "Blood Detection of EGFR Mutation For Iressa Treatment", "status": "UNKNOWN", "last_update": "2017-02-24", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02296125", "title": "AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-04-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02299765", "title": "Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC", "status": "TERMINATED", "last_update": "2017-11-27", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02321293", "title": "A Open-label Prospective Cohort Trial of Curcumin Plus Tyrosine Kinase Inhibitors (TKI) for EGFR -Mutant Advanced NSCLC", "status": "UNKNOWN", "last_update": "2015-09-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02326285", "title": "Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIB", "status": "TERMINATED", "last_update": "2018-01-23", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02347839", "title": "NEoadjuvant Gefitinib fOllowed by Surgery and gefiTinib In unresectAble sTage III NSCLC With EGFR Mutations.", "status": "WITHDRAWN", "last_update": "2024-12-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02350361", "title": "Endostar Combination With Chemotherapy and EGFR-TKI in Lung Cancer Rechallenging Treatment After Acquired Resistance.", "status": "UNKNOWN", "last_update": "2015-01-29", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02387086", "title": "Gefitinib Combined With Thalidomide to Treat NSCLC", "status": "UNKNOWN", "last_update": "2015-03-12", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02411448", "title": "A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02518802", "title": "Pemetrexed Combined With Synchronous Gefitinib as Adjuvent Therapy in Patient With EGFR Mutant Lung Adenocarcinoma", "status": "UNKNOWN", "last_update": "2015-08-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02588261", "title": "A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations", "status": "TERMINATED", "last_update": "2024-12-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02701231", "title": "Low-frequency Rotating Magnetic System Combined With Systemic Anti-tumor Therapy for Advanced Lung Cancer", "status": "UNKNOWN", "last_update": "2016-03-09", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02714010", "title": "EGFR-TKI Concurrent With/Without WBRT in Brain Metastasis From NSCLC", "status": "UNKNOWN", "last_update": "2017-10-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02736513", "title": "Intracranial Activity of AZD9291 (TAGRISSO) in Advanced EGFRm NSCLC Patients With Asymptomatic Brain Metastases", "status": "UNKNOWN", "last_update": "2021-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02747953", "title": "Gilotrif (Afatinib) in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib", "status": "COMPLETED", "last_update": "2021-03-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02787447", "title": "Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy", "status": "UNKNOWN", "last_update": "2016-11-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02788058", "title": "A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy", "status": "UNKNOWN", "last_update": "2016-06-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02804776", "title": "PRe-Operative Gefitinib in Resectable EGFR Mutation Positive Lung Cancer With Sector Sequencing for Biomarker Discovery", "status": "COMPLETED", "last_update": "2021-06-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02824458", "title": "A Study of Gefitinib With or Without Apatinib in Patients With Advanced Non-squamous Non-Small-Cell Lung Cancer Harboring EGFR Mutations", "status": "UNKNOWN", "last_update": "2016-07-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02859077", "title": "EGFR-TKI With Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism", "status": "UNKNOWN", "last_update": "2016-08-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02889692", "title": "Clinical Study of Chinese Medicine Plus Targeted Therapy Maintenance in Advanced Pulmonary Adenocarcinoma", "status": "COMPLETED", "last_update": "2019-04-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02893332", "title": "Stereotactic Body Radiation Therapy (SBRT) in Newly Diagnosed Advanced Staged Lung Adenocarcinoma (Sindas)", "status": "TERMINATED", "last_update": "2021-02-03", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02906163", "title": "First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy", "status": "UNKNOWN", "last_update": "2016-09-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02929693", "title": "Clinical Study of YYJD Decoction Combined With Gefitinib in Advanced Pulmonary Adenocarcinoma", "status": "UNKNOWN", "last_update": "2019-04-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02951637", "title": "Chemotherapy Plus Gefitinib for Advanced Lung Adenocarcinoma and Sensitive EGFR Mutations: a Randomized Controlled Trial", "status": "UNKNOWN", "last_update": "2016-11-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03002844", "title": "EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism", "status": "UNKNOWN", "last_update": "2016-12-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03040973", "title": "Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03050411", "title": "Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2017-02-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03119519", "title": "Local Non-salvage Radiotherapy for Synchronous Oligometastatic Non-small-cell Lung Cancer.", "status": "UNKNOWN", "last_update": "2020-03-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03264794", "title": "the Clinical Trial of Gefitinib(Non - Small Cell Lung Cancer)", "status": "UNKNOWN", "last_update": "2017-08-29", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03267654", "title": "Gefitinib With Chemotherapy or Anti-angiogenesis in NSCLC Patients With Bim Deletion or Low EGFR Mutation Abundance", "status": "UNKNOWN", "last_update": "2020-08-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03292133", "title": "A Study of EGF816 and Gefitinib in TKI-na\u00efve EGFR-mutant Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2025-06-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03333343", "title": "Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03341494", "title": "EGFR Mutation Positive NSCLC Patients With Gefitinib and Thalidomide", "status": "UNKNOWN", "last_update": "2017-11-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03374280", "title": "Pemetrexed/Cisplatin Intercalating Gefitinib Treating EGFR Wild NSCLC", "status": "UNKNOWN", "last_update": "2019-03-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03381430", "title": "Gefitinib Combine Radiotherapy as Therapy for Patients With NSCLC Harbouring Sensitive Mutations of EGFR", "status": "UNKNOWN", "last_update": "2017-12-22", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03389256", "title": "Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC", "status": "UNKNOWN", "last_update": "2018-01-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03457337", "title": "S-1 Plus Gefitinib Versus Gefitinib Monotherapy in Patients With EGFR-sensitive Mutation Advanced Non-squamous NSCLC", "status": "UNKNOWN", "last_update": "2020-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03461185", "title": "Anti-angiogenesis Combine With EGFR-TKI in Advanced Non-squamous Non Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2018-03-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03486496", "title": "Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR Mutation", "status": "UNKNOWN", "last_update": "2018-04-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03595644", "title": "Maintenance Targeted Therapy With or Without Stereotactic Body Radiation Therapy for Stage IV Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2021-04-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03599518", "title": "DS-1205c With Gefitinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2023-02-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03602027", "title": "Phase I Study of the Combination of Anlotinib With Gefitinib", "status": "UNKNOWN", "last_update": "2018-07-26", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03656393", "title": "To Evaluate the Efficacy and Safety of Gefitinib in Adjuvant Chemotherapy for Lung Adenocarcinoma", "status": "UNKNOWN", "last_update": "2018-09-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03758287", "title": "Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative", "status": "COMPLETED", "last_update": "2026-05-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03766490", "title": "Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2019-01-30", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03787992", "title": "Alflutinib Mesylate Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer \uff08FLAG\uff09", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-04-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03849768", "title": "A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients", "status": "UNKNOWN", "last_update": "2023-01-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03866499", "title": "A Study of BPI-7711 Capsule in Non-small Cell Lung Cancer Patients", "status": "UNKNOWN", "last_update": "2024-08-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03944772", "title": "Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-01-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04028778", "title": "Gefitinib in Combination With Anlotinib or Placebo in Previously Untreated EGFR-mutant NSCLC", "status": "UNKNOWN", "last_update": "2019-11-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04143607", "title": "ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-06-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04193007", "title": "The Role of Brain Radiotherapy in Patients With Asymptomatic Brain Metastasis in the Era of Targeted Therapy for NSCLC", "status": "UNKNOWN", "last_update": "2019-12-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04239833", "title": "A Study of SH-1028 Tablets Versus Gefitinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2020-01-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04358562", "title": "Gefitinib With Anlotinib in Advanced Non-squamous NSCLC Patients With Uncleared Plasma ctDNA EGFRm After First-line Treatment With Gefitinib", "status": "UNKNOWN", "last_update": "2020-04-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04390984", "title": "Drug-drug Interaction Study of Gefitinb on Apatinib in NSCLC Patients", "status": "UNKNOWN", "last_update": "2021-01-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04401059", "title": "Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC\uff1aProspective Study", "status": "UNKNOWN", "last_update": "2023-12-27", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04874844", "title": "JY025 is a First-line Treatment for EGFR Mutated NSCLC Phase II and III Clinical Trials of Efficacy and Safety", "status": "UNKNOWN", "last_update": "2021-05-10", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07271446", "title": "An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer", "status": "COMPLETED", "last_update": "2025-12-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07458919", "title": "Therapy for Advanced NSCLC With EGFR 19delins Mutation", "status": "NOT_YET_RECRUITING", "last_update": "2026-03-09", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" } ] }, "GLESATINIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02954991", "title": "Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2024-04-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ICOTINIB": { "n": 82, "n_observational": 5, "n_active": 7, "n_withdrawn": 0, "trials": [ { "nct": "NCT05104788", "title": "A Study of Icotinib With Chemotherapy as Neoadjuvant Therapy for Patients With EGFRm Positive Resectable Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2021-11-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05536505", "title": "Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC", "status": "RECRUITING", "last_update": "2022-09-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06041776", "title": "Adjuvant Befotertinib in Stage IB-IIIB Non-small Cell Lung Cancer With Positive EGFR Sensitive Mutations", "status": "RECRUITING", "last_update": "2023-09-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06517953", "title": "Befotertinib and Icotinib for NSCLC With Uncommon EGFR Mutations", "status": "RECRUITING", "last_update": "2024-07-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01040780", "title": "Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) Patients", "status": "COMPLETED", "last_update": "2014-02-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01465243", "title": "Dose Escalation Of Icotinib In Previously Treated Patients With Routine Dose", "status": "COMPLETED", "last_update": "2014-02-17", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01514877", "title": "Icotinib Combined With Whole Brain Radiotherapy in Treating Multiple Brain Metastases From Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2014-07-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01516983", "title": "Icotinib Combined With WBRT For NSCLC Patients With Brain Metastases and EGFR Mutation", "status": "COMPLETED", "last_update": "2014-02-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01646450", "title": "First-line Treatment With Icotinib in Elder NSCLC EGFR Mutated Patients", "status": "UNKNOWN", "last_update": "2015-09-09", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01665417", "title": "Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma", "status": "UNKNOWN", "last_update": "2017-02-08", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01688713", "title": "Phase II Trial of Double Dose of Icotinib in Treating Brain Metastases From Non-small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2012-09-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01690390", "title": "Dose Escalation of Icotinib in Advanced Non-small Cell Lung Carcinoma (NSCLC) Patients Evaluated as Stable Disease", "status": "UNKNOWN", "last_update": "2014-12-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01707329", "title": "Icotinib in Combination With Chemotherapy Versus Chemotherapy Alone in Patients Progressed After Icotinib Treatment", "status": "UNKNOWN", "last_update": "2015-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01720901", "title": "Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib Therapy", "status": "SUSPENDED", "last_update": "2015-05-22", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01724801", "title": "Icotinib or Whole Brain Irradiation in EGFR-mutant Lung Cancer", "status": "COMPLETED", "last_update": "2017-03-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01744925", "title": "Icotinib at Different Doses in Second-line Treatment for Non-small Cell Lung Cancer Patients With Wild Type EGFR", "status": "UNKNOWN", "last_update": "2017-02-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01843647", "title": "Neoadjuvant Therapy of Icotinib in Epidermal Growth Factor Receptor Mutated NSCLC Patients", "status": "UNKNOWN", "last_update": "2015-07-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01926171", "title": "Icotinib With Whole Brain Radiation Therapy in NSCLC Patients With Brain Metastases", "status": "UNKNOWN", "last_update": "2015-07-15", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01929200", "title": "Icotinib as Adjuvant Therapy in Treating Non-small-cell Lung Cancer Patients With Positive EGFR Mutation", "status": "UNKNOWN", "last_update": "2015-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01963195", "title": "Evaluation of the High Dose of Icotinib in Advanced Lung Cancer Patients After Failure of Target Therapy", "status": "UNKNOWN", "last_update": "2017-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01996098", "title": "Icotinib Following Chemotherapy Versus Chemotherapy as Adjuvant Therapy in Stage IIA-IIIA NSCLC With EGFR Mutation", "status": "TERMINATED", "last_update": "2024-09-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02009605", "title": "Icotinib in Previously Treated Non/Light-smoking Patients With Advanced Squamous Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2015-03-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02027090", "title": "High Dose Versus Routine Dose Icotinib in Advanced Non-small Cell Lung Cancer Patients With Stable Disease", "status": "UNKNOWN", "last_update": "2015-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02031601", "title": "Intercalated Combination of Chemotherapy and Tyrosine Kinase Inhibitors as First-line Treatment for Patients With Non-Small-Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2016-03-29", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02044328", "title": "Icotinib as an Adjuvant Therapy for Patients With Stage IIA-IIIA Adenocarcinoma With EGFR Mutation", "status": "COMPLETED", "last_update": "2022-02-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02062515", "title": "Icotinib in Advanced Non-small Cell Lung Cancer (NSCLC) With Hepatic Insufficiency", "status": "UNKNOWN", "last_update": "2015-07-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02066870", "title": "Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI", "status": "UNKNOWN", "last_update": "2015-03-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02103257", "title": "Sequential Icotinib Plus Chemotherapy Versus Icotinib Alone as First-line Treatment in Stage IIIB/IV Lung Adenocarcinoma", "status": "UNKNOWN", "last_update": "2015-04-29", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02125240", "title": "Icotinib Versus Placebo as Adjuvant Therapy in EGFR-mutant Lung Adenocarcinoma", "status": "UNKNOWN", "last_update": "2018-07-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02191059", "title": "Phase II Clinical Study of Intermittent High Dose of Icotinib in Combination With Docetaxel to Treat Lung Cancer", "status": "UNKNOWN", "last_update": "2014-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02194556", "title": "Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC", "status": "UNKNOWN", "last_update": "2014-07-18", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02215356", "title": "Icotinib With Concurrent Radiotherapy Versus Chemotherapy With Concurrent Radiotherapy in Non-small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2014-08-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02264210", "title": "Icotinib for Completed Resected IB NSCLC With EGFR Mutation", "status": "COMPLETED", "last_update": "2024-09-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02272127", "title": "Study of Chemotherapy Plus Icotinib to Treat EGFR Mutation-positive Non-small-cell Lung Cancer", "status": "UNKNOWN", "last_update": "2014-10-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02283424", "title": "Icotinib as the Adjunctive Treatment After Surgery in Stage I-IIIB Lung Adenocarcinoma Patients With EGFR Gene Mutation", "status": "UNKNOWN", "last_update": "2014-11-05", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02375022", "title": "Rh-Endostatin in Combination With Icotinib for Advanced NSCLC With EGFR Mutations", "status": "UNKNOWN", "last_update": "2015-03-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02404675", "title": "High Dose Icotinib in Advanced Non-small Cell Lung Cancer With EGFR 21 Exon Mutation", "status": "UNKNOWN", "last_update": "2017-07-28", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02407366", "title": "Icotinib With Concurrent Radiotherapy vs. Chemoradiotherapy in Non-small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2015-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02430974", "title": "Chemotherapy of NSCLC With or Without Icotinib", "status": "UNKNOWN", "last_update": "2015-04-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02448797", "title": "Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutation", "status": "UNKNOWN", "last_update": "2021-07-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02486354", "title": "Icotinib in Advanced Metastatic Patients With NSCLC Previously Treated With Chemotherapy", "status": "COMPLETED", "last_update": "2015-07-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02714010", "title": "EGFR-TKI Concurrent With/Without WBRT in Brain Metastasis From NSCLC", "status": "UNKNOWN", "last_update": "2017-10-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02726568", "title": "High Dose Icotinib With Sequential SRS For NSCLC Patients Harboring EGFR Mutation With Brain Metastases", "status": "UNKNOWN", "last_update": "2019-02-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02737774", "title": "Alternating Icotinib and Chemotherapy for Advanced Non-small Cell Lung Cancer With EGFR Mutation", "status": "UNKNOWN", "last_update": "2020-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02738983", "title": "RT Plus EGFR-TKI for Wild-type NSCLC", "status": "UNKNOWN", "last_update": "2016-04-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02744664", "title": "Cryotherapy Combine Icotinib for Advanced NSCLC Treatment", "status": "COMPLETED", "last_update": "2020-05-27", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02778893", "title": "Conmana Combined With Thalidomide to Treat NSCLC", "status": "UNKNOWN", "last_update": "2016-05-20", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02787447", "title": "Radiotherapy Combined With Thymosin for Metastatic NSCLC Patients Who Showed Stable Disease After First Line TKI Therapy", "status": "UNKNOWN", "last_update": "2016-11-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02788058", "title": "A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy", "status": "UNKNOWN", "last_update": "2016-06-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02820116", "title": "The Role of Icotinib in the Perioperative Treatment of IIIA - IIIB NSCLC Patients With EGFR Mutation", "status": "UNKNOWN", "last_update": "2016-06-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02883543", "title": "First-line Icotinib With Concurrent Radiotherapy for NSCLC With EGFR Mutation", "status": "UNKNOWN", "last_update": "2016-08-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02889692", "title": "Clinical Study of Chinese Medicine Plus Targeted Therapy Maintenance in Advanced Pulmonary Adenocarcinoma", "status": "COMPLETED", "last_update": "2019-04-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02960607", "title": "High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLC", "status": "UNKNOWN", "last_update": "2016-11-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02961270", "title": "Icotinib in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutation", "status": "UNKNOWN", "last_update": "2016-11-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03008109", "title": "Endostar Plus EGFR-TKI\uff08Epidermal Growth Factor Receptor-Tyrosine-Kinase Inhibitor\uff09 as a Treatment of EGFR Mutation-positive NSCLC", "status": "UNKNOWN", "last_update": "2017-01-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03123484", "title": "\u03b2-elemene Combine With EGFR-TKI for Advanced EGFR-TKI-resistant NSCLC", "status": "UNKNOWN", "last_update": "2017-04-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03151161", "title": "Intermittent and Maintenance of Icotinib in Combination With Pemetrexed/Carboplatin Compared With Icotinib Single Drug in \u2162b/IV Non Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Mutation", "status": "UNKNOWN", "last_update": "2018-06-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03153358", "title": "Icotinib Combined With SBRT for Patients With Metastatic Non-squamous NSCLC With EGFR Mutation", "status": "UNKNOWN", "last_update": "2017-05-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03258671", "title": "IMRT and Timing in Combination With EGFRTKI for Stage IV Non-small-cell Lung Cancer", "status": "UNKNOWN", "last_update": "2017-08-25", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03346811", "title": "Efficiency of Icotinib in Plasma ctDNA EGFR Mutation-positive Patients Diagnosed With Lung Cancer", "status": "UNKNOWN", "last_update": "2017-11-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03349203", "title": "Icotinib as Neoadjuvant and Adjuvant Therapy in EGFR-mutant Stage IIIB or Oligometastasis Non-small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2018-07-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03396185", "title": "Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2018-07-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03402464", "title": "Icotinib Combined With Dihydroaremisinin (DHA) Therapy in Patients With Advanced NSCLC", "status": "UNKNOWN", "last_update": "2018-01-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03544814", "title": "EGFR-TKI Combined With Concurrent or Sequential Chemotherapy for Patients of Gradual Progression", "status": "COMPLETED", "last_update": "2019-10-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03595644", "title": "Maintenance Targeted Therapy With or Without Stereotactic Body Radiation Therapy for Stage IV Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2021-04-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03736837", "title": "Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC", "status": "COMPLETED", "last_update": "2021-03-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03749213", "title": "Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage \u2162A-N2 Non-small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2018-11-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03754530", "title": "Icotinib Combined With Radiation Therapy For NSCLC Patients With Brain Metastases and EGFR Mutation", "status": "UNKNOWN", "last_update": "2018-11-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03766490", "title": "Anlotinib Hydrochloride Combined With EGFR TKIs in Advanced Non-small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2019-01-30", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03983811", "title": "Adjuvant Chemotherapy With or Without Intercalated Icotinib", "status": "UNKNOWN", "last_update": "2019-06-12", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03992885", "title": "Clinical Study of Combination Therapy With Ectiecinib, Pemetrexed and Platinum in Patients With Metastatic Non-squamous Non-small Cell Lung Cancer With EGFR Mutations.", "status": "UNKNOWN", "last_update": "2019-06-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04007835", "title": "Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI", "status": "UNKNOWN", "last_update": "2019-07-05", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04058704", "title": "A Study to Determine the Efficiency For Brain Metastasis NSCLC Patients Treated With Icotinib Alone or Combined With Radiation Therapy", "status": "UNKNOWN", "last_update": "2019-08-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04206072", "title": "D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLC", "status": "COMPLETED", "last_update": "2025-08-11", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04401059", "title": "Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC\uff1aProspective Study", "status": "UNKNOWN", "last_update": "2023-12-27", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04797806", "title": "Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Concomitant Mutation NSCLC", "status": "UNKNOWN", "last_update": "2021-03-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05007938", "title": "Befotertinib and Icotinib in Treatment-naive Patients With Advanced EGFR-Mutant Lung Cancer", "status": "UNKNOWN", "last_update": "2024-08-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05132985", "title": "Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2021-12-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05263947", "title": "Bevacizumab Combined With Double Doses of Icotinib in Advanced NSCLC Patients With EGFR L858R Mutation", "status": "COMPLETED", "last_update": "2026-02-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05514314", "title": "A Multicenter Prospective Study to Assess the Effects of Adjuvant Icotinib in EGFRm Stage I NSCLC With High-risk of Disease Recurrence After Complete Resection", "status": "UNKNOWN", "last_update": "2022-08-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06955325", "title": "Umbrella Trial of Adjuvant Therapy in Completely Resected High-risk Stage IA-IB NSCLC: Focus on Driver Mutations", "status": "NOT_YET_RECRUITING", "last_update": "2025-05-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07458919", "title": "Therapy for Advanced NSCLC With EGFR 19delins Mutation", "status": "NOT_YET_RECRUITING", "last_update": "2026-03-09", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" } ] }, "IMGATUZUMAB": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 1, "trials": [ { "nct": "NCT01185847", "title": "A Study of RO5083945 in Combination With Chemotherapy Versus Chemotherapy Alone in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2016-01-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01702714", "title": "A Study of RO5083945 in Combination With Cisplatin and Gemcitabine or Carboplatin and Paclitaxel in Patients With Advanced or Recurrent Non-Small Cell Lung Cancer of Squamous Histology Who Have Not Received Prior Chemotherapy for The Metastatic Disease", "status": "WITHDRAWN", "last_update": "2016-11-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "INCB-086550": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT04629339", "title": "Study of INCB086550 in Select Solid Tumors", "status": "TERMINATED", "last_update": "2025-03-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "KBP5209": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02442414", "title": "A Phase 1 Study of KBP-5209 in Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2022-03-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03574402", "title": "Phase II Umbrella Study Directed by Next Generation Sequencing", "status": "UNKNOWN", "last_update": "2022-12-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "LAPATINIB": { "n": 8, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00073008", "title": "A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2017-02-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00313599", "title": "Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2014-07-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00528281", "title": "A Phase II Trial of Lapatinib (TYKERB) + Pemetrexed (ALIMTA) in Advanced Non Small Cell Lung Cancer With an Initial Dose Finding Phase", "status": "COMPLETED", "last_update": "2017-11-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01184482", "title": "Lapatinib and Cetuximab in Patients With Solid Tumors", "status": "COMPLETED", "last_update": "2013-10-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01218529", "title": "Lapatinib and WBRT for Patients With Brain Metastases From Lung or Breast Tumors", "status": "COMPLETED", "last_update": "2014-12-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01306045", "title": "Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies", "status": "COMPLETED", "last_update": "2024-10-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02230553", "title": "Lapatinib Plus Trametinib in KRAS Mutant NSCLC", "status": "COMPLETED", "last_update": "2025-07-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04591431", "title": "The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy", "status": "UNKNOWN", "last_update": "2023-10-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "LAPATINIB DITOSYLATE": { "n": 8, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00073008", "title": "A Study Of Oral GW572016 In Advanced Or Metastatic Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2017-02-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00313599", "title": "Lapatinib and Paclitaxel in Treating Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2014-07-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00528281", "title": "A Phase II Trial of Lapatinib (TYKERB) + Pemetrexed (ALIMTA) in Advanced Non Small Cell Lung Cancer With an Initial Dose Finding Phase", "status": "COMPLETED", "last_update": "2017-11-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01184482", "title": "Lapatinib and Cetuximab in Patients With Solid Tumors", "status": "COMPLETED", "last_update": "2013-10-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01218529", "title": "Lapatinib and WBRT for Patients With Brain Metastases From Lung or Breast Tumors", "status": "COMPLETED", "last_update": "2014-12-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01306045", "title": "Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies", "status": "COMPLETED", "last_update": "2024-10-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02230553", "title": "Lapatinib Plus Trametinib in KRAS Mutant NSCLC", "status": "COMPLETED", "last_update": "2025-07-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04591431", "title": "The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy", "status": "UNKNOWN", "last_update": "2023-10-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "LAROTRECTINIB": { "n": 5, "n_observational": 0, "n_active": 4, "n_withdrawn": 0, "trials": [ { "nct": "NCT06563999", "title": "Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.", "status": "RECRUITING", "last_update": "2026-04-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02576431", "title": "A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors", "status": "COMPLETED", "last_update": "2026-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03155620", "title": "Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03213704", "title": "Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "LAZERTINIB": { "n": 32, "n_observational": 6, "n_active": 20, "n_withdrawn": 0, "trials": [ { "nct": "NCT05469022", "title": "Neoadjuvant Lazertinib Therapy in EGFR-Mutation Positive Lung Adenocarcinoma Detected by BALF Liquid Biopsy", "status": "RECRUITING", "last_update": "2022-07-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05498428", "title": "A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06106802", "title": "Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06156527", "title": "A Randomized Phase II Study of LAZE rtiNib Alone Versus Lazertinib Plus bevaCizumab for NSCLC With EGFR + & Smoker", "status": "RECRUITING", "last_update": "2023-12-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06667076", "title": "A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)", "status": "RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07586202", "title": "A Study of Neoadjuvant Amivantamab With Either Lazertinib or Chemotherapy in Participants With Resectable EGFR-Mutated NSCLC", "status": "RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07699328", "title": "A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-07-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07774520", "title": "A Randomized Study to Evaluate the Efficacy of a Reduced Starting Dose of Lazertinib (Leclaza) and Preemtive Magnesium Supplementation to Prevent Lazertinib(Leclaza)-Induced Peripheral Neuropathy", "status": "RECRUITING", "last_update": "2026-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02609776", "title": "Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04075396", "title": "A Study of Lazertinib in Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Positive Advanced Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2025-04-29", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04077463", "title": "A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04085315", "title": "Alisertib in Combination With Osimertinib in Metastatic EGFR-mutant Lung Cancer", "status": "COMPLETED", "last_update": "2026-08-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04248829", "title": "Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)", "status": "COMPLETED", "last_update": "2026-06-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04487080", "title": "A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04965090", "title": "A Study of Amivantamab and Lazertinib in People With Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2025-12-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04988295", "title": "A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05162274", "title": "Clinical Trial to Assess Bioequivalence of Lazertinib Between Two Formulations in Healthy Volunteers.", "status": "COMPLETED", "last_update": "2024-12-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05167851", "title": "The Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2021-12-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05299125", "title": "Amivantamab, Lazertinib, and Pemetrexed for First-line Treatment of Recurrent/Metastatic Non-small Cell Lung Cancers With Epidermal Growth Factor Receptor Mutations", "status": "COMPLETED", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05326425", "title": "Lazertinib in Patients With NSCLC With Asymptomatic or Mild Symptomatic Brain Metastases After Failure of EGFR TKI.", "status": "UNKNOWN", "last_update": "2022-04-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05338619", "title": "A Study of Lazertinib as Consolidation Therapy in Patients With Locally Advanced, Unresectable, EGFR-Mutant Non-Small Cell Lung Cancer (Stage III) Following Chemoradiation Therapy", "status": "UNKNOWN", "last_update": "2023-09-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05388669", "title": "A Study of Lazertinib With Subcutaneous Amivantamab Compared With Intravenous Amivantamab in Participants With Epidermal Growth Factor Receptor (EGFR)-Mutated Advanced or Metastatic Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05477615", "title": "Lazertinib/Pemetrexed/Carboplatin After Osimertinib Failure in NSCLC With Brain Metastases", "status": "UNKNOWN", "last_update": "2022-07-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05601973", "title": "Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05663866", "title": "Premedication to Reduce Amivantamab Associated Infusion Related Reactions", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05701384", "title": "Lazertinib 160mg in EGFR T790M NSCLC", "status": "UNKNOWN", "last_update": "2023-01-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05786430", "title": "Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior Lazertinib", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06020989", "title": "Lazertinib and Chemotherapy Combination in EGFR-mutant NSCLC Patients Without ctDNA Clearance After lead-in Lazertinib Monotherapy", "status": "UNKNOWN", "last_update": "2023-09-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06120140", "title": "Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06268210", "title": "Neoadjuvant Lazertinib With or Without Chemotherapy for Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07469488", "title": "A Clinical Trial on the Outcomes of Comprehensive Enhanced Prophylaxis Management (CEPM) in Chinese Patients With EGFR-Mutated Advanced NSCLC Receiving Amivantamab-Based Regimens", "status": "NOT_YET_RECRUITING", "last_update": "2026-03-13", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07507188", "title": "Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients With EGFR-mutant, Locally Advanced or Metastatic/Recurrent Non-Small Cell Lung Cancer (INSTAR Study)", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "LORLATINIB": { "n": 43, "n_observational": 22, "n_active": 26, "n_withdrawn": 1, "trials": [ { "nct": "NCT04322890", "title": "Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation", "status": "RECRUITING", "last_update": "2024-10-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05014464", "title": "ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma", "status": "RECRUITING", "last_update": "2024-09-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06092086", "title": "Lorlatinib as the First-line Treatment in China Advanced ALK+ NSCLC", "status": "RECRUITING", "last_update": "2023-10-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06378892", "title": "A Study to Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib", "status": "RECRUITING", "last_update": "2024-04-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06487078", "title": "Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context", "status": "RECRUITING", "last_update": "2026-05-06", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07415005", "title": "Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-05-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07491497", "title": "A Phase 1/2 Study of TRI-611 in ALK-Positive NSCLC", "status": "RECRUITING", "last_update": "2026-09-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07617337", "title": "AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07784959", "title": "Study of NXP900 With Lorlatinib in ALK+ Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01970865", "title": "A Study Of PF-06463922 An ALK/ROS1 Inhibitor In Patients With Advanced Non Small Cell Lung Cancer With Specific Molecular Alterations", "status": "COMPLETED", "last_update": "2024-08-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02584634", "title": "Study to Evaluate Safety, Efficacy, Pharmacokinetics And Pharmacodynamics Of Avelumab In Combination With Either Crizotinib Or PF-06463922 In Patients With NSCLC. (Javelin Lung 101)", "status": "TERMINATED", "last_update": "2023-07-07", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02927340", "title": "A Study of Lorlatinib in Advanced ALK and ROS1 Rearranged Lung Cancer With CNS Metastasis in the Absence of Measurable Extracranial Lesions", "status": "UNKNOWN", "last_update": "2021-03-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03052608", "title": "A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03184168", "title": "Single-dose Study of [14C]Lorlatinib (PF-06463922) Metabolism In Healthy Male Volunteers", "status": "COMPLETED", "last_update": "2017-09-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03439215", "title": "PF-06463922 for Crizotinib Pretreated ROS1 Positive Non-small-cell Lung Cancer", "status": "UNKNOWN", "last_update": "2021-07-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03612154", "title": "Study of Lorlatinib in ROS1 Rearranged NSCLC", "status": "UNKNOWN", "last_update": "2022-04-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03726333", "title": "Hepatic Impairment Study for Lorlatinib in Cancer Patients", "status": "TERMINATED", "last_update": "2024-06-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03737994", "title": "Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2026-04-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03909971", "title": "A Study of Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China", "status": "COMPLETED", "last_update": "2025-11-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04111705", "title": "Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2025-04-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04127110", "title": "Activity of Lorlatinib Based on ALK Resistance Mutations Detected on Blood in ALK Positive NSCLC Patients", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-11-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04292119", "title": "Lorlatinib Combinations in Lung Cancer", "status": "UNKNOWN", "last_update": "2021-03-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04362072", "title": "Study of Lorlatinib In People With ALK-positive Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2025-06-11", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04541407", "title": "Temodar Plus Tyrosine Kinase Inhibitors for Progressive CNS Disease", "status": "COMPLETED", "last_update": "2023-05-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04541706", "title": "Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India", "status": "COMPLETED", "last_update": "2024-12-20", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04621188", "title": "Lorlatinib After Failure of First-line TKI in Patients With Advanced ROS1-positive NSCLC (ALBATROS)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04634110", "title": "Brigatinib Before Brain Irradiation Trial (B3i Trial)", "status": "TERMINATED", "last_update": "2022-10-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04800822", "title": "PF-07284892 in Participants With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2026-06-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05144997", "title": "Lorlatinib Continuation Study", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-26", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05195619", "title": "Personalized DC Vaccines in Non Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-07-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05297890", "title": "A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05740943", "title": "Induction Lorlatinib in Stage III Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05948462", "title": "Lorlatinib in Combination With Chemotherapy in Participants With Metastatic Anaplastic Lymphoma Kinase Positive (ALK+) Non-small Cell Lung Cancer (NSCLC) Who Progressed on Single-agent Lorlatinib", "status": "WITHDRAWN", "last_update": "2023-12-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06007937", "title": "A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06282874", "title": "Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-09", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06682884", "title": "Lorlatinib as Neoadjuvant Treatment in Stage IB-IIIB ALK-rearranged Non-Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-11-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06858410", "title": "Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-03-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06893354", "title": "Explore the Mechanisms Underlying Disease Resistance and Potential Primary Resistance Mechanism of Induction Therapy Lorlatinib in Resectable Non-small Cell Lung Cancer (NSCLC) Harboring ALK Positive Mutation Revealed by Single-cell RNA Sequencing and Spatial Transcriptomics", "status": "NOT_YET_RECRUITING", "last_update": "2025-03-25", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07083687", "title": "Lorlatinib in ROS1+ NSCLC With Brain Metastasis", "status": "NOT_YET_RECRUITING", "last_update": "2025-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07671560", "title": "Efficacy and Safety of Ensartinib Combined With Anlotinib in Lorlatinib-Resistant ALK-Positive NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-26", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07674368", "title": "Rucaparib Monoclonal Antibody for Lorlatinib-Induced Hypercholesterolemia / Mixed", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-01", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07750704", "title": "Lorlatinib Plus Sacituzumab Tirumotecan With Peripheral ctDNA Guidance as First-Line Therapy for ALK Fusion-Positive NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07782359", "title": "Impact of Using a GLP1 on Treatment Related Side Effects of Lung Cancer Patients Receiving Lorlatinib", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "LY-3009120": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02014116", "title": "A Study of LY3009120 in Participants With Advanced Cancer or Cancer That Has Spread to Other Parts of Their Body", "status": "TERMINATED", "last_update": "2019-12-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "MARGETUXIMAB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT03219268", "title": "A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms", "status": "COMPLETED", "last_update": "2023-12-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "MATUZUMAB": { "n": 3, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT06735391", "title": "A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations", "status": "RECRUITING", "last_update": "2024-12-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00111839", "title": "Effects of Matuzumab in Combination With Pemetrexed for the Treatment of Advanced Lung Cancer", "status": "COMPLETED", "last_update": "2018-04-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05354700", "title": "A Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy in Patients With Extensive Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2022-05-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "MERESTINIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02920996", "title": "Merestinib In Non-Small Cell Lung Cancer And Solid Tumors", "status": "TERMINATED", "last_update": "2024-04-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "MILCICLIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT05651269", "title": "Milciclib in Combination With Gemcitabine in Advanced NSCLC", "status": "UNKNOWN", "last_update": "2022-12-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "MOBOCERTINIB": { "n": 6, "n_observational": 3, "n_active": 3, "n_withdrawn": 1, "trials": [ { "nct": "NCT02716116", "title": "A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03807778", "title": "A Study of Mobocertinib in Japanese Adults With Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04051827", "title": "Drug-Drug Interaction Study of TAK-788 and Midazolam in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2025-07-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04129502", "title": "TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04576208", "title": "A Study to Evaluate the Impact of Management Strategies on Gastrointestinal-Related Adverse Events in Participants With Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations Receiving TAK-788", "status": "WITHDRAWN", "last_update": "2020-12-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05241873", "title": "(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations", "status": "TERMINATED", "last_update": "2025-02-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "MONOMETHYL": { "n": 4, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT05941507", "title": "A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2025-09-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03236935", "title": "Phase Ib of L-NMMA and Pembrolizumab", "status": "COMPLETED", "last_update": "2026-04-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03574753", "title": "Lung-MAP S1400K: c-MET Positive", "status": "COMPLETED", "last_update": "2021-10-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06549816", "title": "A Study of SGN-B6A in Chinese Participants With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2025-12-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "MOTESANIB": { "n": 8, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00094835", "title": "Study to Evaluate Motesanib With or Without Carboplatin/Paclitaxel or Panitumumab in the Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2016-03-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00101907", "title": "Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Patients With Advanced Cancer", "status": "TERMINATED", "last_update": "2014-03-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00324597", "title": "AMG 706 and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma", "status": "UNKNOWN", "last_update": "2013-09-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00369070", "title": "A Phase 2 Trial of AMG 706 or Bevacizumab in Combination With Chemo for Advanced NSCLC", "status": "TERMINATED", "last_update": "2018-01-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00460317", "title": "MONET1-MOtesanib NSCLC Efficacy and Tolerability Study", "status": "TERMINATED", "last_update": "2015-09-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00510445", "title": "Study of GRN163L With Paclitaxel and Carboplatin in Patients With Advanced or Metastatic Non Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2015-12-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01137968", "title": "Imetelstat as Maintenance Therapy After Initial Induction Chemotherapy in Non-small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2016-01-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02629848", "title": "Study of Motesanib (AMG 706) in Combination With Paclitaxel and Carboplatin for Advanced Non-Squamous Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2015-12-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "MUBRITINIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00034281", "title": "Safety and Tolerability Study of TAK-165 in Subjects With Tumors Expressing HER2", "status": "COMPLETED", "last_update": "2012-02-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "NAPORAFENIB": { "n": 3, "n_observational": 0, "n_active": 2, "n_withdrawn": 0, "trials": [ { "nct": "NCT02974725", "title": "A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma", "status": "TERMINATED", "last_update": "2025-04-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03333343", "title": "Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05907304", "title": "A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "NAQUOTINIB": { "n": 6, "n_observational": 0, "n_active": 0, "n_withdrawn": 1, "trials": [ { "nct": "NCT02113813", "title": "A Dose Escalation Study of ASP8273 in Subjects With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations", "status": "COMPLETED", "last_update": "2024-11-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02192697", "title": "An Open Study of ASP8273 in Patients With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) Mutations", "status": "TERMINATED", "last_update": "2024-11-14", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02500927", "title": "A Study of ASP8273 in Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor-Na\u00efve Patients With Non-Small Cell Lung Cancer Harboring EGFR Mutations", "status": "TERMINATED", "last_update": "2024-11-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02588261", "title": "A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations", "status": "TERMINATED", "last_update": "2024-12-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03042013", "title": "A Study for Subjects Who Are Participating in an Astellas-sponsored ASP8273 Study", "status": "WITHDRAWN", "last_update": "2017-07-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03082300", "title": "A Study of ASP8273 in Subjects With Non-small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Mutations", "status": "TERMINATED", "last_update": "2024-11-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "NAVTEMADLIN": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 1, "trials": [ { "nct": "NCT05027867", "title": "KRT-232 in Subjects With Relapsed or Refractory Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2023-08-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05705466", "title": "Study of Navtemadlin Plus Pembrolizumab as Maintenance Therapy in Locally Advanced and Metastatic Non-Small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2024-03-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "NAZARTINIB": { "n": 9, "n_observational": 0, "n_active": 2, "n_withdrawn": 1, "trials": [ { "nct": "NCT02108964", "title": "A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies", "status": "COMPLETED", "last_update": "2024-12-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02323126", "title": "Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2022-02-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02335944", "title": "Study of Safety and Efficacy of EGFR-TKI EGF816 in Combination With cMET Inhibitor INC280 in Adult Patients With EGFR Mutated Non Small Cell Lung Cancer.", "status": "TERMINATED", "last_update": "2023-06-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02900664", "title": "A Study of PDR001 in Combination With CJM112, EGF816, Ilaris\u00ae (Canakinumab) or Mekinist\u00ae (Trametinib)", "status": "COMPLETED", "last_update": "2022-03-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03040973", "title": "Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03292133", "title": "A Study of EGF816 and Gefitinib in TKI-na\u00efve EGFR-mutant Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2025-06-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03333343", "title": "Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03516214", "title": "EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer Harboring Activating EGFR Mutations", "status": "COMPLETED", "last_update": "2024-02-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03529084", "title": "Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations", "status": "WITHDRAWN", "last_update": "2019-11-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "NECITUMUMAB": { "n": 17, "n_observational": 0, "n_active": 3, "n_withdrawn": 1, "trials": [ { "nct": "NCT00981058", "title": "First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin", "status": "COMPLETED", "last_update": "2025-06-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00982111", "title": "First-line Treatment of Patients With Stage IV Nonsquamous Non-Small Cell Lung Cancer With Necitumumab (IMC-11F8) and Pemetrexed-Cisplatin", "status": "COMPLETED", "last_update": "2022-01-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01606748", "title": "A Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin", "status": "COMPLETED", "last_update": "2019-09-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01763788", "title": "A Study of Necitumumab in the First-Line Treatment of Stage IV Squamous Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2019-10-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01769391", "title": "A Study of Necitumumab and Chemotherapy in Participants With Stage IV Squamous Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2019-09-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01788566", "title": "A Study of Gemcitabine-Cisplatin Chemotherapy Plus Necitumumab in the First-Line Treatment of Participants With Squamous Lung Cancer", "status": "COMPLETED", "last_update": "2016-06-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02392507", "title": "A Study of Nab-Paclitaxel and Carboplatin Plus Necitumumab (LY3012211) in Participants With Stage IV Squamous NSCLC", "status": "COMPLETED", "last_update": "2020-11-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02411591", "title": "A Study of Necitumumab and Abemaciclib in Participants With Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2020-07-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02443337", "title": "A Study of LY3023414 and Necitumumab in Squamous Lung Cancer", "status": "TERMINATED", "last_update": "2020-12-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02451930", "title": "A Study of the Combination of Necitumumab (LY3012211) and Pembrolizumab (MK3475) in Participants With NSCLC", "status": "COMPLETED", "last_update": "2020-10-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02496663", "title": "Osimertinib and Necitumumab in Treating Patients With EGFR-Mutant Stage IV or Recurrent Non-small Cell Lung Cancer Who Have Progressed on a Previous EGFR Tyrosine Kinase Inhibitor", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02789345", "title": "A Study of Ramucirumab (LY3009806) or Necitumumab (LY3012211) Plus Osimertinib in Participants With Lung Cancer", "status": "COMPLETED", "last_update": "2024-02-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02941601", "title": "A Study of Gemcitabine-Carboplatin Plus Necitumumab (LY3012211) in Chemotherapy-Na\u00efve Participants With Locally Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)", "status": "WITHDRAWN", "last_update": "2019-09-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03054038", "title": "Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2022-04-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03574818", "title": "Necitumumab in the Neoadjuvant Setting With Gemcitabine in Surgically Resectable - 14X-US-I001", "status": "TERMINATED", "last_update": "2020-03-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03944772", "title": "Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-01-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04285671", "title": "Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "NERATINIB": { "n": 4, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00266877", "title": "Study Evaluating the Safety Of HKI-272 (Neratinib) In Subjects With Advanced Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2018-04-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01827267", "title": "Neratinib With and Without Temsirolimus for Patients With HER2 Activating Mutations in Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2018-07-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01953926", "title": "Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations", "status": "TERMINATED", "last_update": "2024-03-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06519110", "title": "Neratinib Tablets Monotherapy for Advanced Solid Tumors With HER2 Mutations", "status": "UNKNOWN", "last_update": "2024-07-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "NIMOTUZUMAB": { "n": 16, "n_observational": 0, "n_active": 2, "n_withdrawn": 2, "trials": [ { "nct": "NCT04235114", "title": "Evaluation of 89Zr-DFO-nimotuzumab for Non-invasive Imaging of EGFR+ Cancers by Positron Emission Tomography (PET)", "status": "RECRUITING", "last_update": "2024-01-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04459065", "title": "Evaluation of IRDye800CW-nimotuzumab in Lung Cancer Surgery", "status": "RECRUITING", "last_update": "2024-01-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00369447", "title": "A Study of Nimotuzumab in Combination With External Radiotherapy in Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2011-07-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00872482", "title": "A Study of Nimotuzumab in Combination With Radiation Therapy in Patients With Brain Metastases", "status": "TERMINATED", "last_update": "2011-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00983047", "title": "Nimotuzumab Plus Docetaxel in Chemotherapy-Refractory/Resistant Patients With Advanced Non-Small-Cell Lung Cancer", "status": "TERMINATED", "last_update": "2015-08-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00985998", "title": "Nimotuzumab in Combination With Cisplatin and Docetaxel for Patients With Advanced Non-small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2015-08-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01393080", "title": "Nimotuzumab in Combination With Paclitaxel Liposome and Carboplatin (TP Regimen) for the Advanced NSCLC Patients", "status": "UNKNOWN", "last_update": "2016-02-17", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01498562", "title": "Phase II Study of Gefitinib Plus Nimotuzumab Versus Gefitinib in Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2014-12-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01861223", "title": "Afatinib Plus Nimotuzumb for NSCLC", "status": "UNKNOWN", "last_update": "2014-02-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02428764", "title": "Neoadjuvant Nimotuzumab Plus Gemcitabine and Carboplatin in Unresectable Stage III Squamous Cell Lung Carcinoma", "status": "WITHDRAWN", "last_update": "2024-12-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02549261", "title": "Nimotuzumab in Combination With Radiochemotherapy for Patients With Stage IIIA/IIIB Non-small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2015-09-15", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02577341", "title": "Nimotuzumab Combined With Chemoradiotherapy for Unresectable Locally Advanced Squamous Cell Lung Cancer", "status": "COMPLETED", "last_update": "2021-02-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02947386", "title": "Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2023-10-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03574402", "title": "Phase II Umbrella Study Directed by Next Generation Sequencing", "status": "UNKNOWN", "last_update": "2022-12-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04833205", "title": "Clinical Efficacy and Safety of EGFR-TKI Combined With Nimotuzumab in the Treatment of Leptomeningeal Metastases From Lung Cancer", "status": "UNKNOWN", "last_update": "2021-04-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06022276", "title": "Nimotuzumab for EGFR-amplified Advanced Pan Solid Tumors", "status": "UNKNOWN", "last_update": "2023-09-01", "phase": "NA", "study_type": "INTERVENTIONAL" } ] }, "NINGETINIB": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT03758287", "title": "Ningetinib (CT053PTSA) Plus Gefitinib in Stage IIIB or IV NSCLC Patients With EGFR Mutation and T790M Negative", "status": "COMPLETED", "last_update": "2026-05-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03838848", "title": "KN046 in Patients With Advanced Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2023-03-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "OLMUTINIB": { "n": 5, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01588145", "title": "Phase I/II Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of HM61713 in NSCLC Patients", "status": "COMPLETED", "last_update": "2018-04-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02444819", "title": "Phase II Trial to Evaluate the Efficacy and Safety of HM61713 as the 1st-line NSCLC Anticancer Therapy", "status": "COMPLETED", "last_update": "2018-04-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02485652", "title": "Phase II Trial of HM61713 for the Treatment of \u22652nd Line T790M Mutation Positive Adenocarcinoma of the Lung", "status": "TERMINATED", "last_update": "2021-01-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03228277", "title": "Olmutinib Trial in T790M (+) NSCLC Patients Detected by Liquid Biopsy Using BALF Extracellular Vesicular DNA", "status": "COMPLETED", "last_update": "2019-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04510415", "title": "Olmutinib 600 mg QD in Patients With T790M-positive NSCLC After Treatment With an EGFR-TKI", "status": "TERMINATED", "last_update": "2020-08-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "ONARTUZUMAB": { "n": 7, "n_observational": 0, "n_active": 0, "n_withdrawn": 1, "trials": [ { "nct": "NCT00854308", "title": "A Study of MetMAb Administered to Patients With Advanced Non-Small Cell Lung Cancer, in Combination With Tarceva (Erlotinib)", "status": "COMPLETED", "last_update": "2017-03-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01456325", "title": "A Study of Onartuzumab (MetMAb) in Combination With Tarceva (Erlotinib) in Participants With Met Diagnostic-Positive Non-Small Cell Lung Cancer Who Have Received Chemotherapy For Advanced or Metastatic Disease (MetLung)", "status": "COMPLETED", "last_update": "2016-11-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01496742", "title": "A Study of Onartuzumab (MetMAb) in Combination With Bevacizumab (Avastin) Plus Platinum And Paclitaxel or With Pemetrexed Plus Platinum in Patients With Non-Squamous Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2016-09-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01519804", "title": "A Study of Onartuzumab (MetMAb) Versus Placebo in Combination With Paclitaxel Plus Platinum in Patients With Squamous Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2016-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01887886", "title": "A Study of Onartuzumab in Combination With Erlotinib in Patients With MET-Positive Stage IIIB or IV Non-Small Cell Lung Cancer Carrying an Activating Epidermal Growth Factor Receptor (EGFR) Mutation", "status": "COMPLETED", "last_update": "2016-11-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02031744", "title": "A Study of the Efficacy and Safety of MetMAb Combined With Tarceva in Patients With Met-Positive Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2017-03-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02044601", "title": "Biomarker-Integrated Approach of Targeted Therapy for Lung Cancer Elimination Plus External Beam Radiation Therapy (BATTLE-XRT)", "status": "WITHDRAWN", "last_update": "2014-04-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "OSIMERTINIB": { "n": 167, "n_observational": 33, "n_active": 94, "n_withdrawn": 1, "trials": [ { "nct": "NCT03191149", "title": "Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change", "status": "RECRUITING", "last_update": "2026-08-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04322890", "title": "Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation", "status": "RECRUITING", "last_update": "2024-10-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04486833", "title": "Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib", "status": "RECRUITING", "last_update": "2026-01-21", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04762199", "title": "MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-03-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05142189", "title": "Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-07-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05281406", "title": "Additional Chemotherapy for EGFRm Patients with the Continued Presence of Plasma CtDNA EGFRm At Week 3 After Start of Osimertinib 1st-line Treatment (PACE-LUNG)", "status": "RECRUITING", "last_update": "2025-02-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05382728", "title": "Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)", "status": "RECRUITING", "last_update": "2024-01-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05498428", "title": "A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05528458", "title": "Osimertinib to Suppress the Progression of Remaining GGN for EGFR Mutation-positive Stage IB-IIIA Lung Adenocarcinoma", "status": "RECRUITING", "last_update": "2026-04-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05536505", "title": "Adjuvant Treatment Based on MRD for EGFR Mutant NSCLC", "status": "RECRUITING", "last_update": "2022-09-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05624996", "title": "Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05642572", "title": "Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)", "status": "RECRUITING", "last_update": "2026-06-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05805631", "title": "Intrathecal Pemetrexed for Leptomeningeal Metastasis in EGFR-Mutant NSCLC", "status": "RECRUITING", "last_update": "2026-03-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06109558", "title": "The Efficacy and Safety of LMV-12 Combined With Osimertinib in NSCLC", "status": "RECRUITING", "last_update": "2024-05-30", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06304441", "title": "Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer", "status": "RECRUITING", "last_update": "2025-09-29", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06350097", "title": "Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06363734", "title": "Osimertinib Plus Dalpiciclib in Patients With EGFR-mutant, CDK4/6 Pathway Aberrant, Advanced Non-small Cell Lung Cancer Following Acquired Resistance to Third-generation EGFR TKI: a Phase II Trial", "status": "RECRUITING", "last_update": "2024-04-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06394674", "title": "High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With Osimertinib", "status": "RECRUITING", "last_update": "2024-07-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06498986", "title": "A Study of BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2025-05-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06618287", "title": "A Study to Evaluate the Safety, Tolerability, Drug Levels, and Preliminary Efficacy of BMS-986507 Combinations in Adult Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06735391", "title": "A Clinical Study of JMT101 in Combination With Osimertinib Versus Osimertinib Alone as First-Line Treatment for Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Harboring Epidermal Growth Factor Receptor (EGFR) Sensitive Mutations", "status": "RECRUITING", "last_update": "2024-12-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06741085", "title": "A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brain", "status": "RECRUITING", "last_update": "2026-06-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06838273", "title": "A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04)", "status": "RECRUITING", "last_update": "2026-04-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06868485", "title": "A Study to Assess the Efficacy of WSD0922-FU in Patients With C797S+ Advanced Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2025-09-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07100080", "title": "Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)", "status": "RECRUITING", "last_update": "2026-08-25", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07185997", "title": "Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations", "status": "RECRUITING", "last_update": "2026-09-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07229729", "title": "A Study of SHR-A2102 in Combination With Other Anti-tumor Therapies for Resectable Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2025-12-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07315113", "title": "Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-07-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07322783", "title": "Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification", "status": "RECRUITING", "last_update": "2026-01-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07323641", "title": "Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-04-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07329322", "title": "Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-08-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07379476", "title": "Local Ablative Therapy to Oligoresidual Metastasis in EGFR Mutated Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-02-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07398599", "title": "Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II Study", "status": "RECRUITING", "last_update": "2026-04-23", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07505173", "title": "Hippocampus-Protective Radiotherapy Combined With Osimertinib for Symptomatic Brain Metastases in EGFR-Mutated Lung Cancer", "status": "RECRUITING", "last_update": "2026-04-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07637448", "title": "EGFR-TKIs Plus PD-1 in EGFR-Mutant Advanced NSCLC", "status": "RECRUITING", "last_update": "2026-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07640789", "title": "A Study Comparing BL-B01D1 in Combination With Osimertinib Versus Osimertinib Alone in Patients With Locally Advanced, Unresectable EGFR-mutated Non-small Cell Lung Cancer(Stage III) Whose Disease Has Not Progressed Following Definitive Platinum-based Chemoradiation Therapy(PANKU-Lung08)", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07642024", "title": "A Study of BL-B01D1 in Combination With Osimertinib as Perioperative Therapy in Patients With EGFR-mutated Resectable Non-small Cell Lung Cancer(PANKU-Lung09)", "status": "RECRUITING", "last_update": "2026-08-03", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07738172", "title": "Osimertinib With or Without Primary Lung Tumor Resection for EGFR-Mutant Oligometastatic Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01802632", "title": "AZD9291 First Time In Patients Ascending Dose Study", "status": "COMPLETED", "last_update": "2026-04-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02151981", "title": "AZD9291 (Osimertinib) Versus Platinum-Based Doublet-Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2025-01-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02157883", "title": "Study to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI Medicine (Such as Iressa or Tarceva)", "status": "COMPLETED", "last_update": "2025-11-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02163733", "title": "Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2024-01-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02197234", "title": "Study to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLC", "status": "COMPLETED", "last_update": "2025-11-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02197247", "title": "Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLC", "status": "COMPLETED", "last_update": "2021-07-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02224053", "title": "Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy Volunteers", "status": "COMPLETED", "last_update": "2016-06-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02228369", "title": "Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2021-01-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02296125", "title": "AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-04-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02317016", "title": "Study to Assess the Effect of AZD9291 on the Blood Levels of Rosuvastatin, in Patients With EGFRm+ Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2018-07-31", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02411448", "title": "A Study of Ramucirumab (LY3009806) in Combination With Erlotinib in Previously Untreated Participants With EGFR Mutation-Positive Metastatic NSCLC (RELAY)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-16", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02454933", "title": "Study of AZD9291 Plus MEDI4736 Versus AZD9291 Monotherapy in NSCLC After Previous EGFR TKI Therapy in T790M Mutation Positive Tumours", "status": "COMPLETED", "last_update": "2024-09-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02503722", "title": "Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02504346", "title": "AZD9291, an Irreversible EGFR-TKI, in Relapsed EGFR-mutated Non-small Cell Lung Cancer Patients Previously Treated With an EGFR-TKI, Coupled to Extensive Translational Studies", "status": "UNKNOWN", "last_update": "2023-03-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02511106", "title": "AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02520778", "title": "Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2024-08-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02529995", "title": "Phase I, Study in Chinese NSCLC Patients", "status": "COMPLETED", "last_update": "2020-02-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02664935", "title": "National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-04-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02736513", "title": "Intracranial Activity of AZD9291 (TAGRISSO) in Advanced EGFRm NSCLC Patients With Asymptomatic Brain Metastases", "status": "UNKNOWN", "last_update": "2021-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02759835", "title": "Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib", "status": "COMPLETED", "last_update": "2024-06-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02769286", "title": "Osimertinib in First and Second Line Treatment of NSCLC Harboring EGFR Mutations From Circulating Tumor DNA", "status": "COMPLETED", "last_update": "2021-08-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02803203", "title": "Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers", "status": "COMPLETED", "last_update": "2023-09-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02824952", "title": "Neo-adjuvant Trial With AZD9291 in EGFRm+ Stage IIIA/B NSCLC", "status": "UNKNOWN", "last_update": "2021-11-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02841579", "title": "Osimertinib (AZD9291) in First-line Locally Advanced or Metastatic NSCLC Patients With EGFR and EGFR T790M", "status": "COMPLETED", "last_update": "2025-01-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02908750", "title": "Study to Assess the Effect of Osimertinib (TAGRISSO\u2122 ) on Blood Levels of Fexofenadine in Patients With EGFRm+ NSCLC", "status": "COMPLETED", "last_update": "2022-11-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02954523", "title": "Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations", "status": "TERMINATED", "last_update": "2024-07-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02959749", "title": "Osimertinib or Docetaxel-bevacizumab as Third-line Treatment in EGFR T790M Mutated Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2018-02-14", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02997501", "title": "T790M Plasma Testing Methodology Comparison and Clinical Validation", "status": "COMPLETED", "last_update": "2024-03-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03040973", "title": "Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03050411", "title": "Apatinib Combine With EGFR-TKI for Advanced EGFR-TKI-resistant Non-Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2017-02-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03133546", "title": "Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M", "status": "COMPLETED", "last_update": "2026-08-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03239340", "title": "A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib", "status": "COMPLETED", "last_update": "2024-10-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03318939", "title": "Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation", "status": "TERMINATED", "last_update": "2026-06-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03381274", "title": "Oleclumab (MEDI9447) Epidermal Growth Factor Receptor Mutant (EGFRm) Non-small Cell Lung Cancer (NSCLC) Novel Combination Study", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-13", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03392246", "title": "A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor na\u00efve Advanced EGFR Mutant Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03460275", "title": "Osimertinib as First-line Therapy for Patients With Late-stage Lung Cancer", "status": "UNKNOWN", "last_update": "2018-03-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03463525", "title": "Open-label PET Study With [11C]Osimertinib in Patients With EGFRm NSCLC and Brain Metastases", "status": "COMPLETED", "last_update": "2023-01-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03497767", "title": "A Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain Metastases", "status": "COMPLETED", "last_update": "2024-05-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03567642", "title": "A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung Cancers", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03586453", "title": "Osimertinib In EGFR Mutant Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03778229", "title": "Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03784599", "title": "T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLC", "status": "TERMINATED", "last_update": "2022-11-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03810066", "title": "Exploring the Theragnostic Value of Osimertinib in EGFR-mutated Lung Cancer (THEROS)", "status": "COMPLETED", "last_update": "2024-05-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03831932", "title": "Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-31", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03833154", "title": "Durvalumab With Stereotactic Body Radiation Therapy (SBRT) vs Placebo With SBRT in Early Stage Unresected Non-small Cell Lung Cancer (NSCLC) Patients/ Osimertinib Following SBRT in Patients With Early Stage Unresected NSCLC Harboring an EGFR Mutation", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-20", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03858491", "title": "Pharmacokinetic Boosting of Osimertinib", "status": "COMPLETED", "last_update": "2022-09-26", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03891615", "title": "Niraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung Cancer", "status": "UNKNOWN", "last_update": "2020-12-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03940703", "title": "A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)", "status": "COMPLETED", "last_update": "2026-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03944772", "title": "Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-01-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04148066", "title": "ctDNA Guided Treatment of Early Resistance to Targeted Treatment", "status": "COMPLETED", "last_update": "2023-10-10", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04148898", "title": "Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal Metastasis", "status": "UNKNOWN", "last_update": "2019-11-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04233021", "title": "Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR Mutation", "status": "COMPLETED", "last_update": "2025-02-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04316351", "title": "Efficacy and Safety of Toripalimab (JS001) Combined With Pemetrexed and Anlotinib for Patients With T790M Positive Non-Small Cell Lung Cancer After Osimertinib Resistance", "status": "UNKNOWN", "last_update": "2020-07-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04338243", "title": "Glumetinib Combined With Osimertinib in the Treatment of Relapsed and Metastatic Non-small Cell Lung Cancer Patients Who Failed to Receive EGFR Inhibitors", "status": "UNKNOWN", "last_update": "2020-04-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04356118", "title": "Efficacy and Safety of Recombinant Human Endostatin in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis", "status": "UNKNOWN", "last_update": "2020-05-27", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04425681", "title": "Osimertinib With Bevacizumab for Leptomeningeal Metastasis From EGFR-mutation Non-Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2020-06-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04448379", "title": "Efficacy and Safety of JMT101 Combined With Afatinib (or Osimertinib) in Patients With Non-Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2020-12-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04479306", "title": "Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-04-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04487080", "title": "A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04517526", "title": "Efficacy and Safety of Platinum-based Chemotherapy + Bevacizumab + Durvalumab, and Salvage SBRT for IV Non-Small Cell Lung Cancer Patients With EGFR Mutations After Failure of First Line Osimertinib: A Multicenter, Prospective, Phase II Clinical Study", "status": "UNKNOWN", "last_update": "2020-08-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04545710", "title": "Osimertinib and Abemaciclib in EGFR Mutant Non-Small Cell Lung Cancer After Osimertinib Resistance", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-08-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04563871", "title": "Efficacy and Safety of 80mg Osimertinib in Patients With Non-small Cell Lung Cancer(NSCLC)", "status": "COMPLETED", "last_update": "2026-07-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04606771", "title": "A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04695925", "title": "Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 Mutations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-15", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04721015", "title": "Study of Intravenous (IV) ABBV-637 Alone or in Combination With IV Docetaxel/Osimertinib to Assess Adverse Events and Change in Disease Activity in Adult Participants With Relapsed/Refractory (R/R) Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-07-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04743505", "title": "Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04769388", "title": "Osimertinib Plus Chemotherapy vs Osimertinib in EGFRm NSCLC With Persistence Week-3 ctDNA EGFRm After 1L Osimertinib", "status": "COMPLETED", "last_update": "2026-08-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04770688", "title": "Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib", "status": "COMPLETED", "last_update": "2024-08-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04772235", "title": "Phase I Study of Repotrectinib and Osimertinib in NSCLC Patients", "status": "UNKNOWN", "last_update": "2024-04-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04811001", "title": "Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations", "status": "UNKNOWN", "last_update": "2023-02-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04816214", "title": "Study Evaluating Efficacy and Safety of Capmatinib in Combination With Osimertinib in Adult Subjects With Non-small Cell Lung Cancers as Second Line Therapy", "status": "TERMINATED", "last_update": "2024-03-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04862780", "title": "(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC", "status": "TERMINATED", "last_update": "2025-02-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04959981", "title": "A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC", "status": "COMPLETED", "last_update": "2023-07-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04974879", "title": "Osimertinib Combined With Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions Metastatic Non-Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2023-03-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05009836", "title": "Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05015608", "title": "Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification", "status": "COMPLETED", "last_update": "2026-05-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05017025", "title": "Aurora Kinase Inhibitor LY3295668 in Combination With Osimertinib for the Treatment of Advanced or Metastatic EGFR-Mutant Non-squamous Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05020769", "title": "SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer.", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-26", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05085054", "title": "Salvage Surgery Following Downstaging of Advanced Non-small Cell Lung Cancer by Targeted Therapy (SDANT)", "status": "UNKNOWN", "last_update": "2022-05-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05089916", "title": "Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05104281", "title": "Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2023-03-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05120349", "title": "A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05132777", "title": "Efficacy and Safety of JMT101 Combined With Osimertinib in Patients With Non-Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2021-11-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05153408", "title": "(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC", "status": "TERMINATED", "last_update": "2023-06-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05166616", "title": "Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05195619", "title": "Personalized DC Vaccines in Non Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-07-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05215951", "title": "Osimertinib Plus Chemotherapy in Uncommon EGFRm NSCLC", "status": "TERMINATED", "last_update": "2025-10-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05228015", "title": "Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2024-11-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05256290", "title": "Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR Mutations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05261399", "title": "Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05364073", "title": "Study of Furmonertinib in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Activating, Including Uncommon, Epidermal Growth Factor Receptor (EGFR) or Human Epidermal Growth Factor Receptor 2 (HER2) Mutations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05489731", "title": "VIC-1911 Combined With Osimertinib for EGFR -Mutant Non-small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2023-06-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05493501", "title": "Aumolertinib With Chemotherapy or Alone Compared With Osimertinib in Patients With Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2024-05-02", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05498389", "title": "EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer", "status": "UNKNOWN", "last_update": "2023-06-01", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05507606", "title": "Study of Osimertinib+Bevacizumab+Chemotherapy for EGFR+ Advanced Non-Small Cell Lung Cancer With Concurrent Mutations", "status": "UNKNOWN", "last_update": "2022-08-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05526755", "title": "A Study of 5 Years of Adjuvant Osimertinib in Completely Resected Epidermal Growth Factor Receptor Mutation (EGFRm) Non-small Cell Lung Carcinoma (NSCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05546866", "title": "Study to Assess the Efficacy and Safety of Adjuvant Osimertinib in NSCLC With Uncommon EGFRm", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05583409", "title": "SBRT Combined With Osimertinib Compared With Osimertinib for Stage IV NSCLC", "status": "UNKNOWN", "last_update": "2022-10-17", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05693090", "title": "Tipifarnib and Osimertinib in EGFR-mutated Non-Small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2023-03-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05801029", "title": "A Study to Investigate Safety and Efficacy of Osimertinib and Amivantamab in Participants With Non-small Cell Lung Cancer With Common Epidermal Growth Factor Receptor Mutations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05816252", "title": "A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05880706", "title": "A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05954871", "title": "Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer", "status": "COMPLETED", "last_update": "2025-11-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05998993", "title": "Study to Evaluate SBRT for EGFR Mutant NSCLC Patients Receiving Osimertinib (CULTRO)", "status": "NOT_YET_RECRUITING", "last_update": "2023-08-21", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06014827", "title": "Biologically Guided Radiation Therapy (BgRT) and Stereotactic Body Radiation Therapy (SBRT) to Tyrosine Kinase Inhibitor in Oligoprogressive Oncogenic Positive Non-Small Cell Lung Carcinoma", "status": "SUSPENDED", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06018688", "title": "Osimertinib Combined With Aspirin Neoadjuvant Therapy for Resectable EGFR Mutated NSCLC Patients.", "status": "UNKNOWN", "last_update": "2023-09-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06067776", "title": "Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2023-10-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06142617", "title": "A Prospective Study of Pembrolizumab Combining Chemotherapy in Advanced NSCLC Patients With EGFR Exon 21 Point Mutation.", "status": "NOT_YET_RECRUITING", "last_update": "2023-11-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06185400", "title": "RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations", "status": "NOT_YET_RECRUITING", "last_update": "2023-12-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06323148", "title": "Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)", "status": "NOT_YET_RECRUITING", "last_update": "2024-03-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06391944", "title": "JMT101 Combined With Osimertinib in Patients With Stage \u2162b-\u2163 Non-small Cell Lung Cancer (NSCLC) Characterized by Epithermal Growth Factor Receptor (EGFR) Common Mutations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2024-04-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06436144", "title": "Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2024-05-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06452433", "title": "Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.", "status": "NOT_YET_RECRUITING", "last_update": "2024-06-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06530719", "title": "A Study to Evaluate the Efficacy of Osimertinib in Patients With EGFR-sensitive Mutated Non-small Cell Lung Cancer Progression After Receiving Adjuvant Targeted Therapy Following Radical Surgery", "status": "NOT_YET_RECRUITING", "last_update": "2024-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06709274", "title": "Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2024-11-29", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06752408", "title": "Aumolertinib Versus Osimertinib As First-line Therapy for Patients with EGFR Mutated Locally Advanced or Metastatic Non-small-cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2024-12-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06908772", "title": "Glumetinib Combined With Osimertinib Treatment for Non-Small Cell Lung Cancer Patients", "status": "NOT_YET_RECRUITING", "last_update": "2025-04-03", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06918782", "title": "Real-world Experience With Combination Chemotherapy and Osimertinib in Poor Prognostic Group of Metastatic EGFR-mutated Lung Adenocarcinoma", "status": "NOT_YET_RECRUITING", "last_update": "2025-04-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07038460", "title": "A Multicenter Phase II Randomized Trial of Limertinib Followed by Sintilimab and Chemotherapy vs. Limertinib Followed by Limertinib and Chemotherapy as Neoadjuvant Therapy in Resectable Stage II-IIIB EGFR-Mutant NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2025-06-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07177092", "title": "Primary Tumor Resection Plus Osimertinib in Advanced EGFR-mutant Non-small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07271446", "title": "An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer", "status": "COMPLETED", "last_update": "2025-12-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07285148", "title": "A Study to Evaluate ANS014004 in Combination With EGFR-TKI in Non-Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2025-12-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07376382", "title": "A Phase \u2162 Clinical Study of SYS6010 in Combination With Osimertinib in Patients With Locally Advanced or Metastatic NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07458919", "title": "Therapy for Advanced NSCLC With EGFR 19delins Mutation", "status": "NOT_YET_RECRUITING", "last_update": "2026-03-09", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07486648", "title": "Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L Osimertinib", "status": "NOT_YET_RECRUITING", "last_update": "2026-03-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07507188", "title": "Collaborative Clinical-translational Cohort of Amivantamab Plus Lazertinib and Amivantamab Plus Chemotherapy in Patients With EGFR-mutant, Locally Advanced or Metastatic/Recurrent Non-Small Cell Lung Cancer (INSTAR Study)", "status": "NOT_YET_RECRUITING", "last_update": "2026-04-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07603791", "title": "Phase II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of ALK202 for Injection in Combination With Drugs in NSCLC Participants.", "status": "NOT_YET_RECRUITING", "last_update": "2026-05-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07680790", "title": "Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-24", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "PANITUMUMAB": { "n": 18, "n_observational": 1, "n_active": 5, "n_withdrawn": 1, "trials": [ { "nct": "NCT03582124", "title": "Panitumumab-IRDye800 in Detecting Cancer in Participants With Lung Cancer During Surgery", "status": "RECRUITING", "last_update": "2026-02-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05786924", "title": "Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies", "status": "RECRUITING", "last_update": "2026-06-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06983743", "title": "A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07094113", "title": "AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-07-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07094204", "title": "A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors", "status": "RECRUITING", "last_update": "2026-05-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00004879", "title": "Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer", "status": "COMPLETED", "last_update": "2013-01-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00034346", "title": "ABX-EGF in Combination With Paclitaxel and Carboplatin for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2007-12-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00094835", "title": "Study to Evaluate Motesanib With or Without Carboplatin/Paclitaxel or Panitumumab in the Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2016-03-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00101907", "title": "Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of Patients With Advanced Cancer", "status": "TERMINATED", "last_update": "2014-03-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00101920", "title": "ABX-EGF as Second Line Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2010-10-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00352950", "title": "Safety Evaluation of Panitumumab and Sirolimus in Advanced Non-Small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2018-09-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00425204", "title": "Study for Patients Who Have Benefited and Tolerated Prior Panitumumab Treatment", "status": "COMPLETED", "last_update": "2008-09-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00979212", "title": "Chemotherapy and Radiation Therapy With or Without Panitumumab in Treating Patients With Stage IIIA Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2022-06-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01038037", "title": "First-Line Chemotherapy and Panitumumab in Advanced Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2014-12-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01042288", "title": "Carboplatin, Pemetrexed, and Panitumumab in Patients With Advanced Non-Squamous K-ras Wild Type NSCLC", "status": "COMPLETED", "last_update": "2016-05-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01061788", "title": "A Trial of AMG 479, Everolimus (RAD001) and Panitumumab in Patients With Advanced Cancer - QUILT-3.007", "status": "COMPLETED", "last_update": "2019-08-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01088620", "title": "Panitumumab Plus Pemetrexed and Cisplatin (PemCisP) Versus PemCis in the First-line Treatment of Patients With Non-small Cell Lung Cancer", "status": "SUSPENDED", "last_update": "2013-03-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05084859", "title": "A Study Evaluating the Safety, Pharmacokinetics, and Preliminary Efficacy of Orally Administered SM08502 Combined With Hormonal Therapy or Chemotherapy in Subjects With Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2024-08-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "PELITINIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00067548", "title": "Study Evaluating EKB-569 in Advanced Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2009-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "PERTUZUMAB": { "n": 9, "n_observational": 0, "n_active": 4, "n_withdrawn": 0, "trials": [ { "nct": "NCT05150691", "title": "A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05786716", "title": "DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations", "status": "RECRUITING", "last_update": "2025-12-02", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00063154", "title": "Safety and Effect of Pertuzumab in Patients With Advanced Non-Small Cell Lung Cancer, Which Has Progressed After Prior Chemotherapy", "status": "COMPLETED", "last_update": "2015-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00855894", "title": "A Study of the Combination of Erlotinib and Pertuzumab in Patients With Relapsed Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2013-05-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02507375", "title": "A Study of Pertuzumab With Erlotinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2015-10-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03845270", "title": "Her2-positive Lung Cancer Treated With Dedicated Drug", "status": "COMPLETED", "last_update": "2023-12-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04591431", "title": "The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy", "status": "UNKNOWN", "last_update": "2023-10-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07377916", "title": "Clinical Study of SHR-A1811 Combined With Pertuzumab as Second-Line Therapy in Patients With HER2-Altered Advanced NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2026-01-30", "phase": "NA", "study_type": "INTERVENTIONAL" } ] }, "PF-06459988": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 1, "trials": [ { "nct": "NCT02297425", "title": "A Study For Patients With EGFRm (Epidermal Growth Factor Receptor Mutant) Lung Cancer", "status": "WITHDRAWN", "last_update": "2015-01-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "PLB1003": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT03130881", "title": "Phase I Study of a Selective ALK Inhibitor PLB1003 in Patients With ALK+ NSCLC.", "status": "UNKNOWN", "last_update": "2020-03-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "POZIOTINIB": { "n": 8, "n_observational": 0, "n_active": 0, "n_withdrawn": 1, "trials": [ { "nct": "NCT01819428", "title": "NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung Adenocarcinoma", "status": "TERMINATED", "last_update": "2016-03-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02979821", "title": "Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001)", "status": "COMPLETED", "last_update": "2018-05-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03066206", "title": "Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC", "status": "TERMINATED", "last_update": "2026-02-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03318939", "title": "Phase 2 Study of Poziotinib in Participants With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation", "status": "TERMINATED", "last_update": "2026-06-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04044170", "title": "Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation", "status": "TERMINATED", "last_update": "2020-11-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04402008", "title": "Study of Poziotinib in Japanese Patients With NSCLC", "status": "TERMINATED", "last_update": "2024-06-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05045404", "title": "Poziotinib and Ramucirumab for the Treatment of EGFR Exon 20 Mutant Stage IV Non-small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2023-09-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05378763", "title": "A Study of Poziotinib in Previously Treated Participants With Locally Advanced or Metastatic NSCLC Harboring HER2 Exon 20 Mutations", "status": "SUSPENDED", "last_update": "2026-09-01", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "PRALSETINIB": { "n": 8, "n_observational": 2, "n_active": 5, "n_withdrawn": 0, "trials": [ { "nct": "NCT04302025", "title": "A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04322890", "title": "Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation", "status": "RECRUITING", "last_update": "2024-10-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06563999", "title": "Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.", "status": "RECRUITING", "last_update": "2026-04-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07704658", "title": "Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-10", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03037385", "title": "Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2025-05-31", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04222972", "title": "A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)", "status": "TERMINATED", "last_update": "2026-03-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04591431", "title": "The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy", "status": "UNKNOWN", "last_update": "2023-10-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07418879", "title": "A Real-world Study of Pralsetinib Combined With Leucogen in the Treatment of RET Fusion-positive NSCLC", "status": "NOT_YET_RECRUITING", "last_update": "2026-02-18", "phase": "NA", "study_type": "INTERVENTIONAL" } ] }, "PYROTINIB": { "n": 14, "n_observational": 1, "n_active": 5, "n_withdrawn": 0, "trials": [ { "nct": "NCT04144569", "title": "PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC", "status": "RECRUITING", "last_update": "2024-09-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05482568", "title": "A Trial of Injectable SHR-A1811 in Combination With Pyrotinib or SHR-1316 in Subjects With Advanced Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-04-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05751018", "title": "Phase II Clinical Study of Pyrotinib in First-line Treatment of Primary HER2-amplified/Mutated Advanced Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2025-12-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06563999", "title": "Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.", "status": "RECRUITING", "last_update": "2026-04-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02535507", "title": "Efficacy and Safety of Pyrotinib in Patients With HER2 Mutation Advanced Non-Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2015-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02834936", "title": "A Clinica Study of Pyrotinib in Patients of Advanced Non-Small Cell Lung Cancer With HER2 Mutation", "status": "COMPLETED", "last_update": "2025-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03574402", "title": "Phase II Umbrella Study Directed by Next Generation Sequencing", "status": "UNKNOWN", "last_update": "2022-12-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04063462", "title": "Phase 2 Study of Pyrotinib in Previously Treated Patients With NSCLC Having EGFR or ERBB2 Exon 20 Insertion Mutation", "status": "UNKNOWN", "last_update": "2019-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04382300", "title": "Pyrotinib Plus Thalidomide in Advanced NSCLC Patients Harboring HER2 Exon 20 Insertions", "status": "UNKNOWN", "last_update": "2021-01-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04447118", "title": "Phase 3 Study of Pyrotinib Versus Docetaxel in Patients With Advanced Non-squamous NSCLC Harboring a HER2 Exon 20 Mutation Who Failed Platinum Based Chemotherapy", "status": "COMPLETED", "last_update": "2025-12-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04706949", "title": "Pyrotinib Combined With Pemetrexed Plus Carboplatin in the First-line Treatment", "status": "UNKNOWN", "last_update": "2021-01-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05016544", "title": "Inetetamab in Combination With Pyrotinib in HER2 Mutant or Amplified Advanced Non-small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2021-08-23", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05745740", "title": "A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation", "status": "UNKNOWN", "last_update": "2023-11-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06185400", "title": "RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations", "status": "NOT_YET_RECRUITING", "last_update": "2023-12-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "REGORAFENIB": { "n": 11, "n_observational": 1, "n_active": 4, "n_withdrawn": 2, "trials": [ { "nct": "NCT04701476", "title": "TATE and Pembrolizumab (MK3475) in mCRC and NSCLC", "status": "RECRUITING", "last_update": "2026-04-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06047379", "title": "Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis", "status": "RECRUITING", "last_update": "2026-07-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01187615", "title": "Determination of Safety, Efficacy, and Pharmacokinetics of \"Regorafenib\" Combined With Pemetrexed and Cisplatin in Patients With Nonsquamous Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2014-07-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02259725", "title": "Regorafenib in Treating Patients With Advanced or Metastatic Neuroendocrine Tumors", "status": "COMPLETED", "last_update": "2021-12-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02795156", "title": "Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic Alterations", "status": "COMPLETED", "last_update": "2023-12-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02955940", "title": "An Open-Label Study to Enable Continued Treatment Access for Subjects Previously Enrolled in Studies of Ruxolitinib", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03475953", "title": "A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors", "status": "UNKNOWN", "last_update": "2023-03-03", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03520842", "title": "Regorafenib and Methotrexate in Treating Participants With Recurrent or Metastatic KRAS Mutated Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2023-08-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05582031", "title": "Regorafenib With Tislelizumab in Patients With Selected Mismatch Repair-Proficient/Microsatellite Stable Cancers", "status": "WITHDRAWN", "last_update": "2023-06-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06946849", "title": "Second-line Regimen Combined With Radiotherapy Versus Without Radiotherapy in Patients With Locally Advanced/Oligometastatic ICC After Failure of First-line Treatment\uff1aan Open-label, Randomized, Controlled Phase II Clinical Study", "status": "NOT_YET_RECRUITING", "last_update": "2025-04-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07137390", "title": "A Trial of Regorafenib Plus Lorigerlimab as Neoadjuvant Therapy for Patients With pMMR/MSS, Resectable, Lung-limited Metastatic Colorectal Cancer", "status": "WITHDRAWN", "last_update": "2026-03-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "REPOTRECTINIB": { "n": 5, "n_observational": 1, "n_active": 4, "n_withdrawn": 0, "trials": [ { "nct": "NCT03093116", "title": "A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements", "status": "RECRUITING", "last_update": "2026-05-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06315010", "title": "Repotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain Metastasis", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06552234", "title": "Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC", "status": "RECRUITING", "last_update": "2026-07-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04772235", "title": "Phase I Study of Repotrectinib and Osimertinib in NSCLC Patients", "status": "UNKNOWN", "last_update": "2024-04-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06140836", "title": "A Study of Repotrectinib Versus Crizotinib in Participants With Locally Advanced or Metastatic Tyrosine Kinase Inhibitor (TKI)-na\u00efve ROS1-positive Non-Small Cell Lung Cancer (NSCLC) (TRIDENT-3)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "ROCILETINIB": { "n": 7, "n_observational": 1, "n_active": 0, "n_withdrawn": 1, "trials": [ { "nct": "NCT01526928", "title": "Study to Evaluate Safety, Pharmacokinetics, and Efficacy of Rociletinib (CO-1686) in Previously Treated Mutant Epidermal Growth Factor Receptor (EGFR) in Non-Small Cell Lung Cancer (NSCLC) Patients", "status": "TERMINATED", "last_update": "2020-08-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02147990", "title": "Multicenter Study of Rociletinib Administered to Patients With Previously Treated Mutant EGFR Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2020-08-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02186301", "title": "TIGER-1: Safety and Efficacy Study of Rociletinib (CO-1686) or Erlotinib in Patients With EGFR-mutant/Metastatic NSCLC Who Have Not Had Any Previous EGFR Directed Therapy", "status": "TERMINATED", "last_update": "2019-05-07", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02322281", "title": "TIGER-3: Open Label, Multicenter Study of Rociletinib (CO-1686) Mono Therapy Versus Single-agent Cytotoxic Chemotherapy in Patients With Mutant EGFR NSCLC Who Have Failed at Least One Previous EGFR-Directed TKI and Platinum-doublet Chemotherapy", "status": "TERMINATED", "last_update": "2019-08-14", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02580708", "title": "Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2018-10-02", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02630186", "title": "A Phase 1b/2 Study of Safety and Efficacy of Rociletinib in Combination With MPDL3280A in Patients With Advanced or Metastatic EGFR-mutant NSCLC", "status": "TERMINATED", "last_update": "2019-07-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02705339", "title": "Rociletinib Genomic Landscape in Non-small Cell Lung Cancer (NSCLC)", "status": "WITHDRAWN", "last_update": "2016-05-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ROVALPITUZUMAB TESIRINE": { "n": 10, "n_observational": 1, "n_active": 0, "n_withdrawn": 1, "trials": [ { "nct": "NCT01901653", "title": "Rovalpituzumab Tesirine (SC16LD6.5) in Recurrent Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2018-08-09", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02674568", "title": "Study of Rovalpituzumab Tesirine (SC16LD6.5) for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2021-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02819999", "title": "A Study of Rovalpituzumab Tesirine (SC16LD6.5) in the Frontline Treatment of Patients With Extensive Stage Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2020-03-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02874664", "title": "A Study of Rovalpituzumab Tesirine to Study Cardiac Ventricular Repolarization in Subjects With Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2018-09-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03000257", "title": "A Study of Budigalimab (ABBV-181) in Participants With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2022-04-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03026166", "title": "A Study of Rovalpituzumab Tesirine Administered in Combination With Nivolumab and With or Without Ipilimumab for Adults With Extensive-Stage Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2020-07-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03033511", "title": "A Study of Rovalpituzumab Tesirine as Maintenance Therapy Following First- Line Platinum-Based Chemotherapy in Participants With Extensive Stage Small Cell Lung Cancer (MERU)", "status": "TERMINATED", "last_update": "2021-07-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03061812", "title": "Study Comparing Rovalpituzumab Tesirine Versus Topotecan in Subjects With Advanced or Metastatic Small Cell Lung Cancer With High Levels of Delta-like Protein 3 (DLL3) and Who Have First Disease Progression During or Following Front-line Platinum-based Chemotherapy (TAHOE)", "status": "COMPLETED", "last_update": "2021-02-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03086239", "title": "A Study on the Safety and Tolerability of Rovalpituzumab Tesirine in Japanese Patients With Advanced, Recurrent Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2021-08-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03334487", "title": "Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2018-12-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "SALIRASIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00531401", "title": "Study of Salirasib to Treat Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2011-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "SAPITINIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02117167", "title": "SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients", "status": "COMPLETED", "last_update": "2024-01-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "SAR-125844": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02435121", "title": "A Study Assessing Efficacy and Safety of SAR125844 in NSCLC Patients With MET Amplification", "status": "COMPLETED", "last_update": "2016-03-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "SAVOLITINIB": { "n": 19, "n_observational": 1, "n_active": 11, "n_withdrawn": 0, "trials": [ { "nct": "NCT04322890", "title": "Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation", "status": "RECRUITING", "last_update": "2024-10-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05777278", "title": "Savolitinib Plus Docetaxel as 2L in EGFR/ALK/ROS1/MET ex14m-wildtype NSCLC With MET Overexpression", "status": "RECRUITING", "last_update": "2023-10-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06563999", "title": "Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.", "status": "RECRUITING", "last_update": "2026-04-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07322783", "title": "Osimertinib Combined With Savolitinib in the Treatment of NSCLC With Low Copy Number MET Amplification", "status": "RECRUITING", "last_update": "2026-01-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02117167", "title": "SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients", "status": "COMPLETED", "last_update": "2024-01-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02143466", "title": "AZD9291 in Combination With Ascending Doses of Novel Therapeutics", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02374645", "title": "A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLC", "status": "COMPLETED", "last_update": "2020-04-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02897479", "title": "A Phase II Study of HMPL-504 in Lung Sarcomatoid Carcinoma and Other Non-small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2021-11-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03778229", "title": "Osimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior Osimertinib", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03833440", "title": "Precision Immuno-Oncology for Advanced Non-small Cell Lung Cancer Patients With PD-1 ICI Resistance", "status": "UNKNOWN", "last_update": "2024-05-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03944772", "title": "Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-01-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04322578", "title": "Crizotinb or Standard Chemotherapy in Met Exon 14 Skipping Advanced NSCLC", "status": "UNKNOWN", "last_update": "2024-06-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04606771", "title": "A Study Comparing Savolitinib Plus Osimertinib vs Savolitinib Plus Placebo in Patients With EGFRm+ and MET Amplified Advanced NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04923945", "title": "Savolitinib for Treating Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Patients", "status": "COMPLETED", "last_update": "2025-03-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05009836", "title": "Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05015608", "title": "Study on Savolitinib Combined With Osimertinib in Treatment of Advanced NSCLC With MET Amplification", "status": "COMPLETED", "last_update": "2026-05-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05163249", "title": "Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLC", "status": "UNKNOWN", "last_update": "2024-02-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05261399", "title": "Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib Treatment", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05374603", "title": "Savolitinib Combine With Durvalumab in EGFR Wild-type Locally Advanced or Metastatic NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "SELPERCATINIB": { "n": 11, "n_observational": 2, "n_active": 9, "n_withdrawn": 1, "trials": [ { "nct": "NCT03155620", "title": "Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03157128", "title": "A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03899792", "title": "A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03944772", "title": "Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-01-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04194944", "title": "A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04268550", "title": "Targeted Treatment for RET Fusion-Positive Advanced Non-Small Cell Lung Cancer (A LUNG-MAP Treatment Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04280081", "title": "A Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer and Other Tumors With RET Activation", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04320888", "title": "Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment Trial", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04591431", "title": "The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy", "status": "UNKNOWN", "last_update": "2023-10-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04819100", "title": "A Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-03-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05364645", "title": "Testing the Use of Targeted Treatment for RET Positive Advanced Non-small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2024-07-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "SIMOTINIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT01772732", "title": "Safety, Tolerability, and Pharmacokinetics of Multiple Ascending Doses of Simotinib Hydrochloride in Patients With Advanced NSCLC", "status": "UNKNOWN", "last_update": "2015-04-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "SIREMADLIN": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02890069", "title": "A Study of PDR001 in Combination With LCL161, Everolimus or Panobinostat", "status": "COMPLETED", "last_update": "2023-01-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "SORAFENIB": { "n": 44, "n_observational": 3, "n_active": 0, "n_withdrawn": 2, "trials": [ { "nct": "NCT00064350", "title": "Sorafenib in Treating Patients With Refractory Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2023-06-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00098254", "title": "BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2012-05-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00098540", "title": "Sorafenib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2016-12-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00101413", "title": "BAY43-9006 - Phase II Study in Non-Small Cell Lung Carcinoma (NSCLC)", "status": "COMPLETED", "last_update": "2013-10-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00107432", "title": "Sorafenib Tosylate in Treating Patients With Malignant Mesothelioma.", "status": "COMPLETED", "last_update": "2013-06-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00182689", "title": "Sorafenib in Treating Patients With Extensive Stage Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2014-05-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00300885", "title": "A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)", "status": "TERMINATED", "last_update": "2014-11-04", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00411671", "title": "BATTLE Program: Sorafenib in Patients With NSCLC", "status": "COMPLETED", "last_update": "2016-02-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00417248", "title": "Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib for Inoperable Stage III Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2016-07-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00449033", "title": "A Phase III Randomized, Double-blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients With Stage IIIb With Effusion and Stage IV Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2015-04-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00454194", "title": "Pemetrexed Disodium With or Without Sorafenib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2017-03-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00456716", "title": "Sorafenib in BAC or Never-Smokers With Lung Adenocarcinoma", "status": "COMPLETED", "last_update": "2010-03-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00466232", "title": "Phase I Study of Weekly Topotecan in Combination With Sorafenib in Treatment of Relapsed Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2015-12-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00473486", "title": "Study in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pemetrexed and Carboplatin Plus or Minus Sorafenib", "status": "TERMINATED", "last_update": "2010-01-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00532025", "title": "Sorafenib in Resected Non-small Cell Lung Carcinoma", "status": "TERMINATED", "last_update": "2009-07-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00533585", "title": "BAY 43-9006 in Previously Untreated Patients With Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2016-02-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00543335", "title": "Sorafenib and Thoracic Radiation for Patients With Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2018-11-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00547443", "title": "Sorafenib and High-Dose Carboplatin, Paclitaxel, and External-Beam Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2019-01-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00558636", "title": "A Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)", "status": "TERMINATED", "last_update": "2013-12-27", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00600015", "title": "Sorafenib/Erlotinib Versus Erlotinib Alone in Previously Treated Advanced Non-Small-Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2022-03-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00609804", "title": "Sorafenib and Erlotinib or Sorafenib Alone in Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib", "status": "COMPLETED", "last_update": "2016-04-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00635791", "title": "Phase I Study of Vorinostat and Sorafenib in Advanced Cancer", "status": "COMPLETED", "last_update": "2013-06-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00647426", "title": "Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC", "status": "COMPLETED", "last_update": "2019-10-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00703638", "title": "Sorafenib, Pemetrexed, and Cisplatin in Treating Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2017-11-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00722969", "title": "Erlotinib and Sorafenib in Chemonaive Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2009-03-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00726986", "title": "Sorafenib, Cisplatin, and Etoposide in Treating Patients With Extensive-Stage Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2014-11-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00754923", "title": "Sorafenib in Treating Non-Smokers or Former Light Smokers With Relapsed or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2019-03-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00801385", "title": "Sorafenib and Erlotinib in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer That Has Not Responded to Chemotherapy", "status": "UNKNOWN", "last_update": "2009-08-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00801801", "title": "Study of Low Dose Chemotherapy Plus Sorafenib as Initial Therapy for Patients With Advanced Non-Squamous Cell NSCLC", "status": "TERMINATED", "last_update": "2017-05-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00827177", "title": "Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2014-01-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00863746", "title": "A 3rd/4th Line Placebo-controlled Trial of Sorafenib in Patients With Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC).", "status": "COMPLETED", "last_update": "2015-01-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00870532", "title": "Study of Combination of Metronomic Oral Vinorelbine and Sorafenib in Patients With Advanced Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2013-11-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00922584", "title": "Sorafenib Treatment in Non-Small Cell Lung Cancer After Failure of Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor", "status": "COMPLETED", "last_update": "2013-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00933777", "title": "SORAVE - Sorafenib and Everolimus in Solid Tumors", "status": "COMPLETED", "last_update": "2016-05-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00954278", "title": "Intra-patient Dose Escalation Study of Sorafenib in Advanced Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2019-11-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01005797", "title": "Study of Panobinostat in Combination With Sorafenib in Kidney, Soft Tissue or Lung Cancers", "status": "COMPLETED", "last_update": "2017-03-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01032850", "title": "Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma", "status": "TERMINATED", "last_update": "2021-06-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01069328", "title": "Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2013-11-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01159327", "title": "Study of Sorafenib Maintenance in Patients With ED-SCLC After Response to Induction Chemotherapy", "status": "TERMINATED", "last_update": "2015-11-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01171482", "title": "Comparison Study of Sorafenib and 5-fluorouracil/Mitomycin for Metastatic Hepatocellular Carcinoma", "status": "TERMINATED", "last_update": "2017-04-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01178411", "title": "An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols", "status": "COMPLETED", "last_update": "2021-03-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01248247", "title": "BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2022-01-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01953406", "title": "The Efficacy of 5-fluorouracil/Mitomycin for the Patients With Pulmonary Metastasis of Hepatocellular Carcinoma", "status": "WITHDRAWN", "last_update": "2016-04-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03468426", "title": "A Study to Test Different Doses of BI 836880 Combined With Ezabenlimab in Patients With Advanced Non-small Cell Lung Cancer Followed by Other Types of Advanced Solid Tumours", "status": "COMPLETED", "last_update": "2025-11-10", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "SOTORASIB": { "n": 32, "n_observational": 4, "n_active": 15, "n_withdrawn": 4, "trials": [ { "nct": "NCT05398094", "title": "Clinical Trial of AMG510 in Stage III Unresectable NSCLC KRAS p.G12C Patients and Ineligible for Chemo-radiotherapy", "status": "RECRUITING", "last_update": "2026-04-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05631249", "title": "Sotorasib in Previously Treated Locally Advanced or Metastatic NSCLC Subjects With Mutated KRAS p.G12C", "status": "RECRUITING", "last_update": "2025-05-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05815173", "title": "Ladarixin With Sotorasib in Advanced NSCLC", "status": "RECRUITING", "last_update": "2025-12-30", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05920356", "title": "A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06249282", "title": "Carfilzomib in Combination With Sotorasib for the Treatment of Patients With KRAS G12C Mutated Advanced or Metastatic Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-04-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06481813", "title": "Prospective, Longitudinal Biocollection in Thoracic Oncology, Including Newly Diagnosed Lung Cancer Patients", "status": "RECRUITING", "last_update": "2026-01-21", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06582771", "title": "A Study of Sotorasib in People With Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07012031", "title": "Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07563738", "title": "A 2-part Phase 1/2 Open-label Trial on ODM-212", "status": "RECRUITING", "last_update": "2026-05-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04303780", "title": "Study to Compare AMG 510 \"Proposed INN Sotorasib\" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).", "status": "COMPLETED", "last_update": "2026-07-22", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04625647", "title": "Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-12-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04892017", "title": "Study of Inlexisertib (DCC-3116) in Participants With RAS/MAPK Pathway Mutant Solid Tumors", "status": "TERMINATED", "last_update": "2026-04-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04933695", "title": "A Study of Sotorasib (AMG 510) in Participants With Stage IV NSCLC Whose Tumors Harbor a KRAS p.G12C Mutation in Need of First-line Treatment", "status": "TERMINATED", "last_update": "2026-07-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04959981", "title": "A Study of Anti-Cancer Therapies Targeting the MAPK Pathway in Patients With Advanced NSCLC", "status": "COMPLETED", "last_update": "2023-07-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05054725", "title": "Combination Study of RMC-4630 and Sotorasib for NSCLC Subjects With KRASG12C Mutation After Failure of Prior Standard Therapies", "status": "COMPLETED", "last_update": "2026-01-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05074810", "title": "Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05118854", "title": "A Phase II Study of Neoadjuvant Sotorasib in Combination With Cisplatin or Carboplatin and Pemetrexed for Surgically Resectable Stage IIA-IIIB Non-Squamous Non-Small Cell Lung Cancer With a KRAS p.G12C Mutation", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05180422", "title": "A Phase I/II Study of AMG 510 in Combination With MVASI in Patients With Advanced, Unresectable or Metastatic KRAS G12C Mutant NSCLC With Asymptomatic Brain Metastasis", "status": "WITHDRAWN", "last_update": "2023-10-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05311709", "title": "Sotorasib in Advanced KRASG12C-mutated Non-small Cell Lung Cancer Patients With Comorbidities", "status": "UNKNOWN", "last_update": "2023-11-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05313009", "title": "Tarlox and Sotorasib in Patients With KRAS G12C Mutations", "status": "TERMINATED", "last_update": "2025-12-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05374538", "title": "VIC-1911 Monotherapy in Combination With Sotorasib for the Treatment of KRAS G12C-Mutant Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2025-05-01", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05400577", "title": "Sotorasib in KRAS G12C Mutated, Resectable, Stage Ib-IIIA NSCLC", "status": "WITHDRAWN", "last_update": "2023-07-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05451056", "title": "An Open-label, Phase 2trial of Sotorasib in KRAS G12C-mutant Non-small-cell Lung Cancer(NSCLC) Patients and a Translational Study to Find Acquired Resistance Mechanism to Sotorasib", "status": "UNKNOWN", "last_update": "2022-07-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05480865", "title": "SHP2 Inhibitor BBP-398 in Combination With Sotorasib in Patients With Advanced Solid Tumors and a KRAS-G12C Mutation", "status": "TERMINATED", "last_update": "2024-12-12", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05815186", "title": "Ladarixin With Sotorasib in Advanced NSCLC - Phase II", "status": "WITHDRAWN", "last_update": "2024-03-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06068153", "title": "AMG510 (sotorasib) Plus Lenvatinib As Second-line Treatment in Patients with KRASG12C Mutant, Metastatic NSCLC", "status": "WITHDRAWN", "last_update": "2024-11-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06127940", "title": "K-SAB Trial - Sotorasib Followed by SBRT to 1-3 Lesions in Advanced NSCLC With KRASG12C Mutation", "status": "UNKNOWN", "last_update": "2023-11-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06314763", "title": "Rivaroxaban Sotorasib Interaction Study", "status": "COMPLETED", "last_update": "2024-04-30", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06333678", "title": "A Study Comparing Sotorasib With Durvalumab in People With Non-Small Cell Lung Cancer (NSCLC)", "status": "TERMINATED", "last_update": "2026-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06333951", "title": "Anvumetostat Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol) (MTAPESTRY 104).", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06497556", "title": "A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-18", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07543172", "title": "CIMAvax-EGF With KRAS G12C Inhibitor for the Treatment of Advanced, KRAS G12C Mutated Non Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "SUGEMALIMAB": { "n": 9, "n_observational": 3, "n_active": 8, "n_withdrawn": 0, "trials": [ { "nct": "NCT04770207", "title": "Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs", "status": "RECRUITING", "last_update": "2024-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05623267", "title": "Sugemalimab as Consolidation Therapy in Patients With LS-SCLC Following cCRT or sCRT", "status": "RECRUITING", "last_update": "2023-08-07", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05940532", "title": "A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLC", "status": "RECRUITING", "last_update": "2023-07-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06217757", "title": "Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC", "status": "RECRUITING", "last_update": "2026-05-05", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06617416", "title": "A Study of AK104 in Subjects With Unresectable Locally Advanced NSCLC", "status": "RECRUITING", "last_update": "2025-03-12", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06987734", "title": "Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab for Patients With Resectable Stage II-IIIA Non-small-cell Lung Cancer Patients", "status": "RECRUITING", "last_update": "2025-06-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07247227", "title": "Real-world First-line Sugemalimab-Chemotherapy in Advanced NSCLC", "status": "RECRUITING", "last_update": "2025-11-25", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06031597", "title": "Radiotherapy Combined With ICIs as Treatment for LA-NSCLC After Failing Induction Immunochemotherapy", "status": "UNKNOWN", "last_update": "2023-09-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07190027", "title": "Immunodynamics-Guided Optimization of Individualized Immunochemotherapy in Advanced Driver-Negative NSCLC: A Randomized Trial", "status": "NOT_YET_RECRUITING", "last_update": "2025-09-24", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "SUNITINIB": { "n": 35, "n_observational": 0, "n_active": 3, "n_withdrawn": 2, "trials": [ { "nct": "NCT04893785", "title": "A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM)", "status": "RECRUITING", "last_update": "2024-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05024214", "title": "Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors", "status": "RECRUITING", "last_update": "2026-03-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00092001", "title": "Study Of SU011248 In Patients With Metastatic Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2008-10-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00113516", "title": "A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2010-05-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00265317", "title": "A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 (Sunitinib) Is Better Than Erlotinib Alone", "status": "COMPLETED", "last_update": "2013-02-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00372775", "title": "Study Tests The Safety And Effectiveness Of SU011248 In Patients With Non-Small Cell Lung Cancer Having Brain Metastases", "status": "COMPLETED", "last_update": "2011-02-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00392444", "title": "Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma", "status": "COMPLETED", "last_update": "2014-05-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00428220", "title": "A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.", "status": "COMPLETED", "last_update": "2019-06-27", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00430261", "title": "Phase II Trial of Sunitinib in BAC or Never-Smokers With Any Lung Adenocarcinoma", "status": "COMPLETED", "last_update": "2010-10-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00434226", "title": "A Study of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer (SABRE-L)", "status": "TERMINATED", "last_update": "2009-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00453154", "title": "Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-06-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00457392", "title": "A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone", "status": "COMPLETED", "last_update": "2013-10-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00528619", "title": "A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2011-04-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00555256", "title": "A Phase I Study of SUNITINIB and Rapamycin in Advanced Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2016-05-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00581789", "title": "Erlotinib and Sunitinib in NSCLC", "status": "COMPLETED", "last_update": "2019-11-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00616109", "title": "Sunitinib Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With ES-SCLC", "status": "COMPLETED", "last_update": "2014-04-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00620347", "title": "Sunitinib as a Second-line Treatment for Patients With Recurrent Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2013-06-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00693992", "title": "Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy", "status": "COMPLETED", "last_update": "2026-06-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00695292", "title": "Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2021-11-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00698815", "title": "Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2022-02-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00712504", "title": "Study Of SU011248 In Combination With Docetaxel In Patients With Advanced Cancer", "status": "COMPLETED", "last_update": "2008-11-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00748163", "title": "Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Sunitinib as First-Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2018-08-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00864721", "title": "Sunitinib Non Small Cell Lung Cancer Patients Over 70", "status": "COMPLETED", "last_update": "2018-10-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00890747", "title": "Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy", "status": "COMPLETED", "last_update": "2014-03-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00936832", "title": "Sunitinib Malate and Combination Chemotherapy as Front-Line Therapy in Treating Patients With Metastatic Rectal Cancer That Cannot Be Removed by Surgery", "status": "WITHDRAWN", "last_update": "2022-08-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00953459", "title": "Sunitinib Malate in Treating Patients With Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2018-07-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01019798", "title": "Salvage Therapy With Sunitinib,Docetaxel and Platinum on Metastatic or Unresectable Non Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2009-11-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01210053", "title": "Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2010-09-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01216371", "title": "Resection of Pulmonary Metastasis in Clear Cell Renal Cell Carcinoma +/-Adjuvant Sunitinib Therapy (SMAT)", "status": "TERMINATED", "last_update": "2026-08-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01306045", "title": "Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies", "status": "COMPLETED", "last_update": "2024-10-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01402089", "title": "Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients", "status": "COMPLETED", "last_update": "2016-02-02", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01803503", "title": "Docetaxel With or Without Low-dose, Short Course Sunitinib in Refractory Solid Tumors", "status": "UNKNOWN", "last_update": "2016-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01829217", "title": "Sunitinib in Never-Smokers With Lung Adenocarcinoma", "status": "COMPLETED", "last_update": "2018-10-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01850147", "title": "Sequential Use of Low-dose Sunitinib With Chemotherapy in Advanced NSCLC After Failure of Conventional Regimen", "status": "UNKNOWN", "last_update": "2013-05-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "SUNITINIB MALATE": { "n": 35, "n_observational": 0, "n_active": 3, "n_withdrawn": 2, "trials": [ { "nct": "NCT04893785", "title": "A Trial Evaluating the Activity and Safety of Combination Between Cabozantinib and Temozolomide in Lung and GEP-NENS Progressive After Everolimus, Sunitinib or PRRT (CABOTEM)", "status": "RECRUITING", "last_update": "2024-06-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05024214", "title": "Phase Ib/II Trial of Envafolimab Plus Lenvatinib for Subjects With Solid Tumors", "status": "RECRUITING", "last_update": "2026-03-25", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00092001", "title": "Study Of SU011248 In Patients With Metastatic Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2008-10-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00113516", "title": "A Study Of SU011248 As Therapy In Patients With Locally Advanced Or Metastatic Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2010-05-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00265317", "title": "A Study In Patients With Non-Small Cell Lung Cancer Testing If Erlotinib Plus SU011248 (Sunitinib) Is Better Than Erlotinib Alone", "status": "COMPLETED", "last_update": "2013-02-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00372775", "title": "Study Tests The Safety And Effectiveness Of SU011248 In Patients With Non-Small Cell Lung Cancer Having Brain Metastases", "status": "COMPLETED", "last_update": "2011-02-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00392444", "title": "Sunitinib in Treating Patients With Advanced Malignant Pleural Mesothelioma", "status": "COMPLETED", "last_update": "2014-05-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00428220", "title": "A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.", "status": "COMPLETED", "last_update": "2019-06-27", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00430261", "title": "Phase II Trial of Sunitinib in BAC or Never-Smokers With Any Lung Adenocarcinoma", "status": "COMPLETED", "last_update": "2010-10-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00434226", "title": "A Study of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Patients With Advanced Non-Small Cell Lung Cancer (SABRE-L)", "status": "TERMINATED", "last_update": "2009-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00453154", "title": "Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2026-06-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00457392", "title": "A Study In Patients With Non-Small Cell Lung Cancer To Test If Erlotinib Plus SU011248 Is Better Than Erlotinib Alone", "status": "COMPLETED", "last_update": "2013-10-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00528619", "title": "A Study To Find The Best Dose Of SU011248 When Given With Pemetrexed, Pemetrexed And Cisplatin Or Pemetrexed And Carboplatin In Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2011-04-08", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00555256", "title": "A Phase I Study of SUNITINIB and Rapamycin in Advanced Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2016-05-06", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00581789", "title": "Erlotinib and Sunitinib in NSCLC", "status": "COMPLETED", "last_update": "2019-11-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00616109", "title": "Sunitinib Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With ES-SCLC", "status": "COMPLETED", "last_update": "2014-04-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00620347", "title": "Sunitinib as a Second-line Treatment for Patients With Recurrent Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2013-06-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00693992", "title": "Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy", "status": "COMPLETED", "last_update": "2026-06-23", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00695292", "title": "Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2021-11-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00698815", "title": "Pemetrexed and/or Sunitinib as Second-Line Therapy in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2022-02-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00712504", "title": "Study Of SU011248 In Combination With Docetaxel In Patients With Advanced Cancer", "status": "COMPLETED", "last_update": "2008-11-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00748163", "title": "Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Sunitinib as First-Line Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2018-08-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00864721", "title": "Sunitinib Non Small Cell Lung Cancer Patients Over 70", "status": "COMPLETED", "last_update": "2018-10-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00890747", "title": "Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy", "status": "COMPLETED", "last_update": "2014-03-17", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00936832", "title": "Sunitinib Malate and Combination Chemotherapy as Front-Line Therapy in Treating Patients With Metastatic Rectal Cancer That Cannot Be Removed by Surgery", "status": "WITHDRAWN", "last_update": "2022-08-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00953459", "title": "Sunitinib Malate in Treating Patients With Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2018-07-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01019798", "title": "Salvage Therapy With Sunitinib,Docetaxel and Platinum on Metastatic or Unresectable Non Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2009-11-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01210053", "title": "Sunitinib as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer", "status": "UNKNOWN", "last_update": "2010-09-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01216371", "title": "Resection of Pulmonary Metastasis in Clear Cell Renal Cell Carcinoma +/-Adjuvant Sunitinib Therapy (SMAT)", "status": "TERMINATED", "last_update": "2026-08-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01306045", "title": "Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies", "status": "COMPLETED", "last_update": "2024-10-01", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01402089", "title": "Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients", "status": "COMPLETED", "last_update": "2016-02-02", "phase": "PHASE4", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01803503", "title": "Docetaxel With or Without Low-dose, Short Course Sunitinib in Refractory Solid Tumors", "status": "UNKNOWN", "last_update": "2016-06-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01829217", "title": "Sunitinib in Never-Smokers With Lung Adenocarcinoma", "status": "COMPLETED", "last_update": "2018-10-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01850147", "title": "Sequential Use of Low-dose Sunitinib With Chemotherapy in Advanced NSCLC After Failure of Conventional Regimen", "status": "UNKNOWN", "last_update": "2013-05-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TALETRECTINIB": { "n": 3, "n_observational": 3, "n_active": 3, "n_withdrawn": 0, "trials": [ { "nct": "NCT06564324", "title": "A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07154706", "title": "Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)", "status": "RECRUITING", "last_update": "2026-05-19", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04919811", "title": "Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TARLATAMAB": { "n": 28, "n_observational": 2, "n_active": 26, "n_withdrawn": 1, "trials": [ { "nct": "NCT06598306", "title": "Subcutaneous Tarlatamab in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-308)", "status": "RECRUITING", "last_update": "2026-06-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06814496", "title": "Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors", "status": "RECRUITING", "last_update": "2026-07-20", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06830694", "title": "Clinical Trial for Safety and Effectiveness Evaluation of Tarlatamab (AMG757) With Etoposide, Carboplatin and Atezolizumab in Transformed Small Cell Lung Cancer Patients From Adenocarcinoma After EGFR TKI Treatment", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06937905", "title": "Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)", "status": "RECRUITING", "last_update": "2026-02-11", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06957314", "title": "A Study of Hospital-at-Home for People Receiving Tarlatamab", "status": "RECRUITING", "last_update": "2026-06-12", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07016230", "title": "Study Investigating Tarlatamab (AMG 757) in Patients With Metastatic/Locally Advanced Small-Cell Lung Cancer (SCLC) and Other Poorly Differentiated Neuroendocrine Carcinomas (NECs), With Biomarker Analysis to Characterize Response/Resistance (UNLOCK TARLATAMAB)", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07037758", "title": "A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)", "status": "RECRUITING", "last_update": "2026-05-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07203053", "title": "A Trial of Tarlatamab in Patients With Pretreated Extensive-stage Small Cell Lung Cancer (ES-SCLC) and ECOG PS 2", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07242547", "title": "Study of Tarlatamab as Maintenance Treatment After Chemo-radiotherapy for Limited Stage SCLC Patients", "status": "RECRUITING", "last_update": "2026-07-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07402343", "title": "Tarlatamab for SCLC Brain Metastases", "status": "RECRUITING", "last_update": "2026-07-31", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07423585", "title": "Tarlatamab for the Treatment of Extensive Stage Small-cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-07-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07531095", "title": "Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC)", "status": "RECRUITING", "last_update": "2026-08-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07778316", "title": "Phase 3 Trial of Tarlatamab (SC vs IV) in Extensive-Stage Small Cell Lung Cancer After Platinum Based First-line Chemotherapy (ES-SCLC)", "status": "RECRUITING", "last_update": "2026-08-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07803848", "title": "Study to Confirm Efficacy and Feasibility of Tarlatamab Treatment in Patients With Extensive Stage Small-cell Lung Cancer With Poor Performance Status", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03319940", "title": "Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-19", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04885998", "title": "AMG 757 and AMG 404 in Subjects With Small Cell Lung Cancer (SCLC)", "status": "COMPLETED", "last_update": "2025-09-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05060016", "title": "A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-22", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05361395", "title": "First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05740566", "title": "Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-01-05", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06117774", "title": "Study Evaluating Tarlatamab After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer (LS-SCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-29", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06211036", "title": "Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-12-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06502977", "title": "Study Evaluating Tarlatamab in Chinese Participants With Advanced Small Cell Lung Cancer After Two or More Prior Lines of Treatment", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06745323", "title": "A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With SCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06898957", "title": "Study of Tarlatamab in Combination With YL201 With or Without Anti-programmed Death Ligand 1 (PD-L1) in Participants With Extensive Stage (ES) Small Cell Lung Cancer (SCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-05-20", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07005128", "title": "A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-08", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07328490", "title": "Bispecific T-Cell Engager Tarlatamab and TROP2 Targeted Antibody Drug Conjugate Sacituzumab Govitecan in Previously Treated Extensive-Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancer", "status": "WITHDRAWN", "last_update": "2026-04-28", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07637513", "title": "Tarlatamab and Durvalumab vs. Durvalumab Alone for Limited-Stage-Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07699237", "title": "A Multicenter Phase II Trial to Evaluate Rechallenge With Platinum-based Chemotherapy (Carboplatin, Etoposide) for Progression During Tarlatamab Therapy in Relapsed Extensive Disease Small-cell Lung Cancer (SCLC)", "status": "NOT_YET_RECRUITING", "last_update": "2026-07-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TARLOXOTINIB": { "n": 3, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02454842", "title": "Study for Treatment With TH-4000 (Tarloxotinib) in Epidermal Growth Factor Receptor (EGFR) Mutant, T790M-negative Non-small Cell Lung Cancer (NSCLC) Patients", "status": "TERMINATED", "last_update": "2023-01-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03805841", "title": "Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions", "status": "TERMINATED", "last_update": "2023-06-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05313009", "title": "Tarlox and Sotorasib in Patients With KRAS G12C Mutations", "status": "TERMINATED", "last_update": "2025-12-16", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TAS-115": { "n": 1, "n_observational": 0, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT04999761", "title": "AB122 Platform Study", "status": "RECRUITING", "last_update": "2026-08-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "TELISOTUZUMAB": { "n": 11, "n_observational": 2, "n_active": 8, "n_withdrawn": 1, "trials": [ { "nct": "NCT04928846", "title": "A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05005403", "title": "Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan", "status": "RECRUITING", "last_update": "2026-06-23", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06568939", "title": "A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06772623", "title": "Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations", "status": "RECRUITING", "last_update": "2026-09-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07005102", "title": "A Study to Assess Adverse Events, Change in Disease Activity of Intravenous Telisotuzumab Adizutecan in Combination With Osimertinib as First-Line Treatment in Adult Participants With Locally Advanced Unresectable or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-06-08", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07155187", "title": "A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-07-09", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07323641", "title": "Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-04-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03539536", "title": "Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03574753", "title": "Lung-MAP S1400K: c-MET Positive", "status": "COMPLETED", "last_update": "2021-10-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05513703", "title": "A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)", "status": "TERMINATED", "last_update": "2025-10-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06093503", "title": "Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein", "status": "WITHDRAWN", "last_update": "2024-06-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "TELISOTUZUMAB VEDOTIN": { "n": 7, "n_observational": 2, "n_active": 4, "n_withdrawn": 1, "trials": [ { "nct": "NCT04928846", "title": "A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06568939", "title": "A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)", "status": "RECRUITING", "last_update": "2026-09-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07323641", "title": "Telisotuzumab Vedotin and Osimertinib for the Treatment of Progressive, Incurable, Non Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-04-20", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03539536", "title": "Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03574753", "title": "Lung-MAP S1400K: c-MET Positive", "status": "COMPLETED", "last_update": "2021-10-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05513703", "title": "A Study to Assess Disease Activity of Intravenously (IV) Infused Telisotuzumab Vedotin in Adult Participants With Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)", "status": "TERMINATED", "last_update": "2025-10-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06093503", "title": "Study of Intravenous Telisotuzumab Vedotin in Combination Osimertinib or Standard of Care Chemotherapy to Assess Change in Disease Activity in Adult Participants With Non-Small Cell Lung Cancer That Has a Mutation in the Epidermal Growth Factor Receptor Gene and That Overexpresses the c-Met Protein", "status": "WITHDRAWN", "last_update": "2024-06-26", "phase": "PHASE3", "study_type": "INTERVENTIONAL" } ] }, "TEPOTINIB": { "n": 14, "n_observational": 0, "n_active": 7, "n_withdrawn": 0, "trials": [ { "nct": "NCT06031688", "title": "Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)", "status": "RECRUITING", "last_update": "2026-05-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06106802", "title": "Lazertinib & Tepotinib for EGFR Mutant NSCLC in MET Overexpressed or Amplified Who Progressed After Lazertinib Treatment", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06908993", "title": "Tepotinib vs Standard Treatment in Patients With Advanced MET Exon 14 Mutated Non-Small Cell Lung Cancer Previously Treated", "status": "RECRUITING", "last_update": "2025-12-17", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07619339", "title": "A Study of Tepotinib and Ivonescimab in People With Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-06-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01982955", "title": "Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)", "status": "COMPLETED", "last_update": "2022-11-08", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02864992", "title": "Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-14", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03492437", "title": "Effect of Tepotinib on the PK of the P-gp Substrate Dabigatran Etexilate", "status": "COMPLETED", "last_update": "2023-08-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03531762", "title": "Effect of a Proton Pump Inhibitor on the PK of Tepotinib", "status": "COMPLETED", "last_update": "2023-07-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03940703", "title": "A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2)", "status": "COMPLETED", "last_update": "2026-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04591431", "title": "The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy", "status": "UNKNOWN", "last_update": "2023-10-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04647838", "title": "Tepotinib in Solid Tumors Harboring MET Alterations", "status": "UNKNOWN", "last_update": "2020-12-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04739358", "title": "CNS Dose Escalation/Expansion of Tepotinib in MET-driven NSCLC", "status": "TERMINATED", "last_update": "2023-10-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05782361", "title": "POTENT - Tepotinib in Combination With Pembrolizumab in NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-04-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06083857", "title": "PhI/II Study of Amivantamab and Tepotinib Combo in MET-altered Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TESEVATINIB": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT02616393", "title": "Phase 2 Study of Study of Tesevatinib in Subjects With NSCLC and Brain or Leptomeningeal Metastases", "status": "COMPLETED", "last_update": "2022-03-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TIVANTINIB": { "n": 13, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00777309", "title": "A Randomized Phase 2 Study of Erlotinib + ARQ 197 Versus Erlotinib + Placebo in Previously Treated Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2013-02-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00827177", "title": "Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2014-01-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01069757", "title": "A Study of ARQ 197 in Combination With Erlotinib", "status": "COMPLETED", "last_update": "2017-03-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01178411", "title": "An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols", "status": "COMPLETED", "last_update": "2021-03-10", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01244191", "title": "Tivantinib Plus Erlotinib Versus Placebo Plus Erlotinib for the Treatment of Non-squamous, Non-small-cell Lung Cancer", "status": "TERMINATED", "last_update": "2021-04-06", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01251796", "title": "A Study of ARQ 197 in Combination With Erlotinib", "status": "COMPLETED", "last_update": "2017-03-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01377376", "title": "A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib", "status": "TERMINATED", "last_update": "2016-12-07", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01395758", "title": "Erlotinib Plus Tivantinib (ARQ 197) Versus Single Agent Chemotherapy in Locally Advanced or Metastatic Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2018-04-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01580735", "title": "ARQ 197 Plus Erlotinib in Patient With Locally Advanced or Metastatic EGFR Mutation-positive Non-small-cell Lung Cancer", "status": "COMPLETED", "last_update": "2015-08-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01654965", "title": "Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors", "status": "COMPLETED", "last_update": "2018-04-03", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01861301", "title": "Tivantinib in Treating Patients With Previously Treated Malignant Mesothelioma", "status": "TERMINATED", "last_update": "2016-10-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02049060", "title": "Study of the Combination of Tivantinib Plus Pemetrexed and Carboplatin", "status": "COMPLETED", "last_update": "2021-01-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02608411", "title": "TIvantinib as Maintenance Treatment in Extended Small-cell Lung Cancer (TIMES)", "status": "TERMINATED", "last_update": "2023-10-13", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TOVORAFENIB": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT04985604", "title": "Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors", "status": "TERMINATED", "last_update": "2025-10-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07121829", "title": "Tovorafenib (DAY101) or in Combination With Pimasertib for Participants With Melanoma and Other Solid Tumors", "status": "TERMINATED", "last_update": "2025-08-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "TRASTUZUMAB": { "n": 61, "n_observational": 5, "n_active": 29, "n_withdrawn": 2, "trials": [ { "nct": "NCT04686305", "title": "Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05150691", "title": "A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-08-27", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05785741", "title": "A Study of DB-1310 in Advanced/Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-04-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05786716", "title": "DETERMINE Trial Treatment Arm 04: Trastuzumab in Combination With Pertuzumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With HER2 Amplification or Activating Mutations", "status": "RECRUITING", "last_update": "2025-12-02", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06253871", "title": "A Phase 1/1b Study of IAM1363 in HER2 Cancers", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06625775", "title": "Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06899126", "title": "Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-07-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07012031", "title": "Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07216105", "title": "FT836 With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors", "status": "RECRUITING", "last_update": "2026-09-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07259226", "title": "Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers", "status": "RECRUITING", "last_update": "2025-12-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07428044", "title": "A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-02-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00003881", "title": "Trastuzumab Plus Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2013-06-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00004074", "title": "Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/Neu", "status": "COMPLETED", "last_update": "2013-02-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00004883", "title": "Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-small Cell Lung Cancer That Overexpresses HER2", "status": "COMPLETED", "last_update": "2013-01-16", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00005842", "title": "Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer", "status": "COMPLETED", "last_update": "2013-02-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00014430", "title": "Chemotherapy Plus Trastuzumab in Treating Patients With Breast Cancer", "status": "COMPLETED", "last_update": "2013-03-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00016367", "title": "Cisplatin and Gemcitabine Plus Trastuzumab in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2018-10-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00028535", "title": "Interleukin-12, Paclitaxel, and Trastuzumab in Treating Patients With Solid Tumors", "status": "COMPLETED", "last_update": "2013-06-04", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00301730", "title": "Cellular Adoptive Immunotherapy in Treating a Patient Who Has Undergone a Donor Stem Cell Transplant for Breast Cancer That Has Spread to the Lung", "status": "COMPLETED", "last_update": "2015-04-28", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00433407", "title": "T-Cell Response in Patients Receiving Trastuzumab and/or Chemotherapy for HER2-Positive Solid Tumors", "status": "COMPLETED", "last_update": "2012-10-04", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00758134", "title": "Trastuzumab Therapy in Non-Small Cell Lung Cancer Patients", "status": "TERMINATED", "last_update": "2013-05-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00847366", "title": "Open Label Trial of Perifosine in Patients Currently Being Treated on Perifosine Trials in Solid Tumors or Multiple Myeloma", "status": "COMPLETED", "last_update": "2018-03-15", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01386580", "title": "An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma.", "status": "COMPLETED", "last_update": "2015-01-22", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01445054", "title": "111 Indium CHX-A DTPA Trastuzumab (Indium-Herceptin) for Imaging Breast Cancer", "status": "TERMINATED", "last_update": "2019-03-11", "phase": "EARLY_PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01679743", "title": "GRN1005 for Brain Metastases From Breast or Lung Cancer", "status": "WITHDRAWN", "last_update": "2019-11-15", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01953926", "title": "Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations", "status": "TERMINATED", "last_update": "2024-03-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02226276", "title": "Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-13", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02289833", "title": "A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor (HER)2 Immunohistochemistry (IHC)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2019-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02308020", "title": "A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain", "status": "COMPLETED", "last_update": "2020-12-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02314481", "title": "Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity", "status": "COMPLETED", "last_update": "2026-05-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02393248", "title": "Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)", "status": "TERMINATED", "last_update": "2023-01-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02675829", "title": "Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers", "status": "COMPLETED", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03319459", "title": "FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors", "status": "COMPLETED", "last_update": "2021-11-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03334617", "title": "Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03505710", "title": "DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2025-05-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03784599", "title": "T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLC", "status": "TERMINATED", "last_update": "2022-11-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03845270", "title": "Her2-positive Lung Cancer Treated With Dedicated Drug", "status": "COMPLETED", "last_update": "2023-12-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04042701", "title": "DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04278144", "title": "A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors", "status": "TERMINATED", "last_update": "2025-09-15", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04285671", "title": "Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-17", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04464967", "title": "Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers", "status": "WITHDRAWN", "last_update": "2021-05-12", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04579380", "title": "Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04591431", "title": "The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy", "status": "UNKNOWN", "last_update": "2023-10-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04644068", "title": "Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04644237", "title": "Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2025-11-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04916002", "title": "A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer", "status": "TERMINATED", "last_update": "2026-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05048797", "title": "A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05069935", "title": "FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05081609", "title": "A Study to Investigate Safety and Tolerability of TransCon IL-2 \u03b2/\u03b3 Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05091528", "title": "A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers", "status": "TERMINATED", "last_update": "2022-08-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05143970", "title": "A Phase 1 First-In-Human Study of the Anti-CD73 IPH5301 Alone or in Combination With Chemotherapy and Trastuzumab in Patients With Advanced Solid Tumors", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-06-22", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05246514", "title": "A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05395052", "title": "FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors", "status": "TERMINATED", "last_update": "2023-09-21", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05650879", "title": "ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-07-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06250777", "title": "Efficacy and Safety of T-DXd in HER2-mutant Advanced Lung Cancer Patients With Asymptomatic Brain Metastases", "status": "ENROLLING_BY_INVITATION", "last_update": "2026-02-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07436858", "title": "Whole Body HER2 Quantification With 89Zr-Trastuzumab PET/CT to Asses Zr-trastuzumab Accumulation in HER2-mutated and HER2-overexpressing Metastatic Non-small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-11", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07630077", "title": "Trastuzumab Rezetecan(SHR-A1811) Combined With Ivonescimab (AK112) in Locally Advanced or Metastatic Non-small Cell Lung Cancer Harboring HER2 Gene Abnormalities", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-05", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07631884", "title": "Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor", "status": "NOT_YET_RECRUITING", "last_update": "2026-06-08", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07699952", "title": "First-line Therapy With Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor(EGFR-TKI) Combined With Trastuzumab Rezetecan for Advanced Non-small Cell Lung Cancer(NSCLC) Harboring EGFR Mutations Concomitant With Human Epidermal Growth Factor Receptor 2(HER2) Alterations", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07781202", "title": "A Multicenter, Single-Arm, Prospective Phase II Clinical Study of Trastuzumab Rezetecan Combined With Radiotherapy in Patients With HER2-Mutated Oligoprogressive Advanced Non-Small Cell Lung Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TRASTUZUMAB DERUXTECAN": { "n": 17, "n_observational": 4, "n_active": 13, "n_withdrawn": 0, "trials": [ { "nct": "NCT04686305", "title": "Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC", "status": "RECRUITING", "last_update": "2026-04-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05785741", "title": "A Study of DB-1310 in Advanced/Metastatic Solid Tumors", "status": "RECRUITING", "last_update": "2026-04-06", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06899126", "title": "Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-07-21", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07012031", "title": "Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation", "status": "RECRUITING", "last_update": "2026-09-04", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07259226", "title": "Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers", "status": "RECRUITING", "last_update": "2025-12-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07428044", "title": "A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer", "status": "RECRUITING", "last_update": "2026-02-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03334617", "title": "Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-10-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03505710", "title": "DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing or -Mutated Non-Small Cell Lung Cancer", "status": "TERMINATED", "last_update": "2025-05-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04042701", "title": "DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04644068", "title": "Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-19", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04644237", "title": "Trastuzumab Deruxtecan in Participants With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2025-11-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04916002", "title": "A Trial To Find Out If Vidutolimod Together With Cemiplimab Is Safe And If It Works In Adult Participants With Advanced Cancer Or Metastatic Cancer", "status": "TERMINATED", "last_update": "2026-06-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05048797", "title": "A Study to Investigate the Efficacy and Safety of Trastuzumab Deruxtecan as the First Treatment Option for Unresectable, Locally Advanced/Metastatic Non-Small Cell Lung Cancer With HER2 Mutations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-10", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05091528", "title": "A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers", "status": "TERMINATED", "last_update": "2022-08-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05246514", "title": "A Single Arm Phase 2 Study to Evaluate Efficacy and Safety of Trastuzumab Deruxtecan for Patients With HER2 Mutant NSCLC", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-18", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05650879", "title": "ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-07-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06250777", "title": "Efficacy and Safety of T-DXd in HER2-mutant Advanced Lung Cancer Patients With Asymptomatic Brain Metastases", "status": "ENROLLING_BY_INVITATION", "last_update": "2026-02-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "TRASTUZUMAB EMTANSINE": { "n": 11, "n_observational": 1, "n_active": 6, "n_withdrawn": 0, "trials": [ { "nct": "NCT07259226", "title": "Optimal Methods to Characterize ADC Resistance in Solid Tumors and Identify Clinically Useful Biomarkers", "status": "RECRUITING", "last_update": "2025-12-02", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02226276", "title": "Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-02-13", "phase": "NA", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02289833", "title": "A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor (HER)2 Immunohistochemistry (IHC)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2019-08-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02314481", "title": "Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity", "status": "COMPLETED", "last_update": "2026-05-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02465060", "title": "Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02675829", "title": "Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers", "status": "COMPLETED", "last_update": "2026-09-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03784599", "title": "T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLC", "status": "TERMINATED", "last_update": "2022-11-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04042701", "title": "DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-11-18", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04591431", "title": "The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy", "status": "UNKNOWN", "last_update": "2023-10-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05081609", "title": "A Study to Investigate Safety and Tolerability of TransCon IL-2 \u03b2/\u03b3 Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-11", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05650879", "title": "ELVN-002 in HER2 Mutant Non-Small Cell Lung Cancer", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-07-15", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "TUCATINIB": { "n": 5, "n_observational": 0, "n_active": 3, "n_withdrawn": 0, "trials": [ { "nct": "NCT02892123", "title": "Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers", "status": "COMPLETED", "last_update": "2024-11-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04579380", "title": "Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-08-21", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05091528", "title": "A Safety and Activity Study of SBT6050 in Combination With Other HER2-directed Therapies for HER2-positive Cancers", "status": "TERMINATED", "last_update": "2022-08-18", "phase": "PHASE1/PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06067776", "title": "Osimertinib, Cetuximab, and Tucatinib for the Treatment of EGFR-Mutant Stage IV or Recurrent Non-small Lung Cell Cancer", "status": "NOT_YET_RECRUITING", "last_update": "2023-10-05", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07768358", "title": "Tucatinib Continuation Study", "status": "NOT_YET_RECRUITING", "last_update": "2026-08-28", "phase": "PHASE4", "study_type": "INTERVENTIONAL" } ] }, "VANDETANIB": { "n": 27, "n_observational": 0, "n_active": 0, "n_withdrawn": 2, "trials": [ { "nct": "NCT00047840", "title": "This Study is to Assess the Efficacy and Safety of ZD6474 in Subjects With Non-small Cell Lung Cancer.", "status": "COMPLETED", "last_update": "2016-08-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00059722", "title": "This Study is to Compare the Efficacy of ZD6474 and ZD1839 in Subjects With NSCLC.", "status": "COMPLETED", "last_update": "2016-08-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00066313", "title": "ZD6474 in Treating Patients With Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2016-08-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00071188", "title": "ZD6474 Alone or in Combination With Paclitaxel and Carboplatin in Subjects With Previously Untreated Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC)", "status": "COMPLETED", "last_update": "2016-08-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00252746", "title": "ZD6474 Phase IIa Dose Finding Multicentre Study", "status": "COMPLETED", "last_update": "2016-08-25", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00290537", "title": "Phase II Study of ZD6474 in Advanced NSCLC", "status": "TERMINATED", "last_update": "2016-05-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00312377", "title": "ZACTIMA (an Anti-EGFR / Anti-VEGF Agent) Combined With Docetaxel Compared to Docetaxel in Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2016-09-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00364351", "title": "Efficacy Trial Comparing ZD6474 With Erlotinib in NSCLC After Failure of at Least One Prior Chemotherapy", "status": "COMPLETED", "last_update": "2018-01-25", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00402896", "title": "Malignant Pleural Effusion With ZD6474", "status": "TERMINATED", "last_update": "2016-03-09", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00404924", "title": "ZD6474 (ZACTIMA\u2122) Phase III Study in EGFR Failures", "status": "COMPLETED", "last_update": "2016-09-30", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00410189", "title": "BATTLE Program: ZD6474 in Previously Treated Subjects With NSCLC", "status": "COMPLETED", "last_update": "2015-03-23", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00418886", "title": "Efficacy Study Comparing ZD6474 in Combination With Pemetrexed and Pemetrexed Alone in 2nd Line NSCLC Patients", "status": "COMPLETED", "last_update": "2024-12-31", "phase": "PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00459121", "title": "Vandetanib, Carboplatin, and Paclitaxel in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed by Surgery", "status": "TERMINATED", "last_update": "2019-03-26", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00496275", "title": "Phase I Combination With Vinorelbine or Gemcitabine Plus Cisplatin in Locally Advanced or Metastatic NSCLC", "status": "COMPLETED", "last_update": "2016-08-26", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00506051", "title": "ZD6474(Vandetanib) + Alimta Combo Study", "status": "COMPLETED", "last_update": "2016-08-25", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00613626", "title": "Cisplatin + Etoposide +/- Concurrent ZD6474 in Previously Untreated Extensive Stage Small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2020-02-11", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00687297", "title": "Study of Vandetanib Combined With Chemotherapy to Treat Advanced Non-small Cell Lung Cancer", "status": "COMPLETED", "last_update": "2018-05-30", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00734890", "title": "Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or Lymphoma", "status": "COMPLETED", "last_update": "2012-03-16", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00745732", "title": "Radiation Therapy (XRT) and ZD6474 in Non-Small Cell Lung Cancer (NSCLC)", "status": "TERMINATED", "last_update": "2018-11-14", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00753714", "title": "Zactima in Non Small Cell Lung Cancer (NSCLC) ELderly Patients In Combination With or Versus Gemcitabine", "status": "COMPLETED", "last_update": "2016-10-17", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00777179", "title": "Phase II of Zactima Maintenance for Locally Advanced or Metastatic Non-small-cell Lung Carcinoma (NSCLC) Following Platinum-doublet Chemotherapy", "status": "COMPLETED", "last_update": "2016-10-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00807170", "title": "Investigate the Maximum Tolerated Dose of Vandetanib and Concurrent Whole Brain Radiotherapy (WBRT) in Patients With Non-small Cell Lung Cancer (NSCLC) and Brain Metastases", "status": "TERMINATED", "last_update": "2016-08-29", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT00937417", "title": "S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors", "status": "WITHDRAWN", "last_update": "2017-04-24", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01004419", "title": "Trial of ZD6474 and Faslodex in Non-Small Cell Lung Cancer", "status": "WITHDRAWN", "last_update": "2015-10-02", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01586624", "title": "A Phase I Trial of Vandetanib (AZD6474) and Selumetinib (AZD6244) for Solid Tumours Including Non Small Cell Lung Cancer (VanSel-1)", "status": "COMPLETED", "last_update": "2021-10-07", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01823068", "title": "Vandetanib in Advanced NSCLC With RET Rearrangement", "status": "COMPLETED", "last_update": "2020-12-07", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02117167", "title": "SAFIR02_Lung - Efficacy of Targeted Drugs Guided by Genomic Profiles in Metastatic NSCLC Patients", "status": "COMPLETED", "last_update": "2024-01-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "VEMURAFENIB": { "n": 8, "n_observational": 0, "n_active": 4, "n_withdrawn": 0, "trials": [ { "nct": "NCT04302025", "title": "A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)", "status": "RECRUITING", "last_update": "2026-09-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05768178", "title": "DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.", "status": "RECRUITING", "last_update": "2025-11-24", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02314481", "title": "Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity", "status": "COMPLETED", "last_update": "2026-05-04", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03155620", "title": "Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-07-24", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03178552", "title": "A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2026-09-03", "phase": "PHASE2/PHASE3", "study_type": "INTERVENTIONAL" }, { "nct": "NCT03220035", "title": "Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)", "status": "COMPLETED", "last_update": "2025-01-27", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT04591431", "title": "The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy", "status": "UNKNOWN", "last_update": "2023-10-03", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT05900219", "title": "Efficacy and Safety of HL-085 Combined With Vemurafenib in BRAF V600E Patients With Non-small Cell Lung Cancer: a Phase II Clinical Study", "status": "UNKNOWN", "last_update": "2023-06-12", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "XL-281": { "n": 1, "n_observational": 0, "n_active": 0, "n_withdrawn": 0, "trials": [ { "nct": "NCT00451880", "title": "Study of XL281 in Adults With Solid Tumors", "status": "COMPLETED", "last_update": "2011-10-13", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "ZALUTUMUMAB": { "n": 2, "n_observational": 0, "n_active": 0, "n_withdrawn": 1, "trials": [ { "nct": "NCT00460551", "title": "Zalutumumab in Combination With Chemo-Radiation in a Certain Type of Lung Cancer", "status": "TERMINATED", "last_update": "2011-12-06", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT01449357", "title": "Zalutumumab in Non-Small Cell Lung Cancer (NSCLC) Patients Refractory to Tyrosine Kinase Inhibitors", "status": "WITHDRAWN", "last_update": "2011-10-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] }, "ZANIDATAMAB": { "n": 4, "n_observational": 0, "n_active": 3, "n_withdrawn": 0, "trials": [ { "nct": "NCT06253871", "title": "A Phase 1/1b Study of IAM1363 in HER2 Cancers", "status": "RECRUITING", "last_update": "2026-09-09", "phase": "PHASE1", "study_type": "INTERVENTIONAL" }, { "nct": "NCT06695845", "title": "A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors", "status": "RECRUITING", "last_update": "2026-07-10", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT07192068", "title": "Clinical Trial Evaluating the Activity of Zanidatamab for the Treatment of Patients With Solid Tumors With an Alteration of the HER2 Gene.", "status": "RECRUITING", "last_update": "2025-12-19", "phase": "PHASE2", "study_type": "INTERVENTIONAL" }, { "nct": "NCT02892123", "title": "Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers", "status": "COMPLETED", "last_update": "2024-11-27", "phase": "PHASE1", "study_type": "INTERVENTIONAL" } ] }, "ZENOCUTUZUMAB": { "n": 1, "n_observational": 1, "n_active": 1, "n_withdrawn": 0, "trials": [ { "nct": "NCT02912949", "title": "A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)", "status": "ACTIVE_NOT_RECRUITING", "last_update": "2025-04-29", "phase": "PHASE2", "study_type": "INTERVENTIONAL" } ] } } } }